VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 14 (1-16 junio/2025)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el ojetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Noticias en la Web

La OMS advierte sobre una nueva variante de la COVID-19

2 jun. La Organización Mundial de la Salud (OMS) ha advertido del aumento de casos de COVID-19 a nivel mundial causados por una nueva variante del SARS-CoV-2, denominada NB.1.8.1, que ha puesto ya bajo vigilancia, precisando que por el momento el riesgo para la salud pública se considera "bajo".

"Aunque el riesgo para la salud pública se considera bajo, el organismo la ha puesto bajo vigilancia ante el aumento del número de casos"

Así lo recoge en el informe de evaluación de riesgos elaborado por el Grupo Asesor Técnico sobre la Evolución de los Virus (TAG-VE, por sus siglas en inglés), publicado el pasado 23 de mayo. En el mismo, apunta que se espera que las vacunas disponibles en la actualidad contra la COVID-19 sigan siendo eficaces contra esta variante, tanto en casos sintomáticos como graves.

Según explica, a 18 de mayo de 2025 se habían identificado 518 secuencias de NB.1.8.1 provenientes de 22 países, lo que representa el 10,7% de las secuencias disponibles a nivel mundial en la semana epidemiológica número 17 de este año, es decir, el periodo comprendido entre el 21 y el 27 de abril.

La OMS detalla que esta cifra "sigue siendo baja" respecto a otras variantes en circulación; LP.8.1 representa la mayoría de casos, con un 39%, aunque está en descenso. Sin embargo, señala que se trata de un aumento significativo en la prevalencia de NB.1.8.1 con respecto al 2,5% registrado cuatro semanas antes, en la semana epidemiológica 14, que comprende entre el 31 de marzo y el 6 de abril.

En concreto, entre las semanas epidemiológicas 14 y 17, la prevalencia de NB.1.8.1 aumentó del 8,9 al 11,7% en la Región de la OMS del Pacífico Occidental; del 1,6 al 4,9% en la región de la OMS de las Américas; y del 1 al 6% en la región europea. Mientras, en la región del sudeste asiático sólo existen cinco secuencias de esta variante, y no se ha detectado ninguna en la región africana ni en la región del Mediterráneo oriental.

La NB.1.8.1 es una variante del SARS-CoV-2 derivada de la variante recombinante XDV.1.5.1 y su primera muestra se recolectó el 22 de enero de 2025. Pese a su rápido crecimiento, la OMS puntualiza que NB.1.8.1 sólo presenta una evasión inmunitaria adicional mínima en comparación con la variante LP.8.1.

Aunque se han reportado aumentos en los casos y las hospitalizaciones en algunos países de la región del Pacífico occidental, donde se encuentra la mayor proporción de variantes NB.1.8.1, no hay informes que sugieran que la gravedad de la enfermedad asociada sea mayor en comparación con otras variantes circulantes.

Recomendaciones

Ante esta situación, la OMS y su Grupo Técnico Asesor sobre la Evolución del Virus han reiterado sus recomendaciones a los Estados miembro para que prioricen medidas específicas para abordar mejor las incertidumbres relacionadas con el escape inmunológico y NB.1.8.1.

De este modo, han aconsejado a los países realizar ensayos de neutralización con sueros humanos representativos de la comunidad afectada, así como con sueros de modelos animales sin tratamiento previo infectados con virus vivos aislados NB.1.8.1. Además, han sugerido realizar una evaluación comparativa para detectar cambios en los indicadores de gravedad, ya sean continuos o *ad hoc*.

Igualmente, el organismo internacional ha afirmado que continúa evaluando de forma periódica el impacto de las distintas variantes del virus en el rendimiento de las vacunas, junto a su Grupo Técnico Asesor sobre la Composición de las Vacunas contra la COVID-19.

Por último, ha señalado que revisará esta evaluación de riesgos a medida que se disponga de más evidencia y datos de otros países.

Fuente: Diario de Sevilla. Disponible en https://n9.cl/6gdkd

Study: New mRNA vaccine is more scalable and adaptable to continuously evolving viruses

Jun 3. A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study by researchers at University of Pittsburgh School of Public Health and the Pennsylvania State University. The study was published today in npj Vaccines.

"The virus changes, moving the goal post, and updating the vaccine takes some time."

Suresh Kuchipudi, Ph.D., senior author, chair of Infectious Diseases and Microbiology, Pitt Public Health"

Though highly effective at inducing an immune response, current mRNA vaccines, such as those used to prevent COVID-19, present two significant challenges: the high amount of mRNA needed to produce them and the constantly evolving nature of the pathogen.

To address these challenges, the researchers created a proof-of-concept COVID-19 vaccine using what's known as a "trans-amplifying" mRNA platform. In this approach, the mRNA is separated into two fragments-the antigen sequence and the replicase sequence-the latter of which can be produced in advance, saving crucial time in the event a new vaccine must be developed urgently and produced at scale.

Additionally, the researchers analyzed the spike-protein sequences of all known variants of the SARS-CoV-2 for commonalities, rendering what's known as a "consensus spike protein" as the basis for the vaccine's antigen.

In mice, the vaccine induced a robust immune response against many strains of SARS-CoV-2.

"This has the potential for more lasting immunity that would not require updating, because the vaccine has the potential to provide broad protection," said Kuchipudi. "Additionally, this format requires an mRNA dose 40 times less than conventional vaccines, so this new approach significantly reduces the overall cost of the vaccine."



The lessons learned from this study could inform more efficient vaccine development for other constantly evolving RNA viruses with pandemic potential, Kuchipudi said. "We hope to apply the principles of this lower-cost, broad-protection antigen design to pressing challenges like bird flu."

Other authors on the study were Abhinay Gontu, Padmaja Jakka, Ph.D., Maurice Byukusenge, D.V.M., Ph.D., D.A.C.V.M., Meera Surendran Nair, Bhushan M. Jayarao, M.V.Sc., Ph.D., M.P.H., Marco Archetti, Ph.D., and Ruth H. Nissly, Ph.D.,

all of Pennsylvania State University; and Sougat Misra, Ph.D., Shubhada K. Chothe, Ph.D., M.V.Sc., B.V.Sc., Santhamani Ramasamy, Ph.D., D.A.C.V.M., and Lindsey C. LaBella, all of Pitt.

This research was supported by chair funds from the Huck Institutes of the Life Sciences and Interdisciplinary Innovation Fellowship at the One Health Microbiome Center at Pennsylvania State University.

Fuente: News Medical Life Sciences. Disponible en https://n9.cl/paifj

La vacuna argentina ARVAC mostró protección frente a nuevas variantes de la COVID-19

3 jun. La fórmula actualizada genera inmunidad frente a las variantes más recientes del SARS-CoV-2, incluyendo JN.1, KP.3.1.1 y XEC, según señaló un estudio publicado en la revista internacional *Vaccine*. Expertos explicaron a Infobae su mecanismo de acción y eficacia.

Si bien parece olvidado por estas latitudes, la realidad es que el coronavirus sigue entre nosotros, evolucionando en nuevas mutaciones y contagiando a miles de personas diariamente en todo el mundo.

Ante esto, la ciencia argentina no se queda atrás y los investigadores argentinos que desarrollaron una nueva formulación de la vacuna ARVAC, de fabricación nacional, siguen dando batalla al virus que logró paralizar al mundo hace cinco años.

Los resultados mostraron que la nueva fórmula mejorada de ARVAC logra generar inmunidad frente a las variantes más recientes del SARS-CoV-2, incluyendo JN.1, KP.3.1.1 y XEC, y además demostró reactividad cruzada contra el SARS-CoV-1, el virus que provocó un brote de 2003, muchos años antes de la pandemia de 2020.

Los resultados del estudio fueron publicados en la revista *Vaccine*, del grupo *Nature*, y marcan un avance importante en la carrera científica por una inmunización de amplio espectro contra los sarbecovirus, la subfamilia de coronavirus que incluye al SARS-CoV-2 y a su antecesor de principios del siglo XXI.

En diálogo con Infobae, el doctor Ricardo Teijeiro (MN 58065), infectólogo del Hospital Pirovano y miembro de la Sociedad Argentina de Infectología (SADI) señaló que la variante XEC que está circulando fuertemente en los países asiáticos, es bastante contagiosa, aunque no agresiva.

“Es una subvariante de las otras mutaciones. Y justo esta vacuna ARVAC monovalente es para JN.1, que es una de las variantes de la cual se generó esta XEC”, sostuvo el experto.

El trabajo fue liderado por el Instituto de Investigaciones Biotecnológicas de la Universidad Nacional de San Martín (UNSAM), el CONICET y el Laboratorio Pablo Cassará, y contó con la colaboración de grupos de investigación del Reino Unido e Italia. La propuesta parte de una hipótesis concreta: frente a la aparición constante de nuevas variantes con mayor capacidad de evasión inmunológica, la actualización de las vacunas debe ser dinámica y basada en combinaciones estratégicas de antígenos.

En este caso, el equipo utilizó una formulación bivalente que combina el antígeno de la variante Gamma —circulante en América del Sur en 2021— con un componente adaptado a sublinajes más recientes, como XBB.1.5 o JN.1.

Esta elección técnica se basa en una observación experimental: mientras que las vacunas monovalentes contra XBB.1.5 o JN.1 inducen una buena respuesta frente a linajes emparentados, su eficacia disminuye cuando se trata de variantes filogenéticamente más alejadas. La inclusión del antígeno Gamma permite ampliar esa cobertura y generar una respuesta más robusta.

El doctor Hugo Pizzi, infectólogo, epidemiólogo y Magister en Salud Pública afirmó que este desarrollo es un paso enorme para la Argentina, para su expertise.

"Esta vacuna fue desarrollada con la plataforma y tecnología similar a la que se hace la de la hepatitis B, que nos ha dado muy buen resultado. Y entre los estudios que se hicieron para esta vacuna, se probó que brinda una protección contra el cuadro grave de la COVID-19 bastante notorio. Lo mismo para el efectuado como protección prolongada. Una de las cosas que tiene esta fórmula que me agradó mucho es que tiene la posibilidad de adaptarse a nuevas variantes como la que hoy se está viniendo circulando en Tailandia, China, y ahora en Estados Unidos", afirmó el experto que es profesor de la Universidad Nacional de Córdoba.

Y concluyó: "Y otra cosa es que soluciona mucho el tema de su logística y distribución, ya que tiene una forma de conservarse más simple que otras. Y al ser una producción argentina es todo más simple, en cuanto a su producción y distribución. Sabemos a dónde mandarlas, conocemos los efectores de salud que la compran, las provincias, municipalidades que las necesitarán, las droguerías que pueden distribuirla, o sea, lo que es la logística también. Yo creo que tiene muchas ventajas. Además, su reacción de formación de anticuerpos es muy buena, del 90% comprobado".

En los ensayos preclínicos realizados en modelos murinos, las vacunas bivalentes generaron altos niveles de anticuerpos neutralizantes, tanto a nivel sistémico como pulmonar. Además, se observó una activación sostenida de células T, en particular del subtipo CD4+, en todas las formulaciones ensayadas. Esta respuesta inmunitaria celular es un elemento clave para una protección duradera frente a infecciones virales, ya que actúa más allá de los anticuerpos neutralizantes inmediatos.

"En este trabajo aportamos evidencia de que incluir el antígeno de circulación más reciente JN.1, junto con el antígeno Gamma, amplía notablemente el espectro de protección", explicó Juliana Cassataro, investigadora del CONICET y líder del proyecto, en un comunicado de la UNSAM.

La formulación combinada no sólo cubre desde la cepa original detectada en Wuhan, conocida como Ancestral, hasta las variantes que circulaban a principios de 2024, sino que también mostró neutralización cruzada contra el SARS-CoV-1. Esto posiciona a la nueva vacuna como candidata para un uso más allá de la COVID-19 y como base para una estrategia pan-sarbecovirus.

El desarrollo fue liderado por la UNSAM el CONICET y el Laboratorio Cassará con participación de equipos científicos del Reino Unido e Italia

La vacuna ARVAC es una plataforma de subunidad proteica que emplea un fragmento del dominio de unión al receptor (RBD) de la proteína espiga del SARS-CoV-2. Se trata de un enfoque diferente al de las vacunas de ARN mensajero, ya que utiliza proteínas recombinantes purificadas en lugar de material genético.

Entre sus ventajas se destacan un perfil de seguridad favorable, la facilidad de almacenamiento y transporte, y la posibilidad de reformularla con relativa rapidez ante nuevas variantes. El componente clave es el RBD dimérico, que imita la estructura del virus y desencadena una respuesta inmunitaria específica.

La ciencia argentina frente a un virus en evolución constante

Desde su aprobación por la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) en 2023, la vacuna ARVAC fue adaptada en línea con las recomendaciones de la Organización Mundial de la Salud.

En marzo de 2025, la ANMAT autorizó una nueva actualización con el antígeno JN.1, lo que permitió su disponibilidad en farmacias y centros de vacunación privados de Argentina. La combinación Gamma + JN.1 se convirtió así en la primera formulación bivalente nacional con proyección hacia una cobertura extendida.

El diseño experimental que dio lugar a esta nueva versión de ARVAC respondió a una necesidad concreta: compensar la caída en la eficacia de las vacunas disponibles frente a las nuevas variantes.

Desde la aparición de Ómicron en 2021, y particularmente de sus sublinajes XBB y JN.1, se observaron niveles crecientes de evasión inmunológica. Esto redujo significativamente la efectividad de las vacunas previas, tanto monovalentes como bivalentes, desarrolladas por distintos fabricantes.

Los estudios realizados por el equipo argentino mostraron que, mientras las vacunas monovalentes adaptadas a XBB.1.5 generaron buenos niveles de anticuerpos frente a ese sublinaje, su efecto se reducía frente a JN.1, hoy predominante en diversas regiones del mundo.

En ese contexto, los investigadores propusieron una solución: recuperar el antígeno Gamma como refuerzo de memoria inmunológica y sumarle el componente actualizado. El resultado fue una formulación que no sólo cubre variantes actuales, sino que también ofrece protección cruzada frente a eventuales mutaciones futuras.

La plataforma de subunidad proteica ARVAC representa una de las pocas alternativas desarrolladas fuera de los grandes polos farmacéuticos del norte global.

A diferencia de otras vacunas cuya producción depende de acuerdos internacionales o de procesos tecnológicos complejos, ARVAC puede fabricarse y adaptarse localmente. Esto abre una vía concreta hacia la soberanía científica y tecnológica en materia de inmunizaciones, especialmente en un contexto en el que la circulación de nuevas variantes es impredecible.

“La circulación del linaje JN.1 fue posteriormente reemplazada por sublinajes JN.1, incluyendo KP.2, KP.3 y XEC”, se detalla en el artículo científico publicado en Vaccines. Frente a esta dinámica, los autores subrayan la importancia de una estrategia flexible y de largo plazo. “Tener una vacuna que actúe como base para una formulación universal frente a los sarbecovirus sería un hito para la salud pública global. Y desde Argentina estamos trabajando para conseguirlo”, expresó Cassataro.

La investigación también forma parte de una discusión más amplia sobre el futuro de las vacunas contra la COVID-19. Con foco en explorar alternativas con mayor amplitud, como las formulaciones bivalentes que incorporan antígenos con diferencias filogenéticas más marcadas.

El trabajo liderado por investigadores argentinos se inscribe en esa línea de búsqueda. La inclusión del antígeno Gamma, que proviene de una variante ya superada en términos de circulación, responde a una lógica inmunológica comprobada: al combinarlo con un componente más reciente, se activa una respuesta

capaz de abarcar diferentes ramas del árbol evolutivo del virus.

Además, la capacidad de neutralización frente al SARS-CoV-1 sugiere que la formulación podría tener aplicaciones en futuras emergencias sanitarias vinculadas a coronavirus zoonóticos.

La apuesta por una vacuna pan-sarbecovirus no es solo teórica. En la práctica, los datos presentados respaldan una estrategia concreta de salud pública. El uso de vacunas bivalentes con diseño intencionado —es decir, con antígenos seleccionados por su complementariedad— puede convertirse en una herramienta clave para evitar que cada nueva variante implique una nueva formulación desde cero.

Los próximos pasos del proyecto incluyen ensayos clínicos más amplios y estudios de efectividad poblacional, así como la evaluación del impacto de esta formulación en grupos de riesgo o personas con inmunocompromiso. El desafío principal sigue siendo anticiparse a la evolución del virus y ofrecer una protección que no dependa exclusivamente de una única mutación dominante.

“Gracias al trabajo de científicos y científicas de nuestro país, logramos desarrollar una vacuna que se adapta a la evolución del virus y que puede posicionarse entre las más avanzadas a nivel internacional”, expresaron los responsables del proyecto en redes institucionales.

En un contexto donde el virus continúa modificándose y desplazando cepas previas, la experiencia de ARVAC demuestra que es posible responder desde el sur global con innovación, evidencia y capacidad técnica.

Fuente: Infobae. Disponible en https://n9.cl/mbrna

Avanza el desarrollo regional de vacunas mRNA contra la influenza A(H5N1) con apoyo de OPS

6 jun. Expertos internacionales visitaron la empresa farmacéutica Sinergium Biotech para apoyar el desarrollo de la vacuna contra el virus de la influenza A(H5N1) en base a la tecnología de ARN mensajero (mRNA). El encuentro se enmarca en los esfuerzos de la Organización Mundial de la Salud (OMS), el *Medicines Patent Pool* (MPP) y la Organización Panamericana de la Salud (OPS) por fortalecer las capacidades regionales de preparación ante futuras pandemias como parte del Programa de Transferencia de Tecnología de Vacunas de mRNA.

El encuentro reunió a los integrantes del comité científico que apoya técnicamente el proyecto y que está conformado por expertos internacionales en desarrollo de vacunas, incluyendo expertos de CEPI, MPP, OMS y OPS. También participó el equipo técnico de Sinergium Biotech quien lidera el consorcio conformado además por la empresa sudafricana Afrigen y el Instituto de Investigaciones en Microbiología y Parasitología Médica UBA-CONICET (IVMPAM), que presentaron los avances del proyecto y recibieron retroalimentación por parte del comité.

Durante la visita, Sinergium Biotech presentó sus avances en el desarrollo tecnológico de la vacuna, se visitaron las instalaciones, y los expertos presentaron las recomendaciones para el avance en las próximas etapas de estudios de fase 1 y preparación para una potencial producción con estándares de buenas prácticas de manufactura (GMP).

Eva Jané Llopis, representante de la OPS en Argentina destacó la relevancia de este esfuerzo:

> *"El avance de este proyecto para el desarrollo en Argentina de una vacuna candidata con tecnología ARN mensajero (ARNm) para la prevención de la Influenza aviar A (H5N1) es de suma importancia dado que los virus que causan esta enfermedad constituyen un importante riesgo para la salud pública debido a su amplia circulación en animales y a la posibilidad de causar una futura pandemia en humanos. La transferencia de tecnología es crítica para la soberanía sanitaria de la Región de las Américas en materia de insumos fundamentales como las vacunas, fortaleciendo la producción y capacidades regionales y globales con el liderazgo de la Argentina."*

Por su parte, Alejandro Gil, CEO de Sinergium Biotech resaltó la importancia del encuentro:

> *"Desde Sinergium celebramos los avances obtenidos y el espacio de intercambio científico y colaboración interdisciplinaria que reúne a investigadores tanto del ámbito privado como de universidades y de todos los miembros de OPS, OMS y MPP. Confirmamos nuestro compromiso de continuar realizando todo lo que esté a nuestro alcance para desarrollar vacunas en la plataforma de ARNm y ser parte del aporte de soluciones para toda la región de las Américas."*

Amin Khan, quien preside el comité técnico-científico, remarcó:

> *"El modelo que estamos aplicando aquí - donde un país con capacidad técnica lidera el desarrollo y luego transfiere el conocimiento - es el camino para evitar la desigualdad que vivimos durante la COVID-19."*

Como próximo paso, el equipo completará las pruebas preclínicas, mientras avanza en la construcción de una nueva planta de producción de ARNm que estará operativa en 2026. Argentina compartirá los aprendizajes y resultados de este desarrollo con otros países de ingresos medios y bajos a través del Programa de Transferencia de Tecnología ARNm que la OMS lanzó en 2021.

Innovación tecnológica para la salud pública

La pandemia de COVID-19 demostró el potencial de las plataformas de vacunas basadas en mRNA para ofrecer respuestas rápidas y eficaces. A partir de esta experiencia, la OMS lanzó en 2021 el Programa de Transferencia de Tecnología de mRNA, con el objetivo de establecer capacidades de producción en 15 países de ingresos bajos y medianos.

Sinergium Biotech, como socio clave del programa, lidera el desarrollo de una vacuna candidata contra el H5N1 utilizando tecnología mRNA. Este esfuerzo no solo busca fortalecer la capacidad productiva para fortalecer la soberanía nacional y regional, sino también compartir conocimientos, materiales y tecnología con otros socios del programa, promoviendo así una red regional de producción y respuesta ante emergencias sanitarias.

Fuente: OPS. Disponible en https://acortar.link/kb04WQ

Nuevo virus HKU5-CoV-2 en China genera alerta por potencial pandémico

6 jun. En un desarrollo que ha capturado la atención de la comunidad científica internacional, un nuevo virus denominado HKU5-CoV-2, identificado en febrero de 2025 en China, ha sido señalado como una potencial amenaza pandémica. Este coronavirus, derivado de murciélagos, ha levantado alarmas debido a su capacidad para interactuar con células humanas y su proximidad genética con virus altamente peligrosos como el MERS.

Descubrimiento y origen del HKU5-CoV-2

El HKU5-CoV-2 fue detectado inicialmente en murciélagos de la especie *Pipistrellus abramus*, una especie común en China. Este virus pertenece a la subespecie de merbecovirus, un grupo que incluye al virus responsable del Síndrome Respiratorio de Oriente Medio (MERS), conocido por su alta tasa de letalidad, estimada en un 34%. Aunque su primera documentación ocurrió en 2005 en murciélagos japoneses, las muestras actuales fueron recolectadas de regiones del sur y este de China, como Guangdong, Fujian, Zhejiang, Anhui y Guangxi, lo que sugiere una amplia distribución geográfica.

El virus fue identificado por investigadores del Instituto de Virología de Wuhan, un centro que ha estado en el centro de controversias debido a teorías sobre el origen del SARS-CoV-2. Los estudios iniciales, publicados en *Nature Communications*, revelaron que el HKU5-CoV-2 tiene una capacidad notable para infectar una amplia gama de animales, lo que aumenta el riesgo de zoonosis, es decir, la transmisión de animales a humanos.

Un paso cerca de la transmisión humana

Las investigaciones han mostrado que el HKU5-CoV-2 puede unirse al receptor ACE2 humano, el mismo utilizado por el SARS-CoV-2 para infectar células humanas. Experimentos de laboratorio, incluyendo pruebas con virus vivos, modelado proteico, simulaciones de IA y microscopía crioelectrónica, han demostrado que el virus puede infectar y replicarse en células humanas de las vías respiratorias y el intestino . Sin embargo, no lo hace tan eficientemente como el SARS-CoV-2, lo que sugiere que, aunque tiene el potencial, no está tan bien adaptado para infectar humanos.

El profesor Michael Letko, de la Universidad Estatal de Washington, ha advertido que el HKU5-CoV-2 podría estar "solo un pequeño paso" de mutar para adquirir la capacidad de transmitirse entre humanos, lo que podría desencadenar una pandemia global. Esta preocupación se basa en la identificación de una variante específica, conocida como linaje 2 (HKU5-CoV-2), que ya puede unirse al receptor ACE2 humano, aumentando las posibilidades de spillover, o salto de especies .

A pesar de estas advertencias, hasta la fecha, no hay casos confirmados de infección humana con HKU5-CoV-2. Los expertos, como el profesor David Heymann de la London School of Hygiene & Tropical Medicine, han enfatizado que, aunque el virus tiene potencial, no hay evidencia de circulación humana ni de transmisión persona a persona.

Comparación con otros virus y riesgos asociados

El HKU5-CoV-2 comparte similitudes con el SARS-CoV-2 y el MERS-CoV, pero también presenta diferencias clave. Mientras que el SARS-CoV-2 se adaptó rápidamente a la infección humana, el HKU5-CoV-2 no entra en las células humanas tan fácilmente, lo que reduce su capacidad actual de infección. Sin embargo, su relación con el MERS-CoV, que ha causado 858 muertes desde 2012 y se ha reportado en 27 países, resalta la necesidad de vigilancia constante. El MERS-CoV se transmite principalmente a través de camellos, pero el HKU5-CoV-2 podría tener un rango de hospedadores más amplio, incluyendo animales como minks y civets, que podrían actuar como intermediarios en la transmisión a humanos.

El riesgo pandémico se ve exacerbado por factores como el comercio ilegal de vida silvestre y la deforestación, que facilitan el contacto entre humanos y animales portadores de virus. Los científicos han señalado que el virus podría requerir solo una pequeña mutación para volverse altamente transmisible, especialmente a través de intermediarios animales, lo que lo convierte en una amenaza latente.

Recomendaciones y medidas preventivas

Los científicos han destacado la necesidad de monitorear de cerca este virus y otros similares para prevenir su propagación a la población humana. La lección aprendida de la pandemia de COVID-19 es que la preparación y la respuesta rápida son clave para mitigar el impacto de nuevas amenazas virales. Entre las medidas recomendadas se incluyen:

- Vigilancia epidemiológica: Monitorear poblaciones de murciélagos y otros animales potencialmente portadores para detectar cambios en el virus.
- Regulación del comercio de vida silvestre: Reducir el contacto entre humanos y animales salvajes para minimizar el riesgo de zoonosis.
- Investigación y desarrollo: Avanzar en la comprensión del virus para desarrollar posibles tratamientos y vacunas, si fuera necesario.
- Educación pública: Informar a la población sobre los riesgos de enfermedades emergentes sin generar pánico innecesario.

El profesor Heymann ha enfatizado que "virus recién identificados en animales, como el HKU5-CoV-2, son un recordatorio de que debemos permanecer alertas y mantener informada a la población sobre las amenazas potenciales de enfermedades".

Análisis detallado de la investigación

Los estudios sobre el HKU5-CoV-2 han utilizado una variedad de métodos para evaluar su potencial pandémico. Por ejemplo, los investigadores emplearon pruebas con virus vivos, modelado proteico, simulaciones de IA y microscopía crioelectrónica para analizar cómo el virus interactúa con las células humanas. En particular, se crearon pseudovirus mediante edición genética para probar la capacidad de infección, encontrando que, mientras las células de murciélago se infectaban fácilmente, las células humanas requerían mutaciones específicas para ser infectadas .

El análisis estructural, publicado en Cell, reveló que el dominio de unión al receptor (RBD) del HKU5-CoV-2 comparte características con otros coronavirus que utilizan ACE2, como los sarbecovirus (incluyendo SARS-CoV-2) y NL63, un virus del resfriado común. Esto sugiere una adaptación potencial a humanos, aunque limitada en la actualidad.

Tabla de comparación: HKU5-CoV-2 vs. Otros Coronavirus

Característica	HKU5-CoV-2	SARS-CoV-2	MERS-CoV
Origen	Murciélagos (*Pipistrellus abramus*)	Murciélagos, probable intermediario	Camellos, origen en murciélagos
Receptor de Entrada	ACE2 humano (linaje 2)	ACE2 humano	DPP4 humano
Tasa de Letalidad	Desconocida (sin casos humanos)	~2% (variante dependiente)	~34%
Transmisión Humana	No confirmada	Alta, persona a persona	Limitada, principalmente zoonótica
Riesgo Pandémico Actual	Potencial, requiere mutación	Alta (histórico)	Moderado, brotes localizados

Aunque el HKU5-CoV-2 representa un riesgo potencial, no hay evidencia actual de que esté causando infecciones humanas. Su capacidad para interactuar con células humanas y su relación con virus pandémicos como el MERS-CoV subrayan la importancia de la vigilancia continua y la investigación científica. Las autoridades sanitarias y la comunidad internacional deben permanecer atentas para responder rápidamente ante cualquier cambio en el comportamiento del virus, aprendiendo de las lecciones de la pandemia de COVID-19.

Fuente: Diario de Morelos. Disponible en https://acortar.link/lUvcxl

ImmunoPrecise identifica objetivo para vacuna universal contra el dengue

6 jun. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), líder en bioterapéuticos impulsados por inteligencia artificial con una capitalización de mercado de 26,5 millones de dólares, ha realizado un descubrimiento significativo en la lucha contra la fiebre del dengue. Según el análisis de InvestingPro, la empresa parece infravalorada según las estimaciones de Valor razonable, a pesar de operar con niveles moderados de deuda y mantener un ratio de liquidez saludable de 2,32. La plataforma LENSai™ de la compañía, que utiliza su tecnología patentada HYFT®, ha identificado un epítopo altamente conservado presente en los cuatro serotipos del virus del dengue. Este hallazgo podría allanar el camino para el desarrollo de una vacuna universal contra el dengue, un avance importante dado el impacto global del virus y el desafío de su rápida mutación.

El descubrimiento se realizó completamente mediante análisis *in silico*, un método que simula experimentos en un ordenador. Al identificar una parte del virus que permanece inalterada en todos los serotipos, la investigación de ImmunoPrecise sugiere la posibilidad de crear una vacuna que pueda desencadenar una respuesta inmune capaz de eliminar el virus, independientemente de las mutaciones. Mientras que los ingresos de la empresa ascienden a 16,5 millones de dólares en los últimos doce meses con un margen de beneficio bruto del 51%, los datos de InvestingPro revelan que la empresa está quemando rápidamente efectivo, una característica común entre las empresas biotecnológicas en fase de desarrollo.

La Dra. Jennifer Bath, directora ejecutiva de ImmunoPrecise, afirmó que este avance es un testimonio del potencial de la IA en biología, permitiendo una comprensión más profunda de la biología del virus.

Los patrones HYFT de la empresa, derivados de datos de secuencia, coincidieron con firmas estructurales en todos los serotipos del dengue, confirmando la persistencia del objetivo.

El éxito con el dengue ha llevado a ImmunoPrecise a extender su plataforma de diseño de vacunas impulsada por IA a otras enfermedades infecciosas y posibles aplicaciones en oncología. La plataforma integral LENSai de la empresa integra las huellas universales patentadas HYFT® con aprendizaje profundo para identificar y refinar epítopos candidatos, agilizando las primeras etapas del desarrollo de vacunas.

El virus del dengue es conocido por sus cuatro serotipos distintos, que complican la inmunidad y el desarrollo de vacunas. El descubrimiento de ImmunoPrecise representa un paso crítico para superar estos desafíos al identificar un componente viral estable que podría conducir a una protección amplia contra la enfermedad.

Esta noticia se basa en un comunicado de prensa y refleja el compromiso de ImmunoPrecise Antibodies Ltd. con el avance del descubrimiento de fármacos a través de tecnologías innovadoras de IA. Las declaraciones prospectivas de la empresa destacan los beneficios anticipados y aplicaciones más amplias de sus plataformas LENSai™ y HYFT®, así como la posible expansión a objetivos de enfermedades adicionales. La acción ha mostrado un fuerte impulso con un rendimiento del 56% en los últimos seis meses, aunque los analistas no anticipan rentabilidad este año. Para obtener información más profunda sobre la salud financiera y las perspectivas de crecimiento de IPA, los inversores pueden acceder a análisis completos y 6 consejos adicionales a través de los informes de investigación detallados de InvestingPro, disponibles para más de 1.400 acciones estadounidenses.

En otras noticias recientes, ImmunoPrecise Antibodies Ltd. informó sus resultados financieros para el tercer trimestre del año fiscal 2025, con ingresos estables de 6,2 millones de dólares canadienses. La empresa registró una pérdida neta de 21,5 millones de dólares, significativamente impactada por un cargo único por deterioro de 21,2 millones de dólares. Excluyendo este cargo, las pérdidas habrían sido similares a las cifras del año anterior. H.C. Wainwright recientemente ajustó su precio objetivo para ImmunoPrecise, reduciéndolo a 5,00 dólares desde 7,00 dólares, mientras mantiene una calificación de Compra. Este ajuste coincide con una asociación estratégica que se espera genere 8 millones de dólares en ingresos durante 18 meses, con potencial para 2 millones adicionales. La asociación implica el uso de la tecnología de IA BioStrand y la plataforma B-cell Select de ImmunoPrecise para el desarrollo de fármacos contra el cáncer. Benchmark también mantuvo una calificación de Compra Especulativa, destacando la generación estable de ingresos y el potencial a largo plazo de los servicios de desarrollo de fármacos de la empresa. La filial de IA de ImmunoPrecise, BioStrand, ha mostrado un fuerte crecimiento, contribuyendo significativamente a los ingresos de la empresa. La reciente colaboración de la empresa subraya la integración de la IA en el descubrimiento de fármacos, con el objetivo de mejorar la eficiencia y precisión en el desarrollo de tratamientos contra el cáncer.

Fuente: Investing.com. Disponible en https://acortar.link/V6sm88

Breakthrough mRNA Delivery Targets Resting T Cells in HIV

6 jun. A recent study published in *Nature Communications* introduces a groundbreaking approach to HIV treatment by effectively delivering mRNA to resting CD4+ T cells, a significant challenge in the field. The researchers, from the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia, developed a lipid nanoparticle (LNP) formulation, termed LNP X, capable of transfecting these hard-to-reach cells without inducing toxicity or activation.

"Our hope is that this new nanoparticle design could be a new pathway to an HIV cure," said Dr. Paula Cevaal, a research fellow at the Doherty Institute and co-first author of the study.

The researchers identified a novel LNP formulation with the unique capability to transfect CD4+ T cells without the need for pre-stimulation. Using this formulation, called LNP X, they encapsulated two mRNA-based latency-reversing agents (LRAs), which demonstrated efficient activation of HIV transcription in CD4+ T cells from people living with HIV on antiretroviral therapy ex vivo.

LNP X was engineered by replacing the conventional ionizable lipid DLin-MC3-DMA with SM-102 and incorporating β-sitosterol, enhancing its ability to deliver mRNA into the cytosol of resting T cells. This formulation achieved up to 76% transfection efficiency in non-stimulated CD4+ T cells, a notable improvement over existing methods.

The study demonstrated that LNP X could deliver mRNA encoding the HIV Tat protein, a potent activator of HIV transcription. In ex vivo experiments using CD4+ T cells from individuals on antiretroviral therapy, Tat-LNP X significantly increased HIV RNA transcription without causing cellular activation or toxicity. This suggests that LNP X can reverse HIV latency effectively while maintaining cell viability.

Furthermore, LNP X was used to co-deliver components of the CRISPR activation system, including dCas9-VP64 mRNA, MS2-p65-HSF1 mRNA, and guide RNAs targeting the HIV long terminal repeat region. This approach successfully activated HIV transcription in resting CD4+ T cells, highlighting the versatility of LNP X in delivering complex RNA-based therapeutics.

To the researchers' knowledge, this is the first demonstration of successful, non-toxic in vitro transfection of primary T cells without the need for T cell pre-stimulation, a condition previously believed to be essential for efficient LNP transfection. These data suggest that the superior potency of LNP X results from increased cellular association and enhanced efficiency of mRNA translation after cytosolic delivery, which contrasts with earlier hypotheses that attributed improved performance to enhanced endosomal escape mediated by β-sitosterol.

"In the field of biomedicine, many things eventually don't make it into the clinic—that is the unfortunate truth; I don't want to paint a prettier picture than what is the reality," Cevaal shared with The Guardian. "But in terms of specifically the field of HIV cure, we have never seen anything close to as good as what we are seeing, in terms of how well we are able to reveal this virus."

Fuente: doc wire news. Disponible en https://acortar.link/0tU5OV

OMS aprueba vacuna y anticuerpo para proteger a lactantes del virus respiratorio sincitial

7 jun. La Organización Mundial de la Salud (OMS) ha emitido una recomendación clave para reducir las infecciones graves por virus respiratorio sincitial (RSV) en niños: la introducción de una vacuna materna y un anticuerpo monoclonal de acción prolongada.

El RSV es un virus altamente contagioso que causa infecciones respiratorias graves en lactantes y niños pequeños.

Cada año, provoca alrededor de 100 mil muertes infantiles, la mitad de ellas en bebés menores de seis meses, así como más de 3.6 millones de hospitalizaciones en menores de cinco años.

El 97% de los casos graves ocurren en países de ingresos bajos y medios, donde el acceso a tratamientos de soporte, como oxígeno e hidratación, es limitado.

La propuesta avalada por el Grupo Asesor Estratégico de Expertos en Inmunización (SAGE) de la OMS incluye dos medidas complementarias:

- Vacuna para embarazadas: Se aplicará a partir de la semana 28 de gestación, preferentemente durante visitas prenatales rutinarias. Esto permite la transferencia de anticuerpos al bebé, ofreciendo protección desde el nacimiento.
- Anticuerpo monoclonal para lactantes: Se administra en una sola dosis al nacer o durante la primera visita médica, brindando una protección de al menos cinco meses. Es especialmente efectivo cuando se aplica antes de los seis meses de edad y debe aplicarse antes del inicio de la temporada de circulación del virus.

Aunque el RSV suele provocar síntomas leves similares a los del resfriado común, puede generar complicaciones como bronquiolitis y neumonía, especialmente en bebés prematuros, niños con enfermedades subyacentes y adultos mayores con inmunodepresión.

La OMS subraya la urgencia de implementar estas medidas preventivas, especialmente en regiones con servicios de salud limitados, para reducir significativamente la mortalidad infantil y la sobrecarga hospitalaria causada por este virus.

Fuente: CANAL 7. Disponible en https://n9.cl/kt3yf

China aprueba primera vacuna de alta eficacia contra el Virus del Papiloma Humano

8 jun. China ha aprobado la primera vacuna denominada nonavalente contra el virus del papiloma humano (VPH) desarrollada íntegramente dentro del país. El fármaco, que actúa contra nueve tipos de patógenos distintos, ha sido incluido en la lista oficial publicada por la Administración Nacional de Productos Médicos. Así lo informa Xinhua News Agency, socio de la red TV BRICS.

Con esta aprobación, China se convierte en el segundo país del mundo con capacidad para producir de forma independiente una vacuna de alta valencia contra el VPH. Según Zhang Jun, director del Instituto de Salud Pública de la Universidad de Xiamen, la nueva vacuna ampliará el acceso a la inmunización y contribuirá significativamente a reducir el riesgo de cáncer de cuello uterino.

El desarrollo del fármaco tomó 18 años. Durante este tiempo, los científicos superaron importantes desafíos técnicos, logrando sintetizar partículas del virus utilizando bacterias *E. coli* y completando con éxito las fases

principales de los ensayos clínicos. Desde 2019, se han realizado cinco estudios de gran escala que demostraron la seguridad de la vacuna y su capacidad para generar una fuerte respuesta inmunitaria.

Según la Organización Mundial de la Salud, cada año se registran en el mundo alrededor de 700.000 casos de cáncer relacionados con el VPH, de los cuales unos 530.000 corresponden a cáncer de cuello uterino. La vacunación reduce el riesgo de infección en un 94%.

Por otro lado, el socio de TV BRICS, Mehr News Agency, informó que Irán presentará este verano una vacuna contra el cáncer, desarrollada por el Instituto Nacional de Ingeniería Genética y Biotecnología. En Rusia, según el medio Trinity Mirror, también parte de la red, se está desarrollando una vacuna que será gratuita y representa un avance clave en el tratamiento oncológico.

Fuente: TV BRICS. Disponible en https://n9.cl/cu9h5a

Next-Gen COVID-19 Vaccine Market Intelligence Report and Segment Analysis

Jun 9. The global next-gen COVID-19 vaccine market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034. This surge is attributed to evolving consumer preferences and technological advancements reshaping the industry.

The next-gen COVID-19 vaccine market is estimated to grow significantly due to the growing number of COVID-19 cases. Apart from this, the viruses mutate rapidly then other organisms, due to which the development of new vaccines becomes necessary to ensure that people build immunity against the new variants. Additionally, many government initiatives are being taken in different countries to tackle the ongoing issues of COVID -19 and to prevent the occurrence of any pandemic in the future. Many companies are collaborating with each other and government organizations to conduct clinical trials for developing next-gen COVID-19 vaccines.

Why Next-Gen COVID-19 Vaccine being Developed?

Companies are still researching vaccinations with novel concepts and ideas, even after the COVID-19 outbreak ended about two years ago. This is due to the fact that COVID-19 instances are still occurring and that prevention and therapy must change along with the virus itself. The COVID-19 pandemic's medical, social, and economic costs, as well as the development and appearance of new strains, have brought attention to the pressing need for next-generation vaccines that are more durable, have a wider range of protection, and can stop infection and transmission.

Next-Gen COVID-19 Vaccine Market Trends

In May 2025, the next-generation, universal vaccination platform, called Generation Gold Standard, was developed by the National Institutes of Health (NIH) and the U.S. Department of Health and Human Services (HHS) utilizing a whole-virus platform that has been inactivated by beta-propiolactone (BPL). The United States is spending $500 million to create vaccinations that are universal. (Source - NIH)

In June 2024, the Vaccine Alliance's Board of Gavi announced a number of decisions that offer a framework for accelerating global immunization. These decisions include the Alliance's 2026-2030 strategy, the approval of "Gavi 6.0," the expansion of Gavi's vaccine portfolio, and plans to support regional manufacturing and global health security through the African Vaccine Manufacturing Accelerator and a First Response Fund for use in future pandemics. (Source - Gavi)

What is the Role of AI in the Next-Gen COVID-19 Vaccine Market?

With the advent of artificial intelligence (AI), a new era in vaccine development has dawned, offering unprecedented opportunities to accelerate the process. Machine learning and deep learning are examples of artificial intelligence (AI) systems that use genetic information, immune system connections, and protein structures to predict antigenic epitopes, assess immunogenicity, and rank antigens for more research. These cutting-edge technologies provide opportunities never before possible. As AI-driven vaccine research advances and computer resources become more accessible, it holds great promise to transform public health and combat infectious diseases worldwide.

Market Dynamics

Driver. Genetic Mutation in the Virus Promotes the Need for New Vaccines

Rapid viral evolution has led to several instances throughout human history where newly emerging viruses have posed a serious threat to public health. It was expected that SARS-CoV-2 variants would evolve given the large global prevalence of COVID-19 infections. Even while vaccinations have been the most effective tool in the fight against the pandemic, there are still a number of obstacles to overcome. The introduction of viral variations is one of the most immediate risks.

Restraint. High Cost of Vaccine Development

The high cost of vaccine development hampers the next-gen COVID-19 vaccine market. The direct expenses of producing a vaccine include the price of labor, raw materials, components, analytics, and the documentation of the procedure and test findings. The development and administration of quality systems, production and QC planning, distribution and warehousing, inventory control, and overhead activities like marketing, sales, and regulation are examples of indirect expenses.

Opportunity. Is mRNA the Future of the Next-Gen COVID-19 Vaccine Market?

mRNA vaccines' enormous therapeutic potential has been highlighted by the COVID-19 pandemic. Twenty-three (17%) of the COVID-19 vaccines now undergoing clinical trials are mRNA-based candidates. Following the discovery of mRNA, which resulted in several scientific breakthroughs, there was a surge in studies in this area, which led to the development of RNA-based vaccines.

What is the Major Factor of North America's Dominance in 2024?

North America dominated the next-gen COVID-19 vaccine market in 2024. The dominance of the region is mainly because of the presence of key market players. These market players are highly competitive and continuously collaborate and invest in new research and clinical trials for the development of next-gen COVID-19 vaccines. Apart from this, the region has advanced infrastructure and government support for conducting studies and testing. Countries like the U.S. and Canada are the major contributors to the region's dominance.

The U.S. Next-Gen COVID-19 Vaccine Market Trends

The U.S. has made progress toward a yearly COVID-19 booster program within the last five years. The U.S. strategy has been the most aggressive when compared to vaccination programs in all of Europe. The FDA's new COVID-19 concept strikes a compromise between a dedication to gold-standard research and regulatory flexibility. In addition to approving vaccinations for high-risk individuals, the FDA will need solid, gold-standard data on low-risk individuals. In addition to helping the FDA choose its future course, these clinical studies will

yield knowledge that the American public and healthcare professionals sorely need.

The Canada Next-Gen COVID-19 Vaccine Market Trends

Canada boasts one of the highest immunization rates in the world because of a strong vaccine supply plan. For 2023 and beyond, Canada has obtained vaccinations from Pfizer, Moderna, and Novavax, with the possibility to buy extra doses if necessary. Once Health Canada has approved the use of next-generation COVID-19 vaccines, which are created by vaccine providers to guard against mutations or variations of concern, these agreements also give people the freedom to acquire them.

Government Support is Promoting the Asia Pacific

Asia Pacific is estimated to host the fastest-growing next-gen COVID-19 vaccine market during the forecast period. Asia Pacific has a large population base, which increases the chances of COVID-19 cases growth. Governments are taking major steps to develop new vaccines to tackle the growing issue of virus mutation. Companies are collaborating in order to advance in vaccine development.

The China Next-Gen COVID-19 Vaccine Market Trends

China is still taking stringent steps to stop the spread of SARS-CoV-2 as of 2025. China has stuck to its "dynamic zero-COVID" strategy, even while the rest of the world has embraced a "living with the virus" mentality. This entails strict traveler quarantine regulations, widespread testing programs, and regional lockdowns. With the extensive dissemination of updated vaccinations that target new variations, China's immunization plan has placed a strong emphasis on local vaccine manufacture. China has adopted next-generation vaccinations by 2025, bringing it closer to international norms.

The India Next-Gen COVID-19 Vaccine Market Trends

As more businesses are ready to introduce them in response to an increase in new cases in various regions of the world, namely Singapore, next-generation COVID-19 vaccinations may soon be accessible in India. A next-generation COVID-19 vaccine to fight the XBB1.5 strain of the Sars-CoV-2 virus has started clinical testing, and Hyderabad-based Biological E anticipates early results. With a local clinical trial waiver for emergency use, a Subject Expert Committee (SEC) last month suggested authorizing the Pune-based Serum Institute of India (SII) to develop a Covid-19 vaccine based on the Omicron XBB1.5 version.

Pandemic Preparation Expenditure is Driving Europe

Europe is expected to grow significantly in the next-gen COVID-19 vaccine market during the forecast period. Increased research funding and the existence of regionally significant market players are responsible for the industry's expansion. Due to rising investments, Europe is seeing an increase in the number of biopharmaceutical businesses. Furthermore, the market is expanding as a result of the European Medicines Agency's (EMA) simplification of regulatory approvals in order to hasten the launch of novel vaccines. Additionally, the market is expanding as a result of rising expenditures in pandemic preparation, which are supporting the creation of next-generation vaccines for newly developing infectious illnesses. Similarly, market demand is being supported by increased investment for vector-based and mRNA technologies that improve manufacturing efficacy and efficiency.

The Germany Next-Gen COVID-19 Vaccine Market Trends

One of the world's most inventive nations for a long time has been Germany. Another illustration of Germany's

diverse scientific and innovative environment is BioNTech. By 2025, Germany is on track to meet its goal of allocating 3.5% of its GDP to research and innovation. The goal of the Medical Research Act, which went into effect in full on October 30, 2024, is to maintain Germany's competitiveness as a pharmaceutical site. It specifically calls for adjustments to expedite approval processes, simplify contract negotiations, and enhance inter-authority collaboration.

The UK Next-Gen COVID-19 Vaccine Market Trends

Early on in the COVID-19 pandemic, the National Institute for Health and Care Research (NIHR) created a single, UK-wide procedure to rank COVID-19 research as urgent public health research. In a variety of patient cohorts and throughout all stages of human trials, the Department of Health and Social Care (DHSC) is still funding a number of national clinical trial "platforms." With assistance from the NIHR Clinical Research Network around the United Kingdom, they are evaluating a number of therapeutic and preventative possibilities in order to find and enroll patients.

Top Companies in the Next-Gen COVID-19 Vaccine Market

Fuente: Towards Healthcare. Disponible en https://acortar.link/NzH3nF

Nirsevimab de Sanofi amplía la duración de la protección frente al VRS

9 jun. El estudio NIRSE-GAL confirma que nirsevimab protege eficazmente durante seis meses a los lactantes frente al VRS, principal causa de bronquiolitis y neumonía. Los nuevos datos de la temporada 2024-25 muestran una reducción notable de hospitalizaciones.

El virus respiratorio sincitial (VRS) ha erigido a España como un país de referencia mundial en innovación en salud pública. Por un lado, por el éxito de las campañas de inmunización universal a lactantes llevadas a cabo en todas las comunidades autónomas las temporadas 2023-2024 y 2024-2025, tanto en lo que se refiere a la agilidad de la implementación como por las coberturas; por el otro, por la obtención de datos de efectividad e impacto en vida real. Así lo pone de manifiesto el proyecto NIRSE-GAL desarrollado por la Dirección Xeral de Saude Pública de la Xunta de

Galicia y el Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS).

NIRSE-GAL, fue uno de los pioneros en el mundo en ilustrar casi en tiempo real la efectividad y el impacto en salud pública de Beyfortus® (nirsevimab), el primer y único anticuerpo monoclonal para proteger a todos los bebés del VRS. En el 43º congreso anual de la Sociedad Europea de Enfermedades Infecciosas Pediátricas (ESPID) celebrado en Bucarest se ha presentado la evidencia en vida real de esta temporada 2024-2025: por un lado, una reducción de las tasas de hospitalización por VRS en comparación con temporadas previas a la implementación del anticuerpo monoclonal de Sanofi, similar a la constatada en 2023-2024 y en los diferentes grupos de población de lactantes (tanto los nacidos antes como durante la temporada de máxima circulación del virus); y por el otro, una disminución de las consultas de atención primaria por bronquiolitis aguda respecto al 2022-2023. Además, también ha evidenciado que, en su segunda temporada de VRS, los menores inmunizados durante el 2023-2024 no han mostrado evidencia de infección compensatoria, enfermedad agravada o reemplazo por otros agentes respiratorios.

Los resultados agregados de la temporada 2023-2024 de NIRSE-GAL constataban una reducción de las hospitalizaciones por infecciones respiratorias de las vías bajas (IRVB o LRTI, en inglés) relacionadas con el VRS del 89,2% en la cohorte general (bebés nacidos antes de temporada) y en un 95,2% en la estacional (bebés nacidos durante la temporada), en comparación con los cinco anteriores otoño-inviernos sin estrategia de inmunización (excluyendo las temporadas de pandemia de la COVID). Además, confirman que durante el 2023-2024 hubo la circulación del virus fue elevada: los niños en su segunda temporada de VRS que no recibieron nirsevimab mostraron una tasa acumulada de hospitalización debido al virus significativamente mayor que la de temporadas anteriores ($p < 0,0001$).

El Dr. José Antonio Navarro explica: "Los datos y la evidencia en vida real que hemos obtenido en España constatan el cambio de paradigma en el abordaje e impacto del VRS con la llegada de nirsevimab. Varios estudios han demostrado una importante reducción de las hospitalizaciones y la carga ambulatoria, lo que implica una liberación significativa de los recursos sanitarios. Además, significan una drástica disminución del sufrimiento infantil y la angustia familiar asociada a estas hospitalizaciones. Cada ingreso evitado representa un bebé que no tiene que pasar por el trauma de una enfermedad grave y una familia que se ahorra días de preocupación y noches sin dormir."

Por su parte, Marta Díez, directora general de Vacunas para Sanofi Iberia, dice: "Es un orgullo para Sanofi España que nuestro país haya liderado la inmunización de bebés frente al VRS en todo el mundo como lo ha hecho. Primeramente, apostando por la innovación en salud pública con agilidad y compromiso por parte de todos los agentes implicados; las autoridades sanitarias, la comunidad médico-científica y nosotros, Sanofi. Y una vez puesta en marcha con éxito la primera campaña de inmunización frente al VRS para todos los lactantes, seguir trabajando codo con codo para recoger datos de la máxima calidad de la eficacia e impacto de nirsevimab en vida real, tal como se ha hecho con NIRSE-GAL. Pues, como compañía líder en la prevención de virus e infecciones respiratorias como el virus respiratorio sincitial o la gripe, estamos convencidos de que el análisis de la implementación de las soluciones preventivas es clave para que las decisiones de salud pública puedan ser lo más transformadoras posible."

Basándose en NIRSE-GAL, la Universidad de Chile ha desarrollado el estudio independiente NIRSE-CL. Éste ha analizado la efectividad e impacto de Beyfortus® a nivel nacional durante el invierno austral de 2024 y, tal como se compartió en ESPID 2025, ha constatado una importante reducción de mortalidad por complicaciones del VRS: de 13 en el año 2023 a 0 en 2024 con la implementación del anticuerpo monoclonal

de Sanofi. Asimismo, como en el caso del proyecto gallego, el chileno también ha evidenciado una prevención de hospitalizaciones por IRVB debido a virus respiratorio sincitial superior al 76% en bebés nacidos antes de la temporada y del 85% en nacidos durante los meses de mayor circulación del virus. NIRSE-CL incluyó a más de 145.000 lactantes, alrededor de la mitad nacidos antes de la temporada de frío.

Chile fue el primer país del hemisferio sur en implementar una estrategia de protección frente al VRS a todos los lactantes que se enfrentan a su primera temporada de VRS.

Seis meses de protección para todos los lactantes

Sanofi ha presentado nuevos datos del estudio clínico de fase IIIb HARMONIE, publicado en The Lancet Child & Adolescent Health, en el 43º congreso de la Sociedad Europea de Enfermedades Infecciosas Pediátricas.

Los resultados amplían el tiempo de protección de nirsevimab a seis meses para todos los lactantes, al demostrar que este innovador anticuerpo monoclonal redujo las hospitalizaciones por VRS en un 82,7%.

Fuente: IMMÉDICO. Disponible en https://acortar.link/U8hPF4

'Vaccine Safety Pyramid Scheme': FDA Approves Meningococcal Vaccine for Infants Without Placebo-Controlled Trials

Jun 9. The U.S. Food and Drug Administration (FDA) has expanded its approval of Sanofi Pasteur's MenQuadfi meningococcal vaccine to include infants as young as 6 weeks old.

> *"The FDA expanded approval of Sanofi's MenQuadfi, a meningococcal vaccine, to include infants as young as 6 weeks old, even though 5.3% of infants who participated in clinical trials experienced a serious adverse event. The FDA approved the drug based on trials that compared MenQuadfi to a similar, previously approved vaccine, not a placebo, in what attorney Aron Siri called a "vaccine safety pyramid scheme."*

The vaccine, designed to protect against meningococcal disease — meningitis and meningococcal septicemia — was previously recommended for children ages 2 and older.

According to the package insert, during the six months following the clinical trials, 5.3% of infants ages 6 weeks to 23 months who received the MenQuadfi shot experienced a serious adverse event.

The FDA defines a serious adverse event as a reaction that leads to hospitalization, death, disability, or that requires intervention to prevent permanent damage, or constitutes some other important medical event, such as breathing problems.

The types of serious adverse events ranged from cardiac arrest, respiratory distress and failure, febrile convulsions and seizures, to a wide range of infections, according to reports on the clinicaltrials.gov website.

Children's Health Defense (CHD) Senior Scientist Karl Jablonowski said the reports of infections and convulsions indicate immune system dysfunction that could be linked to vaccination.

'Good example of a vaccine safety pyramid scheme'

The FDA approved MenQuadfi for the younger age group because the agency considered adverse event rates to be similar to those found to be associated with GSK's Menveo, another approved meningococcal vaccine. In the case of Menveo, 3.6% of infants who got the shot experienced serious adverse events.

In other words, because Menveo is considered safe, and MenQuadifi's serious adverse event rates are only slightly higher than those of Menveo, the FDA can conclude that MenQuadifi is also safe despite the high rates of serious adverse events, according to attorney Aaron Siri.

However, Menveo was licensed based on a trial in which the vaccine's safety and efficacy were compared to yet another meningococcal vaccine, Menactra, Siri said.

He wrote:

"Menactra was licensed based on a trial in which Menomune was used as a control; and Menomune was not licensed based on a proper placebo-controlled trial. In fact — and this is mind twisting -– the package insert for Menomune lists the clinical trial for Menactra (in which Menomune was used as the control) as the basis for its safety."

Siri called this circular evidence for vaccine safety, where vaccine approvals are based on comparisons to other vaccines — none of which were ever safety tested against a true placebo — "a good example of a vaccine safety pyramid scheme."

The result is that clinical trials show the last two pneumococcal vaccines have 5.3% and 3.6% of infants experiencing serious adverse events, "and no one bats an eye. They grant licensure," Siri wrote.

He added:

"A pyramid scheme of safety, at the bottom of which there is no baseline on which safety is being judged. Just a get-it-licensed-to-profit shell game. FDA and pharma have nothing to lose here.

"We, as taxpayers, will pay for all of the harms suffered and, worst of all, the children who are injected and harmed and their families will really pay for the harms."

Lower age group means more doses in first 18 months of life

According to the package insert for MenQuadfi, younger infants receive more doses.

Adults and children ages 2 and up can receive a single shot. For infants who begin the vaccination course between ages 6-23 months, the vaccine is administered as a two-dose series.

As is typical with vaccines, the dose size — 0.5mL — doesn't vary from infant to adult.

However, for the newly expanded group of infants who begin the course of vaccination at age 6 weeks, the vaccine is approved as a four-dose series of shots administered during the first 18 months of life.

For this group, in addition to high rates of serious adverse events, there were also high rates of less serious side effects. For example, among infants ages 6 weeks through 34 months, 38.5-45.6% experienced tenderness, 12.5-19.5% experienced erythema, 27.3-42.1% cried abnormally, 7.8%-17.6% experienced fever and 3.5%-13.2% vomited.

The insert also warns that the Guillain-Barré syndrome has been linked to other similar pneumococcal vaccines and may be a potential risk.

Infants in the clinical trials received the pneumococcal vaccines at the same time that they received other vaccines, including diphtheria, tetanus pertussis, inactivated polio and Haemophilus influenzae type b vaccines, Prevnar 13 (a different pneumococcal vaccine), rotavirus vaccine, hepatitis B vaccines, MMRII vaccines and varicella vaccines and hepatitis A vaccines.

Similar to the MenQuadfi vaccine, many of the other vaccines are administered at ages 2 months, 4 months, 6 months and 15-18 months of age, or at some point before the child reaches 18 months.

Vaccine safety advocates have long called for vaccines to undergo safety testing in clinical trials against true inert placebos, rather than against other vaccines or placebos containing the same excipients (preservatives and adjuvants) in the vaccine being tested.

They argue that without true placebo testing, it's impossible to ascertain true risk profiles for the products, and that such comparative trials are considered the "gold standard" for evaluating all other pharmaceutical products.

The lack of adequate safety testing has also been a concern of Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr., who co-authored a book with CHD Chief Scientific Officer Brian Hooker on the published data comparing outcomes for vaccinated and unvaccinated people.

Kennedy announced earlier this year that all new vaccines will have to undergo placebo testing, a rule that would mark "a radical departure from past practices," an HHS spokesperson told The Washington Post.

HHS did not at the time indicate how the changes would be implemented, or what would be considered "new" vaccines.

Fuente: THE DEFENDER. Disponible en https://n9.cl/6s1w5r

Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate

Jun 12. Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), regardless of prior dengue exposure. Recruitment for the trial has begun, and the first participants are now enrolling in Singapore.

"Study will evaluate a single dose of V181 for the prevention of dengue disease caused by any of the four serotypes of the dengue virus regardless of previous exposure."

"Approximately half of the world's population live in areas with a risk for dengue, making it a serious public health threat," said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, global clinical development, Merck Research Laboratories. "The initiation of the MOBILIZE-1 study, the first Phase 3 trial in our clinical development program, marks a key milestone in our work to help address this widespread mosquito-borne disease. If successful, V181 could provide an important single-dose option for at risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe." Merck is committed to research and innovation that aims to help protect the millions of people at risk for dengue virus infection and is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is a significant health threat.

About MOBILIZE-1 (NCT07013487)

MOBILIZE-1, also known as V181-005, is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, immunogenicity and efficacy of V181, an investigational vaccine for the prevention of dengue disease. The study aims to enroll approximately 12,000 healthy individuals 2 to 17 years of age who will be randomized to receive either a single dose of V181 or placebo. The study is planned to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific region, including Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. The primary endpoints of the study are safety and efficacy of a single dose of V181 in preventing symptomatic virologically confirmed dengue (VCD) of any severity, due to any of the four dengue serotypes, regardless of prior dengue exposure. The key secondary efficacy endpoint is evaluating a single dose of V181 in preventing symptomatic VCD of any severity due to each of the four dengue serotypes, regardless of prior dengue exposure. Additional secondary endpoints include evaluating a single dose of V181 in preventing symptomatic VCD with warning signs, severe VCD and hospitalization.

About V181

V181 is a live attenuated quadrivalent vaccine currently being investigated for the prevention of dengue disease caused by any of the four dengue virus types (DENV-1, DENV-2, DENV-3, and DENV-4). V181 is designed to be a single-dose vaccination and is being studied in individuals to provide protection against dengue, including severe forms, whether the individuals have been previously infected with the dengue virus or had no prior infections.

About Dengue disease

Dengue disease is one of the fastest growing mosquito-borne diseases that affects not just the health but often the economic stability of communities across the globe. It is a rapidly emerging cause of serious and sometimes debilitating illness in tropical and subtropical countries. With approximately half of the world's population, or four billion people, at risk for dengue disease, it represents a critical public health challenge. Globally, around 105 million dengue viral infections occur annually, with approximately 50-60 million being symptomatic on average per year. While the majority of infections are uncomplicated, serious illness caused by dengue can be severe and lead to death (on average, ~4-11 million cases result in hospitalizations per year and there is an average annual incidence of ~29,000 dengue-related deaths worldwide). Symptoms of mild dengue fever may include a high fever, a rash and muscle and joint pain. Dengue fever might evolve to severe dengue, formerly known as dengue hemorrhagic fever, which can cause severe bleeding, a sudden drop in blood pressure, and in rare cases, death.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

Fuente: MERCK. Disponible en https://n9.cl/ukwdl

GSK concede la licencia de la vacuna candidata contra la Shigella a Bharat Biotech para su desarrollo continuo

12 jun. GSK anuncia que ha concedido la licencia de su vacuna candidata contra la Shigella, altSonflex, a Bharat Biotech International Limited (BBIL). El acuerdo allana el camino para el desarrollo continuo y la posible distribución de la vacuna en países de ingresos bajos y medios, donde la Shigella, la principal causa bacteriana de diarrea, supone una importante amenaza para la salud de los niños menores de cinco años.

El ensayo clínico de Fase I y el análisis estadístico provisional realizado hasta la fecha a partir de los ensayos de Fase II han demostrado resultados prometedores y han confirmado el cumplimiento de los criterios de éxito de inmunogenicidad preestablecidos. La vacuna candidata contra la Shigella utiliza la innovadora tecnología GMMA (módulos generalizados para antígenos de membrana), una novedosa plataforma descubierta y desarrollada por científicos del equipo de Salud Global de GSK que utiliza pequeñas partículas liberadas naturalmente por las bacterias, llamadas vesículas de membrana externa (OMV), para administrar antígenos que activan el sistema inmunitario. La tecnología GMMA es económica y escalable, lo que la hace ideal para producir vacunas asequibles para países de bajos ingresos, al tiempo que estimula de forma natural una fuerte respuesta inmunitaria, a menudo sin necesidad de adyuvantes, y ofrece versatilidad para combatir diversas enfermedades bacterianas, como la Shigella.

Thomas Breuer, director de Salud Global de GSK, ha afirmado «dado que los niños pequeños de los países de bajos ingresos se ven afectados de manera desproporcionada por la Shigella, el desarrollo de una vacuna de bajo coste es un objetivo importante para la salud pública mundial. Al no existir vacunas autorizadas ampliamente disponibles, el desarrollo de nuestra vacuna candidata contra la Shigella, que ha demostrado resultados prometedores en los ensayos clínicos, nos llena de orgullo. Estamos orgullosos de colaborar con Bharat Biotech, cuya experiencia en el desarrollo y suministro de vacunas para enfermedades infecciosas, especialmente como proveedor de confianza de Gavi, la Alianza para las Vacunas, y UNICEF, les posiciona para seguir avanzando en esta importante labor. Este acuerdo nos permite combinar nuestras fortalezas en ciencia, investigación y tecnología con la capacidad de Bharat Biotech para desarrollar y suministrar vacunas a gran escala, lo que podría prevenir enfermedades y salvar vidas en todo el mundo».

El urgente desafío que plantea el aumento de las bacterias entéricas resistentes a los antimicrobianos, incluida la Shigella, pone de relieve el amplio impacto que podría tener una vacuna contra la Shigella, más allá de ayudar a reducir las tasas de enfermedad y mortalidad. Tiene el potencial de reducir indirectamente el consumo de antibióticos y ayudar a combatir el aumento de la resistencia a los antimicrobianos (RAM).

Tras la transferencia de tecnología, GSK colaborará con BBIL en el diseño del ensayo de Fase III y apoyará los esfuerzos de BBIL para conseguir financiación externa. Esta colaboración se basa en la relación existente entre GSK y la empresa biotecnológica india, tras un acuerdo de transferencia de productos y licencia en 2021 para la primera vacuna contra la malaria del mundo, RTS,S.

Krishna Ella, presidenta ejecutiva de Bharat Biotech, ha expresado que «como líder del mercado de vacunas contra infecciones diarreicas, entre las que se incluyen el rotavirus, la fiebre tifoidea, la poliomielitis, la salmonela no tifoidea, el cólera y la paratifoidea, Bharat Biotech se enorgullece de colaborar con GSK con el objetivo de desarrollar una vacuna candidata contra la Shigella. La shigelosis sigue siendo un grave problema de salud pública, especialmente entre los niños menores de cinco años de los países de ingresos bajos y medios, donde el acceso a una intervención médica oportuna y eficaz puede ser limitado. La ausencia de una vacuna autorizada, junto con la creciente amenaza de la resistencia a los antimicrobianos, subraya la urgencia de desarrollar soluciones preventivas eficaces y asequibles. Bharat Biotech se compromete a aprovechar su experiencia en el desarrollo y la fabricación de vacunas para garantizar que, si tiene éxito, esta innovadora vacuna llegue a quienes más la necesitan. Este acuerdo de licencia refleja nuestro compromiso compartido con la equidad sanitaria mundial y nos posiciona para avanzar con altSonflex hasta la fase final de desarrollo y, si tiene éxito, a través de los procesos reglamentarios y la fabricación a gran escala. El uso de la tecnología GMMA representa un avance potencial en el diseño de vacunas que se alinea con nuestra misión de crear vacunas accesibles y basadas en la ciencia. Junto con GSK, nuestro objetivo es contribuir a la lucha contra la Shigella, prevenir el sufrimiento y ayudar a combatir el aumento de la resistencia a los antimicrobianos, que sigue amenazando millones de vidas en todo el mundo».

El anuncio subraya la ambición compartida de GSK y BBIL de adelantarse juntos a la enfermedad y lograr un impacto en la salud a gran escala a través de la ciencia de vanguardia y la colaboración.

Fuente: EL GLOBAL FARMA. Disponible en https://n9.cl/v6ov9n

Una nueva vacuna contra la enfermedad de Lyme demuestra ser eficaz en todos los grupos de edad

12 jun. Una vacuna en investigación para la enfermedad de Lyme, llamada VLA15, ha demostrado ser eficaz y segura en pacientes de entre 5 y 65 años de edad, generando respuestas inmunes particularmente robustas en niños y adolescentes.

Así se desprende de los resultados preliminares de un ensayo clínico de fase 2 que se está llevando a cabo en varios puntos de Estados Unidos en los que la patología es endémica, de los que ha dado cuenta un artículo publicado en la prestigiosa revista médica The Lancet Infectious Diseases.

Una vacuna para todas las edades

Concretamente, los investigadores que están desarrollando el suero probaron varios patrones vacunales en una población de 625 participantes que incluían niños, adolescentes y adultos con edades globalmente

comprendidas entre los 5 y los 65 años. A estas personas se les asignaron aleatoriamente regímenes de tres dosis, de dos dosis o de ninguna.

Posteriormente, se midió su respuesta inmune frente a la proteína superficial A (OspA) de la espiroqueta (un tipo de bacteria) causante de la enfermedad de Lyme a los siete y a los doce meses, y se recogieron reportes de cualquier efecto adverso local o sistémico que se produjese dentro de los siete días siguientes a la administración de alguna de las dosis.

De este modo, se comprobó que efectivamente la respuesta inmune era significativamente mayor en cualquiera de los grupos que había recibido alguna dosis de la vacuna, y especialmente en el que recibió tres dosis. También se observó que la inmunogenicidad del suero era mayor en los niños y en los adolescentes que en los adultos, tanto en el régimen de dos dosis como en el de tres.

Una respuesta inmune robusta, sobre todo en niños

La presencia de anticuerpos contra la proteína OspA se redujo entre el séptimo y el duodécimo mes, pero aún así se mantuvo por encima del nivel de base en los grupos vacunados.

También se produjeron más efectos secundarios en las personas que recibieron el suero, aunque ninguno de ellos fue grave, por lo que se consideró que la vacuna tiene un buen perfil de seguridad que la hace candidata de seguir probándose en humanos para conseguir una potencial aprobación en el futuro próximo.

En la práctica, este trabajo supone un avance importante en el desarrollo de una vacuna contra la borreliosis de Lyme como herramienta preventiva fundamental. Esto resulta especialmente prometedor y relevante en un contexto en el que esta enfermedad avanza cada vez más su incidencia en países como Estados Unidos o España.

Fuente: 20 Minutos. Salud. Disponible en https://n9.cl/jfowu

Nuevas vacunas para enfermedades emergentes: avances en el virus del Nipah

15 jun. Cada cierto tiempo el brote de una patología infecciosa estrangula el sistema sanitario de un país o amenaza su salud pública. Algunos de estos brotes, dado el carácter de globalización de la actual sociedad, saltan y se convierten en epidemias, e incluso en pandemias como ha ocurrido con la COVID-19. Las vacunas son herramientas de inmunización que ayudan a prevenir actualmente muchas infecciones que podrían suponer o supusieron un problema de salud pública: sarampión, poliomielitis, difteria, meningitis, herpes zóster, gripe o rotavirus, entre otras.

"El desarrollo de nuevas vacunas está tomando cada vez más peso para enfermedades que no contaban con una herramienta de inmunización. Oxford avanza en la lucha frente al Nipah "

También existen muchas patologías que todavía no cuentan con estas herramientas que salvan millones de vidas al año. La investigación en este punto está aumentando, con nuevas opciones para enfermedades que no cuentan con vacunas. De las 98 innovaciones en este campo que están actualmente en marcha, el 42% de candidatas está dirigida a enfermedades sin esta opción de inmunización, como recoge el *pipeline* de 2024 de *Vaccines Europe*.

Un ejemplo es el virus del Nipah, de la familia del sarampión. Este patógeno causó hace casi dos años un importante brote en la India, con dos fallecimientos. En los últimos años este virus de origen zoonótico, que se notificó por primera vez en Malasia en 1998, ha mostrado una alta tasa de mortalidad en los humanos

(40% – 75%), debido, en gran parte, a su manifestación con síntomas neurológicos como encefalitis o meningoencefalitis. Así, según datos de la Organización Mundial de Salud (OMS), desde entonces se han notificado 415 muertes de los 750 casos registrados.

> *"El virus Nipah es considerada "una enfermedad infecciosa de alto riesgo."*

Se transmite por murciélagos, los cuales conviven con dos mil millones de personas. Como señaló a este medio Octavio Arce, miembro de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y experto en virus emergentes y de altos riesgo por la Universidad Autónoma de Madrid, se trata de un patógeno que "no es tan contagioso como pudiera ser el SARS-CoV-2 o algunos otros virus que están más adaptados al humano", pero sí presenta una alta letalidad y solo cuenta con un tratamiento sintomático. De hecho, es considerada "una enfermedad infecciosa de alto riesgo".

EUROPA REFUERZA LA INVESTIGACIÓN EN NIPAH

La prevención es actualmente una de las líneas estratégicas que más se está desarrollando en este ámbito, con vacunas en distintas fases de estudio. Una de las primeras vacunas en ser testadas en humanos ha sido la desarrollada por la Universidad de Oxford. En enero de 2024 se conoció dicha autorización que ha supuesto un "hito muy importante en la identificación de una solución que podría prevenir la aparición de brotes locales y, al mismo tiempo, ayudar al mundo a prepararse para una futura pandemia global", señaló por entonces el profesor Brian Angus, investigador principal del ensayo y profesor de enfermedades infecciosas en el Centro de Medicina Tropical Clínica y Salud Global de la Universidad de Oxford.

> *"El reconocimiento de EMA PRIME a la vacuna candidata contra el virus Nipah de Oxford ayudará a acelerar el desarrollo de esta vacuna tan necesaria ."*

Recientemente, además, ha recibido la designación para el programa PRIority Medicines (PRIME) de la Agencia Europea de Medicamentos (EMA, por sus siglas en inglés), un reconocimiento que es la primera vez que recibe una institución académica de Reino Unido. "El apoyo adicional ofrecido por EMA PRIME se ha otorgado con base en datos preclínicos convincentes y evidencia clínica preliminar, y ayudará a acelerar el desarrollo y la aprobación regulatoria de la vacuna ChAdOx1 NipahB, que actualmente se encuentra en un ensayo clínico de fase I", explican desde la universidad. Desde la EMA han argumentado que dada la complejidad de un ensayo clínico con suficiente potencial, "es esencial una interacción regulatoria estrecha con el Grupo de Trabajo de Emergencia de la EMA para definir una vía sensata de generación de evidencia previa a la autorización".

El profesor Brian Angus, investigador jefe del Programa de Vacunas Nipah de Oxford en el Grupo de Vacunas de Oxford, ha incidido en que este apoyo regulatorio específico para nuestro programa de vacunas supone un gran impulso para la búsqueda de una solución a los brotes del virus Nipah. "Esperamos que los resultados de estos ensayos nos permitan proteger a algunas de las poblaciones con mayor riesgo, a la vez que ayudamos al mundo a evitar una futura pandemia global", ha explicado en un mensaje similar al del Dr. Kent Kester, Director Ejecutivo de Investigación y Desarrollo de Vacunas de la Coalición para las Innovaciones en Preparación para Epidemias (CEPI), iniciativa financiadora de los ensayos.

"El reconocimiento de PRIME a la vacuna candidata contra el virus Nipah de Oxford, respaldada por la CEPI,

ayudará a acelerar el desarrollo de esta vacuna tan necesaria, al facilitar una interacción más temprana y estrecha con los organismos reguladores, y representa un paso crucial para garantizar la protección de las personas contra futuros brotes mortales del virus", ha subayado el Dr. Kester.

Un importante paso pues, no en vano, como señala la EMA, "la enfermedad del virus Nipah en humanos se asocia con una morbilidad significativa y una alta tasa de mortalidad, con el consiguiente impacto en la salud pública. La creciente frecuencia de encuentros humanos con murciélagos frugívoros y su propagación a zonas densamente pobladas está ampliando las posibilidades de transmisión del virus Nipah, lo que aumenta su potencial de brote".

Fuente: ConSalud.es. Disponible en https://n9.cl/k8so1f

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2025/06/01"[Date - Publication] : "2025/06/16"[Date - Publication])) 919 records.

Viral Hepatitis.

Neuhoff BKS.Clin Obstet Gynecol. 2025 Jun 1;68(2):180-187. doi: 10.1097/GRF.0000000000000938. Epub 2025 Apr 18.PMID: 40247447

Preclinical Safety.

Wolff RK, Blanchard JD.J Aerosol Med Pulm Drug Deliv. 2025 Jun;38(3):136-144. doi: 10.1089/jamp.2025.52511.isam.PMID: 40445826

Vaccine hesitancy for allergist-immunologists.

Moser CA.Ann Allergy Asthma Immunol. 2025 Jun 9:S1081-1206(25)00285-6. doi: 10.1016/j.anai.2025.06.009. Online ahead of print.PMID: 40499649

Efficacy and safety of cancer vaccine therapy in malignant melanoma: a systematic review.

Seta T, Nakamura S, Oura M, Yokoyama K, Nishikawa Y, Hoshino N, Ninomiya K, Shimoi T, Hotta K, Nakayama T.Int J Clin Oncol. 2025 Jun;30(6):1080-1097. doi: 10.1007/s10147-025-02753-x. Epub 2025 May 6.PMID: 40329122

Therapeutic mRNA vaccine applications in oncology.

Elliott L, Foster T, Castillo P, Mendez-Gomez H, Sayour EJ.Mol Ther. 2025 Jun 4;33(6):2610-2618. doi: 10.1016/j.ymthe.2025.04.044. Epub 2025 May 6.PMID: 40336197

The advent of clinical self-amplifying RNA vaccines.

Casmil IC, Jin J, Won EJ, Huang C, Liao S, Cha-Molstad H, Blakney AK.Mol Ther. 2025 Jun 4;33(6):2565-2582. doi: 10.1016/j.ymthe.2025.03.060. Epub 2025 Apr 3.PMID: 40186353

2025: new infectious diseases and the re-emergence of vaccine-preventable infections.

Stevens D.Curr Opin Infect Dis. 2025 Jun 1;38(3):199-200. doi: 10.1097/QCO.0000000000001104. Epub 2025 May 1.PMID: 40304219

Mycobacterium tuberculosis Antigen Rv1471 Induces Innate Immune Memory and Adaptive Immunity Against Infection.

Huang X, Wu J, Xu J, Wang H, Chen Z, Fan XY, Hu Z.J Infect Dis. 2025 Jun 2;231(5):1127-1140. doi: 10.1093/infdis/jiae572.PMID: 39541425

Identification of a seasonal influenza vaccine-induced broadly protective neuraminidase antibody.

Madsen A, Okba NMA, Pholcharee T, Matz HC, Lv H, Ibanez Trullen M, Zhou JQ, Turner JS, Schmitz AJ, Han F, Horvath SC, Malladi SK, Krammer F, Wu NC, Ellebedy AH.J Exp Med. 2025 Jun 2;222(6):e20241930. doi: 10.1084/jem.20241930. Epub 2025 Apr 3.PMID: 40178595

Challenges in developing new tuberculosis vaccines.

Sadigurschi G, Kuschnir MCC, Dos Santos EAP, da Silva BRA, Marques CMC, de Andrade RC, Vianna CM, de Barros DG, Mazzi MT, Lago EA, Dos Santos EM, Maia MLS.Mem Inst Oswaldo Cruz. 2025 Jun 9;120:e240236. doi: 10.1590/0074-02760240236. eCollection 2025.PMID: 40498907

What's Old Is New Again: Measles.

Naureckas Li C, Kaplan SL, Edwards KM, Marshall GS, Parker S, Mary Healy C.Pediatrics. 2025 Jun 1;155(6):e2025071332. doi: 10.1542/peds.2025-071332.PMID: 40211105

Bibliometrics analysis and knowledge mapping of pertussis vaccine research: trends from 1994 to 2023.

Tan C, Xiao Y, Chen S, Liu T, Zhou J, Zhang S, Hu Y, Zhou J, She Z, Tian B, Wu A, Li C.Infection. 2025 Jun;53(3):1001-1012. doi: 10.1007/s15010-024-02414-7. Epub 2024 Oct 17.PMID: 39417957

Flagellins as Vaccine Adjuvants and Cancer Immunotherapy: Recent Advances and Future Prospects.

Talukder A, Rahman MM, Rahi MS, Pountney DL, Wei MQ.Immunology. 2025 Jun 10. doi: 10.1111/imm.70001. Online ahead of print.PMID: 40491306

Across continents and pandemics: Vaccine science for global health.

Kim J.Hum Vaccin Immunother. 2025 Dec;21(1):2511356. doi: 10.1080/21645515.2025.2511356. Epub 2025 Jun 11.PMID: 40498473

Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery.

Suzuki Y, Yakuwa M, Sato M, Samaridou E, Beck-Broichsitter M, Maeki M, Tokeshi M, Yamada Y, Harashima H, Sato Y.J Control Release. 2025 Jun 10;382:113687. doi: 10.1016/j.jconrel.2025.113687. Epub 2025 Apr 3.PMID: 40187650

Molecular characterization of porcine epidemic diarrhea virus in Sichuan from 2023 to 2024.

Xie B, Yan W, Yang X, Fan H.Microb Pathog. 2025 Jun;203:107486. doi: 10.1016/j.micpath.2025.107486. Epub 2025 Mar 15.PMID: 40097028

Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice.

Kwon DI, Mao T, Israelow B, Santos Guedes de Sá K, Dong H, Iwasaki A.Nat Immunol. 2025 Jun;26(6):908-919. doi: 10.1038/s41590-025-02156-0. Epub 2025 May 13.PMID: 40360777

CRISPR-Cas: a game-changer in vaccine development and the fight against viral infections.

Yang F, Aliyari S, Zhu Z, Zheng H, Cheng G, Zhang S.Trends Microbiol. 2025 Jun;33(6):650-664. doi: 10.1016/j.tim.2025.02.006. Epub 2025 Mar 10.PMID: 40069074

Encapsulin nanoparticle-conjugated p54 protein boosts immune responses against African swine fever virus.

Zhang Y, Ru Y, Zhao L, Hao R, Yang Y, Shen C, Shi Z, Zheng H.Int J Biol Macromol. 2025 Jun;311(Pt 3):143912. doi: 10.1016/j.ijbiomac.2025.143912. Epub 2025 May 3.PMID: 40324494

Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review.

Houlder EL, da Silva LF, van Diepen A, Amaral MS, Wilson RA, Hokke CH, Roestenberg M, Bakker WAM.PLoS Negl Trop Dis. 2025 Jun 2;19(6):e0012956. doi: 10.1371/journal.pntd.0012956. eCollection 2025 Jun.PMID: 40455825

Lipid nanoparticles encapsulating both adjuvant and antigen mRNA improve influenza immune cross-protection in mice.

Wei L, Zhu W, Dong C, Kim JK, Ma Y, Denning TL, Kang SM, Wang BZ.Biomaterials. 2025 Jun;317:123039. doi: 10.1016/j.biomaterials.2024.123039. Epub 2024 Dec 22.PMID: 39724768

Bioprofiling and vaccine development for Zika virus.

Shi H, Feng S, Naeem A, Huang B, Tan W, Zheng L, Liang XJ, Yang M, Huang Y.Sci China Life Sci. 2025 Jun 3. doi: 10.1007/s11427-024-2851-4. Online ahead of print.PMID: 40471494

The mRNA vaccine expressing fused structural protein of PRRSV protects piglets against PRRSV challenge.

Mou C, Zhao X, Zhuo C, He Q, Xu M, Shi K, Han T, Xu S, Chen Z.Vet Microbiol. 2025 Jun;305:110534. doi: 10.1016/j.vetmic.2025.110534. Epub 2025 Apr 25.PMID: 40318244

Controlled Human Infection Studies Accelerate Vaccine Development.

Laurens MB.J Infect Dis. 2025 Jun 2;231(5):1112-1116. doi: 10.1093/infdis/jiaf053.PMID: 39879637

Serological screening and Vaccine Update in a cohort of Multiple Sclerosis Patients as a strategy to prevent infection reactivation during immunosuppressant therapy.

Reis GFB, de Castro ACAF, Berezin EN.Mult Scler Relat Disord. 2025 Jun;98:106416. doi: 10.1016/j.msard.2025.106416. Epub 2025 Apr 4.PMID: 40220724

A jab is not a vaccine; it's a 'shot'.

Demjén Z, Elena Semino, Gleave R.Public Health. 2025 Jun 9;245:105815. doi: 10.1016/j.puhe.2025.105815. Online ahead of print.PMID: 40494211

Vaccine Backsliding Will Ripple Around The Globe.

Torbay R.Health Aff (Millwood). 2025 Jun;44(6):768. doi: 10.1377/hlthaff.2025.00477.PMID: 40456035

Systematic mapping review of preclinical and clinical studies of Staphylococcus aureus vaccines.

Lapeyre R, Rezk N, McClean S, Moore AC.Vaccine. 2025 Jun 7;61:127333. doi: 10.1016/j.vaccine.2025.127333. Online ahead of print.PMID: 40483883

A Lyme disease mRNA vaccine targeting Borrelia burgdorferi OspA induces strong immune responses and prevents transmission in mice.

Tahir D, Geolier V, Bruant H, Le Flèche-Matéos A, Mallet A, Varloud M, Civat C, Girerd-Chambaz Y, Montano S, Pion C, Ferquel E, Pavot V, Choumet V.Mol Ther Nucleic Acids. 2025 Mar 12;36(2):102514. doi: 10.1016/j.omtn.2025.102514. eCollection 2025 Jun 10.PMID: 40226328

Computationally designed proteins mimic antibody immune evasion in viral evolution.

Youssef N, Gurev S, Ghantous F, Brock KP, Jaimes JA, Thadani NN, Dauphin A, Sherman AC, Yurkovetskiy L, Soto D, Estanboulieh R, Kotzen B, Notin P, Kollasch AW, Cohen AA, Dross SE, Erasmus J, Fuller DH, Bjorkman PJ, Lemieux JE, Luban J, Seaman MS, Marks DS.Immunity. 2025 Jun 10;58(6):1411-1421.e6. doi: 10.1016/j.immuni.2025.04.015. Epub 2025 May 8.PMID: 40345199

On the adjuvanticity of hyaluronan: The case of a SARS-CoV-2 vaccine.

Dalla Pietà A, Genova B, Penna A, Sinigaglia A, Vogiatzis S, Barzon L, Pagliari M, Bonfante F, Torrigiani F, Sofia T, Verin R, Tosi A, Carpanese D, Sommaggio R, Barbieri V, Dalla Santa S, Zuccolotto G, Grigoletto A, Pasut G, Rosato A.J Control Release. 2025 Jun 10;382:113674. doi: 10.1016/j.jconrel.2025.113674. Epub 2025 Mar 29.PMID: 40164435

Genetic adjuvants: A paradigm shift in vaccine development and immune modulation.

Spunde K, Korotkaja K, Sominskaya I, Zajakina A.Mol Ther Nucleic Acids. 2025 Apr 8;36(2):102536. doi: 10.1016/j.omtn.2025.102536. eCollection 2025 Jun 10.PMID: 40336572

Addressing influenza in Bangladesh: closing evidence and policy gaps with strategic interventions.

Hassan MZ, Haider S, Aleem MA, Islam MA, Shuvo TA, Bhuiya S, Rahman M, Rahman M, Shirin T, Chowdhury F.Lancet Reg Health Southeast Asia. 2025 May 19;37:100592. doi: 10.1016/j.lansea.2025.100592. eCollection 2025 Jun.PMID: 40496144

Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.

Sasaki E, Hamaguchi I, Hasegawa H, Takahashi Y.Vaccine. 2025 Jun 11;58:127267. doi: 10.1016/j.vaccine.2025.127267. Epub 2025 May 17.PMID: 40383081

Bioinspired Membrane-Based Cancer Vaccines for Immunotherapy: Progress and Perspectives.

Miao Y, Ge J, Zheng L, Liu G.Small. 2025 Jun;21(22):e2412679. doi: 10.1002/smll.202412679. Epub 2025 Apr 21.PMID: 40255117

HPV Vaccine Uptake and its Predictors among Adolescent Girls and Young Women Living with HIV-in Central Uganda.

Kabarambi A, Kizito S, Hunleth J, Silver MI, Niyonzima N, Ssewamala F.AIDS Behav. 2025 Jun;29(6):1859-1865. doi: 10.1007/s10461-025-04654-6. Epub 2025 Mar 10.PMID: 40063202

Robust Multiepitope Vaccine from Glycoproteins Against Human Metapneumovirus Genotypes A2a, A2b, and A2c by Utilizing Immunoinformatics and Reverse Vaccinology Approaches.

Khatrawi EM, Luqman Ali S, Ali SY, Abduldayeva A, Mugibel MAA.Viral Immunol. 2025 Jun;38(5):157-171. doi: 10.1089/vim.2025.0021. Epub 2025 May 22.PMID: 40401430

Biochemical and hematological reference intervals in rhesus and cynomolgus macaques and implications for vaccine and drug development.

Yan X, Arcoverde Cerveira R, Ols S, Lenart K, Hellgren F, Miranda M, Engstrand O, Reinhardt A, Eriksson B, Loré K.Lab Anim (NY). 2025 Jun;54(6):141-155. doi: 10.1038/s41684-025-01547-y. Epub 2025 May 16.PMID: 40379874

Individual- and population-associated heterogeneity in vaccine-induced immune responses. The impact of inflammatory status and diabetic comorbidity.

Joosten SA.Semin Immunol. 2025 Jun;78:101964. doi: 10.1016/j.smim.2025.101964. Epub 2025 May 9.PMID: 40347921

Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.

Bajema KL, Yan L, Li Y, Argraves S, Rajeevan N, Fox A, Vergun R, Berry K, Bui D, Huang Y, Lin HM, Hynes DM, Lucero-Obusan C, Schirmer P, Cunningham F, Huang GD, Aslan M, Ioannou GN.Lancet Infect Dis. 2025 Jun;25(6):625-633. doi: 10.1016/S1473-3099(24)00796-5. Epub 2025 Jan 20.PMID: 39848264

Immunogenicity and preclinical efficacy characterization of ShecVax, a combined vaccine against Shigella and enterotoxigenic Escherichia coli.

Li S, Upadhyay I, Seo H, Vakamalla SSR, Madhwal A, Sack DA, Zhang W.Infect Immun. 2025 Jun 10;93(6):e0000425. doi: 10.1128/iai.00004-25. Epub 2025 Apr 10.PMID: 40208039

Sociodemographic and Occupational Factors Associated With Coronavirus Disease 2019 Vaccine and Influenza Vaccine Uptake Among Healthcare Workers, in Albania, 2022-2023: A Multicenter Study.

Xhaferi A, Bino S, Daja R, Vasili A, Sulo J, Mebonia N, Ndreu E, Nika M, Jani N, Dabaj E, Sustarova N, Moçi A, Toçi D, Fico A, Tomini E, Robinson S, Jorgensen P, Katz MA.Clin Infect Dis. 2025 Jun 3:ciaf202. doi: 10.1093/cid/ciaf202. Online ahead of print.PMID: 40459287

Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges.

Zheng L, Feng H.Animal Model Exp Med. 2025 Jun 5. doi: 10.1002/ame2.70018. Online ahead of print.PMID: 40469015

Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth.

Jasset OJ, Lopez Zapana PA, Bahadir Z, Shook L, Dennis M, Gilbert E, Liu ZA, Yinger RV, Bald C, Bradford CG, Silfen AH, Klein SL, Pekosz A, Permar S, Konnikova L, Yonker LM, Lauffenburger D, Nelson A, Elovitz MA, Edlow AG.Am J Obstet Gynecol. 2025 Jun;232(6):554.e1-554.e15. doi: 10.1016/j.ajog.2024.10.053. Epub 2024 Nov 7.PMID: 39515450

Vaccine effectiveness of inactivated and mRNA COVID-19 vaccine platform during Delta and Omicron wave in Jakarta, Indonesia: A test-negative case-control study.

Burhan E, Azzumar F, Sinuraya FAG, Prasetyo S, Gayatri D, Ariawan I, Rakasiwi MID, Afladhia HL, Ilham AF, Akbar I, Wiyarta E.PLoS One. 2025 Jun 9;20(6):e0320779. doi: 10.1371/journal.pone.0320779. eCollection 2025.PMID: 40489510

Iterative selection of lipid nanoparticle vaccine adjuvants for rapid elicitation of tumoricidal CD8+ T cells.

Luo Y, Zhou S, Song Y, Huang WC, Wilding GE, Jablonski J, Quinn B, Lovell JF.Bioact Mater. 2025 Feb 18;48:189-199. doi: 10.1016/j.bioactmat.2025.01.028. eCollection 2025 Jun.PMID: 40046011

Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines.

Obeng RC, Escobar DJ, Vadasz B, Zheng W, Ju JY, Booth AL, Yang GY, Al Diffalha S, Dhall D, Westerhoff M, Xue Y.Arch Pathol Lab Med. 2025 Jun 1;149(6):556-560. doi: 10.5858/arpa.2024-0095-OA.PMID: 39246098

Familial Educational Factors and COVID-19 Vaccine Beliefs Among Mexican-Origin Youth.

Zhang T, Wen W, Coulter KM, Tse HW, Kim SY.J Immigr Minor Health. 2025 Jun;27(3):465-471. doi: 10.1007/s10903-025-01678-x. Epub 2025 Apr 1.PMID: 40167869

Enhancing faith and interfaith based facilitators and reducing related barriers to enhance vaccine acceptance: a qualitative study.

Garfield S, Ali F, Murdan S.Vaccine. 2025 Jun 6;61:127348. doi: 10.1016/j.vaccine.2025.127348. Online ahead of print.PMID: 40482459

Understanding RSV Vaccine Hesitancy: Exploring Decision-Making Pathways.

Kim N, Seo J, Yoon D, Kim JN.Health Commun. 2025 Jun 5:1-16. doi: 10.1080/10410236.2025.2504109. Online ahead of print.PMID: 40474390

COVID-19 vaccine safety studies among special populations: A systematic review and meta-analysis of 120 observational studies and randomized clinical trials.

Mohammadi S, Sisay MM, Saraswati PW, Osman AK, Zuithoff NPA, Weibel D, Sturkenboom M, Ahmadizar F.Vaccine. 2025 Jun 4;61:127342. doi: 10.1016/j.vaccine.2025.127342. Online ahead of print.PMID: 40472669

Erratum to "Safety and immunogenicity of the measles-mumps-rubella vaccine in immunocompromised children with inflammatory bowel disease, or after liver transplantation: An observational study" [Vaccine 59 (2025) 127288].

Keutler A, Lainka E, Hudert C, Bufler P, Almanzar G, Hick S, Prelog M, Speth F, Posovszky C.Vaccine. 2025 Jun 9;61:127357. doi: 10.1016/j.vaccine.2025.127357. Online ahead of print.PMID: 40494227

Trust and Trustworthiness: Considerations for COVID-19 Vaccine Receipt in the Chicago Metropolitan Area.

Bishop-Royse J, Gutierrez-Kapheim M, Silva A, Lomahan S, Jindal M, Krogen M, Vu M, Martin M.J Community Health. 2025 Jun;50(3):395-405. doi: 10.1007/s10900-024-01424-8. Epub 2024 Dec 16.PMID: 39681790

Metabolomic Profiling of Leukemic Hematopoiesis: Effects of BNT162b2 mRNA COVID-19 Vaccine Administration.

Erdoğdu B, Kaplan O, Fidan BB, Çelebier M, Malkan ÜY, Haznedaroglu IC.Curr Mol Med. 2025 Jun 3. doi: 10.2174/0115665240361878250601074746. Online ahead of print.PMID: 40464175

Interim estimates of 2024-2025 COVID-19 vaccine effectiveness among adults aged 18 years-VISION and IVY networks, September 2024 to January 2025.

Pereira MR.Am J Transplant. 2025 Jun;25(6):1148. doi: 10.1016/j.ajt.2025.03.026. Epub 2025 Apr 1.PMID: 40180183

Fake news, misinformation, vaccine hesitancy and the role of community engagement in COVID-19 vaccine acceptance in Southern Ghana.

Kuatewo M, Ebelin W, Doegah PT, Aberese-Ako M, Lissah S, Kpordorlor AG, Kpodo L, Djokoto S, Ansah E.PLoS One. 2025 Jun 10;20(6):e0316969. doi: 10.1371/journal.pone.0316969. eCollection 2025.PMID: 40493632

Glucocorticoid Dosing and Implications for Vaccination: Evolution of Global Definitions.

Wang X, Patel C, Giles ML, Burns P, Macartney K, Teh B, Williams PC.Clin Infect Dis. 2025 Jun 4;80(5):998-1004. doi: 10.1093/cid/ciae613.PMID: 39692483

Progress of Immune-Inducible Biomaterials for Post-Ablation Cancers.

Zhao S, Zhang Z, Wu X, Chen Y, Li W, Bao J, Zhang X, Chen B.Adv Healthc Mater. 2025 Jun 9:e2500785. doi: 10.1002/adhm.202500785. Online ahead of print.PMID: 40489192

HPV Vaccination Knowledge, Attitudes, and Behaviors Among Clinic Teams in North Texas.

Thompson EL, Griner SB, Akpan IN, Maness SB, Meadows RJ, Fulda KG, Cano ME, Barnett TE.J Cancer Educ. 2025 Jun 5. doi: 10.1007/s13187-025-02659-2. Online ahead of print.PMID: 40473919

Pharmacovigilance analysis of spondyloarthritis following HPV vaccination based on the VAERS database.

Yang N, Di J, Feng H.Sci Rep. 2025 Jun 6;15(1):20023. doi: 10.1038/s41598-025-05753-z.PMID: 40481254

Understanding COVID-19 vaccine hesitancy during parenthood in British Columbia.

Halonen A, Fan HSL, Masina S, Chooniedass R, Keys E, Tarrant M.Vaccine. 2025 Jun 3;61:127305. doi: 10.1016/j.vaccine.2025.127305. Online ahead of print.PMID: 40466483

Association Between Medical Debt and Vaccine Uptake in the USA, 2021-2022.

Himmelstein KEW, Mohareb AM.J Gen Intern Med. 2025 Jun;40(8):1851-1858. doi: 10.1007/s11606-024-09183-x. Epub 2024 Nov 5.PMID: 39500843

Global and Regional Burden of Vaccine-Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data.

Lee JE, Jo H, Cho H, Oh J, Jeong YD, Lee S, Park J, Kim HJ, Son Y, Kim S, Lee H, Jacob L, Pizzol D, Woo HG, Hwang J, Yon DK.J Med Virol. 2025 Jun;97(6):e70408. doi: 10.1002/jmv.70408.PMID: 40454841

Unreliable Vaccine Information and the Erosion of Science.

Jacobs JW, Booth GS.JAMA. 2025 Jun 10;333(22):1947-1948. doi: 10.1001/jama.2025.5723.PMID: 40202831

A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi (MENACWY-TT).

Dinleyici EC, Ciftci E, Somer A, Yilmaz D, Tezer H.Hum Vaccin Immunother. 2025 Dec;21(1):2516949. doi: 10.1080/21645515.2025.2516949. Epub 2025 Jun 10.PMID: 40493501

Future immunisation strategies to prevent Streptococcus pneumoniae infections in children and adults.

Ramos B, Vadlamudi NK, Han C, Sadarangani M.Lancet Infect Dis. 2025 Jun;25(6):e330-e344. doi: 10.1016/S1473-3099(24)00740-0. Epub 2025 Mar 17.PMID: 40112854

Bridging the vaccine divide.

Ndembi N, Mutesa L, Muvunyi CM, Kim JH.Nat Med. 2025 Jun 2. doi: 10.1038/s41591-025-03728-1. Online ahead of print.PMID: 40456911

Structural insights from vaccine candidates for EV-D68.

Cheng J, Krug PW, Lei H, Moss DL, Lang ZC, Morton AJ, Shen CH, Pletnev S, Huang RK, Pierson TC, Zhou T, Ruckwardt TJ, Kwong PD.Commun Biol. 2025 Jun 4;8(1):860. doi: 10.1038/s42003-025-08253-y.PMID: 40467847

Role of malaria exposure and off-target responses on RTS,S/AS02(A) vaccine immunogenicity and protection in Mozambican children.

Fuentes E, Jairoce C, Macià D, Mayer L, Torres-Yaguana JP, Vidal M, Santano R, Narum DL, Cavanagh D, Gamain B, Coppel RL, Beeson JG, Dutta S, Sacarlal J, Aguilar R, Moncunill G, Dobaño C.NPJ Vaccines. 2025 Jun 6;10(1):116. doi: 10.1038/s41541-025-01167-0.PMID: 40473700

Patterns and Correlates of Utilization of Mental Health Services, Distress, and Flourishing Among Academic Medical Trainees and Faculty Throughout the COVID Pandemic and Beyond.

Soller M, Moffit M, Kesserwani C, Ladd B.Acad Psychiatry. 2025 Jun;49(3):248-253. doi: 10.1007/s40596-025-02139-1. Epub 2025 Apr 14.PMID: 40229637

Does Policy Uncertainty Boost Vaccine Hesitancy? Political Controversy, the FDA, and COVID-19 Vaccine Hesitancy in Fall 2020.

Carpenter D, Dardet ME, Bhaskar A, Rand LZ, Feldman WB, Kesselheim AS.J Health Polit Policy Law. 2025 Jun 1;50(3):397-437. doi: 10.1215/03616878-11670184.PMID: 39545681

Feasibility and Acceptability of Recommending HPV Vaccine at Ages 9-10 Years.

Tietbohl CK, Gurfinkel D, Duran D, Saville A, Clark E, O'Leary S, Albertin C, Beaty B, Vangala S, Szilagyi PG, Kempe A.Pediatrics. 2025 Jun 2:e2024069625. doi: 10.1542/peds.2024-069625. Online ahead of print.PMID: 40451241

Immunological responses against bovine viral diarrhoea virus types 1 and 2 after administration of a commercial subunit vaccine measured by ELISA and serum neutralisation on serum and milk samples.

Montbrau C, Gibert M, Taberner E, Tapiolas M, Teixeira R, Prenafeta A.Vet Rec Open. 2025 Mar 6;12(1):e70006. doi: 10.1002/vro2.70006. eCollection 2025 Jun.PMID: 40051772

Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review.

Harper DM, Navarro-Alonso JA, Bosch FX, Paavonen J, Stanley M, Sasieni P, Yébenes M, Martínez-Martínez N, Rodriguez Á, García A, Martín-Gomez L, Vallejo-Aparicio L, Carrión H, Ruiz García Y.Hum Vaccin Immunother. 2025 Dec;21(1):2497608. doi: 10.1080/21645515.2025.2497608. Epub 2025 Jun 9.PMID: 40485552

DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets.

Bhojnagarwala PS, Jose J, Zhao S, Weiner DB.Mol Ther. 2025 Jun 4;33(6):2719-2739. doi: 10.1016/j.ymthe.2025.04.008. Epub 2025 Apr 9.PMID: 40211538

Control measures for neglected tropical diseases: vaccine updates.

Chavda VP, Vuppu S, Mishra T, Sharma N, Kamaraj S, Mishra S, Sureshbhai B, Matsoukas J, Apostolopoulos V.Expert Rev Vaccines. 2025 Dec;24(1):535-555. doi: 10.1080/14760584.2025.2517712. Epub 2025 Jun 14.PMID: 40485377

Corrigendum to "Human papillomavirus awareness, vaccination rate, and sociodemographic covariates of vaccination status in a low-income country: A cross-sectional study in the rural Busoga region of Uganda" [Vaccine 53 (2025) 127089].

Einarson TA, Musana E, Balonde J, Lorentzen KB, Kallestrup R, Juncker M, Damoi JO, Nakami S, Kallestrup P.Vaccine. 2025 Jun 11;58:127204. doi: 10.1016/j.vaccine.2025.127204. Epub 2025 May 16.PMID: 40381514

Information on Measles, Mumps and Rubella Vaccine in the Copenhagen School Health Records Register.

Altindag O, Andersen M, Baker JL, Greve J, Tekin E.Scand J Public Health. 2025 Jun;53(4):383-390. doi: 10.1177/14034948241247882. Epub 2024 Apr 28.PMID: 38679814

Real-world safety profile of live attenuated Japanese encephalitis vaccine before and after the vaccine administration law.

Zhang C, Liu Y, Luo X, Han L, Shen J.PLoS One. 2025 Jun 16;20(6):e0326257. doi: 10.1371/journal.pone.0326257. eCollection 2025.PMID: 40522977

Comparison between the safety of the HPV vaccine versus placebo: a systematic review and meta-analysis of randomized clinical trials.

Santos SAD, Sato MY, Basilio PHG, Pereira ME, Julião RC, Arruda NDC, Silva DPD, Oliveira CS, Costa-Junior VHS, Guiloski IC.J Pediatr (Rio J). 2025 Jun 5:S0021-7557(25)00089-0. doi: 10.1016/j.jped.2025.04.009. Online ahead of print.PMID: 40425051

Trends in co-administration of adult vaccinations in the US retail pharmacy setting.

Agrawal N, Yehoshua A, Vietri JT, Hu T, Pond T, Tort MJ, Yang J, Welch V, Boikos C, Deng S, Zheng H, Goswami A, Sharma M, Sato R.Expert Rev Vaccines. 2025 Dec;24(1):470-478. doi: 10.1080/14760584.2025.2514517. Epub 2025 Jun 5.PMID: 40455419

Biophysical fitness landscape design traps viral evolution.

Mohanty V, Shakhnovich EI.bioRxiv [Preprint]. 2025 Jun 10:2025.03.30.646233. doi: 10.1101/2025.03.30.646233.PMID: 40236159

First case of lupus induced by the Shingrix vaccine: a case report and literature review.

Arévalo-Cañas C, Arévalo-Serrano J, de Mon-Soto MÁ.Clin Rheumatol. 2025 Jun 11. doi: 10.1007/s10067-025-07529-2. Online ahead of print.PMID: 40500571

Polygenic prediction of cellular immune responses to mumps vaccine.

Coombes BJ, Ovsyannikova IG, Schaid DJ, Warner ND, Poland GA, Kennedy RB.Genes Immun. 2025 Jun 10. doi: 10.1038/s41435-025-00335-5. Online ahead of print.PMID: 40494895

Human papillomavirus vaccine administration opportunities at well visits in adolescents.

Saxena K, Ai L, Martino A, Mohamed AFS, Wang D, Zheng Y, Oliver K.BMC Public Health. 2025 Jun 4;25(1):2084. doi: 10.1186/s12889-025-23235-9.PMID: 40468233

Emerging Thrombotic Disorders Associated with Virus-Based Innovative Therapies: From VITT to AAV Gene Therapy-Related Thrombotic Microangiopathy.

Benemei S, Gatto F, Marcucci R, Gresele P.Thromb Haemost. 2025 Jun;125(6):513-522. doi: 10.1055/a-2413-4345. Epub 2024 Sep 11.PMID: 39260400

Efficacy of human papillomavirus vaccines in the prevention of male genital diseases: a systematic review.

Kardoust Parizi M, Singla N, Matsukawa A, Tsuboi I, Mancon S, Miszczyk M, Chlosta P, Shariat SF.BJU Int. 2025 Jun;135(6):902-907. doi: 10.1111/bju.16692. Epub 2025 Mar 11.PMID: 40070078

Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women.

Lupton D, Whitten T, Tay AK, Beek K, Green M, Hassoun F, Moussa B, Silove D, Rees S.Vaccine. 2025 Jun 11;58:127251. doi: 10.1016/j.vaccine.2025.127251. Epub 2025 May 19.PMID: 40394778

Vaccine wastage rates and attributed factors in rural and urban areas in Uganda: Case of Mukono and Kalungu districts.

Ninsiima M, Muhoozi M, Luzze H, Kasasa S.PLOS Glob Public Health. 2025 Jun 10;5(6):e0003745. doi: 10.1371/journal.pgph.0003745. eCollection 2025.PMID: 40493663

Melanoma immunotherapy by nanosphere-vaccine elicited CD4+ and CD8+ T-cell response for tumor regression.

Javvaji K, Vangala V, Sayana SB, Maturi B, Bhamidipati K, Brunt KR, Misra S, Kandimalla R, Puvvada N.Nanomedicine. 2025 Jun;66:102817. doi: 10.1016/j.nano.2025.102817. Epub 2025 Apr 5.PMID: 40194752

Long-term Response to SARS-CoV-2 mRNA Vaccine in Adolescents.

Han MS, Choi S, Yoon Y, Kim YK, Cho HK, Yun KW, Song SH, Ahn B, Kim YK, Choi SH, Choe YJ, Lim H, Choi EB, Kim K, Hyeon S, Lee S, Na YJ, Kim BC, Lee YK, Choi EH, Ahn S, Lee H.Pediatr Infect Dis J. 2025 Jun 1;44(6):550-556. doi: 10.1097/INF.0000000000004709. Epub 2025 Jan 28.PMID: 39889733

Transforming trade for vaccine equity: Policy gaps and barriers.

Pepperrell T, Koivusalo M, Grant L, McCallum A.PLOS Glob Public Health. 2025 Jun 16;5(6):e0004012. doi: 10.1371/journal.pgph.0004012. eCollection 2025.PMID: 40523010

Advances in transmission-blocking vaccines against *Plasmodium falciparum* and *Plasmodium vivax*.

Tachibana M, Takashima E, Torii M, Wu Y, Sattabongkot J, Tsuboi T.Expert Rev Vaccines. 2025 Jun 9. doi: 10.1080/14760584.2025.2517720. Online ahead of print.PMID: 40488614

Computer Integrated Dominant Epitopes Evoke Protective Immune Response Against Streptococcus pneumoniae.

Chandpa HH, Naskar S, Meena J.Immunology. 2025 Jun;175(2):180-199. doi: 10.1111/imm.13920. Epub 2025 Mar 8.PMID: 40056072

Central American fathers' perspectives on HPV vaccination: A qualitative study conducted in the United States.

Nogueira DL, Delgado D, Moreno VA, Valdez MJ, Lucero D, Nieto AH, Rodriguez-Cruz N, Lindsay AC.Glob Public Health. 2025 Dec;20(1):2516696. doi: 10.1080/17441692.2025.2516696. Epub 2025 Jun 9.PMID: 40488415

Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials.

Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Ackerman ME, Weiner JA, Modlin J, Arita M, Bandyopadhyay AS, Gast C, Sáez-Llorens X, Rüttimann RW, Van Damme P, De Coster I, Wright PF.Lancet Microbe. 2025 Jun;6(6):101028. doi: 10.1016/j.lanmic.2024.101028. Epub 2025 Apr 30.PMID: 40318674

Safety and Immunogenicity of Live Attenuated Vaccine Administration in Patients Undergoing Treatment With Dupilumab and Apremilast: A Systematic Review.

Larney C, Foley P, Daniel BS.Australas J Dermatol. 2025 Jun;66(4):199-203. doi: 10.1111/ajd.14464. Epub 2025 Mar 24.PMID: 40125904

Impact of COVID-19 and factors associated with long COVID and COVID-19 vaccine uptake in people with HIV in the United Kingdom: Results from Positive Voices 2022.

Nakagawa F, Palich R, Kall M, Sewell J, Smith C, Kelly C, Kitt H, Pelchen-Matthews A, Aghaizu A, Sparrowhawk A, Mackie N, Djuretic T, Schoeman S, Humphreys C, Lipman M, Lampe FC, Rodger AJ; PV2022 Study Group.HIV Med. 2025 Jun;26(6):923-939. doi: 10.1111/hiv.70026. Epub 2025 May 1.PMID: 40313005

Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023-2024.

Irving SA, Crane B, Weintraub ES, Patel SA, Razzaghi H, Daley MF, Dixon B, Donahue JG, Fuller CC, Fuller S, Getahun D, Glenn SC, Hambidge SJ, Jackson LA, Jacobson KB, Kharbanda EO, Maro JC, O'Leary ST, Schmidt T, Sznajder K, Weinfield NS, Williams JTB, Zerbo O, Naleway AL.Pediatrics. 2025 Jun 1;155(6):e2024070240. doi: 10.1542/peds.2024-070240.PMID: 40324788

COVID-19 serological survey utilizing antenatal serum samples in British Columbia.

Márquez AC, Beitari S, Valadbeigy T, Sbihi H, Zlosnik J, Forward L, Mansour S, Nesbitt Z, Tanunliong G, Krajden M, Jassem A, Sekirov I, Money D; Antenatal Serostudies Team.Vaccine. 2025 Jun 4;61:127310. doi: 10.1016/j.vaccine.2025.127310. Online ahead of print.PMID: 40472672

Ferritin nanoparticle complex with porcine epidemic diarrhea virus spike protein induces neutralizing antibody response against PEDV in mouse models.

Sudaraka Tennakoon MSBWTMN, Park JY, Lee HM, Ryu JH, Shin HJ.Microb Pathog. 2025 Jun;203:107509. doi: 10.1016/j.micpath.2025.107509. Epub 2025 Mar 25.PMID: 40147557

Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis.

Trusinska D, Lee B, Ferdous S, Kwok HHY, Gordon B, Gao J, Ma L, Xiong H, Sheikh SA, Schwarze J, Busby J, Gibbons C, Drysdale SB, Ritchie SL, Williams T, Shi T.EClinicalMedicine. 2025 Jun 3;84:103281. doi: 10.1016/j.eclinm.2025.103281. eCollection 2025 Jun.PMID: 40524797

Experience conducting COVID-19 vaccine effectiveness studies in response to the COVID-19 pandemic in Japan and the Philippines: lessons for future epidemics and potential pandemics.

Arashiro T, Berba RP, Calayo JP, Solante R, Suzuki S, Shin J, Suzuki M, Hibberd M, Ariyoshi K, Smith C.Western Pac Surveill Response J. 2025 Jun 4;16(2):1-8. doi: 10.5365/wpsar.2025.16.2.1157. eCollection 2025 Apr-Jun.PMID: 40497080

A disposition-belief-motivation framework for COVID-19 boosters: Prospective tests in a U.S. sample.

Bogg T, Milad E, Godfrey O.Health Psychol. 2025 Jun 9. doi: 10.1037/hea0001526. Online ahead of print.PMID: 40489155

Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.

Hung SH, Torres JL, Chen F, Giang E, Ward AB, Law M.Vaccine. 2025 Jun 11;58:127239. doi: 10.1016/j.vaccine.2025.127239. Epub 2025 May 16.PMID: 40381513

Influenza Vaccination in the Pediatric Emergency Department: A Missed Opportunity.

Walsh PS, Lipshaw MJ, Wendt WJ, Prasad S, Baumer-Mouradian SH.Hosp Pediatr. 2025 Jun 1;15(6):466-473. doi: 10.1542/hpeds.2024-008186.PMID: 40419281

Development of multiplexed flow based assay for simultaneous identification and estimation of meningococcal capsular polysaccharide serogroups A, C, W, Y and X for conjugate vaccine manufacturing.

Patni S, Verma R, Desarda M, Naikwade S, Deorukhakar H, Dhere R, Mallya A.J Immunol Methods. 2025 Jun 8;542:113895. doi: 10.1016/j.jim.2025.113895. Online ahead of print.PMID: 40494493

Glanders: An ancient and emergent disease with no vaccine or treatment on site.

Torres AG.PLoS Negl Trop Dis. 2025 Jun 11;19(6):e0013160. doi: 10.1371/journal.pntd.0013160. eCollection 2025 Jun.PMID: 40498787

Australian healthcare providers' awareness of and practices related to vaccine safety surveillance.

Carter N, King C, Deng L, Wood N, Quinn H.Public Health Res Pract. 2025 Jun;35:PU24016. doi: 10.1071/PU24016.PMID: 40504986

Development and Efficacy of a Chitosan Nanoparticle-Based Immersion Vaccine Targeting Segment 4 of Tilapia Lake Virus.

Thanapasuk C, Tattiyapong P, Yamkasem J, Kitiyodom S, Setthawong P, Lertwanakarn T, Surachetpong W.J Fish Dis. 2025 Jun;48(6):e14106. doi: 10.1111/jfd.14106. Epub 2025 Feb 28.PMID: 40018974

Pausing Chikungunya Vaccination and Accelerated Approval.

Prasad V, Kaslow DC, Yang S.JAMA. 2025 Jun 5. doi: 10.1001/jama.2025.9393. Online ahead of print.PMID: 40471755

COVID-19 vaccine hesitancy among parents of children with systemic lupus erythematosus.

Sausukpaiboon K, Penboon N, Rianthavorn P.Clin Exp Pediatr. 2025 Jun;68(6):454-462. doi: 10.3345/cep.2024.01340. Epub 2025 Feb 3.PMID: 39901720

Vaccination decisions and social capital in Japan.

Okubo T, Noy I.SSM Popul Health. 2025 Feb 26;30:101769. doi: 10.1016/j.ssmph.2025.101769. eCollection 2025 Jun.PMID: 40124530

Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.

Chanda C, Kibengo F, Mutua M, Ogada F, Muturi-Kioi V, Akis Yildirim BM, Amondi M, Baines A, Basajja V, Borthwick N, Bosire K, Chambula E, Chetty P, Chinyenze K, Chirro O, Crook A, De Bont J, Fernandez N, Ejou P, Farah B, Glaze M, Gombe B, Gumbe A, Hayes P, Itwi S, Juma S, Kabarambi A, Kabengele C, Kafeero P, Kakande A, Kanungi J, Kidega W, King D, Mahira R, Malogo R, Matsoso M, Michelo C, Moyo A, Mugaba S, Mugenya I, Muhumuza P, Mujadidi YF, Muriuki M, Musale V, Mutua G, Muwowo M, Mwale F, Mwangi I, Nakimbugwe M, Namuyanja A, Nduati E, Nielsen L, Nyange J, Oino G, Okech B, Omosa-Manyonyi G, Otieno D, Palmer S, Phiri H, Ramko K, Rutishauser RL, Sayeed E, Sajabi R, Serwanga J, G-T Wee E, Wenden C, Cicconi P, Fast P, Gilmour J, Jaoko W, Kaleebu P, Kilembe W, Kuipers H, Sanders EJ, Hanke T.Lancet Microbe. 2025 Jun;6(6):101041. doi: 10.1016/j.lanmic.2024.101041. Epub 2025 May 16.PMID: 40388952

Detoxification techniques for bacterial toxins: A pathway to effective toxoid vaccines.

Esmaeilnejad-Ahranjani P, Shahali Y, Dadar M.Toxicon. 2025 Jun;260:108365. doi: 10.1016/j.toxicon.2025.108365. Epub 2025 Apr 17.PMID: 40246205

Epitope-driven vaccine design against Listeria monocytogenes: an in-silico approach.

Kumar S, Moolchandani S.In Silico Pharmacol. 2025 Jun 9;13(2):83. doi: 10.1007/s40203-025-00365-x. eCollection 2025.PMID: 40503559

Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges.

Focosi D, Sullivan DJ, Franchini M.Expert Rev Anti Infect Ther. 2025 Jun;23(6):351-358. doi: 10.1080/14787210.2025.2473044. Epub 2025 Mar 4.PMID: 40007187

Abundance of single filamentous bacteria, and expression of differentiated Th17 cells, their signature cytokine IL-17 A, and retinoic acid receptor are predictive of poor rotavirus vaccine take.

Bubuluma R, Seheri M, Magwira CA.Virol J. 2025 Jun 3;22(1):180. doi: 10.1186/s12985-025-02816-5.PMID: 40462108

A report for the fifth International Workshop on Rotavirus and Norovirus in China.

Wang SJ, Glass R, Jiang B, Kirkwood C, Parashar U, Duan ZJ, Wang XY.Hum Vaccin Immunother. 2025 Dec;21(1):2512647. doi: 10.1080/21645515.2025.2512647. Epub 2025 Jun 9.PMID: 40485371

Development of a herpes zoster vaccination intention scale and identification of factors associated with vaccine hesitancy among middle-aged and older attendees in community health centers: A Protection Motivation Theory based study.

Gao Y, Wei T, Gong R, Cai L, Sheng Y, Shang M, Ni Y.Hum Vaccin Immunother. 2025 Dec;21(1):2516947. doi: 10.1080/21645515.2025.2516947. Epub 2025 Jun 16.PMID: 40524390

Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions.

Voutouri C, Munn LL, Stylianopoulos T, Jain RK.PLoS Comput Biol. 2025 Jun 12;21(6):e1013163. doi: 10.1371/journal.pcbi.1013163. Online ahead of print.PMID: 40504865

Chimeric hemagglutinin and M2 mRNA vaccine for broad influenza subtype protection.

Yi D, Liu Q, Guo S, Li Q, Zhang Y, Li N, Zhang Q, Lv K, An N, Han L, Chen H, Wang Y, Chang C, Shao H, Wang J, Li X, Bao L, Wang D, Liao G, Huang C, Zhang W, Dong Y, Shu Y, Cen S.NPJ Vaccines. 2025 Jun 5;10(1):113. doi: 10.1038/s41541-025-01178-x.PMID: 40473642

Modelling the interplay between responsive individual vaccination decisions and the spread of SARS-CoV-2.

Wallrafen-Sam K, Quesada MG, Lopman BA, Jenness SM.Epidemics. 2025 Jun;51:100831. doi: 10.1016/j.epidem.2025.100831. Epub 2025 Apr 23.PMID: 40318563

Leveraging pre-vaccination antibody titres across multiple influenza H3N2 variants to forecast the post-vaccination response.

Stacey H, Carlock MA, Allen JD, Hanley HB, Crotty S, Ross TM, Einav T.EBioMedicine. 2025 Jun;116:105744. doi: 10.1016/j.ebiom.2025.105744. Epub 2025 May 26.PMID: 40424667

Exploring the multifaceted roles of resuscitation-promoting factors in tuberculosis: Implications for diagnosis, vaccine development, and drug targeting.

Tanriver G, Ali Khan S, Góra A, Chegou NN, Mahmoudi S.Biotechnol Rep (Amst). 2025 Mar 13;46:e00886. doi: 10.1016/j.btre.2025.e00886. eCollection 2025 Jun.PMID: 40201451

Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.

Albadr RJ, Sameer HN, Athab ZH, Adil M, Yaseen A, Allela OQB.Biol Proced Online. 2025 Jun 3;27(1):20. doi: 10.1186/s12575-025-00269-2.PMID: 40461976

C3 glomerulopathy and acute kidney injury after mRNA-1273 (Moderna) COVID-19 vaccine and genetical analysis.

Chao MV, Peng CH, Chang FP, Wang YC.Clin Nephrol. 2025 Jun 2. doi: 10.5414/CN111570. Online ahead of print.PMID: 40454525

Critical COVID-19 in children and adolescents during the 2022 Omicron Surge in Taiwan: Risk factors and vaccine effectiveness.

Tsai JY, Liu YC, Wu JH, Huang SM, Hu YL, Chang LY, Fang CT.J Formos Med Assoc. 2025 Jun;124(6):529-535. doi: 10.1016/j.jfma.2024.11.018. Epub 2024 Dec 4.PMID: 39638682

Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial.

Luabeya AKK, Rozot V, Imbratta C, Ratangee F, Shenje J, Tameris M, Mendelsohn SC, Geldenhuys H, Fisher M, Musvosvi M, Young C, Mulenga H, Bilek N, Mabwe S, Jelsbak IM, Rodríguez E, Puentes E, Doce J, Aguilo N, Martin C, Pillay C, Tait D, Russell M, Van Der Merve A, Rutkowski K, Hunt D, Ginsberg A, Scriba TJ, Hatherill M; A050 team.Lancet Glob Health. 2025 Jun;13(6):e1030-e1042. doi: 10.1016/S2214-109X(25)00046-4. Epub 2025 Apr 15.PMID: 40250461

Estimating Standard-Dose and High-Dose Fluzone Vaccine Efficacies for Influenza A Based on Hemagglutination Inhibition Titers.

Hammerton SM, Billings WZ, Hemme H, Ross TM, Shen Y, Handel A.J Infect Dis. 2025 Jun 2;231(5):1336-1345. doi: 10.1093/infdis/jiae615.PMID: 39670611

Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.

Chakraborty C, Lo YH, Bhattacharya M, Das A, Wen ZH.Mol Ther Nucleic Acids. 2025 Mar 28;36(2):102527. doi: 10.1016/j.omtn.2025.102527. eCollection 2025 Jun 10.PMID: 40291378

Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEV(R) concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study.

Thuluva S, Matur RV, Gunneri S, Mogulla R, Dhar C, Yerroju V, Balne N, Chakravarthy BS, Narang M, Mahantshetti NS, Pandey AK.IJID Reg. 2025 Feb 25;15:100611. doi: 10.1016/j.ijregi.2025.100611. eCollection 2025 Jun.PMID: 40176856

Size-controlled immunomodulatory and vaccine adjuvant potentials of self-assembled hyaluronic acid nanoparticles: Activation and recruitment of immune cells.

Chu PC, Birhan YS, Zhao MH, Syu WJ, Chen PY, Lin YT, Lai PS.Int J Biol Macromol. 2025 Jun;314:144265. doi: 10.1016/j.ijbiomac.2025.144265. Epub 2025 May 15.PMID: 40381765

Impact of non-digestible carbohydrates and prebiotics on immunity, infections, inflammation and vaccine responses: a systematic review of evidence in healthy humans and a discussion of mechanistic proposals.

Arioz Tunc H, Calder PC, Cait A, Dodd GF, Gasaly Retamal NYI, Guillemet D, James D, Korzeniowski KJ, Lubkowska A, Meynier A, Ratajczak W, Respondek F, Thabuis C, Vaughan EE, Venlet N, Walton G, Gasser O, de Vos P.Crit Rev Food Sci Nutr. 2025 Jun 14:1-74. doi: 10.1080/10408398.2025.2514700. Online ahead of print.PMID: 40516031

Genotype III-Based Japanese Encephalitis Vaccines Exhibit Diminished Neutralizing Response to Reemerging Genotype V.

Lee AR, Kim WJ, Choi H, Kim SH, Hong SY, Shim SM, Lee HI, Song JM, Kim SJ, Ishikawa T, Kang JM, Eom HS, Seo SU.J Infect Dis. 2025 Jun 2;231(5):1281-1289. doi: 10.1093/infdis/jiae589.PMID: 39574290

Social Connections and COVID19 Vaccination.

Basu AK, Chau NH, Firsin O.Health Econ. 2025 Jun;34(6):1188-1213. doi: 10.1002/hec.4953. Epub 2025 Mar 15.PMID: 40088475

Multimodal Regulation of Dendritic Cells via Mineralized Vaccines for Postsurgical Tumor Relapse Prevention.

Gu Z, Li L, Xu P, Li C, Liu B, Zhu P, Xie W, Zhang LW, Wang Y, Wang Y.ACS Nano. 2025 Jun 3;19(21):19901-19917. doi: 10.1021/acsnano.5c02846. Epub 2025 May 22.PMID: 40401399

Newborn screening programs promote vaccine acceptance among parents in Turkey: a cross-sectional study.

Erdal İ, Kahraman AB, Yıldız Y, Yalçın SS.Postgrad Med. 2025 Jun;137(5):423-438. doi: 10.1080/00325481.2025.2504866. Epub 2025 May 15.PMID: 40347114

Impact of Universal Varicella Vaccination in Israel: A Time-series Analysis, 2003 to 2020.

Fallach N, Lasalvia P, Pawaskar M, Chodick G, Greenberg D, Kujawski SA.Pediatr Infect Dis J. 2025 Jun 1;44(6):593-598. doi: 10.1097/INF.0000000000004787. Epub 2025 Mar 19.PMID: 40106737

A detailed examination of coronavirus disease 2019 (COVID-19): Covering past and future perspectives.

Yasmin S, Ansari MY.Microb Pathog. 2025 Jun;203:107398. doi: 10.1016/j.micpath.2025.107398. Epub 2025 Feb 20.PMID: 39986548

Projected health and economic effects of nonavalent versus bivalent human papillomavirus vaccination in preadolescence in the Netherlands.

Sollie B, Berkhof J, Bogaards JA.BMC Med. 2025 Jun 9;23(1):339. doi: 10.1186/s12916-025-04170-3.PMID: 40484946

Clinical progress note: Haemophilus influenzae type b.

Ewing A, Haldeman S, Ratner AJ.J Hosp Med. 2025 Jun;20(6):603-606. doi: 10.1002/jhm.70059. Epub 2025 Apr 9.PMID: 40205699

Neonatal antibiotics impair infant vaccine responses.

Minton K.Nat Rev Immunol. 2025 Jun;25(6):402. doi: 10.1038/s41577-025-01176-z.PMID: 40269274

HPV vaccination coverage, hesitancy, and barriers: Insights from a serial cross-sectional study in Shanghai, China (2019-2024).

Ji M, Huang Z, Yan H, Ren J, Wagner AL, Sun X, Boulton ML.Hum Vaccin Immunother. 2025 Dec;21(1):2513707. doi: 10.1080/21645515.2025.2513707. Epub 2025 Jun 9.PMID: 40490962

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever.

Spurgers K, Wynn M, Charles L, Hamm S, Matassov D, Gerardi C, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of Vaccines by Technology Working Group (BRAVATO; ex-V3SWG).Vaccine. 2025 Jun 11;58:127137. doi: 10.1016/j.vaccine.2025.127137. Epub 2025 May 13.PMID: 40367816

Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns.

Violari A, Otwombe K, Hahn W, Chen S, Josipovic D, Baba V, Angelidou A, Smolen KK, Levy O, Mkhize NN, Woodward Davis AS, Martin TM, Haynes BF, Williams WB, Sagawa ZK, Kublin JG, Polakowski L, Brewinski Isaacs M, Yen C, Tomaras G, Corey L, Janes H, Gray GE.J Clin Invest. 2025 Apr 3;135(11):e186927. doi: 10.1172/JCI186927. eCollection 2025 Jun 2.PMID: 40178906

Unpacking COVID-19 Vaccine Hesitancy: A Network Analysis Perspective on Related Beliefs and Responses.

Karademas E, Paschali A.Int J Behav Med. 2025 Jun 16. doi: 10.1007/s12529-025-10378-7. Online ahead of print.PMID: 40524089

Motivational interviewing for vaccine uptake in Latinx adults (MI Vacuna): Study protocol for a pragmatic multiple-period cluster-randomized crossover trial.

Scrivano RM, van de Water BJ, Rueras N, Alfonso J, McManama O'Brien KH, Soto X, Caumeran VJS, Campos BM, Mancusi M, Diehl B, Southwick E, Moreno E, Bora C, Armbruster S, Abuelezam NN, Calvo R, Haneuse S, Davison KK.Contemp Clin Trials. 2025 Jun 14:107987. doi: 10.1016/j.cct.2025.107987. Online ahead of print.PMID: 40523466

The evaluation of a novel multi-epitope vaccine against human papillomavirus and Candida albicans.

Ahmadifar F, Balali E, Khadivi R, Hashemi M, Jebali A.J Genet Eng Biotechnol. 2025 Jun;23(2):100489. doi: 10.1016/j.jgeb.2025.100489. Epub 2025 May 2.PMID: 40390500

BNT162b2 COVID-19 vaccination elicits the expansion of $CD16^{+}CD8^{+}$ T cells endowed with natural killer cell features.

De Pasquale C, Drommi F, Calabrò A, Botta C, Sidoti Migliore G, Carrega P, Vento G, Gaeini A, Pezzino G, Freni J, Bonaccorsi I, Vitale M, Filaci G, Fenoglio D, Iemmo R, Costa G, Cavaliere R, Ferlazzo G, Campana S.J Allergy Clin Immunol. 2025 Jun;155(6):1981-1992. doi: 10.1016/j.jaci.2025.01.024. Epub 2025 Jan 31.PMID: 39894227

Genetic diversity and impact of vaccination on influenza A (H1N1)pdm09 in Mar del Plata, Argentina: a 2015-2020 molecular epidemiological study.

Uez O, Culasso A, Lerman A, Cimmino C, Campos R, Marcone DN.Infect Dis (Lond). 2025 Jun;57(6):574-587. doi: 10.1080/23744235.2025.2466118. Epub 2025 Feb 21.PMID: 39982428

A tailored nanocarrier DMON and CpGs synergistically drive the formulation of a highly immunogenic and long-acting vaccine against echinococcosis.

Xin T, Gao X, Tao S, Zhou C, Zhang Z, Ding J, Ru J, Li Y.Mater Today Bio. 2025 May 12;32:101868. doi: 10.1016/j.mtbio.2025.101868. eCollection 2025 Jun.PMID: 40487171

Thermostabilization of a model viral-vectored oral thin film vaccine.

Yardy A, Wang IQ, Rasco Y, Lenihan G, Mayo JD, Mu J, Macphail B, Larché M, Adronov A.Int J Pharm. 2025 Jun 10;678:125662. doi: 10.1016/j.ijpharm.2025.125662. Epub 2025 May 8.PMID: 40348301

Practice, beliefs and intent in influenza vaccination among Hispanic patients during the pandemic: An interventional study.

Mou J, LaSalle G, Pflugeisen C, Sherls-Jones J, Castañeda H, Zaragoza G, Smith C, Mays J, Villarreal N.Vaccine. 2025 Jun 11;58:127207. doi: 10.1016/j.vaccine.2025.127207. Epub 2025 May 14.PMID: 40373636

Magnetic Microcarrier-Based Whole Tumor Cell Vaccines for Tumor Prevention and Immunotherapy.

Wu S, Liu C, Li K, Li F, Li Y, He S, Tian H.ACS Nano. 2025 Jun 17;19(23):21468-21483. doi: 10.1021/acsnano.5c02569. Epub 2025 Jun 6.PMID: 40476671

Brucella inactivated vaccine elicits immunity against B. melitensis infection in mice and guinea pigs.

Hu R, Zhang Q, Wang W, Ren W, Yao M, Xu Y, Zhang H, Sheng J, Wang Y, Chen C, Ma Z.Biomed Pharmacother. 2025 Jun;187:118077. doi: 10.1016/j.biopha.2025.118077. Epub 2025 Apr 24.PMID: 40280033

Maintaining the value of influenza vaccination - the shift from quadrivalent to trivalent vaccines: an expert review.

Fisman D, Pérez-Rubio A, Postma M, Smith DS, Mould-Quevedo J.Expert Rev Vaccines. 2025 Dec;24(1):499-508. doi: 10.1080/14760584.2025.2515597. Epub 2025 Jun 8.PMID: 40462760

The power of story: what Victorian novels can teach us about public health.

Tange AK.Curr Opin Infect Dis. 2025 Jun 1;38(3):228-233. doi: 10.1097/QCO.0000000000001103. Epub 2025 Mar 27.PMID: 40152190

Computational identification of B and T-cell epitopes for designing a multi-epitope vaccine against SARS-CoV-2 spike glycoprotein.

Nguyen TL, Nguyen TB, Kim H.J Struct Biol. 2025 Jun;217(2):108177. doi: 10.1016/j.jsb.2025.108177. Epub 2025 Feb 11.PMID: 39947305

Does Experience of Vaccination Improve Vaccine Confidence and Trust? Policy Feedback Effects of Mass COVID-19 Vaccination in the United States.

Choi Y, Fox A.J Health Polit Policy Law. 2025 Jun 1;50(3):371-396. doi: 10.1215/03616878-11670176.PMID: 39545679

Immunoinformatics-driven design of a multi-epitope vaccine against nipah virus: A promising approach for global health protection.

Shabbir MA, Amin A, Hasnain A, Shakeel A, Gul A.J Genet Eng Biotechnol. 2025 Jun;23(2):100482. doi: 10.1016/j.jgeb.2025.100482. Epub 2025 Mar 27.PMID: 40390484

Bioinformatics analysis of innovative multi-epitope vaccine utilizing MAGE-A, MAM-A, and Gal-3 for breast cancer management.

Aali F, Doosti A, Shakhsi-Niaei M.Sci Rep. 2025 Jun 5;15(1):19774. doi: 10.1038/s41598-025-04089-y.PMID: 40473741

Quantifying the zoonotic risk profile of European influenza A viruses in swine from 2010 to 2020 inclusive.

Coggon A, Lopes S, Simon G, Arendsee Z, Chen K-F, Chiapponi C, Essen S, Everett H, Hervé S, Hufnagel DE, Mollett B, Moreno A, Pekosz A, Richard G, Rothman RE, Shaw-Saliba K, Van Reeth K, Venkatesh D, Brown IH, Anderson TK, Baker AL, Lewis NS.J Virol. 2025 Jun 4:e0030625. doi: 10.1128/jvi.00306-25. Online ahead of print.PMID: 40464577

Survival Analysis and Socio-Cognitive Factors in the Timing of COVID-19 Vaccination Among Mexican-Origin Youth.

Kim SY, Wen W, Coulter KM, Du Y, Tse HW, Hou Y, Chen S, Shen Y.J Racial Ethn Health Disparities. 2025 Jun;12(3):1630-1640. doi: 10.1007/s40615-024-01995-1. Epub 2024 Apr 5.PMID: 38580808

Streptococcus suis manganese transporter mutant as a live attenuated vaccine: Safety, efficacy, and virulence reversion mechanisms.

Wiebe M, Ingebritson A, Sholeh M, Tichenor C, Visek C, Victoria J, Beck M, Tiwari R, Hardwidge P, Zhu L.Vet Microbiol. 2025 Jun;305:110521. doi: 10.1016/j.vetmic.2025.110521. Epub 2025 Apr 14.PMID: 40239440

Assay for rapid quantification of capped and tailed intact mRNA.

Gao RY, Hu T, Taylor AW, Lacey R, Thomas KN, McCormick C, Miller DF, Rowlen KL, Dawson ED.Vaccine. 2025 Jun 3;61:127339. doi: 10.1016/j.vaccine.2025.127339. Online ahead of print.PMID: 40466481

Coronavirus Disease 2019 and Influenza Vaccination Compliance Among Healthcare Workers at the Primary Health Care Corporation, Qatar, 2020-2024: A Retrospective Study.

Alhajri S, Alyafei AA, Semaan S, AlNuaimi AA, Al Muslemani MA.Cureus. 2025 Jun 11;17(6):e85761. doi: 10.7759/cureus.85761. eCollection 2025 Jun.PMID: 40503544

Psychological reactance to vaccine mandates on Twitter: a study of sentiments in the United States.

Hsieh PH.J Public Health Policy. 2025 Jun;46(2):269-283. doi: 10.1057/s41271-025-00554-0. Epub 2025 Jan 19.PMID: 39828759

Designing of an efficient DC-inducing multi-epitope vaccine against Epstein Barr virus targeting the GP350 using immunoinformatics and molecular dynamic simulation.

Fatahi G, Abdollahi M, Nashtahosseini Z, Minoo S, Mostafavi M, Saeidi K.Biochem Biophys Rep. 2025 Mar 3;42:101966. doi: 10.1016/j.bbrep.2025.101966. eCollection 2025 Jun.PMID: 40114673

Impact of digital communication message on HPV vaccine decision-making among Japanese mothers: A randomized controlled trial.

Kobayashi K, Masuda K, Wu JT, Lin L.Vaccine. 2025 Jun 3;61:127327. doi: 10.1016/j.vaccine.2025.127327. Online ahead of print.PMID: 40466485

Factors associated with human papillomavirus (HPV) patient-clinician communication and HPV vaccine uptake among adults in the United States.

Owens HN, Brownstein NC, Whiting J, Arevalo M, Kasting ML, Vadaparampil ST, Head KJ, Christy SM.Prev Med. 2025 Jun;195:108280. doi: 10.1016/j.ypmed.2025.108280. Epub 2025 Apr 4.PMID: 40188881

Regional mobility and COVID-19 vaccine hesitancy: Evidence from China.

Wang-Lu H, Valerio Mendoza OM, Chen S, Geldsetzer P, Adam M.Vaccine. 2025 Jun 11;58:127179. doi: 10.1016/j.vaccine.2025.127179. Epub 2025 May 13.PMID: 40367815

Associations Between Psychosocial Influence, Positive Thinking, and Vaccine Attitudes in Patients with Schizophrenia During the COVID-19 Pandemic.

Li DJ, Wang WC, Chou FH, Hsu ST, Hsieh KY, Lin GG, Wu PJ, Liu CL, Wu HC, Huang JJ.Psychol Res Behav Manag. 2025 Jun 10;18:1307-1318. doi: 10.2147/PRBM.S516814. eCollection 2025.PMID: 40525101

Addressing vaccine hesitancy in the training of healthcare professionals: Insights from the VAX-TRUST project.

Augusto FR, Guerreiro CS, Morais R, Mendonça J, Beja A, Correia T, Hilário AP.Public Health Pract (Oxf). 2024 Dec 19;9:100569. doi: 10.1016/j.puhip.2024.100569. eCollection 2025 Jun.PMID: 39877314

An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant.

Uraki R, Kiso M, Ito M, Yamayoshi S, Halfmann P, Jain S, Suthar MS, Lopes TJS, Jounai N, Miyaji K, Takeshita F, Kawaoka Y.EBioMedicine. 2025 Jun 6;117:105794. doi: 10.1016/j.ebiom.2025.105794. Online ahead of print.PMID: 40482468

Community Health Worker Influence on COVID-19 Vaccine Uptake in New York City, 2021-2022.

Miller M, Weiss BG, Sakas ZM, Parrella KE, Islam F, Watkins JL; COVID-19 Equity Program Team.Am J Public Health. 2025 Jun;115(6):910-919. doi: 10.2105/AJPH.2025.308039. Epub 2025 Mar 27.PMID: 40146972

Vaccination in dermatology 2025: Update considering current recommendations of the German Standing Committee on Vaccination.

Stoevesandt J, Schmalzing M, Mohme S, Goebeler M.J Dtsch Dermatol Ges. 2025 Jun 11. doi: 10.1111/ddg.15785. Online ahead of print.PMID: 40495641

Attitudes Toward COVID-19 Vaccination Among Pediatric Acute Lymphoblastic Leukemia Patients and Their Caregivers.

Shapiro JR, Shapiro GK, Gupta S, Alexander S, Science M, Watts TH, Bolotin S.Pediatr Blood Cancer. 2025 Jun;72(6):e31696. doi: 10.1002/pbc.31696. Epub 2025 Mar 28.PMID: 40152422

Safety and immunogenicity of a reduced-dose inactivated poliovirus vaccine versus a full-dose inactivated poliovirus vaccine in infants in Bangladesh: a double-blind, non-inferiority, randomised, controlled, phase 3 trial.

Kulkarni PS, Zaman K, Desai SA, Bharati S, Goswami DR, Sharmeen AT, Rana S, Haque W, Khandelwal A, Manney S, Tyagi P, Gairola S, Zade JK, Pisal SS, Dhere RM, Poonawalla CS, Lamberigts C, Parulekar V, Potey AV.Lancet Infect Dis. 2025 Jun 9:S1473-3099(25)00215-4. doi: 10.1016/S1473-3099(25)00215-4. Online ahead of print.PMID: 40505670

It's time to change how we vaccinate for measles.

Sievers BL, Sievers EL.Vaccine. 2025 Jun 9;61:127382. doi: 10.1016/j.vaccine.2025.127382. Online ahead of print.PMID: 40494222

The Roles of Acculturation and Pre-migration Experiences in Influencing the Confidence of Vietnamese Parents in Vaccine Use Among Adolescents.

Pham NT, Vu M.J Community Health. 2025 Jun;50(3):442-453. doi: 10.1007/s10900-024-01428-4. Epub 2024 Dec 19.PMID: 39702660

Characteristic profiling of CHO-cell expressed MERS-CoV RBD-Fc.

Almutairi MM, Chen YL, Lee J, Liu Z, Strych U, Hotez PJ, Bottazzi ME, Chen WH.Int J Biol Macromol. 2025 Jun;311(Pt 2):143678. doi: 10.1016/j.ijbiomac.2025.143678. Epub 2025 May 1.PMID: 40318720

HIV vaccine - Is there a ray of hope in the rugged journey?

Barik G, Fletcher GJ, Alex D, Demosthenes JP, Abraham P, Kannangai R.Indian J Med Microbiol. 2025 Jun 3;56:100885. doi: 10.1016/j.ijmmb.2025.100885. Online ahead of print.PMID: 40472898

Construction and efficacy of a recombinant QX-like infectious bronchitis virus vaccine strain.

Lin L, Feng K, Shao G, Gong S, Liu T, Chen F, Zhang X, Xie Q.Virus Genes. 2025 Jun;61(3):355-364. doi: 10.1007/s11262-025-02140-8. Epub 2025 Feb 27.PMID: 40014292

Cyclodextrin-Based Supramolecular Carrier for Cancer Proteinaceous Antigen.

Obata A, Katanosaka R, Taharabaru T, Arita-Morioka KI, Motozono C, Motoyama K, Higashi T.Mol Pharm. 2025 Jun 2;22(6):3208-3218. doi: 10.1021/acs.molpharmaceut.5c00115. Epub 2025 May 19.PMID: 40388578

Phase II/III randomized immunogenicity and safety study of a Brazilian meningococcal serogroup B vaccine in children.

Martins RM, Maia MLS, Camacho LAB, Noronha TG, von Doellinger VR, Santos AP, Figueira ES, Leal ML, Jessouroun E.Vaccine. 2025 Jun 9;61:127363. doi: 10.1016/j.vaccine.2025.127363. Online ahead of print.PMID: 40494223

Recombinant BCGΔBCG1419c protects outbred mice against M. tuberculosis challenge.

Kurtz SL, Gould V, Flores-Valdez MA, Elkins KL.Vaccine. 2025 Jun 3;61:127347. doi: 10.1016/j.vaccine.2025.127347. Online ahead of print.PMID: 40466484

Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses.

Adelglass JM, Bradley P, Cai MR, Chau G, Kalkeri R, Cloney-Clark S, Zhu M, Cai Z, Eickhoff M, Plested JS, Mallory RM, Dunkle LM.J Allergy Clin Immunol. 2025 Jun;155(6):2063-2074.e6. doi: 10.1016/j.jaci.2025.03.015. Epub 2025 Mar 26.PMID: 40154575

Intention to Use RSVpreF Vaccine or Nirsevimab to Prevent Infant RSV Among Pregnant Individuals.

Callaghan T, Wise LA, Regan AK.Pediatr Infect Dis J. 2025 Jun 3. doi: 10.1097/INF.0000000000004889. Online ahead of print.PMID: 40472256

Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants.

Gontu A, Misra S, Chothe SK, Ramasamy S, Jakka P, Byukusenge M, LaBella LC, Nair MS, Jayarao BM, Archetti M, Nissly RH, Kuchipudi SV.NPJ Vaccines. 2025 Jun 3;10(1):110. doi: 10.1038/s41541-025-01166-1.PMID: 40461576

Leading Vaccine Gap Closure with Community Health Workers: The CPESN Missouri Health Equity Approach.

Patterson ME, Eisenbeis A, Stone A, Galdo JA.J Am Pharm Assoc (2003). 2025 Jun 2:102429. doi: 10.1016/j.japh.2025.102429. Online ahead of print.PMID: 40467031

Factors Associated With Repeat Pediatric Influenza Vaccination Among Inconsistent Vaccinators.

Abraham C, Gilkey MB, Walsh KE, Hickingbotham MR, Galbraith AA.Clin Pediatr (Phila). 2025 Jun;64(5):681-694. doi: 10.1177/00099228241286970. Epub 2024 Oct 18.PMID: 39422922

Empowering Unvaccinated Youth: Feasibility, Acceptability, and Efficacy of a COVID-19 Serious Game-Based Intervention.

Ou L, Chen AC, Reifsnider E, Todd M, Amresh A, Mun CJ.Games Health J. 2025 Jun;14(3):182-194. doi: 10.1089/g4h.2024.0011. Epub 2024 Oct 2.PMID: 39360753

Post-vaccinal seronegative autoimmune encephalitis following recombinant zoster vaccination in two immunocompetent patients.

Madani TA, Khoja AA, Abuzinadah AR, Abbas GM, Alotaibi AA, Alshehri ZI, Madani ST.J Infect Chemother. 2025 Jun;31(6):102713. doi: 10.1016/j.jiac.2025.102713. Epub 2025 Apr 18.PMID: 40254183

A novel killed oil adjuvanted bovine viral diarrhea virus vaccine protects from viremia and clinical manifestations: an immune response and challenge study in cattle.

Ertürk B, Aytoğu G, Yeşilbağ K.Vet Res Commun. 2025 Jun 13;49(4):224. doi: 10.1007/s11259-025-10792-y.PMID: 40512232

Isolation and characterization of GI-19/L1148-like infectious bronchitis virus in China.

Li H, Han J, Wang B, Han Z, Liu S.Virus Res. 2025 Jun;356:199576. doi: 10.1016/j.virusres.2025.199576. Epub 2025 Apr 14.PMID: 40233840

Human papillomavirus vaccine coverage surveys in low- and middle-income countries: current efforts and future considerations for very young adolescents.

Pak L, Rollison J, Rabinowitz M, Faherty LJ.BMJ Glob Health. 2025 Jun 13;10(6):e018731. doi: 10.1136/bmjgh-2024-018731.PMID: 40514218

Engineering a recombination-resistant live attenuated vaccine candidate with suppressed interferon antagonists for PEDV.

Liu M, Aryal B, Niu X, Wang Q.J Virol. 2025 Jun 12:e0045125. doi: 10.1128/jvi.00451-25. Online ahead of print.PMID: 40503881

Exploring the barriers and facilities migrants face in accessing COVID-19 vaccines in Malaysia: A qualitative study.

Loganathan T, Zaini AZ, Majid HA.PLoS One. 2025 Jun 10;20(6):e0326045. doi: 10.1371/journal.pone.0326045. eCollection 2025.PMID: 40493605

Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization.

Carvajal R, Tur C, Borras-Bermejo B, Saylor D, Montalban X, Tintoré M, Otero-Romero S.Mult Scler. 2025 Jun;31(7):754-763. doi: 10.1177/13524585251318513. Epub 2025 Mar 12.PMID: 40071952

A three-part model for the self-controlled case series design to estimate and characterize adverse event risk in an overlapping risk period after multiple vaccines: application to ischemic stroke following Pfizer-BioNTech bivalent COVID-19 vaccine and influenza vaccine.

Xu S, Sy LS, Huang X, Hong V, Han B, Bruxvoort KJ, Lewin B, Holmquist KJ, Qian L.Am J Epidemiol. 2025 Jun 4:kwaf115. doi: 10.1093/aje/kwaf115. Online ahead of print.PMID: 40462345

Antibiotics, microbiota and the calibration of infant vaccine responses.

Feng Y, Pulendran B.Nat Immunol. 2025 Jun;26(6):810-811. doi: 10.1038/s41590-025-02169-9.PMID: 40389563

Optimizing delivery in a multivalent subunit influenza vaccine using mixed polymeric microparticle degradation rates.

Pena ES, Ontiveros-Padilla L, Lukesh NR, Williamson GL, Murphy CT, Hendy DA, Roque JA 3rd, Carlock MA, Ross TM, Ainslie KM, Bachelder EM.J Control Release. 2025 Jun 6;384:113936. doi: 10.1016/j.jconrel.2025.113936. Online ahead of print.PMID: 40482923

Trends in public interest and vaccination coverage for Herpes Zoster.

Corona S, Ianni ML, Cimino E, Muselli M.Public Health Pract (Oxf). 2025 Feb 13;9:100592. doi: 10.1016/j.puhip.2025.100592. eCollection 2025 Jun.PMID: 40040670

Role of glucuronoxylomannan and steryl glucosides in protecting against cryptococcosis.

Matos GS, Querobino SM, Brauer VS, Joffe LS, Pereira de Sa N, Fernandes CM, DaSilva D, da Silva VA, Cavalcanti Neto MP, Normile T, Zhu H, Bhatia SR, Tan L, Azadi P, Heiss C, Doering TL, Del Poeta M.mBio. 2025 Jun 11;16(6):e0098425. doi: 10.1128/mbio.00984-25. Epub 2025 Apr 29.PMID: 40298449

Exploring approaches and advancements in the development and evaluation of multi-epitope subunit vaccines against tick-borne viruses.

Ben Said M, Kratou M.Vet Microbiol. 2025 Jul;306:110577. doi: 10.1016/j.vetmic.2025.110577. Epub 2025 Jun 2.PMID: 40466409

Human adenovirus penton dodecahedron nanoparticles induce an enhanced neutralizing antibody response in mouse model.

Zhou L, Yang Y, Mo C, Zhu Y, Fan Y, Liu W, Li X, Zhou R, Tian X.Vaccine. 2025 Jun 6;61:127380. doi: 10.1016/j.vaccine.2025.127380. Online ahead of print.PMID: 40482460

In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.

Zelba H, Shao B, Rabsteyn A, Reinhardt A, Greve C, Oenning L, Kayser S, Kyzirakos C, Latzer P, Riedlinger T, Bartsch O, Wünsche J, Harter J, Feldhahn M, Bantel Y, Johänning J, Ködding J, Hadaschik D, Schulze M, Battke F, Maksimovic O, Scheble V, Miller AM, Castro M, Blumenthal DT, Glas M, Reardon D, Biskup S.J Immunother Cancer. 2025 Jun 5;13(6):e011070. doi: 10.1136/jitc-2024-011070.PMID: 40480654

Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older During the BA.1/BA.2 Omicron Period.

Lu Y, Matuska K, McEvoy R, Izurieta HS, Hervol JR, Menis M, Lindaas A, Steele WR, Chillarige Y, Wernecke M, Kelman JA, Forshee RA.J Infect Dis. 2025 Jun 2;231(5):1186-1197. doi: 10.1093/infdis/jiae503.PMID: 39404024

Cell-Free Expression of Nipah Virus Transmembrane Proteins for Proteoliposome Vaccine Design.

Hu VT, Ezzatpour S, Selivanovitch E, Sahler J, Pal S, Carter J, Pham QV, Adeleke RA, August A, Aguilar HC, Daniel S, Kamat NP.ACS Nano. 2025 Jun 17;19(23):21290-21306. doi: 10.1021/acsnano.4c16190. Epub 2025 Jun 3.PMID: 40458951

Computationally designed haemagglutinin with nanocage plug-and-display elicits pan-H5 influenza vaccine responses.

Huang CQ, Hills RA, Carnell GW, Vishwanath S, Aguinam ET, Chan ACY, Palmer P, O'Reilly L, Tonks P, Temperton N, Frost SDW, Tiley LS, Howarth MR, Heeney JL.Emerg Microbes Infect. 2025 Jun 6:2511132. doi: 10.1080/22221751.2025.2511132. Online ahead of print.PMID: 40476519

Cost-effectiveness of pentavalent meningococcal (MenABCWY) vaccination among adolescents in the United States.

Dong X, Schillie SF, McNamara LA, Leidner AJ.Vaccine. 2025 Jun 9;61:127332. doi: 10.1016/j.vaccine.2025.127332. Online ahead of print.PMID: 40494224

Preferences for Nonpharmaceutical Interventions During the Endemic Phase of COVID-19: Discrete Choice Experiment.

Wang Y, Har CE, Tan SHX, Cheng HS, Ang IYH.JMIR Public Health Surveill. 2025 Jun 4;11:e67725. doi: 10.2196/67725.PMID: 40470547

Lipid Nanoparticle Development for A Fluvid mRNA Vaccine Targeting Seasonal Influenza and SARS-CoV-2.

Felgner J, Hernandez-Davies JE, Strahsburger E, Silzel E, Nakajima R, Jain A, Laster J, Chiang JL, Tsai Y, Felgner PL, Davies DH, Liang L.NPJ Vaccines. 2025 Jun 11;10(1):123. doi: 10.1038/s41541-025-01153-6.PMID: 40500288

Primary care as determinant of COVID-19 and influenza vaccine uptake.

Kotherová Z, Premat C.Health Econ Policy Law. 2025 Jun 11:1-16. doi: 10.1017/S1744133125100108. Online ahead of print.PMID: 40497372

Development of a novel EV-A71 monoclonal antibody for monitoring vaccine potency.

Le TH, Weng TY, Yen H, Chia MY, Lee MS.PLoS Negl Trop Dis. 2025 Jun 3;19(6):e0013127. doi: 10.1371/journal.pntd.0013127. eCollection 2025 Jun.PMID: 40460346

Audit of linkage to care and administration of immunoprophylaxis to infants born to mothers with chronic hepatitis B infection at Monash Health 2014-2022.

Lenihan C, Pierce AB, Jalil E, Stuart RL.Intern Med J. 2025 Jun;55(6):932-936. doi: 10.1111/imj.70048. Epub 2025 Apr 1.PMID: 40167186

Mpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development.

Eslamkhah S, Aslan ES, Yavas C, Akcalı N, Batur LK, Abuaisha A, Yildirim EE, Solak M, White KN.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun;398(6):6143-6163. doi: 10.1007/s00210-024-03649-9. Epub 2025 Jan 8.PMID: 39777535

Cost-effectiveness of human papillomavirus vaccination among girls aged 9-16 years in China: a meta-analysis.

Fu X, Xia Y, Zhou W, Lu Y.Expert Rev Vaccines. 2025 Dec;24(1):524-534. doi: 10.1080/14760584.2025.2517715. Epub 2025 Jun 13.PMID: 40485390

A real-life multicenter experience for the post-pandemic management of hypersensitivity reactions to Covid-19 vaccines.

Arcolaci A, Guidolin L, Olivieri E, Bilò MB, Bonadonna P, Braschi MC, Crivellaro MA, Martignago I, Matucci A, Nalin F, Parronchi P, Scarmozzino R, Senna G, Simioni L, Vultaggio A, Zanoni G.Vaccine. 2025 Jun 5;61:127337. doi: 10.1016/j.vaccine.2025.127337. Online ahead of print.PMID: 40479930

A Latent Profile Analysis of COVID-19 and Influenza Vaccine Hesitancy among Economically Marginalized Hispanic Mothers of Children under Five Years of Age in the US.

Park YW, Bragard E, Madhivanan P, Fisher CB.J Racial Ethn Health Disparities. 2025 Jun;12(3):1824-1835. doi: 10.1007/s40615-024-02012-1. Epub 2024 May 7.PMID: 38713370

Low-dose intradermal mRNA-1273 boosting vaccine following BBiBP-CorV vaccination during the omicron pandemics.

Chaiwong W, Takheaw N, Laopajon W, Nisoong C, Pata S, Duangjit P, Inchai J, Pothirat C, Bumroongkit C, Deesomchok A, Theerakittikul T, Limsukon A, Tajarernmuang P, Niyatiwatchanchai N, Trongtrakul K, Kasinrerk W, Liwsrisakun C.Vaccine. 2025 Jun 4;61:127330. doi: 10.1016/j.vaccine.2025.127330. Online ahead of print.PMID: 40472671

Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.

Liu J, Chen X, Chen C, Wu J, Xie F, Li J, Han H, Zhao Y, Yang Y.Toxicology. 2025 Jun;514:154107. doi: 10.1016/j.tox.2025.154107. Epub 2025 Mar 8.PMID: 40064458

Factors associated with COVID-19 vaccine confidence among Arab, Asian, Black, Indigenous, and White individuals in Canada: Latent profile analyses.

Moshirian Farahi SMM, Xu Y, Dort J, Caulley L, Beogo I, Dalexis RD, Cénat JM.Vaccine. 2025 Jun 5;61:127358. doi: 10.1016/j.vaccine.2025.127358. Online ahead of print.PMID: 40479929

Cellular response, persistent humoral response and efficacy elicited by a CV-A16 vaccine candidate in mice.

Qin XX, Deng M, Wu J, Yang J, You L, Meng SL, Guo J, Qian SS, Shen S.Vaccine. 2025 Jun 10;61:127276. doi: 10.1016/j.vaccine.2025.127276. Online ahead of print.PMID: 40499348

FDA Review of Novavax's COVID-19 Vaccine-Regulatory Integrity and Deviations From Standard Practice.

Zettler PJ, Cha S, Despres S, Lurie P.JAMA. 2025 Jun 9. doi: 10.1001/jama.2025.9898. Online ahead of print.PMID: 40489310

New-onset Fulminant Type 1 Diabetes Following COVID-19 Vaccination.

Shigematsu T, Yamaguchi Y, Watanabe T, Tsujimoto K, Sato F, Yamada T, Tsujino M.Intern Med. 2025 Jun 1;64(11):1691-1695. doi: 10.2169/internalmedicine.5053-24. Epub 2025 Mar 22.PMID: 40128995

Global Interdependence, Just Vaccine Allocation, and Compensatory Justice: A New Model.

Fredette KJ.Dev World Bioeth. 2025 Jun 8. doi: 10.1111/dewb.12486. Online ahead of print.PMID: 40483724

Metal-organic framework-based delivery systems as nanovaccine for enhancing immunity against porcine circovirus type 2.

Ding LG, Shi M, Yu ED, Xu YL, Zhang YY, Geng XL, Liu F, Li JD, Chen Z, Yu J, Wu JQ.Mater Today Bio. 2025 Mar 27;32:101712. doi: 10.1016/j.mtbio.2025.101712. eCollection 2025 Jun.PMID: 40230641

Sneddon-Wilkinson Disease Induced by COVID-19 Vaccine: An Unusual Presentation.

Cao R, Xu T.Clin Cosmet Investig Dermatol. 2025 Jun 3;18:1375-1378. doi: 10.2147/CCID.S524100. eCollection 2025.PMID: 40486217

[Illuminating the shadows - perspectives on mRNA vaccine adverse events - mechanisms, risks and management]: A review.

Kang H, Sun Y, Fang Z, Ding W, Bai T, Yang K, Jiang D.Int J Biol Macromol. 2025 Jun 5:145010. doi: 10.1016/j.ijbiomac.2025.145010. Online ahead of print.PMID: 40482741

Thymoquinone enhances efficacy of cervical Cancer therapeutic vaccines via modulating $CD8^+$ T cells.

Che Y, Song B, Song Y, Sun J, Zhao X, Zheng J, Shi Y, Duan Y, Shao Y, Yang T, Yang L.Int Immunopharmacol. 2025 Jun 5;157:114605. doi: 10.1016/j.intimp.2025.114605. Epub 2025 May 1.PMID: 40316484

Epitope-Optimized Influenza Hemagglutinin Nanoparticle Vaccine Provides Broad Cross-Reactive Immunity against H9N2 Influenza Virus.

Hao M, Wang Y, Yang W, Xu M, Guan Y, Zhang Y, Chen J.ACS Nano. 2025 Jun 10;19(22):20824-20840. doi: 10.1021/acsnano.5c03199. Epub 2025 Jun 1.PMID: 40452158

Suspicion and other feelings about COVID-19 vaccines and mask-wearing among individuals recovering from substance addiction.

Hassett-Walker C.Public Health Pract (Oxf). 2025 Feb 15;9:100599. doi: 10.1016/j.puhip.2025.100599. eCollection 2025 Jun.PMID: 40040672

Capsular immunity is necessary for protection against some but not all strains of Glaesserella parasuis.

Hau SJ, Luan SL, Weinert LA, Langford PR, Rycroft A, Wren BW, Maskell DJ, Tucker AWD, Brockmeier SL.Vet Microbiol. 2025 Jun;305:110509. doi: 10.1016/j.vetmic.2025.110509. Epub 2025 Apr 11.PMID: 40250105

Correction to: Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2 Omicron Period.

[No authors listed]J Infect Dis. 2025 Jun 2;231(5):e997-e1009. doi: 10.1093/infdis/jiaf137.PMID: 40327046

Investigating the state of vaccine confidence among the general public and parents with children up to 13 years in Flanders (Belgium).

Pattyn J, Hanning N, Valckx S, Claessens T, Karafillakis E, Jong V, Theeten H, Hendrickx G, Van Damme P.Vaccine. 2025 Jun 11;58:127250. doi: 10.1016/j.vaccine.2025.127250. Epub 2025 May 15.PMID: 40378551

[Health status of calves with and without the use of a herd-specific vaccine against Mycoplasmopsis bovis].

Hässig M, Luchsinger P, Buser M, Ernstberger M, Kaske M.Schweiz Arch Tierheilkd. 2025 Jun;167(6):343-350. doi: 10.17236/sat00456.PMID: 40422649

Montmorillonite-Based Oral Vaccine for Colorectal Cancer Immunotherapy through Mucosal Immune Activation.

Yang J, Zhu YX, Chen Z, Tian Z, Lin H, Shi J.J Am Chem Soc. 2025 Jun 3. doi: 10.1021/jacs.5c06776. Online ahead of print.PMID: 40460435

Childhood vaccine hesitancy: The power of metaphors.

Moore DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, Abramov DM, de Azevedo ZMA, Salú MDS, de Vasconcelos ZFM, Gomes Junior SCDS, da Silva Filho OC, Camacho KG.Vaccine. 2025 Jun 11;58:127221. doi: 10.1016/j.vaccine.2025.127221. Epub 2025 May 15.PMID: 40378552

Expression of Concern: Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2 Omicron Period.

[No authors listed]J Infect Dis. 2025 Jun 2;231(5):e996. doi: 10.1093/infdis/jiae549.PMID: 39607799

Effect of an Educational Intervention on Human Papillomavirus Vaccine Hesitancy in a Pediatric Clinic.

Dinescu-Munoz N, Clare A, Lafnitzegger A, Barley Y, Kuzmin N, Takagishi J, Garcia S, Klocksieben F, Gaviria-Agudelo C.J Pediatr Adolesc Gynecol. 2025 Jun;38(3):336-341. doi: 10.1016/j.jpag.2024.12.010. Epub 2024 Dec 17.PMID: 39701491

The development of functional opsonophagocytic assays to evaluate antibody responses to *Klebsiella pneumoniae* capsular antigens.

Lawrence R, Bownes E, Johnson M, Fox H, Huff D, Olave I, Datta A, Goldblatt D, Karaky N.mSphere. 2025 Jun 12:e0017625. doi: 10.1128/msphere.00176-25. Online ahead of print.PMID: 40503906

Perspective: An overemphasis on vaccines for Mpox skewes important lessons from COVID-19 and the need for public health approaches.

Brown GW, von Agris J, Bell D, Sturmberg J, Ridde V, Makali SL, Balaluka GB, Bridge G, Paul E.J Infect Public Health. 2025 Jun;18(6):102749. doi: 10.1016/j.jiph.2025.102749. Epub 2025 Mar 12.PMID: 40088579

Human papillomavirus in Bangladesh: Challenges and opportunities for prevention.

Salauddin M, Irin F, Disha P, Ishi NS, Akter S, Ara R, Ahmed MU, Hossain MG.Gynecol Oncol Rep. 2025 Apr 21;59:101747. doi: 10.1016/j.gore.2025.101747. eCollection 2025 Jun.PMID: 40309315

Exploration of virulence and immune evasion functions of the candidate vaccine antigen SpyAD in the globally disseminated M1T1 group A Streptococcus strain.

Stream A, Dahesh S, Thomas L, Gao NJ, Bjånes E, Kang K, Koh T, Kapoor N, Nizet V.mBio. 2025 Jun 11:e0068325. doi: 10.1128/mbio.00683-25. Online ahead of print.PMID: 40497733

Timeliness of the second dose of measles-containing vaccine uptake and its determinants among children aged 24-36 months in Gondar City, Northwest Ethiopia, 2023: Community-based cross-sectional study design.

Adisu MA.J Virus Erad. 2025 Mar 17;11(2):100594. doi: 10.1016/j.jve.2025.100594. eCollection 2025 Jun.PMID: 40226158

Facile Conjugation Method of CpG-ODN Adjuvant to Intact Virions for Vaccine Development.

Maalouf AA, Zhu H, Zaman A, Carpino N, Hearing J, Bhatia SR, Carrico IS.Chembiochem. 2025 Jun 3;26(11):e202400988. doi: 10.1002/cbic.202400988. Epub 2025 May 21.PMID: 40164565

Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake Using the National Healthcare data System.

Quentin E, Ahmed I, Duong CH, Tubert-Bitter P, Escolano S.Vaccine. 2025 Jun 11;58:127223. doi: 10.1016/j.vaccine.2025.127223. Epub 2025 May 20.PMID: 40398367

Structural characterization and immune activity evaluation of polysaccharide purified from Viola phillipica.

Guo J, Wei T, Chen J, Hong A, He Q, Lin Y, Ren Z, Qin T.Int J Pharm. 2025 Jun 10;678:125689. doi: 10.1016/j.ijpharm.2025.125689. Epub 2025 May 5.PMID: 40334829

Risk of COVID-19 reinfection and vaccine breakthrough infection, Madera County, California, 2021.

Nguyen M, Paul E, Mills PK, Paul S.Am J Epidemiol. 2025 Jun 3;194(6):1595-1602. doi: 10.1093/aje/kwae308.PMID: 39191647

Safety of RTS,S/AS01E vaccine for malaria in African children aged 5 to 17 months: A systematic review and meta-analysis of randomized controlled trials.

Zoa JA, Njemguie Linjouom RM, Nyangono Ndongo M, Nkeck JR.PLOS Glob Public Health. 2025 Jun 16;5(6):e0004387. doi: 10.1371/journal.pgph.0004387. eCollection 2025.PMID: 40522967

Exploring cervical cancer mortality in Brazil: an ecological study on socioeconomic and healthcare factors.

Silva Filho ALD, Romualdo GR, Pinhati MES, Neves GL, Oliveira JA, Moretti-Marques R, Nogueira-Rodrigues A, Tsunoda AT, Cândido EB.Int J Gynecol Cancer. 2025 Jun;35(6):101851. doi: 10.1136/ijgc-2024-005738. Epub 2025 Apr 19.PMID: 39366720

Tough and waterproof microneedles overcome mucosal immunotolerance by modulating antigen release patterns.

He P, He C, Guo R, Ou Y, Chang Y, Xie Z, Tang X, Xu Y, Zhao Y, Wang H, Guo Z, Bai S, Chen Z, Fan F, Du G, Sun X.J Control Release. 2025 Jun 10;382:113740. doi: 10.1016/j.jconrel.2025.113740. Epub 2025 Apr 16.PMID: 40250628

Respiratory syncytial virus prevention in immunocompromised hosts: gaps and opportunities.

Murray A, Chu HY.Curr Opin Infect Dis. 2025 Jun 6. doi: 10.1097/QCO.0000000000001124. Online ahead of print.PMID: 40471043

Funding Strategies to Foster Enabling Basic Science Research in the Development of an HIV Vaccine.

Shapiro SZ.Curr HIV Res. 2025 Jun 3. doi: 10.2174/011570162X360804250527065110. Online ahead of print.PMID: 40464178

Exploring Perceptions of HPV Risks and Motivations to Vaccination in MSM at a Community-Based HIV Clinic.

Lueck JS, Sandhu LS, Richman J, Walker C, Trujillo JP, Callahan D, Smith AC, Ivatury SJ.AIDS Behav. 2025 Jun 2. doi: 10.1007/s10461-025-04752-5. Online ahead of print.PMID: 40451987

Social Determinants of Health Associated With SARS-CoV-2 Testing and Vaccine Attitudes in a Cross-Sectional Study of Latinx Individuals in Oregon.

Budd EL, De Anda S, Halvorson S, Leve LD, Mauricio AM, McWhirter EH, García JIR; Oregon Saludable: Juntos Podemos Community and Scientific Advisory Board; DeGarmo DS.AJPM Focus. 2025 Feb 19;4(3):100326. doi: 10.1016/j.focus.2025.100326. eCollection 2025 Jun.PMID: 40231115

Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH).

Cahn P, Barreto L, Figueroa MI, Fink V, Rolon MJ, Lopardo G, Cassetti I, Ceschel M, Patterson P, Gambardella L, Mernies G, Nava A, Gou J, Wang R, Zhu T, Halperin SA.PLoS One. 2025 Jun 11;20(6):e0312893. doi: 10.1371/journal.pone.0312893. eCollection 2025.PMID: 40498774

Separation of virus-like particles and nano-emulsions for vaccine development by Capillary Zone Electrophoresis.

Elshamy YS, Kinsey C, Rustandi RR, Sutton AT.Anal Chim Acta. 2025 Jun 15;1355:344011. doi: 10.1016/j.aca.2025.344011. Epub 2025 Apr 1.PMID: 40274334

Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine: Correction.

Madhi SA, Kampmann B, Simões EAF, Zachariah P, Pahud BA, Radley D, Sarwar UN, Shittu E, Llapur C, Pérez Marc G, Maldonado Y, Kachikis A, Zar HJ, Swanson KA, Maddalena Lino M, Anderson AS, Gurtman A, Munjal I.Obstet Gynecol. 2025 Jun 1;145(6):e154. doi: 10.1097/AOG.0000000000005947.PMID: 40373323

Pathotyping and molecular serotyping of clinical isolates of Glaesserella parasuis in Taiwan.

Lin WH, Yen CH, Yang CY, Lin CF, Chang YF, Lin CN, Chiou MT.Braz J Microbiol. 2025 Jun;56(2):1283-1289. doi: 10.1007/s42770-025-01620-1. Epub 2025 Feb 11.PMID: 39932660

B-Cell Subset Representation Predicts SARS-CoV-2 Vaccine Response in Solid Organ Transplant Recipients.

Knox JJ, Lee I, Blumberg EA, Rosenfeld AM, Meng W, Liu F, Kearns C, O'Doherty U, Shaked A, Olthoff KM, Luning Prak ET.J Infect Dis. 2025 Jun 3:jiaf250. doi: 10.1093/infdis/jiaf250. Online ahead of print.PMID: 40459569

Young adult perspectives on deciding to get human papillomavirus (HPV) vaccination in urban and rural communities: A qualitative research study.

Sundaram ME, Christianson B, Alonge OD, Doan M, Ljungman H, Polter E, Steinberg A, Bendixsen CG, Williams CL, Belongia EA, Nguyen HQ, VanWormer JJ.Hum Vaccin Immunother. 2025 Dec;21(1):2508572. doi: 10.1080/21645515.2025.2508572. Epub 2025 Jun 11.PMID: 40498650

"Not Only a Matter of Personal Interest"-Vaccination Narratives and the Model of Moral Motives in China and Germany.

Müller S, Wachinger J, Jiao L, Bärnighausen T, Chen S, McMahon SA.Qual Health Res. 2025 Jun;35(7):740-754. doi: 10.1177/10497323241277107. Epub 2024 Oct 12.PMID: 39395153

Prison Vaccination in a pandemic: Geographic disparities and policy insights.

Merritt A, Bansal S.Vaccine. 2025 Jun 11;58:127218. doi: 10.1016/j.vaccine.2025.127218. Epub 2025 May 15.PMID: 40378549

Molecular modeling to design a multiepitope vaccine against emerging tick-borne Yezo virus and its validation through biophysics techniques.

Ayaz H, Suleman M, Shah AA, Abideen SA, Ahmad F, Ali M, Ahmad S, Nawaz A, Khan HA, Hussain I, Irfan M, Waheed Y.In Silico Pharmacol. 2025 Jun 5;13(2):80. doi: 10.1007/s40203-025-00370-0. eCollection 2025.PMID: 40487341

Engineering a novel multi-epitope mRNA vaccine against major bacterial meningitis pathogens: E. coli K1, group B Streptococcus, Listeria monocytogenes, Neisseria meningitidis, and Streptococcus pneumoniae.

Fattahi N, Khoshnood S, Omidi N, Kalani BS.Int J Biol Macromol. 2025 Jun;317(Pt 1):144311. doi: 10.1016/j.ijbiomac.2025.144311. Epub 2025 May 16.PMID: 40383315

Shingles Vaccine Linked to Lower Dementia Risk.

Anderer S.JAMA. 2025 Jun 3;333(21):1856. doi: 10.1001/jama.2025.5644.PMID: 40314936

Temporal trends in vaccine hesitancy among Caribbean health workers: analysis of 2021 and 2024 surveys.

Velandia-Gonzalez M, Rivera T, Puertas EB, Rhoda DA, Brustrom J.Rev Panam Salud Publica. 2025 Jun 10;49:e61. doi: 10.26633/RPSP.2025.61. eCollection 2025.PMID: 40496837

Biogenic silver nanoparticle as an adjuvant in an S1 subunit recombinant vaccine.

de Freitas SB, Neto ACPS, Panagio LA, Collares TV, Seixas FK, Sousa FSS, Hartwig DD.Braz J Microbiol. 2025 Jun;56(2):757-766. doi: 10.1007/s42770-025-01613-0. Epub 2025 Jan 29.PMID: 39878824

["I'm not an anti-vaxxer, but": understanding vaccine hesitancy based on narratives of hesitant parents].

Cunegundes KSA, Machado DM, Vieira NV.Cad Saude Publica. 2025 Jun 9;41(5):e00154624. doi: 10.1590/0102-311XPT154624. eCollection 2025.PMID: 40498917

Disassembly and reassembly of AP205 virus-like particles and the removal of bound RNA for cargo encapsulation.

Wong ZW, Yang D.Int J Biol Macromol. 2025 Jun;315(Pt 2):144641. doi: 10.1016/j.ijbiomac.2025.144641. Epub 2025 May 24.PMID: 40419056

Socio-demographic and behavioral predictors of multiple-dose COVID-19 vaccine uptake among older adults in Hong Kong: A community-based cross-sectional study of the generations connect project.

Wan Jia Aaron H, Yuan R, Chan SCS.Vaccine. 2025 Jun 2;61:127308. doi: 10.1016/j.vaccine.2025.127308. Online ahead of print.PMID: 40460652

Same-day human papilloma virus vaccination improves vaccine uptake in a dermatology sexually transmitted infection clinic: A quality improvement-based model for improving vaccination rates.

Himeles JR, McKenzie C, Manduca S, Shaw KS, Jones Z, Nagler A, Pomeranz MK, Gutierrez D, Zampella JG.J Am Acad Dermatol. 2025 Jun;92(6):1288-1294. doi: 10.1016/j.jaad.2025.01.091. Epub 2025 Feb 4.PMID: 39909346

Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox.

Ahuja R, Vishwakarma P, Kumar V, Khatri R, Chatterjee A, Mishra S, Rizvi ZA, Singh A, Kaur G, Maithil V, Tarane K, Chauhan A, Singh S, Yadav P, Yadav D, Sinha SK, Ali SK, Chatterjee A, Priyadarsiny P, Awasthi A, Prasad VM, Ahmed S, Samal S.NPJ Vaccines. 2025 Jun 6;10(1):117. doi: 10.1038/s41541-025-01174-1.PMID: 40480973

BNT162b2 mRNA vaccine elicits robust virus-specific antibodies but poor cross-protective CD8(+) memory T cell responses in adolescents with type 1 diabetes.

Shen CF, Chang PD, Chou YY, Wang SW, Pan YW, Chen CA, Lin CW, Tsai BY, Tsai PJ, Liu CC, Cheng CM, Ko WC, Shieh CC; Taiwan Pediatric Infectious Disease Alliance (TPIDA).J Microbiol Immunol Infect. 2025 Jun;58(3):294-303. doi: 10.1016/j.jmii.2024.12.009. Epub 2025 Jan 3.PMID: 39765453

Lyophilized SARS-CoV-2 self-amplifying RNA vaccines for microneedle Array patch delivery.

Driskill MM, Coates IA, Hurst PJ, Rajesh NU, Dulay MT, Waymouth RM, Akahata W, Matsuda K, Smith JF, Jacobson GB, Perry JL, Tian S, DeSimone JM.J Control Release. 2025 Jun 9:113944. doi: 10.1016/j.jconrel.2025.113944. Online ahead of print.PMID: 40499765

A factorial design-optimized microfluidic LNP vaccine elicits potent magnesium-adjuvating cancer immunotherapy.

Xie Y, Guo J, Hu J, Li Y, Zhang Z, Zhu Y, Deng F, Qi J, Zhou Y, Chen W.Mater Today Bio. 2025 Mar 24;32:101703. doi: 10.1016/j.mtbio.2025.101703. eCollection 2025 Jun.PMID: 40230646

Priming or Boosting P. falciparum Transmission Blocking Responses with Recombinant Vaccines or Gametocyte Extract.

Song Y, Deng B, Long CA, Li Q, Diakite M, Huang WC, Zhou S, Luo Y, Ivanochko D, MacGill RS, Julien JP, Miura K, Lovell J.J Infect Dis. 2025 Jun 12:jiaf318. doi: 10.1093/infdis/jiaf318. Online ahead of print.PMID: 40503613

'Vaccine preferences and government responsiveness in a public health crisis: Lessons from the Middle East'.

Mazaheri N.Glob Public Health. 2025 Dec;20(1):2499095. doi: 10.1080/17441692.2025.2499095. Epub 2025 Jun 9.PMID: 40488394

Vaccine antigen-based genotyping of Bordetella pertussis by direct Sanger sequencing of clinical samples in Peru from 2018 to 2019.

Juscamayta-López E, Vega-Abad B, Valdivia F, Soto MP, Horna H, García-de-la-Guarda R.Microbiol Spectr. 2025 Jun 3;13(6):e0200424. doi: 10.1128/spectrum.02004-24. Epub 2025 May 14.PMID: 40366145

Replication-deficient whole-virus vaccines against cytomegalovirus induce protective immunity in a guinea pig congenital infection model.

Schleiss MR, Fernández-Alarcón C, Bierle CJ, Geballe AP, Badillo-Guzman A, Tanna CE, Tsriwong K, Blackstad M, Wang JB, McVoy MA.J Virol. 2025 Jun 11:e0020725. doi: 10.1128/jvi.00207-25. Online ahead of print.PMID: 40497723

Pediatric Post-Vaccine Aluminum Granuloma: Morin Stain as a Diagnostic Aid.

Chang JR, Wong A, Diaz-Perez JA, Cai C, Mochel MC.J Cutan Pathol. 2025 Jun;52(6):399-402. doi: 10.1111/cup.14797. Epub 2025 Feb 24.PMID: 39994837

Development and efficacy of a novel mRNA cocktail for the delivery of African swine fever virus antigens and induction of immune responses.

Hu X, Liu C, Rcheulishvili N, Wang Y, Xiong T, Xie F, Wang X, Chen R, Wang PG, He Y.Microbiol Spectr. 2025 Jun 3;13(6):e0290924. doi: 10.1128/spectrum.02909-24. Epub 2025 Apr 29.PMID: 40298440

The validity of test-negative design for assessment of typhoid conjugate vaccine protection: comparison of estimates by different study designs using data from a cluster-randomised controlled trial.

Feng S, Zhang Y, Khanam F, Voysey M, Pitzer VE, Qadri F, Clemens JD, Pollard AJ, Liu X.Lancet Glob Health. 2025 Jun;13(6):e1122-e1131. doi: 10.1016/S2214-109X(25)00056-7. Epub 2025 Apr 16.PMID: 40252689

Avian flu: a swooping threat or just a volatile menace? What clinicians need to know.

Patauner F, Durante-Mangoni E, Bertolino L.Eur J Intern Med. 2025 Jun;136:27-30. doi: 10.1016/j.ejim.2025.04.032. Epub 2025 May 1.PMID: 40312223

Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and shiga prefecture.

Suzuki T, Hirano Y, Kamei K, Miyata K, Kusama M, Karwala P, Moyon C, Crossan C, Ito S, Vietri J, Kakuno F.Expert Rev Pharmacoecon Outcomes Res. 2025 Jun 13. doi: 10.1080/14737167.2025.2519755. Online ahead of print.PMID: 40512072

Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective, single-centre, cohort study and analysis of transcriptomic predictors of response.

Drennan PG, Provine NM, Harris SA, Otter A, Hollett K, Cooper C, De Maeyer RPH, Nassanga B, Ateere A, Pudjohartono MF, Peng Y, Chen JL, Jones S, Fadzillah NHM, Grifoni A, Sette A, Satti I, Murray SM, Rowe C, Mandal S, Hallis B, Klenerman P, Dong T, Richards D, Fullerton J, McShane H, Coles M.Lancet Microbe. 2025 Jun;6(6):101045. doi: 10.1016/j.lanmic.2024.101045. Epub 2025 Apr 23.PMID: 40286799

Exploring the impact of changing government policy on vaccination eligibility for 50-64 year olds: A qualitative thematic analysis in England and Scotland.

Baxter W, Vilanova Echávarri I, Porat T.Hum Vaccin Immunother. 2025 Dec;21(1):2513721. doi: 10.1080/21645515.2025.2513721. Epub 2025 Jun 10.PMID: 40493498

The effect of school-based interventions on HPV vaccine-related knowledge, attitudes, and practices among adolescents in France: Secondary results from the PrevHPV trial.

Dussault JM, Rivera Torres AF, Oudin Doglioni D, Gagneux-Brunon A, Le Duc-Banaszuk AS, Bruel S, Michel M, Gauchet A, Barret AS, Sicsic J, Raude J, Thilly N, Mueller JE; PrevHPV Consortium.Vaccine. 2025 Jun 5;61:127344. doi: 10.1016/j.vaccine.2025.127344. Online ahead of print.PMID: 40479931

A Porphyrin Nanomaterial for Photoimmunotherapy for Treatment of Melanoma.

Fan Z, Pei Q, Sun H, Zhang H, Xie Z, Zhang T, Ma C.Adv Sci (Weinh). 2025 Jun;12(21):e2414592. doi: 10.1002/advs.202414592. Epub 2025 Apr 9.PMID: 40202119

Evaluating the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults: a systematic review and meta-analysis of randomized controlled trials.

Siddiqui E, Khan MS, Khalid M, Chandani HK, Naeem U, Khan MM, Wasti SO.Ther Adv Vaccines Immunother. 2025 Jun 5;13:25151355251344473. doi: 10.1177/25151355251344473. eCollection 2025.PMID: 40485775

Viral vaccines promote endoplasmic reticulum stress-induced unfolding protein response in teleost erythrocytes.

Salvador-Mira M, Gimenez-Moya P, Manso-Aznar A, Sánchez-Córdoba E, Sevilla-Diez MA, Chico V, Nombela I, Puente-Marin S, Roher N, Perez L, Dučić T, Benseny-Cases N, Perez-Berna AJ, Ortega-Villaizan MDM.Eur J Cell Biol. 2025 Jun;104(2):151490. doi: 10.1016/j.ejcb.2025.151490. Epub 2025 Apr 9.PMID: 40252498

The effect of mumps vaccine on the incidence of mumps in Hefei: An interrupted time-series analysis.

Shi T, Qu G, Zhang Y, Hou L, Jin Y.Hum Vaccin Immunother. 2025 Dec;21(1):2511359. doi: 10.1080/21645515.2025.2511359. Epub 2025 Jun 5.PMID: 40470633

The safety of COVID-19 vaccines in a large French series of patients with neuromuscular conditions and the impacts of vaccination on their daily lives.

Barnay M, Foubert-Samier A, Violleau MH, Campana-Salort E, Cintas P, Laforêt P, Mathis S, Péréon Y, Tard C, Sirma F, Attarian S, Solé G.Rev Neurol (Paris). 2025 Jun;181(6):571-578. doi: 10.1016/j.neurol.2025.04.007. Epub 2025 Apr 29.PMID: 40307085

Safety and Immunogenicity of Poultry Vaccine for Protecting Critically Endangered Avian Species against Highly Pathogenic Avian Influenza Virus, United States.

Katzner TE, Blackford AV, Donahue M, Gibbs SEJ, Lenoch J, Martin M, Rocke TE, Root JJ, Styles D, Cooper S, Dean K, Dvornicky-Raymond Z, Keller D, Sanchez C, Dunlap B, Grier T, Jones MP, Nitzel G, Patrick E, Purcell M, Specht AJ, Suarez DL.Emerg Infect Dis. 2025 Jun;31(6):1131-1139. doi: 10.3201/eid3106.241558. Epub 2025 Apr 15.PMID: 40233764

HPV Vaccine Effectiveness by Age, Age at Vaccination, and Timing of Vaccination Relative to Age at First Sex among Men who Have Sex with Men - Seattle, Washington, 2018-2020.

Buchbinder SA, Lin J, Markowitz LE, Hughes JP, Querec TD, Unger ER, Dada D, Iqbal A, Golden MR, Meites E, DeSisto CL, Winer RL.Sex Transm Dis. 2025 Jun 2. doi: 10.1097/OLQ.0000000000002192. Online ahead of print.PMID: 40454692

RFK Jr dismisses entire CDC vaccine advisory panel.

Taylor L.BMJ. 2025 Jun 10;389:r1206. doi: 10.1136/bmj.r1206.PMID: 40494611

Tumor-microenvironment responsive nanomodulator for near infrared photothermal immunotherapy of hepatocellular carcinoma.

Kong F, Xia T, Zhu X, Zeng X, Wang F, Lyu J, Lu L, Wang Z.J Nanobiotechnology. 2025 Jun 5;23(1):417. doi: 10.1186/s12951-025-03440-9.PMID: 40474226

Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countries.

Le Doare K, Benassi V, Cavaleri M, Enwere G, Giersing B, Goldblatt D, Heath P, Hombach J, Isbrucker R, Karampatsas K, Madhi SA, Smith AW.Vaccine. 2025 Jun 11;58:127131. doi: 10.1016/j.vaccine.2025.127131. Epub 2025 May 13.PMID: 40367817

Perceived feasibility of a multicomponent prenatal intervention on childhood vaccinations: Findings from a national cross-sectional survey of prenatal care providers, April-June 2022.

Vasudevan L, Porter RM, Stinnett SS, Hart L, Turner EL, Zullig LL, Vogt TM, Swamy GK, Walter EB, Bednarczyk RA, Orenstein WA, Gray B; ADEPT External Advisory Board.Int J Gynaecol Obstet. 2025 Jun;169(3):1162-1173. doi: 10.1002/ijgo.15970. Epub 2025 Mar 27.PMID: 40145399

Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluster-randomised trial.

Coldiron ME, Soumana I, Baudin E, Langendorf C, Mamiafo Tchoula C, Brah S, Karani A, Gallagher KE, Kagucia EW, Scott JAG, Grais RF.Lancet Infect Dis. 2025 Jun;25(6):634-642. doi: 10.1016/S1473-3099(24)00719-9. Epub 2025 Jan 8.PMID: 39798587

Clinical Impact and Cost-Effectiveness of Updated 2023/24 COVID-19 mRNA Vaccination in High-Risk Populations in the United States.

Joshi K, Dronova M, Paterak E, Nguyen VH, Kopel H, Mansi J, Van de Velde N, Beck E.Infect Dis Ther. 2025 Jun;14(6):1219-1238. doi: 10.1007/s40121-025-01128-z. Epub 2025 Apr 15.PMID: 40232338

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population.

Tzanetakos C, Kokkinaki I, Barmpouni M, Kossyvaki V, Psarra M, Perdrizet J, Gourzoulidis G.Expert Rev Vaccines. 2025 Dec;24(1):486-498. doi: 10.1080/14760584.2025.2515596. Epub 2025 Jun 5.PMID: 40459051

Development of an oral gut-targeted rabies virus-like particles (RVLPs) vaccine with mucosal immune adjuvant LTB via delivering of localized-release microparticles.

Niu J, Zhao Z, Zhang T, Liu Q, Huang L, Li S, Liu H, Yu S, Li L, Jia H, Zheng W, Yang F, Ma X.Emerg Microbes Infect. 2025 Dec;14(1):2515406. doi: 10.1080/22221751.2025.2515406. Epub 2025 Jun 16.PMID: 40476513

The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults Worldwide.

Giannelos N, Curran D, Matthews S, Carrico J, Cunningham AL.Infect Dis Ther. 2025 Jun;14(6):1327-1341. doi: 10.1007/s40121-025-01161-y. Epub 2025 May 21.PMID: 40399558

A theory-based educational intervention to increase mothers' intention to vaccinate their daughters against human papillomavirus: A randomised controlled trial.

Alqethami A, Alhalal E.Patient Educ Couns. 2025 Jun;135:108731. doi: 10.1016/j.pec.2025.108731. Epub 2025 Mar 3.PMID: 40048824

Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.

Ribeiro Dos Santos G, Jawed F, Mukandavire C, Deol A, Scarponi D, Mboera LEG, Seruyange E, Poirier MJP, Bosomprah S, Udeze AO, Dellagi K, Hozé N, Chilongola J, Nasrallah GK, Cauchemez S, Salje H.Nat Med. 2025 Jun 10. doi: 10.1038/s41591-025-03703-w. Online ahead of print.PMID: 40495015

Heat-inactivated Mycobacterium bovis and P22PI protein immunocomplex: Two candidates for use as immunostimulants of innate immune response.

Agulló-Ros I, Burucúa MM, Cheuquepán FA, Domínguez M, Sevilla IA, Martínez R, Plá N, Risalde MA, Marin MS.Vet Microbiol. 2025 Jun;305:110527. doi: 10.1016/j.vetmic.2025.110527. Epub 2025 Apr 21.PMID: 40279721

Immunogenicity of primary and booster MenACWY-TT vaccination in older adults and the importance of IgM.

Visser M, van Rooijen DM, Wolf J, Beckers L, Ohm M, de Jonge MI, Buisman AM, den Hartog G.NPJ Vaccines. 2025 Jun 5;10(1):115. doi: 10.1038/s41541-025-01180-3.PMID: 40473635

Human Papillomavirus Vaccination uptake and associated factors among schools girls aged between 9-14 years in Ethiopia: Performance Monitoring for Action (PMA-ET) 2023, multilevel analysis.

Enyew EB, Kasaye MD, Kebede SD, Feyisa MS, Serbessa NG, Tebeje TM, Tareke AA.PLoS One. 2025 Jun 10;20(6):e0325557. doi: 10.1371/journal.pone.0325557. eCollection 2025.PMID: 40493648

Identification of a linear B-cell epitope in B117L-213 protein of ASFV using monoclonal antibodies.

You L, Liu G, Yan Z, Cai M, Chen Y, Si X, Wang X, Zhang A, Sun A, Han S, Wan B, Du Y, Zhang G.Int Immunopharmacol. 2025 Jul 28;160:114970. doi: 10.1016/j.intimp.2025.114970. Epub 2025 Jun 1.PMID: 40456193

Trump watch: Confusion over covid-19 vaccination, HIV vaccine funding withdrawn, and more.

Looi MK.BMJ. 2025 Jun 3;389:r1145. doi: 10.1136/bmj.r1145.PMID: 40461181

Expression Purification and Immunogenicity Detection of HtsA + FtsB Fusion Protein From Streptococcus pyogenes.

Li J, Ju Y, Jiang M, Wang JX, Li S, Yang XY.Microbiol Immunol. 2025 Jun;69(6):317-325. doi: 10.1111/1348-0421.13217. Epub 2025 Apr 11.PMID: 40213873

Development of a Tetrahymena thermophila-Based Vaccine Expressing Miamiensis avidus Ciliary Proteins to Combat Scuticociliatosis.

Watanabe Y, Kotake M, Matsuoka H, Yoshinaga T, Kitamura SI.J Fish Dis. 2025 Jun;48(6):e14097. doi: 10.1111/jfd.14097. Epub 2025 Feb 9.PMID: 39924163

Cell membrane vaccine delivery system: A review of the recent advances against breast cancer.

Hilles AR, Mahmood S, Widodo RT, Azemi AK, Nordin AH, Mohamad Norpi AS, Abd Jalil MF, Sofian ZM, Mohamed M, Hambali KA, Mohd Sani NI, Rashid R, Nordin ML.Int J Pharm. 2025 Jun 12:125849. doi: 10.1016/j.ijpharm.2025.125849. Online ahead of print.PMID: 40516769

Immunogenicity assessment of a swine fever-swine circovirus type 2 duplex vaccine candidate created using the Zera nanoparticle delivery method.

Wang P, Zhang G, Liu Q, Jiang L, Niu X, Fang M, Gao W, He Y, Li Y, Shu J, Zhang S.Vet Immunol Immunopathol. 2025 Jun;284:110929. doi: 10.1016/j.vetimm.2025.110929. Epub 2025 Apr 5.PMID: 40250144

Challenges and opportunities of vaccination during pregnancy: perspectives of 20 healthcare professionals.

Razai MS, Hargreaves S, Oakeshott P.J Public Health Policy. 2025 Jun;46(2):411-422. doi: 10.1057/s41271-025-00548-y. Epub 2025 Jan 22.PMID: 39843966

Maintenance of service delivery during medical countermeasures deployment: The association between the COVID-19 vaccine rollout and continuity of routine childhood immunization services in Uganda.

Kabwama SN, Razaz N, Ssenkusu JM, Lindgren H, Wanyenze RK, Driwale A, Alfvén T.PLOS Glob Public Health. 2025 Jun 13;5(6):e0004731. doi: 10.1371/journal.pgph.0004731. eCollection 2025.PMID: 40512740

Decade-long protection of the mumps vaccine: Insights from a large-scale serological study.

Qian Z, Chen Y, Zeng L, Liang C, Lin W, Xiong C, Li X, Deng Y, Chen L, Yang Y, Sun L, He J, Sun J.PLoS Negl Trop Dis. 2025 Jun 3;19(6):e0013125. doi: 10.1371/journal.pntd.0013125. eCollection 2025 Jun.PMID: 40460365

Lack of knowledge, not vaccine hesitancy, is the main cause of low human papilloma virus vaccination rate among systemic lupus erythematosus patients in Japan after suspension of proactive recommendation: Analysis of a patients' survey.

Kurita T, Yamamoto A, Hosoya T, Tsuchida M, Yasuda S, Gu Y.J Obstet Gynaecol Res. 2025 Jun;51(6):e16330. doi: 10.1111/jog.16330.PMID: 40437774

Psychometric validation of the COVID-19 vaccine hesitancy scale for primary and booster doses among university students: A cross-sectional study.

AlShurman BA, Majowicz SE, Grindrod K, Goh J, Butt ZA.Vaccine. 2025 Jun 7;61:127368. doi: 10.1016/j.vaccine.2025.127368. Online ahead of print.PMID: 40483882

A Pathogen-Mimicking Monkeypox Virus Nanovaccine Inspired by Assembly of Viral Antigens with β-Glucan and Dendrimer.

Xiao L, Hu L, Zhao X, Shen L, Yu W, Yang Y, Qi J, Hu T.Mol Pharm. 2025 Jun 2;22(6):3033-3044. doi: 10.1021/acs.molpharmaceut.4c01535. Epub 2025 May 14.PMID: 40366370

A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE).

Chen IM, Theile S, Madsen K, Johansen JS, Lorentzen T, Toxværd A, Høgdall E, Svane IM, Nielsen D.Immunooncol Technol. 2025 Apr 20;26:101054. doi: 10.1016/j.iotech.2025.101054. eCollection 2025 Jun.PMID: 40475164

Engineered vesicular cancer vaccines for immunosuppressive microenvironment reversion and in situ vaccine generation.

Li Y, Yu Y, Xia B, Zhao S, Li X, Hu Q, Tian Y, Wang Y, Zhou Y, Yang C, Zhang D, Zhang Z, Kong L.J Control Release. 2025 Jun 10;382:113658. doi: 10.1016/j.jconrel.2025.113658. Epub 2025 Mar 22.PMID: 40122241

Near-complete genome sequence of nervous necrosis virus from big-belly seahorses (*Hippocampus abdominalis*) collected in China.

Yang X, Yi M, Li M, Jia K.Microbiol Resour Announc. 2025 Jun 11:e0016225. doi: 10.1128/mra.00162-25. Online ahead of print.PMID: 40497676

An Intein-Spliced Nipah G Protein Ferritin Nanoparticle Vaccine Provides Complete Protection against Lethal Nipah Virus Challenge.

Chen S, Zhang X, Yao Y, Chuai X, Li K, Zhang B, Ye T, Wu Y, Ran Y, Chen L, Wang S, Wang W, Gong R, Zhang H, Chiu S.ACS Nano. 2025 Jun 17;19(23):21319-21332. doi: 10.1021/acsnano.4c17906. Epub 2025 Jun 2.PMID: 40455749

Avian influenza and use of the H5N1 vaccine to prevent zoonotic infection in Canada.

Nunn A, Sinilaite A, Warshawsky B, Salvadori MI, Bogoch II, Siu W.CMAJ. 2025 Jun 1;197(21):E599-E600. doi: 10.1503/cmaj.250641.PMID: 40456568

Engaging with Social Media: Implications for COVID-19 Research Participation Among Adults Living in the State of Florida.

Akpo JE, Murphy C, Mull J, Gaillard T, Bilello LA, Webb FJ.J Community Health. 2025 Jun;50(3):386-394. doi: 10.1007/s10900-024-01409-7. Epub 2024 Oct 13.PMID: 39396205

Estimating population immunity to SARS-CoV-2 by random sampling from primary and secondary healthcare in Scotland, May 2024.

McCormack MJ, Scott S, Logan N, Raveendran S, Newman J, Santos IA, Bailey D, Murcia PR, Thomson EC, Hosie MJ, Willett BJ.EBioMedicine. 2025 Jun;116:105760. doi: 10.1016/j.ebiom.2025.105760. Epub 2025 May 16.PMID: 40381379

Unexpected renal side effects of mRNA COVID-19 vaccines; a single-center experience and short review.

Pethő Á, Dobi D, Kardos M, Schnabel K.Am J Med Sci. 2025 Jun;369(6):739-744. doi: 10.1016/j.amjms.2025.01.002. Epub 2025 Jan 7.PMID: 39788422

Mobile Flu Fighter! Development and Pilot Implementation of a Mobile Vaccination Program to Reduce Pediatric Influenza Vaccination Disparities.

Denney MR, Moore K, Patterson B, Bialostozky A, Williams E.Clin Pediatr (Phila). 2025 Jun;64(6):830-840. doi: 10.1177/00099228241301848. Epub 2024 Nov 30.PMID: 39614730

Sense-Making During the RTS,S Malaria Vaccine Pilot Implementation in Ghana.

Tani-Eshon ET.Qual Health Res. 2025 Jun 13:10497323251347922. doi: 10.1177/10497323251347922. Online ahead of print.PMID: 40512580

Unprecedented case of rapid-onset autoimmune hepatitis triggered by COVID-19 mRNA vaccination, complicated by concurrent severe hemophagocytic lymphohistiocytosis and acute liver failure in a previously healthy adult: a multidisciplinary approach and review of therapeutic interventions.

Khalil Z, Fouly M, Helito P.Clin J Gastroenterol. 2025 Jun;18(3):408-416. doi: 10.1007/s12328-025-02109-y. Epub 2025 Apr 8.PMID: 40198479

Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children.

Costello LM, Kerns EK, McCulloh RJ, Roberts JR, Blatt DB, Tanski SE, Smith TR, Dehority W, Huntwork MP, Alamarat Z, Delaney MD, Hockett CW, McKee RS, Miller JM, Chang D, Ounpraseuth S, Newcomer SR.Vaccine. 2025 Jun 4;61:127245. doi: 10.1016/j.vaccine.2025.127245. Online ahead of print.PMID: 40472668

DNA vaccination combined with immune checkpoint inhibition eradicates tumors, inducing life-long immunity against breast cancer in mice.

Domínguez-Romero AN, Esquivel-García CA, Martínez-Cortés F, Martínez-Zarco BA, Odales J, Abraham-Ruiz S, Maruri J, Villegas-Ruiz V, Gevorkian G, Manoutcharian K.Mol Immunol. 2025 Jun 7;184:51-63. doi: 10.1016/j.molimm.2025.06.003. Online ahead of print.PMID: 40483788

Cost-effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine in Indian adults aged 50 years.

Kulkarni N, Averin A, Taur S, Huang L, Hariharan D, Atwood M, Gupta N.Expert Rev Pharmacoecon Outcomes Res. 2025 Jun 4:1-13. doi: 10.1080/14737167.2025.2508255. Online ahead of print.PMID: 40462563

Genomic characteristics and pathogenicity of three newly isolated NADC34-like PRRSV strains in China and evaluation of one strain for inactivated vaccine candidate.

Yang H, Song W, Li Z, Zhu Z, Wu W, Peng C, Xie R, Hua L, Chen H, Wu B, Peng Z.Virology. 2025 Jun 11;610:110605. doi: 10.1016/j.virol.2025.110605. Online ahead of print.PMID: 40513364

Env from EIAV vaccine delicately regulates NLRP3 activation via attenuating NLRP3-NEK7 interaction.

Guo X, Liu C, Wang Y, Li H, Ma S, Na L, Ren H, Lin Y, Wang X.PLoS Pathog. 2025 Jun 16;21(6):e1012772. doi: 10.1371/journal.ppat.1012772. Online ahead of print.PMID: 40522989

Lipid-coated nanoparticles enhance the delivery of bacterial virulence factors as a potent toxoid vaccine platform against bacterial infections.

Zhuge D, Xiao Y, Huang Y, Zhong Y, Sun X, Wu J, Liu S, Liang H, Mao W, Yang Y, Lin Y, Wang H, Yang X, Zhang X, Sun W, Liu C, Zhao Y, Chen M, Chen Y.Cell Rep. 2025 Jun 5;44(6):115786. doi: 10.1016/j.celrep.2025.115786. Online ahead of print.PMID: 40482034

Characterization of a suspension Vero cell line for viral vaccine production.

Bourigault L, Bresson C, Jean C, Chevalard C, Kloutz M, Soulet D, Pelissier F, Richard S, Bassard I, Sève N, Charretier C, Pain B.NPJ Vaccines. 2025 Jun 5;10(1):114. doi: 10.1038/s41541-025-01157-2.PMID: 40473628

Long-term immunogenicity of a live attenuated herpes zoster vaccine in patients with systemic lupus erythematosus.

Mok CC, Chan KL, Tse SM.Vaccine. 2025 Jun 5;61:127365. doi: 10.1016/j.vaccine.2025.127365. Online ahead of print.PMID: 40479925

The kinetics of gene expression related to innate and adaptive immunity in the lung and spleen following Newcastle disease virus (NDV) infection in vaccinated broiler chickens employing different vaccination regimes.

Hassanin O, Abdallah F, Mohamed MH, Ahmed MS, Al-Rasheed M, Rashad EM.Vet Microbiol. 2025 Jun;305:110525. doi: 10.1016/j.vetmic.2025.110525. Epub 2025 Apr 19.PMID: 40262238

Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up.

Carazo S, Skowronski DM, Brousseau N, Guay CA, Sauvageau C, Racine É, Talbot D, Ionescu IG, Fafard J, Gilca R, Phimmasone J, De Wals P, De Serres G.PLoS One. 2025 Jun 3;20(6):e0325269. doi: 10.1371/journal.pone.0325269. eCollection 2025.PMID: 40460407

Truncated rotavirus VP4 proteins induce stronger protective immunity compared to P2 - VP8 in animal models.

Chen Y, Luo G, Song F, Wang X, Zhang S, Ge S, Li T, Zhang J, Xia N.Antiviral Res. 2025 Jun;238:106156. doi: 10.1016/j.antiviral.2025.106156. Epub 2025 Apr 5.PMID: 40194664

Salivary oxytocin and anxiety in older adults during the COVID-19 pandemic: A cross-sectional study.

Kunitake Y, Imamura Y, Kunitake H, Ohishi-Fukuchi J, Tateishi H, Matsushima J, Murakawa-Hirachi T, Kojima R, Shiraishi T, Orihashi R, Mizoguchi Y.Psychoneuroendocrinology. 2025 Jun 4;179:107502. doi: 10.1016/j.psyneuen.2025.107502. Online ahead of print.PMID: 40499278

Ionizable Sterol Lipid-Based Three-Component Lipid Nanoparticles for Localized Delivery of mRNA Vaccine with Stronger Cellular Immune Responses.

Wang Z, Yan Z, Yan S, Li J, Wang Q, Yu X, Wang H, Zhao X, Zhu T.ACS Appl Mater Interfaces. 2025 Jun 12. doi: 10.1021/acsami.5c04597. Online ahead of print.PMID: 40503610

Age-Specific Seroprevalence of Measles, Mumps, and Rubella IgG across All Age Groups in Chonburi Province, Thailand after the Coronavirus Disease 2019 Pandemic.

Wanlapakorn N, Vichaiwattana P, Thongmee T, Chansaenroj J, Poovorawan Y.Am J Trop Med Hyg. 2025 Apr 8;112(6):1385-1390. doi: 10.4269/ajtmh.25-0005. Print 2025 Jun 4.PMID: 40203819

Exploring mpox vaccination uptake and tolerability among people living with HIV: A study in an infectious disease unit in Italy.

Gaggioli S, Formica G, Petrini V, Krauss AR, Corsi P, Di Felice A, Fiorelli C, Mantengoli E, Malcontenti C, Francalanci E, Modi G, Trotta M, Kiros ST, Gazzarri E, Zocco N, Zammarchi L, Bartoloni A, Lagi F.Int J STD AIDS. 2025 Jun 12:9564624251349888. doi: 10.1177/09564624251349888. Online ahead of print.PMID: 40501423

What are the key features of an equitable global vaccine strategy for the next pandemic? A qualitative study of pandemic control experts.

Fawole A, Boyer B, Shahid M, Bharali I, McAdams D, Yamey G.Vaccine. 2025 Jun 11;61:127377. doi: 10.1016/j.vaccine.2025.127377. Online ahead of print.PMID: 40505326

Comment on "newborn screening programs promote vaccine acceptance among parents in Turkey".

Daungsupawong H, Wiwanitkit V.Postgrad Med. 2025 Jun 11:1. doi: 10.1080/00325481.2025.2517536. Online ahead of print.PMID: 40474581

Differential clearance rate of proteins encoded on a self-amplifying mRNA COVID-19 vaccine in muscle and lymph nodes.

Kanechi R, Shishido T, Tachikawa M, Nishimura T, Sawada A, Okade H, Ishikawa D, Yamaguchi H, Araki M.Biochem Biophys Rep. 2025 Apr 2;42:101999. doi: 10.1016/j.bbrep.2025.101999. eCollection 2025 Jun.PMID: 40236291

CC180 clade dynamics do not universally explain Streptococcus pneumoniae serotype 3 persistence post-vaccine: a global comparative population genomics study.

Stanley S, Silva-Costa C, Gomes-Silva J, Melo-Cristino J, Malley R, Ramirez M.EBioMedicine. 2025 Jun 3;117:105781. doi: 10.1016/j.ebiom.2025.105781. Online ahead of print.PMID: 40472804

Regulatory T cells define affinity thresholds for $CD8^+$ T cell tumor infiltration.

Mohsen MO, Josi R, Marar SV, Ghimire A, Yang L, Krenger PS, Solé Casaramona A, Speiser DE, De Brot S, Bachmann MF.NPJ Vaccines. 2025 Jun 13;10(1):125. doi: 10.1038/s41541-025-01177-y.PMID: 40514382

A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50-64 years old compared to those with high-risk conditions from US payer perspective.

Vadlamudi NK, Lin CJ, Wateska AR, Zimmerman RK, Smith KJ.BMC Public Health. 2025 Jun 2;25(1):2042. doi: 10.1186/s12889-025-22827-9.PMID: 40457223

In silico identification of Leishmania GP63 protein epitopes to generate a new vaccine antigen against leishmaniasis.

Güvendi M, Can H, Yavuz İ, Özbilgin A, Değirmenci Döşkaya A, Karakavuk M, Ün C, Gürüz AY, Yılmaz İC, Gürsel M, Gürsel İ, Döşkaya M.PLoS Negl Trop Dis. 2025 Jun 5;19(6):e0013137. doi: 10.1371/journal.pntd.0013137. eCollection 2025 Jun.PMID: 40471879

Comparative immunologic profiling of mRNA and protein-conjugated vaccines: acute inflammatory responses and anti-PEG antibody production.

Roh G, Lee J, Park HM, Kwak W, Park HJ, Oh A, Na Y, Ha D, Lee YS, Bae SH, Lee S, Yoon S, Lee S, Jung J, Lee J, Nam JH.Anim Cells Syst (Seoul). 2025 Jun 10;29(1):387-401. doi: 10.1080/19768354.2025.2510984. eCollection 2025.PMID: 40503431

Evaluation of commercial vaccines for efficacy and transmission control against the emergent H5N8 (clade 2.3.4.4b) avian influenza virus in Kazakhstan.

Tabynov K, Kuanyshbek A, Zharmambet K, Yelchibayeva L, Karibayev T, Berdikulov M, Zhumadilova Z, Tabynov K.Virology. 2025 Jun 6;610:110601. doi: 10.1016/j.virol.2025.110601. Online ahead of print.PMID: 40516487

Generation and characterization of infectious clones of chikungunya virus from an Indian strain as a resource towards chikungunya vaccine research.

Mathur G, Mahilkar S, Sunil S.Virus Res. 2025 Jun;356:199571. doi: 10.1016/j.virusres.2025.199571. Epub 2025 Apr 9.PMID: 40216162

Antigenic Characterization of H1N1 Influenza Viruses That Circulated During the 2019-2020 Season in Philadelphia, Pennsylvania.

Mendoza LM, Anderson EM, Leonard AS, McFarland AG, Ort JT, Tanenbaum N, Durosinmi A, Bushman FD, Glaser LJ, Nachamkin I, Hensley SE.Influenza Other Respir Viruses. 2025 Jun;19(6):e70104. doi: 10.1111/irv.70104.PMID: 40452165

Economic and health consequence frames affect COVID-19 vaccine incentive attitudes in Germany- a survey based framing experiment.

Jäckle S, Timmis JK.BMC Public Health. 2025 Jun 4;25(1):2071. doi: 10.1186/s12889-025-23279-x.PMID: 40468235

Modeling the SARS-CoV-2 epidemic and the efficacy of different vaccines across different network structures.

Hartvigsen G, Dimitroff Y.PLoS One. 2025 Jun 5;20(6):e0325129. doi: 10.1371/journal.pone.0325129. eCollection 2025.PMID: 40471924

The characterization of Klebsiella pneumoniae associated with neonatal sepsis in low- and middle-income countries to inform vaccine design.

Nonne F, Molfetta M, Belciug GF, Carducci M, Cianchi V, Zakroff C, Durante S, Zellmer C, Baker S, Stanton TD, Holt KE, Wyres K, Ravenscroft N, Gasperini G, Rossi O, Giannelli C, Berlanda Scorza F, Micoli F.Commun Biol. 2025 Jun 9;8(1):898. doi: 10.1038/s42003-025-08258-7.PMID: 40490475

Development and evaluation of an attenuated Avibacterium paragallinarum strain as a live vaccine candidate for infectious coryza.

Guo M, Wang H, Liu D, Bo Z, Zhang C, Wu Y, Zhang X.Vet Res. 2025 Jun 9;56(1):115. doi: 10.1186/s13567-025-01546-4.PMID: 40490807

Mpox alert: COVID-19's hard-earned lessons put to the test.

Adebiyi BO.One Health. 2025 Feb 25;20:101003. doi: 10.1016/j.onehlt.2025.101003. eCollection 2025 Jun.PMID: 40129479

Experience of maternal immunization among women living with HIV in Belgium: A mixed-methods study.

Touré Y, Martin C, Necsoi C, Delforge M, Konopnicki D, Dauby N.Prev Med Rep. 2025 May 10;54:103107. doi: 10.1016/j.pmedr.2025.103107. eCollection 2025 Jun.PMID: 40474991

Development and characterization of an innovative Flavobacterium oreochromis antigen-encapsulated hydrogel bead for enhancing oral vaccine delivery in hybrid red tilapia (Oreochromis spp.).

Thangsunan P, Thangsunan P, Mahatnirunkul T, Buncharoen W, Saenphet K, Saenphet S, Phaksopa J, Thompson KD, Srisapoome P, Kumwan B, Meachasompop P, Suree N, Uchuwittayakul A.Fish Shellfish Immunol. 2025 Jun 10:110483. doi: 10.1016/j.fsi.2025.110483. Online ahead of print.PMID: 40505878

Immunogenicity of a novel HMT13 adjuvant-based inactivated vaccine against Avian pathogenic Escherichia coli serogroups O36, O78, and O109.

Jia C, Fu J, Wang Z, Li Z, Yu J, Liu Q, Zhang J, Wang X.Poult Sci. 2025 Jun;104(6):105097. doi: 10.1016/j.psj.2025.105097. Epub 2025 Apr 10.PMID: 40209468

Inoculating Against Misleading News Reports About the COVID-19 Vaccine: The Roles of Temporal Frames and Actively Open-Minded Thinking.

Lee SJ.J Health Commun. 2025 Jun 5:1-10. doi: 10.1080/10810730.2025.2514842. Online ahead of print.PMID: 40474505

Selection, Design, and Immunogenicity Studies of ASFV Antigens for Subunit mRNA Cocktail Vaccines with Specific Immune Response Profiles.

Yuan F, Cui J, Wang T, Qin J, Jeon JH, Ding H, Whittaker CA, Xu R, Cao H, Chen J.ACS Infect Dis. 2025 Jun 6. doi: 10.1021/acsinfecdis.5c00029. Online ahead of print.PMID: 40478837

Mass doses of fractional pneumococcal vaccine in humanitarian settings.

Russell FM, Mulholland K, Greenslade L.Lancet Infect Dis. 2025 Jun;25(6):599-601. doi: 10.1016/S1473-3099(24)00768-0. Epub 2025 Jan 8.PMID: 39798582

Exploring College Men's Human Papillomavirus (HPV) Vaccine Behavior and Intention in the United States.

Marshall OH, Henry DS, Merrell LK, Bishop JM.J Community Health. 2025 Jun 14. doi: 10.1007/s10900-025-01489-z. Online ahead of print.PMID: 40515894

The effect of COVID-19 vaccination on change in contact and implications for transmission.

Liu CY, Siegler A, Sullivan P, Jenness SM, Flasche S, Lopman B, Nelson K.Epidemics. 2025 Jun;51:100827. doi: 10.1016/j.epidem.2025.100827. Epub 2025 Apr 9.PMID: 40300469

Daily briefing: Evidence-backed strategies for talking about vaccine hesitancy.

Graham F.Nature. 2025 Jun 10. doi: 10.1038/d41586-025-01847-w. Online ahead of print.PMID: 40500364

Effect of carvacrol to induce autophagy and apoptosis and its interaction with Newcastle disease virus in the chicken embryo model.

Nazaktabar A, Araghi A, Golshahi H, Abbasabadi BM.Braz J Microbiol. 2025 Jun;56(2):1345-1355. doi: 10.1007/s42770-025-01646-5. Epub 2025 Mar 7.PMID: 40053290

Longitudinal population analysis of Plasmodium falciparum apical membrane antigen-1 in Indian field isolates.

Narang G, Hawadak J, Jakhan J, Yadav K, Singh V.Acta Trop. 2025 Jun;266:107630. doi: 10.1016/j.actatropica.2025.107630. Epub 2025 Apr 24.PMID: 40286894

Enhanced Nano-Vaccine Utilizing Biomineralized Virus-like Particles for Efficient Glioblastoma Immunotherapy via the Nose-To-Brain Delivery Pathway.

Wang C, Feng W, Li J, Wang J, Liu L, Ye SH, Zhang Y, Fu J, Zheng H, Chen E, Yang J, Shan W, Ren L.ACS Nano. 2025 Jun 10;19(22):21154-21168. doi: 10.1021/acsnano.5c06051. Epub 2025 May 29.PMID: 40442950

PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine.

Akutagawa K, Miki S, Yamada E, Sakamoto N, Miyazaki T, Sugii N, Zaboronok A, Matsuda M, Ishikawa E.J Neurooncol. 2025 Jun 12. doi: 10.1007/s11060-025-05102-0. Online ahead of print.PMID: 40504311

TMTP1-modified polymeric micelles for the inhibition of ovarian cancer metastasis and recurrence through enhanced photothermal-immunotherapy.

Wang L, Li J, Zhang D, Tan S, Jiang G, Wang X, Li F, Zhou Y, Chen P, Wei R, Xi L.Mater Today Bio. 2025 May 4;32:101825. doi: 10.1016/j.mtbio.2025.101825. eCollection 2025 Jun.PMID: 40487160

Dimethylamino-based synthetic lipidoid nanoparticles for selective mRNA delivery to splenic antigen-presenting cells.

Liang X, Zhang C, Yin Q, Bai Y, Li J, Qiu M.J Control Release. 2025 Jun 10;382:113737. doi: 10.1016/j.jconrel.2025.113737. Epub 2025 Apr 13.PMID: 40233831

Two adolescents with frequently relapsing nephrotic syndrome newly diagnosed after SARS-CoV-2 vaccination: case report and literature review.

Nakazawa E, Uchimura T, Ohyama R, Togashi H, Inaba A, Shiga K, Ito S.CEN Case Rep. 2025 Jun;14(3):461-467. doi: 10.1007/s13730-025-00967-6. Epub 2025 Feb 17.PMID: 39960599

Lipid nanoparticle-encapsulated DNA vaccine encoding African swine fever virus p54 antigen elicits robust immune responses in pigs.

Lai DC, Nguyen TN, Poonsuk K, McVey DS, Vu HLX.Vet Microbiol. 2025 Jun;305:110508. doi: 10.1016/j.vetmic.2025.110508. Epub 2025 Apr 7.PMID: 40250107

Strategies to improve interprofessional communication regarding maternal and infant RSV immunization.

Hossain T, Burnett HQ, Schaffer DeRoo S.Vaccine. 2025 Jun 7;61:127366. doi: 10.1016/j.vaccine.2025.127366. Online ahead of print.PMID: 40483884

Edwardsiella ictaluri type III and type VI secretion system mutant strains as candidates for live attenuated vaccines.

Rogge ML, Elkamel AA, Thune RL.J Aquat Anim Health. 2025 Jun 13;37(2):75-84. doi: 10.1093/jahafs/vsaf005.PMID: 40366275

Multi-criteria decision making and its application to in silico discovery of vaccine candidates for Toxoplasma gondii.

Ellis JT, Kennedy PJ.Vaccine. 2025 Jun 11;58:127242. doi: 10.1016/j.vaccine.2025.127242. Epub 2025 May 15.PMID: 40378548

Detection and identification of highly antigenic proteins from cytoskeleton of Toxoplasma gondii by immune-proteomics.

Lagunas-Cortés N, García-Sánchez BY, Ríos-Castro E, Vega-López MA, González-Pozos S, Diaz-Martín RD, Carranza JM, Ramírez-Flores CJ, Mondragón-Flores R.J Proteomics. 2025 Jun 15;317:105454. doi: 10.1016/j.jprot.2025.105454. Epub 2025 May 6.PMID: 40339902

Bayesian optimization and machine learning for vaccine formulation development.

Li L, Back SI, Ma J, Guo Y, Galeandro-Diamant T, Clénet D.PLoS One. 2025 Jun 11;20(6):e0324205. doi: 10.1371/journal.pone.0324205. eCollection 2025.PMID: 40498693

Grouper interleukin 15-like acts as a cytokine adjuvant in grouper iridovirus subunit vaccine.

Zheng J, Chen H, Liu Q, Lin F, Guo X, Huang X, Qin Q, Huang Y.Fish Shellfish Immunol. 2025 Jun 6;165:110475. doi: 10.1016/j.fsi.2025.110475. Online ahead of print.PMID: 40482865

Development of multivalent SARS-CoV-2 virus-like particle vaccine candidates.

Bezeljak U, Jerman A, Kobal T, Birsa E, Lokar Kosmač M, Žiberna R, Lokar K, Janež N, Ravlić S, Halassy B, Kolenc M, Triglav T, Draksler U, Horvat S, Peterka M.Vaccine. 2025 Jun 14;61:127394. doi: 10.1016/j.vaccine.2025.127394. Online ahead of print.PMID: 40517501

Comparison of Adverse Events in Pregnant Persons Receiving COVID-19 and Influenza Vaccines: A Disproportionality Analysis Using Combined Data from US VAERS and EudraVigilance Spontaneous Report Databases.

Roque-Pereira L, Sisay MM, Ogar CK, Durán CE, van Puijenbroek E, Weibel D, Verhamme K, Sturkenboom M.Drug Saf. 2025 Jun 10. doi: 10.1007/s40264-025-01561-6. Online ahead of print.PMID: 40495022

A Novel Abeta B-cell epitope Vaccine, Abeta1-10 with carrier protein OVA and KLH reduce Abeta-induced neuroinflammation mediated neuropathology in mouse model of Alzheimer's disease.

Park JS, Choe K, Ahmad R, Park HY, Kang MH, Park TJ, Kim MO.Brain Behav Immun. 2025 Jun 6;129:196-205. doi: 10.1016/j.bbi.2025.06.001. Online ahead of print.PMID: 40484150

Utilization of the HPV Brief Motivational Interviewing Skills-Based Training Among University of Minnesota Dental Hygiene Alumni.

Stull CL, Rogers K, Flavin K, Thelen R, Evans MD, Arnett MC.J Dent Hyg. 2025 Jun;99(3):24-37.PMID: 40514077

Antigen-specific Th17 T cells offset the age-related decline in durable T cell immunity.

Sturmlechner I, Jain A, Jiang J, Okuyama H, Mu Y, Own M, Weyand CM, Goronzy JJ.bioRxiv [Preprint]. 2025 Jun 6:2025.06.05.658069. doi: 10.1101/2025.06.05.658069.PMID: 40502174

Humoral and cellular immune responses in people living with HIV following successive COVID-19 vaccine booster doses.

Casado JL, Vizcarra P, Martín-Hondarza A, Moreno A, Pérez-Elías MJ, Fernández-Chica C, Martín-Colmenarejo S, Vallejo A.Clin Microbiol Infect. 2025 Jun 11:S1198-743X(25)00294-0. doi: 10.1016/j.cmi.2025.06.007. Online ahead of print.PMID: 40513829

Disparities in COVID-19 Vaccine Uptake Among Pregnant People in a Diverse Urban Population With High Vaccine Acceptance.

Blauvelt CA, Pullins MJ, Gaw SL.AJPM Focus. 2024 Nov 22;4(3):100303. doi: 10.1016/j.focus.2024.100303. eCollection 2025 Jun.PMID: 39967683

Impact of Interventions to Improve HPV Vaccine Uptake on Other Vaccines Due: A Secondary Analysis of a Randomized Trial.

Jacobson RM, Herrin J, Jenkins G, Griffin JM, St Sauver JL, MacLaughlin KL, Zhu X, Finney Rutten LJ.Acad Pediatr. 2025 Jun 7:102870. doi: 10.1016/j.acap.2025.102870. Online ahead of print.PMID: 40490190

Methodological approach to identify immunogenic epitopes candidates for vaccines against emerging pathogens tailored to defined HLA populations.

Lalinde-Ruiz N, Martínez-Enriquez LC, Alzate Gutierrez D, Hernandez Nieto H, Niño LF, Parra-López CA.Comput Biol Chem. 2025 Jun;116:108389. doi: 10.1016/j.compbiolchem.2025.108389. Epub 2025 Feb 19.PMID: 39986256

Genomic analysis of invasive and non-invasive disease-causing *Streptococcus pneumoniae* isolated from children between 2014 and 2023 in Suzhou, China.

Huang L, King AC, Liu Y, Hung HCH, Bentley SD, Jiang Y, Lv P, Xu X, Lo SW, Chen M.Microb Genom. 2025 Jun;11(6):001398. doi: 10.1099/mgen.0.001398.PMID: 40455658

Influenza neuraminidase active site proximity assay for rapid profiling of inhibitory antibodies and antigenic drift.

Gao J, Landgraf G, Yuan Y, Yu H, Saeidi S, Kang H, Rakic Martinez M, Giurgea L, Lugovtsev V, Gorman J, Memoli M, Chen X, Ye Z, Daniels R.NPJ Vaccines. 2025 Jun 7;10(1):118. doi: 10.1038/s41541-025-01173-2.PMID: 40483362

A propensity score approach and a partitioned approach for the self-controlled case series design to evaluate safety of a 2-dose vaccine series: comment.

Daungsupawong H, Wiwanitkkit V.Am J Epidemiol. 2025 Jun 3;194(6):1800. doi: 10.1093/aje/kwae258.PMID: 39108183

"I'm not aware of anyone having died from chickenpox?": Acceptability of varicella vaccination in the UK, a mixed methods questionnaire and interview study.

Jordan Z, Roderick M, Marlow R, Rowland E.Vaccine. 2025 Jun 11;61:127322. doi: 10.1016/j.vaccine.2025.127322. Online ahead of print.PMID: 40505329

Strengthening the EU Health Technology Assessment Regulation: Integrating National Immunization Technical Advisory Groups for Comprehensive Vaccine Assessments.

Beekman J, de Roo A, Wolters S, Marapin R, Gurgel do Amaral G, Dvortsin E, Quilici S, de Waure C, Petelos E, Postma M, Viceré A.J Mark Access Health Policy. 2025 Apr 18;13(2):16. doi: 10.3390/jmahp13020016. eCollection 2025 Jun.PMID: 40276092

Recombinant Salmonella vector delivery 3M2e-ferritin fusion nanoparticles provide cross protection against H9N2 and H7N9 avian influenza viruses.

Sun W, Li YA, Li Z, Li G, Du Y, Shi H.Vet Microbiol. 2025 Jun;305:110546. doi: 10.1016/j.vetmic.2025.110546. Epub 2025 May 5.PMID: 40339259

Low Incidence of Rejection and De Novo Donor-Specific Antibody Formation Following COVID-19 Vaccination or Infection Among Pediatric Kidney Transplant Recipients.

Pizzo H, Garrison J, Kirshner K, Puliyanda D.Pediatr Transplant. 2025 Jun;29(4):e70084. doi: 10.1111/petr.70084.PMID: 40302377

Learning Lessons from the COVID-19 Pandemic-A Qualitative Assessment of the Experiences of Pregnant Latinas Infected with COVID-19 and Their Perspectives on Vaccination.

Lopez M, Altamirano J, Melchor S, Perez S, Maldonado Y, Aziz N, Igbinosa I.J Racial Ethn Health Disparities. 2025 Jun;12(3):1804-1810. doi: 10.1007/s40615-024-02010-3. Epub 2024 May 6.PMID: 38709334

Does timing of the Bacillus Calmette-Guerin vaccine affect weight in children under the age of 5 years? An observational study in Guinea-Bissau.

Buhl E, Vedel JO, Nanque LM, Correia C, Jensen AM, Fisker AB.Vaccine. 2025 Jun 11;58:127246. doi: 10.1016/j.vaccine.2025.127246. Epub 2025 May 16.PMID: 40381512

Re: 'Safety and immunogenicity of hepatitis E vaccine in compensated liver cirrhosis with chronic hepatitis B' by Liao et al.

Yang Y, Lai R.Clin Microbiol Infect. 2025 Jun 7:S1198-743X(25)00289-7. doi: 10.1016/j.cmi.2025.06.004. Online ahead of print.PMID: 40490192

Efforts toward achieving the goal of ending AIDS by 2030: from antiretroviral drugs to HIV vaccine and cure research.

Xu P, Yuan D, Moog C, Su B.Sci China Life Sci. 2025 Jun;68(6):1849-1851. doi: 10.1007/s11427-024-2840-4. Epub 2025 Mar 4.PMID: 40048070

Post-vaccination evaluation of an erysipelas/parvovirus bivalent vaccine administered to sows during lactation on follicular development and piglet growth.

Sánchez-Tarifa E, García-Vázquez FA, Vela A, Sanjoaquín L, Falceto MV, Fernández-Fontelo A, Gómez-Duran O, Alonso C, Hernández-Caravaca I.Vet Anim Sci. 2025 Mar 15;28:100442. doi: 10.1016/j.vas.2025.100442. eCollection 2025 Jun.PMID: 40212818

Exploring the potential of saponins as adjuvants in lipid-nanoparticle-based mRNA vaccines.

Eygeris Y, Jozic A, Henderson MI, Nelson D, Sahay G.Mol Ther Methods Clin Dev. 2025 May 21;33(2):101495. doi: 10.1016/j.omtm.2025.101495. eCollection 2025 Jun 12.PMID: 40525124

Protective efficacy of the pan-fungal vaccine NXT-2 against vulvovaginal candidiasis in a murine model.

Wychrij DA, Chapman TI, Rayens E, Rabacal W, Willems HME, Oworae KO, Peters BM, Norris KA.NPJ Vaccines. 2025 Jun 2;10(1):112. doi: 10.1038/s41541-025-01171-4.PMID: 40456775

How to speak to a vaccine sceptic: research reveals what works.

Pearson H.Nature. 2025 Jun;642(8067):289-291. doi: 10.1038/d41586-025-01771-z.PMID: 40494925

Engineering a bivalent nanoparticle vaccine with PCV2 capsid protein and PRRSV epitopes.

Ma J, Xiao X, Zhou Y, Huang W, Sun J, Chang X, Xiao S, Fang L.J Nanobiotechnology. 2025 Jun 12;23(1):438. doi: 10.1186/s12951-025-03514-8.PMID: 40506710

Barriers associated with the parental acceptance of human papillomavirus (HPV) vaccination of minors in Asir, Saudi Arabia: A cross-sectional study.

Alshahrani MN, Almutairi D, Zahrani Y, Alsabaani A, Alraey Y, Alshahrani SM.Hum Vaccin Immunother. 2025 Dec;21(1):2513708. doi: 10.1080/21645515.2025.2513708. Epub 2025 Jun 3.PMID: 40462525

Trained immunity driven by Enterococcus faecalis ribosomal protein S11 enhances antigen presentation and boosts influenza vaccine efficacy via nanoparticle delivery.

Zhang JG, Zhou CK, Gao Y, Zhang XM, Ma K, Peng ZR, Luo XY, Liu ZZ, Lin XQ, Chen W, Yang YJ.Int J Biol Macromol. 2025 Jun;315(Pt 1):144179. doi: 10.1016/j.ijbiomac.2025.144179. Epub 2025 May 15.PMID: 40381785

Construction of Heme-Binding Protein Deleted Strain and Using It as an Attenuated Vaccine Against Nocardia seriolae in Hybrid Snakehead (Channa maculata Channa argus).

Wu Y, Liu Y, Yang H, Sirimanapong W, Huang T, Chen J, Xia L.J Fish Dis. 2025 Jun;48(6):e14090. doi: 10.1111/jfd.14090. Epub 2025 Feb 13.PMID: 39945098

Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact.

Hassan IA, Araoye JB, Olawuyi DA, Effiong FB.Vaccine. 2025 Jun 11;61:127376. doi: 10.1016/j.vaccine.2025.127376. Online ahead of print.PMID: 40505328

Quantifying the impact of introducing HPV vaccines in 2006 on 25-29-year-old cervical cancer incidence in 2022.

Semprini J, Devine J, Reimer R.JNCI Cancer Spectr. 2025 Jun 10:pkaf059. doi: 10.1093/jncics/pkaf059. Online ahead of print.PMID: 40493819

Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference.

Phan TTN, Thiono DJ, Hvasta MG, Shah RP, Ajo GP, Huang WC, Lovell JF, Tian S, de Silva AM, Kuhlman B.NPJ Vaccines. 2025 Jun 9;10(1):119. doi: 10.1038/s41541-025-01179-w.PMID: 40490495

Delayed nuclear localization of CRISPR/Cas9-modified fiber of fowl adenovirus serotype 8b reduces pathogenicity in Specific pathogen-free chicken embryonic liver cells.

Ahmed S, Azli B, Abdul Razak M, Hair-Bejo M, Omar AR, Ideris A, Mat Isa N.Microb Pathog. 2025 Jun;203:107482. doi: 10.1016/j.micpath.2025.107482. Epub 2025 Mar 15.PMID: 40097027

Augmented insights and minor adjustments to the role of adhesin proteins in *Acinetobacter baumannii* infections.

Xiao D, Zhong H, Huang Q, Cha M.Infect Immun. 2025 Jun 10;93(6):e0006625. doi: 10.1128/iai.00066-25. Epub 2025 May 23.PMID: 40407336

Germline-targeting Strategies to Induce bNAbs against HIV-1.

Atabey T, Sanders RW, Aldon Y.Curr HIV Res. 2025 Jun 10. doi: 10.2174/011570162X365229250527111140. Online ahead of print.PMID: 40511646

First Report of the Immunogenicity of an Inactivated SARS-CoV-2 (COVID-19) Vaccine in Iranian Patients with Autoimmune Diseases.

Aminzadeh P, Hashempour A, Falahi S, Safari F, Feili M, Kenarkoohi A.Eur J Rheumatol. 2025 Jun 5;12(2):1-6. doi: 10.5152/eurjrheum.2025.24057.PMID: 40524559

Seroepidemiological survey of the population 10 years after the implementation of the varicella vaccine 2-dose immunization strategy.

Fang Q, Mao J, Fu C, Gong X, Zheng C, Yin Z.Hum Vaccin Immunother. 2025 Dec;21(1):2512642. doi: 10.1080/21645515.2025.2512642. Epub 2025 Jun 4.PMID: 40464766

Who is on RFK Jr's new vaccine panel - and what will they do?

Ledford H, Fieldhouse R.Nature. 2025 Jun 12. doi: 10.1038/d41586-025-01852-z. Online ahead of print.PMID: 40514522

Retrospective Wastewater Tracking of Measles Outbreak in Western Switzerland in Winter 2024.

Gan C, Pitton M, de Korne-Elenbaas J, Cobuccio L, Cassini A, Ort C, Julian TR.Environ Sci Technol Lett. 2025 May 22;12(6):689-694. doi: 10.1021/acs.estlett.5c00244. eCollection 2025 Jun 10.PMID: 40520145

Corrigendum to "Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study".

Jain SS, Anderson SA, Steele JM, Wilson HC, Muniz JC, Soslow JH, Beroukhim RS, Maksymiuk V, Jacquemyn X, Frosch OH, Fonseca B, Harahsheh AS, Buddhe S, Ashwath RC, Thacker D, Maskatia SA, Misra N, Su JA, Siddiqui S, Vaiyani D, Vaikom-House AK, Campbell MJ, Klein J, Huang S, Mathis C, Cornicelli MD, Sharma M, Nagaraju L, Ang JY, Uppu SC, Ramachandran P, Patel JK, Han F, Mandell JG, Akam-Venkata J, DiLorenzo MP, Brumund M, Bhatla P, Eshtehardi P, Mehta K, Glover K, Dove ML, Aldawsari KA, Kumar A, Barfuss SB, Dorfman AL, Minocha PK, Yonts AB, Schauer J, Cheng AL, Robinson JD, Powell Z, Srivastava S, Chelliah A, Sanil Y, Hernandez LE, Gaur L, Antonchak M, Johnston M, Reich JD, Nair N, Drugge ED, Grosse-Wortmann L.EClinicalMedicine. 2025 May 21;84:103268. doi: 10.1016/j.eclinm.2025.103268. eCollection 2025 Jun.PMID: 40496878

Alterations in the expression of Bordetella pertussis antigens in relation to the use of acellular pertussis vaccine in Finland.

Niinikoski V, Barkoff AM, Mertsola J, Holubova J, Masin J, Sebo P, He Q.Vaccine. 2025 Jun 11;58:127279. doi: 10.1016/j.vaccine.2025.127279. Epub 2025 May 17.PMID: 40383080

Radiation-Based Multi-Modal Therapy Combining with Immunotherapy to Develop a Vaccine-Like Effective Treatment for Triple-Negative Breast Cancer.

Dai M, Tian Z, Xu F, Yao B, Liang H, Li D, Wang J, Rong J, Liu T, Tang H, Lu H, Zhang W.Breast Cancer (Dove Med Press). 2025 Jun 10;17:483-496. doi: 10.2147/BCTT.S518625. eCollection 2025.PMID: 40524764

Critical appraisal of: "expression of SARS-CoV-2 spike protein in cerebral arteries: implications for hemorrhagic stroke post-mRNA vaccination".

Mueed A, Shariq A, Ashar M.J Clin Neurosci. 2025 Jun;136:111270. doi: 10.1016/j.jocn.2025.111270. Epub 2025 Apr 22.PMID: 40267596

Evaluation of pregnant women's knowledge about RSV and immunization attitudes before infant immunization with monoclonal antibodies in Turkey.

Demirci B, Özkaya-Parlakay A, Yılmaz M, Ekici H, Erçel MM, Türker Ergün G, Yücel SP.J Trop Pediatr. 2025 Jun 7;71(4):fmaf024. doi: 10.1093/tropej/fmaf024.PMID: 40489965

Correction: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.

Díez-Domingo J, Simkó R, Icardi G, Chong CP, Zocchetti C, Syrkina O, Bchir S, Bertrand-Gerentes I.Infect Dis Ther. 2025 Jun;14(6):1379-1380. doi: 10.1007/s40121-025-01150-1.PMID: 40268816

Recall interferon-gamma responses against Coccidioides are a surrogate marker for vaccine response in dogs.

Shubitz LF, Powell DA, Butkiewicz CD, Frelinger JA, Galgiani JN.Am J Vet Res. 2025 Jun 4:1-6. doi: 10.2460/ajvr.25.04.0119. Online ahead of print.PMID: 40466664

Corrigendum to Exploring COVID-19 Vaccine Hesitancy Among Stakeholders in African American and Latinx Communities in the Deep South Through the Lens of the Health Belief Model.

[No authors listed]Am J Health Promot. 2025 Jun;39(5):844. doi: 10.1177/08901171251340785. Epub 2025 Apr 29.PMID: 40296611

The seven steps to success: how to increase seasonal influenza vaccination in secondary care healthcare workers.

Baracaia S, Aziz K, Heffernan C.Br J Nurs. 2025 Jun 5;34(11):540-546. doi: 10.12968/bjon.2025.0113.PMID: 40488572

Investigation of Influenza A(H5N1) Virus Neutralization by Quadrivalent Seasonal Vaccines, United Kingdom, 2021-2024.

Stevenson-Leggett P, Adams L, Greenwood D, Lofts A, Libri V, Williams B, Gandhi S, Swanton C, Gamblin S, Carr EJ, Harvey R, Lewis NS, Wu MY, Wall EC; Crick Neutralization Consortium; Legacy Investigators; Crick Neutralization Consortium and Legacy Investigators.Emerg Infect Dis. 2025 Jun;31(6):1202-1206. doi: 10.3201/eid3106.241796.PMID: 40439507

Historical perspectives in medical humanities: two views on vaccination during the plague pandemic in Calcutta.

Bose U.Monash Bioeth Rev. 2025 Jun 3. doi: 10.1007/s40592-025-00251-4. Online ahead of print.PMID: 40461869

Negative Control Outcome Adjustment in Early-Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants.

Ashby E, Zhang B, Fouda GG, Fong Y, Janes H.Stat Med. 2025 Jun;44(13-14):e70142. doi: 10.1002/sim.70142.PMID: 40492758

Antigen recognition and immune response to monkeypox virus infection: implications for Mpox vaccine design - a narrative review.

Abebaw D, Akelew Y, Adugna A, Teffera ZH, Tegegne BA, Fenta A, Amare GA, Jemal M, Baylie T, Atnaf A.Infez Med. 2025 Jun 1;33(2):151-162. doi: 10.53854/liim-3302-1. eCollection 2025.PMID: 40519344

Brief communication: effect of a one-stop-shop intervention on COVID-19 vaccine uptake among people living with HIV in Nairobi and Kajiado counties, Kenya.

Njuguna N, Gichuhi P, Mutisya J, Kubo E, Odhiambo C, Michler J, Arodi S, Marima R, Mecha J, Otieno CF.AIDS Res Ther. 2025 Jun 13;22(1):62. doi: 10.1186/s12981-025-00730-y.PMID: 40514715

Contraindications to Immunization of Solid Organ Transplant Patients With Varicella Vaccine-Reply.

Feldman AG, Danziger-Isakov LA.JAMA Pediatr. 2025 Jun 2. doi: 10.1001/jamapediatrics.2025.1310. Online ahead of print.PMID: 40455424

Contraindications to Immunization of Solid Organ Transplant Patients With Varicella Vaccine.

Grose C.JAMA Pediatr. 2025 Jun 2. doi: 10.1001/jamapediatrics.2025.1307. Online ahead of print.PMID: 40455459

Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysis.

Bloomfield LE, Pingault NV, Foong RE, French S, Morgan JA, Wadia U, Moore HC, Blyth CC, Richmond PC, Armstrong PK, Effler PV.Med J Aust. 2025 Jun 16;222(11):568-570. doi: 10.5694/mja2.52655. Epub 2025 Apr 28.PMID: 40293046

Artificially tagging tumors with nano-aluminum adjuvant-tethered antigen mRNA recruits and activates antigen-specific cytotoxic T cells for enhanced cancer immunotherapy.

Zhang L, Bai J, Shen A, Zhao J, Su Z, Wang M, Dong M, Xu ZP.Biomaterials. 2025 Jun;317:123085. doi: 10.1016/j.biomaterials.2025.123085. Epub 2025 Jan 3.PMID: 39778272

Impact of Human papillomavirus 9-valent vaccine on viral clearance after surgical treatment: A single-center retrospective observational study.

Palumbo M, Lavitola G, Di Filippo C, Foreste V, Granata M, Imperatore O, Ascione M, Della Corte L, Bifulco G.Eur J Obstet Gynecol Reprod Biol. 2025 Jun;310:113994. doi: 10.1016/j.ejogrb.2025.113994. Epub 2025 Apr 20.PMID: 40267822

Challenges of Vaccine-Induced Thrombotic Thrombocytopenia-Related Kidney Transplantation: Venous Graft Thrombosis in a Pediatric Recipient.

Droste M, Kubitza L, Wesche J, Jeruschke S, Berger M, Kaths M, Baba HA, Greinacher A, Pape L, Thiele T, Büscher AK.Am J Kidney Dis. 2025 Jun 5:S0272-6386(25)00873-X. doi: 10.1053/j.ajkd.2025.03.025. Online ahead of print.PMID: 40482902

Population genetic structure of the fibrinogen-related protein 1 (FREP1) in Iranian isolates of Anopheles stephensi as a promising mosquito-based malaria vaccine candidate.

Kheirkhah O, Pirahmadi S, Mehrizi AA, Raz A.Gene. 2025 Jun 15;953:149436. doi: 10.1016/j.gene.2025.149436. Epub 2025 Mar 21.PMID: 40122414

Immunogen display on virus-like particles assembled from redesigned transcription activator-like effector proteins and nucleic acids: Activation of antigen-presenting cells.

Gonçalves AP, de Haas RJ, Santos AA, Tijhaar E, de Vries R.Int J Biol Macromol. 2025 Jun 9;318(Pt 3):145124. doi: 10.1016/j.ijbiomac.2025.145124. Online ahead of print.PMID: 40499864

Infectivity of a pathogenicity-attenuated *Chlamydia muridarum* mutant in the genital tract.

Li C, Liu Z, Hua Y, Ma C, Zhong G.Infect Immun. 2025 Jun 10;93(6):e0058824. doi: 10.1128/iai.00588-24. Epub 2025 May 23.PMID: 40407332

Identification of candidate vaccine antigens using 2-D gel electrophoresis and immunoproteomics for cross protection against Glaesserella parasuis.

Hau SJ, Eberle KC, Nally JE, Nielsen DW, Lippolis JD, Brockmeier SL.Vet Microbiol. 2025 Jun 9;307:110594. doi: 10.1016/j.vetmic.2025.110594. Online ahead of print.PMID: 40516376

Letters to the Editor: Uptake and Factors Associated with COVID-19 Vaccination Among 3,779,733 Adults Living With and Without Diabetes: A Population Cohort Study in a Universal Health Care Setting.

Hassan SAU, Lohana KJ, Naeem S.Can J Diabetes. 2025 Jun 2:S1499-2671(25)00117-0. doi: 10.1016/j.jcjd.2025.05.008. Online ahead of print.PMID: 40466805

Development of an ORF154-DIVA ELISA for serological differentiation of LSDV-infected and vaccinated animals.

Nokhwal A, Kumar R, Chander Y, Khandelwal N, Verma A, Riyesh T, Tripathi BN, Kumar N.J Virol Methods. 2025 Jun 8;338:115200. doi: 10.1016/j.jviromet.2025.115200. Online ahead of print.PMID: 40494437

Corrigendum to "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine 38 (4) (2020) 830-839].

Nuñez IA, Ross TM.Vaccine. 2025 Jun 11;58:127205. doi: 10.1016/j.vaccine.2025.127205. Epub 2025 May 18.PMID: 40388866

Prevalence, Molecular Characterization, and Immune Status Response of Hepatitis B Virus Among Healthcare Workers in Yaoundé General Hospital, Cameroon, During May to June 2024: A Hospital-Based Cross-Sectional Study.

Atsama-Amougou M, Simo FBN, Tchinda CF, Moukam M, Tongo-Passo M, Moundipa-Fewou P.Health Sci Rep. 2025 Jun 13;8(6):e70913. doi: 10.1002/hsr2.70913. eCollection 2025 Jun.PMID: 40519605

Accelerating Pneumococcal Protection in India: The Case for Rapid Adoption of PCV20 Across Pediatric and Adult Populations.

Varghese R, Gurumoorthy M, Thomas GG, Walia K, Kumar A, Qureshi S, Behera B, Gopinath KG, Gupta R, Goel R, Neeravi A, Putli Bai S, Veeraraghavan B.Indian J Med Microbiol. 2025 Jun 14:100893. doi: 10.1016/j.ijmmb.2025.100893. Online ahead of print.PMID: 40523477

Enhanced Cycling Performance of Li-Rich Oxide Cathode via a Vaccine Effect.

Yao K, Wang Y, Xie X, Li M, Zhang A, Zhang X, Li G, Li L.Angew Chem Int Ed Engl. 2025 Jun 5:e202500183. doi: 10.1002/anie.202500183. Online ahead of print.PMID: 40468978

Travel-related post-exposure rabies consultation at the Thai Travel Clinic, Hospital for Tropical Diseases, Bangkok, Thailand.

Charoenwisedsil R, Soravipukuntorn T, Panyatanakun K, Pisutsan P, Looareesuwan P, Asawapaithulsert P, Imad HA, Schneitler S, Piyaphanee W, Matsee W.Travel Med Infect Dis. 2025 Jun 12:102870. doi: 10.1016/j.tmaid.2025.102870. Online ahead of print.PMID: 40516802

Post hoc analysis: 6 Months immunogenicity after third dose of BNT162b2 vs JNJ-78,436,735 after two doses of BNT162b2 vaccine in solid organ transplant recipients.

Natori Y, Martin E, Mattiazzi A, Arosemena L, Burke GW, Munagala MR, Manickavel S, Sota K, Pallikkuth S, Chen J, Bini J, Simkins J, Anjan S, Vianna RM, Guerra G.Immunol Lett. 2025 Jun;273:106968. doi: 10.1016/j.imlet.2024.106968. Epub 2025 Jan 9.PMID: 39798807

A Canadian multi-province study of COVID-19 vaccine coverage along area-level social determinants in 2021.

Beall RF, Flores Anato JL, D'Souza AG, Velásquez García HA, Ma H, Yang F, Baral SD, Cabaj J, Cooper E, Hollis A, Janjua NZ, Katz A, Leal J, Maheu-Giroux M, May ER, Malikov K, Mishra S, Moloney G, Williamson T.Public Health Pract (Oxf). 2025 Feb 20;9:100594. doi: 10.1016/j.puhip.2025.100594. eCollection 2025 Jun.PMID: 40104250

Coming Full Circle with Preventive Pulmonary Practice: The American Thoracic Society Vaccine Initiative.

Stansbury R, Su G, Stern A, Hrovat A, Parthasarathy S.Am J Respir Crit Care Med. 2025 Jun;211(6):918-921. doi: 10.1164/rccm.202411-2273VP.PMID: 40153551

Improved protection against H9N2 avian influenza virus challenge in chickens by the presence of LTB adjuvant on the 3M2e-NP nanoparticle vaccine delivered by sifA deficient Salmonella.

Wang M, Zhang T, Guo Q, Sun Y, Yang T, Gao Y, Zhang Y, Zhang Y, Ge C, Jia F, Tian Y, Wang W, He Y, Zhang G, Gong J, Wang Z, Jiang Y.Int Immunopharmacol. 2025 Jun 11;161:115075. doi: 10.1016/j.intimp.2025.115075. Online ahead of print.PMID: 40505226

Tanzania confirms its second MVD outbreak: A constantly emerging outbreak calls for effective countermeasures in light of one health approach and preparedness to counter future epidemics.

Mohapatra RK, Sahu AR, Mishra S, Tiady SK, Tuglo LS.One Health. 2025 May 11;20:101070. doi: 10.1016/j.onehlt.2025.101070. eCollection 2025 Jun.PMID: 40486756

Long-acting lenacapavir is a breakthrough for preventing HIV infection, but HIV vaccine research must continue.

Sun C, Li L, Li P, Cai W, Tang X, Shao Y, Chen L.Front Med. 2025 Jun;19(3):543-547. doi: 10.1007/s11684-025-1137-3. Epub 2025 Jun 11.PMID: 40498392

Dermatologic reactions comprise a minority of adverse events following Jynneos monkeypox vaccination: A retrospective pharmacovigilance study.

Pathak GN, Pathak A, Desai AD, Elman SA.J Am Acad Dermatol. 2025 Jun 6:S0190-9622(25)02237-6. doi: 10.1016/j.jaad.2025.05.1444. Online ahead of print.PMID: 40484134

Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.

Hertoghs N, Roels S, Brückner M, Sadoff J, Banbury BL, Akers NK, Howie B, Robins HS, van Roey GA, Tolboom JTBM, Rezelj VV, Hendriks J, Schuitemaker H, Stieh DJ, Le Gars M.EBioMedicine. 2025 Jun 14;117:105809. doi: 10.1016/j.ebiom.2025.105809. Online ahead of print.PMID: 40517603

Respiratory syncytial virus vaccine in older adults did not reduce invasive pneumococcal disease incidence in England.

Rooney G, Litt D, Nikhab A, Ramsay ME, Ladhani SN.Lancet Infect Dis. 2025 Jun;25(6):609-610. doi: 10.1016/S1473-3099(25)00253-1. Epub 2025 Apr 30.PMID: 40318678

Liver-Targeted Tolerogenic Vaccines: A Nano-Membrane Coupled Approach for Autoimmune Disease Therapies.

Chen X, Xie Z, Wu R, He X, Qin M, Wang H, Bai S, Chen Z, He C, Ou Y, Zhao Y, Xie M, Zhang Y, Du G, Sun X.Adv Mater. 2025 Jun 16:e2507743. doi: 10.1002/adma.202507743. Online ahead of print.PMID: 40519000

Investigating endothelial cell transduction and hexon:PF4 binding of ChAdOx1 in the context of VITT.

Lovatt C, Frängsmyr L, Swift EA, Mundy RM, Parker AL.J Thromb Haemost. 2025 Jun 12:S1538-7836(25)00389-7. doi: 10.1016/j.jtha.2025.06.006. Online ahead of print.PMID: 40516826

Finding and filling the knowledge gaps in mechanisms of T cell-mediated TB immunity to inform vaccine design.

Lefrançais E, Hudrisier D, Neyrolles O, Behar SM, Ernst JD.Nat Rev Immunol. 2025 Jun 13. doi: 10.1038/s41577-025-01192-z. Online ahead of print.PMID: 40514544

Correction to "Co-Creating a Theory of Change to Advance COVID-19 Testing and Vaccine Uptake in Underserved Communities".

[No authors listed]Health Serv Res. 2025 Jun;60(3):e14641. doi: 10.1111/1475-6773.14641. Epub 2025 May 13.PMID: 40357537

A New Vaccine Candidate Expressing JUNV GP1-GP2 Against Argentine Hemorrhagic Fever Based on Baculovirus Surface Display.

Tomatis C, Aguiar MCAM, Charo N, Aquila S, Thomas PD, Arrías PN, Pidre ML, Romanowski V, Riera L, Brignone J, Maiza A, Carrera Silva EA, Ferrer MF, Gómez RM.Curr Microbiol. 2025 Jun 13;82(8):334. doi: 10.1007/s00284-025-04320-z.PMID: 40514553

A reply to the letter: comment on "newborn screening programs promote vaccine acceptance among parents in Turkey".

Erdal İ, Kahraman AB, Yıldız Y, Yalçin SS.Postgrad Med. 2025 Jun 11:1-2. doi: 10.1080/00325481.2025.2517532. Online ahead of print.PMID: 40476484

Blood Borders: State laws, vaccine misinformation, and the threat to the United States blood supply.

Jacobs JW, Chooljian DM, Raza S, Stephens LD, Schlafer TD, Cohn CS, Tobian AAR, Bloch EM, Booth GS.Transfusion. 2025 Jun 16. doi: 10.1111/trf.18312. Online ahead of print.PMID: 40521642

Near-complete genome sequencing of the feline coronavirus serotype I strain FIPV-Aqua from a cat with feline infectious peritonitis in Japan.

Tanaka Y, Tanabe E, Sasaki T.Microbiol Resour Announc. 2025 Jun 12;14(6):e0035725. doi: 10.1128/mra.00357-25. Epub 2025 May 20.PMID: 40391907

Editorial Comment on "Peritumoral Infiltration of Regulatory T Cells Reduces the Therapeutic Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Carcinoma In Situ".

Takamatsu K.Int J Urol. 2025 Jun;32(6):747-748. doi: 10.1111/iju.70089. Epub 2025 May 2.PMID: 40318109

Critical appraisal of "Impact of human papillomavirus 9-valent vaccine on viral clearance after surgical treatment: A single-center retrospective observational study".

Mueed A, Amjad F.Eur J Obstet Gynecol Reprod Biol. 2025 Jun;310:114013. doi: 10.1016/j.ejogrb.2025.114013. Epub 2025 Apr 26.PMID: 40312246

"I Don't Understand How These Two Things Go Together": Toward a Theory of Risk Ecologies.

Carrion ML.Health Commun. 2025 Jun;40(7):1248-1256. doi: 10.1080/10410236.2024.2394259. Epub 2024 Aug 26.PMID: 39185706

A response to "Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults".

Beck E, Georgieva M, Van de Velde N, Patterson-Lomba O, Mu F.Curr Med Res Opin. 2025 Jun 2:1-3. doi: 10.1080/03007995.2025.2504627. Online ahead of print.PMID: 40371681

IL-15 functionalized biomimetic hybrid mRNA vaccine for enhanced NSCLC immunotherapy via synergistic activation of T cells and NK cells.

Guo J, Peng L, Ma P, Mai Y, Gao T, Yu N, Zuo W, Yang J.Mater Today Bio. 2025 May 27;32:101914. doi: 10.1016/j.mtbio.2025.101914. eCollection 2025 Jun.PMID: 40520563

Influenza vaccination campaign in the workplace of a spanish bank.

Reinoso-Barbero L, Gieco A, Graterol E, Hernández C, Gómez-Paredes L, Muñoz-Gutiérrez J, Pérez-Herreras C, Gómez-Gallego F.Pathog Glob Health. 2025 Jun 16:1-9. doi: 10.1080/20477724.2025.2520079. Online ahead of print.PMID: 40524334

Preclinical toxicological assessment of an alpha-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs.

Meulewaeter S, De Velder M, Reckelbus D, Mwangi K, Ehouarne T, Aernout I, Engelen Y, Halimi F, Van Herteryck I, De Bels L, Redant V, De la Mane L, Ingels J, Coppens B, Van Calenbergh S, Cornillie P, Holtappels G, Descamps B, Vanrompay D, De Smedt SC, Van den Broeck W, Vandekerckhove B, Devreese M, Verbeke R, Lentacker I.Mol Ther Methods Clin Dev. 2025 May 19;33(2):101493. doi: 10.1016/j.omtm.2025.101493. eCollection 2025 Jun 12.PMID: 40519325

Decreased pathogenicity of triple-mutant of Aeromonas hydrophila flgK, flgL, flgE suggests its potential as a live attenuated vaccine for Carassius auratus.

Xiong C, Liu K, Wu Y, Ai Y, Yu Y, Mabrok M, Abu-Elala N, Li L, Xu H, Li Y, Ye H, Mei H, Wu R.Fish Shellfish Immunol. 2025 Jun 12:110486. doi: 10.1016/j.fsi.2025.110486. Online ahead of print.PMID: 40516799

[Safety study on the simultaneous administration of oral pentavalent recombinant rotavirus attenuated live vaccine and other vaccines in Chaoyang District, Beijing City from 2019 to 2021].

Chen TJ, Zhang J, Li SP, Li L, Jia B, Ma JX, Zhang Z, He JB, Bai YH.Zhonghua Yu Fang Yi Xue Za Zhi. 2025 Jun 6;59(6):942-945. doi: 10.3760/cma.j.cn112150-20241129-00956.PMID: 40518428

Novel synthetic peptide-based vaccine shows promise against prostate cancer.

Vázquez-Arreguín K.Mol Ther Oncol. 2025 Jun 4;33(2):201000. doi: 10.1016/j.omton.2025.201000. eCollection 2025 Jun 18.PMID: 40524857

The rise of serotype 8 is associated with lineages and mutations in the capsular operon with different potential to produce invasive pneumococcal disease.

Pérez-García C, González-Díaz A, Domenech M, Llamosí M, Úbeda A, Sanz JC, García E, Ardanuy C, Sempere J, Yuste J.Emerg Microbes Infect. 2025 Jun 16:2521845. doi: 10.1080/22221751.2025.2521845. Online ahead of print.PMID: 40518969

The Question of Protection: Hepatitis B Vaccine and Waning Antibody Levels.

Grayer D, Jhaveri R.J Pediatric Infect Dis Soc. 2025 Jun 16;14(6):piaf044. doi: 10.1093/jpids/piaf044.PMID: 40519133

Metallo-beta-lactamase NDM-1 serves as a universal vaccine candidate for combatting antimicrobial resistance.

Jing H, Wang X, Zhao Z, Tang Y, Yuan Y, Liao J, Wei H, Chen Z, Gou Q, Zou Q, Hu R, Zhang X, Zhang J.Int J Biol Macromol. 2025 Jun 10;318(Pt 3):145158. doi: 10.1016/j.ijbiomac.2025.145158. Online ahead of print.PMID: 40505900

Corrigendum to "Pediatric HPV vaccination: Provider recommendations matter among hesitant parents" [Vaccine 42(25) (2025) 126166].

Willis DE, Moore R, Selig JP, Amin NS, Li J, Watson D, Brimberry RK, McElfish PA.Vaccine. 2025 Jun 5;61:127343. doi: 10.1016/j.vaccine.2025.127343. Online ahead of print.PMID: 40479928

mRNA-LNP vaccines against Hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models.

Limeres MJ, Gambaro R, Svensson M, Fraude-El Ghazi S, Pretsch L, Frank D, Islan GA, Berti IR, Bros M, Tam YK, Muramatsu H, Pardi N, Gehring S, Cacicedo ML.Mol Ther. 2025 Jun 14:S1525-0016(25)00478-2. doi: 10.1016/j.ymthe.2025.06.027. Online ahead of print.PMID: 40518670

Pre-clinical evaluation of a divalent liposomal vaccine to control invasive candidiasis.

Costa-Barbosa A, Pacheco MI, Gomes AC, Collins T, Vilanova M, Pais C, Correia A, Sampaio P.NPJ Vaccines. 2025 Jun 13;10(1):124. doi: 10.1038/s41541-025-01183-0.PMID: 40514358

Author Correction: Proteolysis-targeting influenza vaccine strains induce broad-spectrum immunity and in vivo protection.

Shen J, Li J, Shen Q, Hou J, Zhang C, Bai H, Ai X, Su Y, Wang Z, Zhang Y, Xu B, Hao J, Wang P, Zhang Q, Ye AY, Li Z, Feng T, Li L, Qi F, Wang Q, Sun Y, Liu C, Xi X, Yan L, Hong H, Chen Y, Xie X, Xie J, Liu X, Du R, Plebani R, Zhang L, Zhou D, Church G, Si L.Nat Microbiol. 2025 Jun 12. doi: 10.1038/s41564-025-02053-0. Online ahead of print.PMID: 40506515

Publisher Correction: Controlling reactogenicity while preserving immunogenicity from a self-amplifying RNA vaccine by modulating nucleocytoplasmic transport.

Wojcechowskyj JA, Jong RM, Mäger I, Flach B, Munson PV, Mukherjee PP, Mertins B, Barcay KR, Folliard T.NPJ Vaccines. 2025 Jun 11;10(1):122. doi: 10.1038/s41541-025-01175-0.PMID: 40500262

Combination of recombinant neuraminidase with cHA-based inactivated split vaccines improves the breadth of cross-reactivity and protection against influenza viruses in mice.

Puente-Massaguer E, Vasilev K, Krammer F.Vaccine. 2025 Jun 12;61:127388. doi: 10.1016/j.vaccine.2025.127388. Online ahead of print.PMID: 40513214

Vaccination equity: a warning from the COVID-19 pandemic.

Alford S.Brain Behav Immun. 2025 Jun 14:S0889-1591(25)00239-9. doi: 10.1016/j.bbi.2025.06.022. Online ahead of print.PMID: 40523536

Author Correction: Bioinformatics approach for the construction of multiple epitope vaccine against omicron variant of SARS-CoV-2.

Zaib S, Akram F, Liaqat ST, Altaf MZ, Khan I, Dera AA, Uddin J, Khan A, Al-Harrasi A.Sci Rep. 2025 Jun 11;15(1):20049. doi: 10.1038/s41598-025-04451-0.PMID: 40500375

Medical societies unite against RFK Jr's COVID vaccine update.

Kirby T.Lancet Respir Med. 2025 Jun 12:S2213-2600(25)00212-7. doi: 10.1016/S2213-2600(25)00212-7. Online ahead of print.PMID: 40517786

RFK Jr names eight new members of vaccine committee after mass firing.

Tanne JH.BMJ. 2025 Jun 13;389:r1227. doi: 10.1136/bmj.r1227.PMID: 40514090

Independent US vaccine body is planned after RFK Jr's mass firing of CDC advisory panel.

Looi MK.BMJ. 2025 Jun 13;389:r1231. doi: 10.1136/bmj.r1231.PMID: 40514087

Author Correction: PROTAR Vaccine 2.0 generates influenza vaccines by degrading multiple viral proteins.

Zhang C, Hou J, Li Z, Shen Q, Bai H, Chen L, Shen J, Wang P, Su Y, Li J, Zhang Q, Liu C, Xi X, Qi F, Chen Y, Xie X, Ye AY, Liu X, Plebani R, Church G, Si L.Nat Chem Biol. 2025 Jun 12. doi: 10.1038/s41589-025-01956-7. Online ahead of print.PMID: 40506514

Completion of Multidose COVID-19 Vaccination Among Adolescents and Adults in Urban Informal Settlements in Nairobi, Kenya.

Ng'oda M, Izudi J, Otieno C, Mwanga D, Sanya RE, Ziraba A.Am J Trop Med Hyg. 2025 Jun 10:tpmd240737. doi: 10.4269/ajtmh.24-0737. Online ahead of print.PMID: 40494313

Dendritic cell-based vaccines, a promising prospect for ending AIDS and eradication of HIV worldwide: A narrative review on the latest updates.

Jolfayi AG, Alipour S, Aminizadeh S, Yaghoubi SM, Sohrabi S, Ghahramanipour Z, Azimi A, Yousefimoghadam F, Baradaran B.Vaccine. 2025 Jun 2;61:127340. doi: 10.1016/j.vaccine.2025.127340. Online ahead of print.PMID: 40460653

Boost your health (Refuerza tu Salud): Design of a randomized controlled trial of a community health worker intervention to reduce inequities in COVID-19 and influenza vaccinations.

Meredith LS, Tobin JN, Cassells A, Howell K, Hernandez HG, Gidengil C, Williamson S, Dong L, Timmins G, Alvarado G, Holder T, Cortez Lainez J, Lin TJ, Lara M.Contemp Clin Trials. 2025 Jun;153:107848. doi: 10.1016/j.cct.2025.107848. Epub 2025 Feb 16.PMID: 39965727

Improved Uptake of Vaccinations in Children With Adverse Events Following Immunization After Specialist Immunization Service Intervention in an Australian Pediatric Hospital.

Yee JS, Doyle R, Wen SC.Pediatr Infect Dis J. 2025 Jun 1;44(6):589-592. doi: 10.1097/INF.0000000000004719. Epub 2025 Jan 7.PMID: 39774648

Identification of a linear B-cell epitope in B117L-213 protein of ASFV using monoclonal antibodies.

You L, Liu G, Yan Z, Cai M, Chen Y, Si X, Wang X, Zhang A, Sun A, Han S, Wan B, Du Y, Zhang G.Int Immunopharmacol. 2025 Jul 28;160:114970. doi: 10.1016/j.intimp.2025.114970. Epub 2025 Jun 1.PMID: 40456193

Assessment of Health Status and Creation of a Registry of Potential Research Participants Aged 1.5 to 50 Years on Bioko Island, Equatorial Guinea.

López Mikue MSA, Jongo SA, Nsue Ndong Nchama VU, Hamad Said A, Mtoro A, Owono Bidjimi G, Owono MA, Mansogo Maye ER, Mangue MEO, Nguema Okomo GN, Ntutumu Pasialo BE, Mandumbi DMO, Mochomuemue FL, Momo Besaha JC, Chuquiyauri R, Kassim KR, Mohamed Ali A, Kibondo UA, Athuman T, Cortez Falla C, Eyono JNM, Smith JM, García GA, Raso J, Nyakarungu E, Mpina M, Daubenberger C, Riloha Rivas M, Schindler T, Lemiale L, Sim BKL, Tanner M, Church LWP, Billingsley PF, Hoffman SL, Richie TL, Abdulla S.Am J Trop Med Hyg. 2025 Apr 8;112(6):1364-1377. doi: 10.4269/ajtmh.24-0143. Print 2025 Jun 4.PMID: 40132218

Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections.

Quirk GE, Schoenle MV, Peyton KL, Uhrlaub JL, Lau B, Liang CY, Burgess JL, Ellingson K, Beitel S, Romine J, Lutrick K, Fowlkes A, Britton A, Tyner HL, Caban-Martinez AJ, Naleway A, Gaglani M, Yoon S, Edwards LJ, Olsho L, Dake M, Valdez R, Gordon A, Diamond MS, LaFleur BJ, Nikolich JŽ, Sprissler R, Worobey M, Bhattacharya D.Nat Immunol. 2025 Jun;26(6):829-836. doi: 10.1038/s41590-025-02162-2. Epub 2025 May 27.PMID: 40425779

Haemophagocytic lymphohistiocytosis (HLH) secondary to measles in an adult with a loss of post-vaccination humoral immunity following rituximab.

Notghi AA, Delahunty J, Tattersall RS, Stone B.Lancet Infect Dis. 2025 Jun 3:S1473-3099(25)00223-3. doi: 10.1016/S1473-3099(25)00223-3. Online ahead of print.PMID: 40480240

Microfluidics combined with electron microscopy for rapid and high-throughput mapping of antibody-viral glycoprotein complexes.

Sewall LM, de Paiva Froes Rocha R, Gibson G, Louie M, Xie Z, Bangaru S, Tran AS, Ozorowski G, Mohanty S, Beutler N, Rogers TF, Burton DR, Shaw AC, Batista FD, Chocarro Ruiz B, Torrents de la Peña A, Ward AB.Nat Biomed Eng. 2025 Jun 3. doi: 10.1038/s41551-025-01411-x. Online ahead of print.PMID: 40461656

Research progress on immune mechanism and control strategy of dsRNA impurities in mRNA vaccine.

Liu X, Hu C, He Q, Bai Y, Zhang X, Fu Z, Ma X, Xu M, Liang Z, Mao Q.Expert Rev Vaccines. 2025 Dec;24(1):457-469. doi: 10.1080/14760584.2025.2510335. Epub 2025 Jun 2.PMID: 40401819

Disparity between expected spatial accessibility and actual travel time to vaccination sites: Implications for COVID-19 immunization delays.

Naderi H, Abbasian Z, Huang Y.SSM Popul Health. 2025 Apr 14;30:101804. doi: 10.1016/j.ssmph.2025.101804. eCollection 2025 Jun.PMID: 40386446

Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques.

Morris DJ, Gorman J, Zhou T, Lora J, Connell AJ, Li H, Liu W, Roark RS, Campion MS, Carey JW, Habib R, Li Y, Martella CL, Park Y, Singh A, Sowers KJ, Teng IT, Wang S, Chohan N, Ding W, Lauer C, Lewis E, Mason RD, Rando JM, Peyton L, Schramm CA, Wagh K, Korber B, Seaman MS, Douek DC, Haynes BF, Kulp DW, Roederer M, Hahn BH, Kwong PD, Shaw GM.Cell Rep. 2025 Jun 13;44(6):115848. doi: 10.1016/j.celrep.2025.115848. Online ahead of print.PMID: 40516049

Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 17-21 February 2025.

Lambach P, Silal S, Sbarra AN, Koh M, Aggarwal R, Farooqui HH, Flasche S, Hogan AB, Kim SY, Leung K, Moss WJ, Portnoy A, Sheel M, Wang XY.Vaccine. 2025 Jun 9;61:127384. doi: 10.1016/j.vaccine.2025.127384. Online ahead of print.PMID: 40494225

Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control.

Peng K, Zhao X, Li H, Fu YX, Liang Y.J Exp Med. 2025 Sep 1;222(9):e20241454. doi: 10.1084/jem.20241454. Epub 2025 Jun 6.PMID: 40479650

Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults 50 Years: A Randomized Clinical Trial.

Rudman Spergel AK, Wu I, Deng W, Cardona J, Johnson K, Espinosa-Fernandez I, Sinkiewicz M, Urdaneta V, Carmona L, Schaefers K, Girard B, Paila YD, Mehta D, Callendret B, Kostanyan L, Ananworanich J, Miller J, Das R, Shaw CA.JAMA. 2025 Jun 10;333(22):1977-1987. doi: 10.1001/jama.2025.5646.PMID: 40332892

Expression of SARS-CoV-2 spike protein in cerebral Arteries: Implications for hemorrhagic stroke Post-mRNA vaccination.

Ota N, Itani M, Aoki T, Sakurai A, Fujisawa T, Okada Y, Noda K, Arakawa Y, Tokuda S, Tanikawa R.J Clin Neurosci. 2025 Jun;136:111223. doi: 10.1016/j.jocn.2025.111223. Epub 2025 Apr 3.PMID: 40184822

Construction and characterization of a gE/gI/TK-gene-deleted recombinant pseudorabies virus variant expressing the GP5 of the highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) and NADC30-like PRRSV.

Zheng HH, Wang LQ, Hou CY, Song YP, Liu S, Zheng LL, Ma SJ, Chen HY.Microb Pathog. 2025 Jun;203:107522. doi: 10.1016/j.micpath.2025.107522. Epub 2025 Apr 1.PMID: 40180235

Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24.

Kissling E, Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Domegan L, Hooiveld M, Oroszi B, Martínez-Baz I, Guiomar R, Latorre-Margalef N, Mlinarić I, Lazar M, Giménez Duran J, Dürrwald R, Enouf V, McKenna A, de Lange M, Túri G, Trobajo-Sanmartín C, Gomez V, Samuelsson Hagey T, Višekruna Vučina V, Cherciu MC, García Vazquez M, Erdwiens A, Masse S, Bennett C, Meijer A, Kristóf K, Castilla J, Rodrigues AP, Kurečić Filipović S, Ivanciuc AE, Bacci S, Kaczmarek M; European primary care VE group.Euro Surveill. 2025 Jun;30(23):2500011. doi: 10.2807/1560-7917.ES.2025.30.23.2500011.PMID: 40511473

The indirect effect of the bivalent human papillomavirus vaccination program: an observational cohort study.

Middeldorp M, Duijster JW, Knol MJ, van Benthem BHB, Berkhof J, King AJ, de Melker HE.BMC Med. 2025 Jun 6;23(1):335. doi: 10.1186/s12916-025-04155-2.PMID: 40481488

Neonatal BCG vaccination to prevent asthma: Results from the MIS BAIR randomized controlled trial.

Pittet LF, Forbes EK, Donath S, Francis KL, Gardiner K, Flanagan KL, Ponsonby AL, Robins-Browne R, Shann F, South M, Vuillermin P, Casalaz D, Curtis N, Messina NL; Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR) Group.Pediatr Allergy Immunol. 2025 Jun;36(6):e70110. doi: 10.1111/pai.70110.PMID: 40464744

Healthcare workers' current practices, knowledge/awareness, barriers, and attitudes/perceptions related to pneumococcal vaccination of older adults: A mixed-methods systematic review.

Akther A, Laurie C, Elton-Marshall T, Ly V, Sulis G.Vaccine. 2025 Jun 2;61:127331. doi: 10.1016/j.vaccine.2025.127331. Online ahead of print.PMID: 40460654

A Genome-Wide Screening of Novel Immunogenic TrLSDV103 Protein of Lumpy Skin Disease Virus and Its Application for DIVA.

Yuan X, Dong J, Xiang Z, Zhang Q, Tao P, Guo A.FASEB J. 2025 Jun 15;39(11):e70676. doi: 10.1096/fj.202500425R.PMID: 40432413

Evaluation of vaccine uptake and opportunity of in-hospital vaccination against pneumococcus in vulnerable hospitalized patients.

Marín-Caba E, Benavente-Fernández A, Morales-Jiménez G, Comino-Fernández S, Cueto-Martín MI, Lirola-Andreu L, Guerrero-Fernández de Alba I, Valero-Ubierna MDC, Jiménez-Moleón JJ, Rivera-Izquierdo M.Vaccine. 2025 Jun 5;61:127364. doi: 10.1016/j.vaccine.2025.127364. Online ahead of print.PMID: 40479927

Evaluating the influence of maternal anti-HBs status on the antibody levels in vaccinated children.

Abu-Freha N, Shibli S, Etzion O, Afianish Y, Amer J, Abu Kaf H, Zohar N, Yardeni D, Safadi R.Clin Res Hepatol Gastroenterol. 2025 Jun;49(6):102608. doi: 10.1016/j.clinre.2025.102608. Epub 2025 Apr 30.PMID: 40315984

High Mortality Due to Pneumococcal Meningitis in Children With Sickle Cell Disease: A French Multicenter Observational Study From 2001 to 2021.

Fafi I, Cohen R, Levy C, Varon E, Amor-Chelihi L, Benhaim P, Houlier M, Koehl B, De Montalembert M, Allali S, Gauthier A, Odièvre MH, Gajdos V, Escoda S, Kamdem A, Costa G, Guillaumat C, Thuret I, Ouldali N, Gaschignard J, Carbonnelle E, De Pontual L, Pham LL.Pediatr Infect Dis J. 2025 Jun 1;44(6):496-502. doi: 10.1097/INF.0000000000004755. Epub 2025 Mar 7.PMID: 40063777

Effectiveness and safety of the recombinant zoster vaccine in individuals 50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study.

Rayens E, Sy LS, Qian L, Wu J, Ackerson BK, Luo Y, Cheng Y, Lin AT, Solano Z, De Jesus J, Amundsen B, Florea A, Ku JH, Chmielewski-Yee E, Oraichi D, Seifert H, Yun H, Tseng HF.Ann Rheum Dis. 2025 Jun;84(6):960-969. doi: 10.1016/j.ard.2025.01.045. Epub 2025 Feb 19.PMID: 39979209

Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States.

Averin A, Quinn E, Atwood M, Weycker D, Shea KM, Law AW.Vaccine. 2025 Jun 11;58:127191. doi: 10.1016/j.vaccine.2025.127191. Epub 2025 May 17.PMID: 40383082

Comparative impact of the COVID-19 pandemic on parental behaviour towards childhood vaccination in Israel and the United Kingdom: A self-controlled matched cross-sectional study.

Omar M, Shibli H, Edelstein M.Vaccine. 2025 Jun 10;61:127385. doi: 10.1016/j.vaccine.2025.127385. Online ahead of print.PMID: 40499347

[Therapeutics and (hypothetical) vaccinations against human cryptosporidia].

Borkens Y.Z Gastroenterol. 2025 Jun;63(6):596-603. doi: 10.1055/a-2551-1670. Epub 2025 Apr 29.PMID: 40300634

Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar.

Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, Al Thani AA, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Butt AA, Abu-Raddad LJ.Elife. 2025 Jun 9;14:e103690. doi: 10.7554/eLife.103690.PMID: 40488740

T-cell responses induced by SARS-CoV-2 index-virus nanoparticle protein vaccine to the ancestral and omicron variants 6 months following primary vaccination.

McMahon WC, Kwatra G, Nunes MC, Izu A, Koen AL, Greffrath J, Shalekoff S, Tiemessen CT, Shinde V, Bennett C, Madhi SA.Commun Med (Lond). 2025 Jun 10;5(1):220. doi: 10.1038/s43856-025-00941-4.PMID: 40494917

Microbiome Metabolite-Incorporated Lipid Nanoparticles Augment CD8⁺ T Cell Memory Potential and Immunity for mRNA Cancer Vaccines.

Yong SB, Ha M, Cho S.ACS Biomater Sci Eng. 2025 Jun 9. doi: 10.1021/acsbiomaterials.5c00738. Online ahead of print.PMID: 40490465

Recent Advances in Immunotherapeutic and Vaccine-Based Approaches for the Treatment of Drug-Resistant Bacterial Infections.

Odoom A, Osman AH, Dzuvor CKO.ACS Infect Dis. 2025 Jun 13;11(6):1366-1402. doi: 10.1021/acsinfecdis.5c00001. Epub 2025 May 2.PMID: 40315159

Breakthrough Infection and Death after COVID-19 Vaccination: A Physics Perspective.

Mortazavi SAR, Jafarzadeh A, Ghadimi-Moghadam A, Mortazavi SMJ, Haghani M, Ghadimi-Moghadam A, Sihver L.J Biomed Phys Eng. 2025 Jun 1;15(3):299-306. doi: 10.31661/jbpe.v0i0.2212-1577. eCollection 2025 Jun.PMID: 40510304

Congenital Rubella Syndrome in the Post-Elimination Era: Why Vigilance Remains Essential.

De Melo LC, Rugna MM, Durães TA, Pereira SS, Callado GY, Pires P, Traina E, Araujo Júnior E, Granese R.J Clin Med. 2025 Jun 5;14(11):3986. doi: 10.3390/jcm14113986.PMID: 40507747

Normative influence in a time of distrust and polarization: how perceived social norms predict COVID-19 vaccination intentions among Black Americans.

Lin T, Wang Y, Thier K, Nan X.J Behav Med. 2025 Jun 9. doi: 10.1007/s10865-025-00578-7. Online ahead of print.PMID: 40489008

Multiple exposures to SARS-CoV-2 Spike enhance cross-reactive antibody-dependent cellular cytotoxicity against SARS-CoV-1.

Beaudoin-Bussières G, Tauzin A, Dionne K, El Ferri O, Benlarbi M, Bourassa C, Medjahed H, Bazin R, Côté M, Finzi A.Virology. 2025 Jun;607:110512. doi: 10.1016/j.virol.2025.110512. Epub 2025 Mar 22.PMID: 40147380

Association Between Back Scent Gland Development and Reproductive Status in Male Brown Bears (Ursus arctos).

Tomiyasu J, Matsumoto N, Katsushima H, Nishijima A, Hagino K, Sakamoto H, Yanagawa Y.J Exp Zool A Ecol Integr Physiol. 2025 Jun;343(5):629-635. doi: 10.1002/jez.2916. Epub 2025 Mar 24.PMID: 40123450

Establishing correlation between in vitro potency and in vivo immunogenicity for mRNA vaccines.

Sanyal G.NPJ Vaccines. 2025 Jun 11;10(1):120. doi: 10.1038/s41541-025-01181-2.PMID: 40500281

Preventing Meningococcal Disease in US Adolescents and Young Adults Through Vaccination.

Presa J, Carrico R, Fergie JE, Hanenberg S, Marshall GS, Rivard K, Shaw J, Zimet GD, Peyrani P, Cane A.Infect Dis Ther. 2025 Jun 3. doi: 10.1007/s40121-025-01166-7. Online ahead of print.PMID: 40461935

Safety of pertussis vaccination in pregnancy and effectiveness in infants: a Danish national cohort study 2019-2023.

Kildegaard H, Jensen A, Andersen PHS, Dalby T, Gram MA, Lidegaard Ø, Stensballe LG.Clin Microbiol Infect. 2025 Jun;31(6):995-1002. doi: 10.1016/j.cmi.2025.03.014. Epub 2025 Mar 20.PMID: 40120753

Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.

Harris C, Kapingidza AB, San JE, Christopher J, Gavitt T, Rhodes B, Janowska K, O'Donnell C, Lindenberger J, Huang X, Sammour S, Berry M, Barr M, Parks R, Newman A, Overton M, Oguin T 3rd, Acharya P, Haynes BF, Saunders KO, Wiehe K, Azoitei ML.J Virol. 2025 Jun 13:e0046525. doi: 10.1128/jvi.00465-25. Online ahead of print.PMID: 40511920

Identification of the Top 15 Drugs Associated With Anaphylaxis: A Pharmacovigilance Study.

Kim TH, Park J, Jo H, Oh J, Lee K, Oh J, Lee H, Smith L, López Sánchez GF, Hwang Y, Yon DK.Clin Exp Allergy. 2025 Jun 8. doi: 10.1111/cea.70092. Online ahead of print.PMID: 40484712

Design, optimization, and evaluation of lyophilized lipid nanoparticles for mRNA-based pulmonary mucosal vaccination.

Lu Y, Yang Y, Yi J, Hong X, Lou J, Li M, Zheng A.Mater Today Bio. 2025 May 4;32:101813. doi: 10.1016/j.mtbio.2025.101813. eCollection 2025 Jun.PMID: 40475859

Comparison of the serological responses in pigs after oral vaccination against classical swine fever using two different types of bait.

Ortmann S, Lindner T, Meyer D, Wiedemann A, Postel A, Becher P, Vos A.Vet Immunol Immunopathol. 2025 Jun;284:110937. doi: 10.1016/j.vetimm.2025.110937. Epub 2025 Apr 14.PMID: 40245471

An insight of Streptococcus pneumoniae serotype 3 genomic profile in Indonesia.

Sari RF, Fadilah F, Maladan Y, Sarassari R, Khoeri MM, Harimurti K, Alimsardjono L, Safari D.J Microbiol Immunol Infect. 2025 Jun;58(3):325-332. doi: 10.1016/j.jmii.2025.01.007. Epub 2025 Feb 11.PMID: 39956730

COVID-19 and the impact of vaccination on the disease morbidity of Polish paediatric patients with inflammatory bowel disease.

Derda E, Meglicka M, Wiernicka A, Osiecki M, Kierkuś J, Szymańska E.Acta Paediatr. 2025 Jun;114(6):1338-1341. doi: 10.1111/apa.17574. Epub 2025 Jan 6.PMID: 39757999

Emerging neuroinfectious diseases: public health implications.

Kim CY, Holroyd KB, Thakur KT.Curr Opin Neurol. 2025 Jun 12. doi: 10.1097/WCO.0000000000001401. Online ahead of print.PMID: 40501312

Effects of Ikaros (IKZF1) gene in the virulence of Marek's disease virus.

Kim T, Niikura M, Dunn JR, Cheng HH, Hearn CJ.Vet Microbiol. 2025 Jun;305:110532. doi: 10.1016/j.vetmic.2025.110532. Epub 2025 Apr 28.PMID: 40318245

COVID-19 dynamic modeling of immune variability and multistage vaccination strategies: A case study in Malaysia.

Nwaibeh EA, Ali MKM.Infect Dis Model. 2024 Dec 19;10(2):505-521. doi: 10.1016/j.idm.2024.12.011. eCollection 2025 Jun.PMID: 39866178

An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses.

Aunins EA, Phan AT, Alameh MG, Dwivedi G, Cruz-Morales E, Christian DA, Tam Y, Bunkofske ME, Peñafiel AZ, O'Dea KM, Merolle M, Furey C, Scott P, Vonderheide RH, Hensley SE, Kedl RM, Weissman D, Hunter CA.Sci Immunol. 2025 Jun 6;10(108):eads1328. doi: 10.1126/sciimmunol.ads1328. Epub 2025 Jun 6.PMID: 40478935

Quantification of residual DTT by high-performance anion-exchange chromatography coupled with pulsed amperometric detection.

Rajendar B, Reddy MVNJ, Adusumilli M, Matur RV.J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Jun 1;1259:124609. doi: 10.1016/j.jchromb.2025.124609. Epub 2025 Apr 16.PMID: 40286484

Needle sharpness is minimally affected by vaccine vial puncture.

Tawil JR, Vitello EC, Agostini-Walesch GM, Mitchell JC, Kreisler RE.J Am Vet Med Assoc. 2025 Mar 19;263(6):725-731. doi: 10.2460/javma.25.01.0025. Print 2025 Jun 1.PMID: 40107237

Dynamic of Pediatric Invasive Bacterial Infections in Switzerland: A 2017-2024 Time-series Analysis of National Data.

Jaboyedoff M, Niederer-Loher A, Kahlert CR, Crisinel PA, Angoulvant F; Swiss Paediatric Surveillance Unit.Pediatr Infect Dis J. 2025 Jun 5. doi: 10.1097/INF.0000000000004886. Online ahead of print.PMID: 40472269

Parenteral vaccination with recombinant EtpA glycoprotein impairs enterotoxigenic *E. coli* colonization.

Vickers TJ, Buckley DP, Khatoon N, Sheikh A, Setu B, Berndsen ZT, Fleckenstein JM.Infect Immun. 2025 Jun 10;93(6):e0060124. doi: 10.1128/iai.00601-24. Epub 2025 May 1.PMID: 40310293

Association Between Child Varicella Vaccination and Zoster in Household Adults: A Retrospective Japanese Cohort Study.

Sato S, Ono S, Sasabuchi Y, Michihata N, Uemura K, Yasunaga H.Acta Paediatr. 2025 Jun;114(6):1392-1398. doi: 10.1111/apa.17582. Epub 2025 Jan 13.PMID: 39804145

Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update.

Magoola M, Niazi SK.Cancers (Basel). 2025 Jun 4;17(11):1882. doi: 10.3390/cancers17111882.PMID: 40507360

The complexity of acute mastoiditis in Swedish children.

Arebro J, Bennet R, Eriksson M, Granath A.Int J Pediatr Otorhinolaryngol. 2025 Jun;193:112346. doi: 10.1016/j.ijporl.2025.112346. Epub 2025 Apr 8.PMID: 40220458

Respiratory syncytial virus preventives for children in Australia: current landscape and future directions.

Barnett ST, Tuckerman J, Barr IG, Crawford NW, Wurzel DF.Med J Aust. 2025 Jun 16;222(11):579-586. doi: 10.5694/mja2.52671. Epub 2025 May 25.PMID: 40413643

Effect of intratumor dendritic cell vaccination with and without chemoradiation in induced oral squamous cell carcinoma of hamsters.

Amr NM, Salem ML, Shoshan MM, Abouzaid BH.Arch Oral Biol. 2025 Jun;174:106252. doi: 10.1016/j.archoralbio.2025.106252. Epub 2025 Apr 5.PMID: 40209655

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).

Áñez G, McGarry A, Woo W, Kotloff KL, Gay CL, Zhu M, Cloney-Clark S, Nelson J, Dunbar H, Cai MR, Cho I, Cai Z, Kalkeri R, Plested JS, Patel N, Smith K, Marchese AM, Glenn GM, Mallory RM, Dunkle LM; 2019CoVn-301 Study Investigators.Vaccine. 2025 Jun 5;61:127362. doi: 10.1016/j.vaccine.2025.127362. Online ahead of print.PMID: 40479932

Plasmodium and Host Immunity: Evasion Strategies and Advances in Malaria Vaccination.

Serrano-Coll H, Aristizábal-Parra LK.Scand J Immunol. 2025 Jun;101(6):e70034. doi: 10.1111/sji.70034.PMID: 40432384

Resurgence of Group A Streptococcal Infections.

Rose W.Indian J Pediatr. 2025 Jun 13. doi: 10.1007/s12098-025-05600-z. Online ahead of print.PMID: 40512320

Bacteremia and Meningitis Caused by Penicillin-resistant Streptococcus pneumoniae Serotype 35B Successfully Treated with Ceftriaxone Combined with Vancomycin Followed by Linezolid.

Tomioka M, Nakamura K, Duan S, Matsumoto K, Shindo T, Hoshi K, Nagao M, Oshima F, Hara Y, Namai Y.Intern Med. 2025 Jun 1;64(11):1761-1766. doi: 10.2169/internalmedicine.3904-24. Epub 2024 Nov 8.PMID: 39523005

Pediatric invasive pneumococcal disease spectrum before third-generation pneumococcal conjugate vaccine implementation.

Levy C, Estivaux A, Varon E, Béchet S, Ouldali N, Hau I, Cohen R.J Pediatric Infect Dis Soc. 2025 Jun 10:piaf056. doi: 10.1093/jpids/piaf056. Online ahead of print.PMID: 40492721

The immune response of Boschveld chickens to a Newcastle disease vaccination program designed for commercial layers.

Hodzi P, Masunda B, Mutibvu T, Charambira T, Mafigu T, Nhara R.Trop Anim Health Prod. 2025 Jun 14;57(5):269. doi: 10.1007/s11250-025-04528-y.PMID: 40515962

Monoclonal antibody neutralizes *Staphylococcus aureus* serine protease-like protein B (SplB)-induced pathology.

Iqbal J, von Fournier J, Wittmann N, Darisipudi MN, Mrochen DM, Smiljanov B, Surmann K, Wockenfuß G, Steil L, Kohler TP, Glinka FL, Peringathara S, Saade C, Fernandes LM, Bornscheuer U, Reichel CA, Bröker BM, Raafat D, Holtfreter S.Infect Immun. 2025 Jun 13:e0017125. doi: 10.1128/iai.00171-25. Online ahead of print.PMID: 40512005

Antiviral Prescription in Children With Influenza in US Emergency Departments: New Vaccine Surveillance Network (NVSN), 2016-2020.

Stopczynski T, Amarin JZ, Antoon JW, Hamdan O, Stewart LS, Chappell J, Spieker AJ, Klein EJ, Englund JA, Weinberg GA, Szilagyi PG, Williams JV, Michaels MG, Boom JA, Sahni LC, Staat MA, Schlaudecker EP, Schuster JE, Selvarangan R, Harrison CJ, Moline HL, Toepfer AP, Campbell AP, Olson SM, Halasa NB.Influenza Other Respir Viruses. 2025 Jun;19(6):e70124. doi: 10.1111/irv.70124.PMID: 40495453

Establishment of a carrot cell plant growth regulators-free system to produce a low-cost vac-cine candidate.

Carreño-Campos C, Elguea Zarate SD, Romero-Maldonado A, Villarreal ML, Rosales-Mendoza S, Ortiz Caltempa A.Planta Med. 2025 Jun 3. doi: 10.1055/a-2626-4703. Online ahead of print.PMID: 40461030

Maternal vaccination decision-making in urban and rural Bengaluru, India: A mixed methods study.

Sundaram N, Kowlgi A, Sahu B, Murthy G, Tam CC.Hum Vaccin Immunother. 2025 Dec;21(1):2506849. doi: 10.1080/21645515.2025.2506849. Epub 2025 Jun 3.PMID: 40460254

Using cancer survivor narratives to increase parents' human papillomavirus vaccination intentions.

Gerend MA, Myers CT, McQueen A, Solatikia F, Boakye EA, Shepherd JE.Health Psychol. 2025 Jun 12. doi: 10.1037/hea0001527. Online ahead of print.PMID: 40504651

Mathematical Modelling and Optimization of Medication Regimens for Combination Immunotherapy of Breast Cancer.

Xiong Z, Xia Y, Xue L, Lei J.Bull Math Biol. 2025 Jun 2;87(7):88. doi: 10.1007/s11538-025-01459-5.PMID: 40455115

Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: A cohort study.

Riedmann U, Chalupka A, Richter L, Werber D, Sprenger M, Willeit P, Rijksen M, Lodron J, Høeg TB, Ioannidis JP, Pilz S.J Infect. 2025 Jun;90(6):106497. doi: 10.1016/j.jinf.2025.106497. Epub 2025 Apr 30.PMID: 40315999

Nanoparticle based oral delivery of vaccines: A promising solution for immunization challenges in developing nations; A comprehensive review.

Tafere C, Siraj EA, Yayehrad AT, Workye M.Int J Pharm. 2025 Jun 14:125848. doi: 10.1016/j.ijpharm.2025.125848. Online ahead of print.PMID: 40523548

Safety of RTS,S/AS01(E) malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study.

Haine V, Oneko M, Debois M, Ndeketa L, Agyapong PD, Boahen O, Harrison SBE, Adeniji E, Kaali S, Kayan K, Owusu-Agyei S, French N, Kariuki S, Devadiga R, Ogutu B, Ansah NA, Orsini M, Ansah PO, Maleta K, Ong'echa JM, Phiri VK, Mzanga P, Jere TM, Azongo DK, Mategula D, Orimbo J, Oduro AR, Otieno W, Kaburise MB, Ababio LO, Sifuna PM, Amoit SK, Olewe F, Oyieko JN, Achieng Oguk E, Guerra Mendoza Y, Awuni D, Sing'oei V, Onyango I, Schuerman L, Ochieng BO, Okoth GO, Nyangulu W, Cherop RY, Odera-Ojwang P, Cravcenco C, Chipatala R, Roman F, Savic M, Asante KP.Lancet Glob Health. 2025 Jun;13(6):e995-e1005. doi: 10.1016/S2214-109X(25)00096-8. Epub 2025 Apr 24.PMID: 40288377

COVID-19 vaccination and pregnancy-induced hypertension risk in women undergoing assisted reproduction.

Ma S, Zheng Y, Fang M, Xiong Y, Hu L, Liu Y, Gong F, Krämer BK, Lin G, Hocher B.Hum Reprod. 2025 Jun 1;40(6):1173-1182. doi: 10.1093/humrep/deaf055.PMID: 40219638

Integrating a conceptual consent permission model from the informed consent ontology for software application execution.

Amith MT, He Y, Smith E, Harris M, Manion F, Tao C.AMIA Jt Summits Transl Sci Proc. 2025 Jun 10;2025:46-55. eCollection 2025.PMID: 40502263

Prophylactic and Therapeutic EBV Vaccination.

Khanna R, Cohen JI.Curr Top Microbiol Immunol. 2025 Jun 7. doi: 10.1007/82_2025_308. Online ahead of print.PMID: 40478309

Pan-viral ORFs discovery using massively parallel ribosome profiling.

Weingarten-Gabbay S, Bauer MR, Stanton AC, Yu Y, Freije CA, Welch NL, Boehm CK, Klaeger S, Verzani EK, López D, Hensley LE, Clauser KR, Carr SA, Abelin JG, Rice CM, Sabeti PC.Science. 2025 Jun 12;388(6752):1218-1224. doi: 10.1126/science.ado6670. Epub 2025 Jun 12.PMID: 40504907

Cost-Effectiveness Analysis of Expanding Influenza Vaccination to Adults Aged 50 and Over in France.

Béraud G, Mosnier A, Guérin O, Cugnardey N, Gillet S, Haond J, Simon S, Berkovitch Q, Gamblin P, Lesage H, Loubet P.Infect Dis Ther. 2025 Jun 8. doi: 10.1007/s40121-025-01168-5. Online ahead of print.PMID: 40483665

Chemical shift assignments of the rib domain in a cell surface protein from Limosilactobacillus reuteri.

Xue Y, Kang X.Biomol NMR Assign. 2025 Jun;19(1):127-131. doi: 10.1007/s12104-025-10228-3. Epub 2025 Apr 7.PMID: 40192991

Impact of vaccination on the ecology of Escherichia coli in commercial Turkey production.

White LM, Weber BP, Mendoza KM, Flores-Figueroa C, Munoz-Aguayo J, Mattison KA, Miller EA, Johnson TJ.Poult Sci. 2025 Jun 9;104(9):105415. doi: 10.1016/j.psj.2025.105415. Online ahead of print.PMID: 40516298

Characteristics of patients with disseminated Bacillus Calmette-Guérin infection: a retrospective study at Namazi Hospital, Southern Iran, from 1991 to 2022.

Sanaei Dashti A, Soflaee Shahrbabak S, Malekzadeh Y, Davarpanah A, Taherifard E, Ahmadkhani A, Pouladfar G, Hamzavi SS, Kadivar MR, Geramizadeh B, Anbardar MH, Shoja K, Taherifard E.J Trop Pediatr. 2025 Jun 7;71(4):fmaf023. doi: 10.1093/tropej/fmaf023.PMID: 40499196

Influences on college health provider practice for routinely screening female college students' HPV vaccination status.

Liebermann E, Si B, Hutchinson MK, Li B, Sutherland MA.BMC Public Health. 2025 Jun 5;25(1):2099. doi: 10.1186/s12889-025-23234-w.PMID: 40474098

Comparative clinical, virological and pathological characterization of equine rotavirus A G3P[12] and G14P[12] infection in neonatal mice.

Gamage C, Holl W, Parreño V, Thieulent CJ, Balasuriya UBR, Vissani MA, Barrandeguy ME, Carossino M.J Gen Virol. 2025 Jun;106(6):002110. doi: 10.1099/jgv.0.002110.PMID: 40471657

Long-term dynamics of SARS-CoV-2 immunity in a university hospital in Colombia: A cohort study.

Caballero N, Monsalve DM, Acosta-Ampudia Y, Fajardo N, Moreno S, Martínez O, González-Uribe C, Ramírez-Santana C, Quintero J.IJID Reg. 2025 Mar 27;15:100641. doi: 10.1016/j.ijregi.2025.100641. eCollection 2025 Jun.PMID: 40391349

De novo design and discovery of broad-spectrum affinity peptide ligands for influenza A vaccines.

Tian Z, Dong X, Sun Y, Shi Q.J Chromatogr A. 2025 Jun 7;1750:465937. doi: 10.1016/j.chroma.2025.465937. Epub 2025 Apr 2.PMID: 40194500

Assessment of In Vitro Models of the Human Buccal Mucosa for Vaccine and Adjuvant Development.

Davis MM, Bajrovic I, Croyle MA.Mol Pharm. 2025 Jun 2;22(6):2868-2880. doi: 10.1021/acs.molpharmaceut.4c01186. Epub 2025 Mar 26.PMID: 40139941

Identification and Pathogenicity Analysis of Feline Calicivirus in Shanghai and Guangdong, China.

Luo D, Xie W, Li N, Peng X, Li K, Zhou X, Wang Z.Transbound Emerg Dis. 2025 Jun 4;2025:8729295. doi: 10.1155/tbed/8729295. eCollection 2025.PMID: 40503218

Anti-PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT-like and VITT-like characteristics.

Nicolson PLR, Montague SJ, Buka RJ, Calvert A, Sheppard JI, Zhang Y, Wang JJ, Sharman J, Hassan E, Harrison J, Lawrence E, El-Dalil P, Parekh D, Osman H, Gordon TP, Nazy I, Warkentin TE, Lester WA.Br J Haematol. 2025 Jun;206(6):1737-1742. doi: 10.1111/bjh.20092. Epub 2025 Apr 29.PMID: 40298004

Poxvirus structural biology for application to vaccine design.

Yu H, Resch W, Moss B.Trends Immunol. 2025 Jun;46(6):455-470. doi: 10.1016/j.it.2025.04.002. Epub 2025 May 7.PMID: 40340168

Norovirus replication, host interactions and vaccine advances.

Prasad BVV, Atmar RL, Ramani S, Palzkill T, Song Y, Crawford SE, Estes MK.Nat Rev Microbiol. 2025 Jun;23(6):385-401. doi: 10.1038/s41579-024-01144-9. Epub 2025 Jan 17.PMID: 39824927

[Changes of hemagglutinin gene characteristics of influenza virus A(H3N2) during the 2022-2024 influenza season in Beijing].

Zhang DT, Peng XM, Zhang L, Zhao JC, Xun J, Chu YH, Zou L, Ji LL, Yang P, Wang QY, Lu GL.Zhonghua Liu Xing Bing Xue Za Zhi. 2025 Jun 10;46(6):1058-1066. doi: 10.3760/cma.j.cn112338-20240807-00481.PMID: 40518402

Dual Roles of GM-CSF in Breast Cancer: Immunomodulation and Therapeutic Implications.

Guo Y, Hu Y, Huang D, Yang J, Fu S, Deng X, Long J, Wang J, Wang Y.Crit Rev Oncol Hematol. 2025 Jun 12:104804. doi: 10.1016/j.critrevonc.2025.104804. Online ahead of print.PMID: 40516637

Prevalence of human adenovirus in children with acute gastroenteritis in the New Vaccine Surveillance Network (NVSN) from 2016 to 2019.

Kinzler AJ, Wikswo ME, Balasubramani GK, D'Agostino HEA, Sax T, Dauer K, Weinberg GA, Szilyagi P, Sahni LC, Boom JA, Schuster JE, Selvarajan R, Harrison CJ, Staat MA, Payne DC, Halasa NB, Klein EJ, Englund JA, Martin JM, Hickey R, Michaels MG, Williams JV.J Clin Virol. 2025 Jun 6;179:105822. doi: 10.1016/j.jcv.2025.105822. Online ahead of print.PMID: 40499355

Maternal transfer of oral vaccine induced anti-OspA antibodies protects Peromyscus spp. from tick-transmitted Borrelia burgdorferi.

Azevedo JF, Joyner G, Kundu S, Samanta K, Gomes-Solecki M.Infect Immun. 2025 Jun 10;93(6):e0021625. doi: 10.1128/iai.00216-25. Epub 2025 May 19.PMID: 40387454

A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.

Thompson EM, Ashley DM, Ayasoufi K, Norberg P, Archer G, Buckley ED, Herndon JE 2nd, Walter A, Archambault B, Flahiff C, Jaggers D, Gorski L, Sanchez LA, Congdon K, Hotchkiss K, Cook SL, Moelker E, Vlahovic G, Reap E, Schroeder K, Randazzo D, Desjardins A, Johnson MO, Peters K, Khasraw M, Friedman H, Mitchell DA, Sampson JH, Landi D.Nat Cancer. 2025 Jun 12. doi: 10.1038/s43018-025-00998-z. Online ahead of print.PMID: 40506525

Impurity profiling of PEGylated myristoyl diglyceride, DMG-PEG 2000, a functional excipient used in mRNA lipid nanoparticle formulations.

Sperber B, Gutmann M, Kehrein J, Lühmann T, Holzgrabe U, Meinel L.Eur J Pharm Biopharm. 2025 Jun 4:114762. doi: 10.1016/j.ejpb.2025.114762. Online ahead of print.PMID: 40480444

Comparison of Perceived Adverse Events After COVID-19 Vaccination Between Pregnant and NonPregnant Women Using Two Cohort Studies in the Netherlands.

Woestenberg PJ, Terpstra AW, van Hunsel F, Lieber T, Maas VYF.Birth Defects Res. 2025 Jun;117(6):e2490. doi: 10.1002/bdr2.2490.PMID: 40476384

Cryo-EM structures of engineered Shiga toxin-based immunogens capable of eliciting neutralizing antibodies with therapeutic potential against hemolytic uremic syndrome.

Cristófalo AE, Sharma A, Cerutti ML, Sharma K, Melero R, Pardo R, Goldbaum FA, Borgnia M, Zylberman V, Otero LH.Protein Sci. 2025 Jun;34(6):e70178. doi: 10.1002/pro.70178.PMID: 40411437

Development of a blocking ELISA employing a VP1-specific monoclonal antibody for the detection of DHAV3 antibodies.

Song C, Li T, Wang J, Guo P, Yang W, Tang N, Qu Y, Li S, Qiu X, Tan L, Sun Y, Liao Y, Ding C.Poult Sci. 2025 Jun;104(6):105080. doi: 10.1016/j.psj.2025.105080. Epub 2025 Apr 5.PMID: 40188623

A review of currently licensed mucosal COVID-19 vaccines.

Tscherne A, Krammer F.Vaccine. 2025 Jun 6;61:127356. doi: 10.1016/j.vaccine.2025.127356. Online ahead of print.PMID: 40482457

Modelling of potential risk areas of pertussis cases in the Philippines using bioclimatic envelopes.

Tomimbang AMG, Dagamac NHA, Komoda AT.Trop Med Int Health. 2025 Jun;30(6):547-555. doi: 10.1111/tmi.14115. Epub 2025 Apr 21.PMID: 40259620

Advancing Protein-Coding RNA Engineering: From Structural Refinement to Biomedical Implementation.

Lu X, Li S, Chi Y, Lin S, Yuan H, Lin Z, Xiao Y, Yin H, Zuo X, Cheng R, Xi J, Chen M, Zou Q.Biotechnol J. 2025 Jun;20(6):e70038. doi: 10.1002/biot.70038.PMID: 40490953

Versatility of LNPs across different administration routes for targeted RNA delivery.

Jallow MB, Huang K, Qiu M.J Mater Chem B. 2025 Jun 6. doi: 10.1039/d5tb00575b. Online ahead of print.PMID: 40476395

In Vivo Evaluation of Pam_2Cys-Modified Cancer-Testis Antigens as Potential Self-Adjuvanting Cancer Vaccines.

Aljohani S, Edmonds AG, Castelletto V, Seitsonen J, Hamley IW, Symonds P, Brentville VA, Durrant LG, Mitchell NJ.J Pept Sci. 2025 Jun;31(6):e70022. doi: 10.1002/psc.70022.PMID: 40326329

An informed deep learning model of the Omicron wave and the impact of vaccination.

Shamsara E, König F, Pfeifer N.Comput Biol Med. 2025 Jun;191:109968. doi: 10.1016/j.compbiomed.2025.109968. Epub 2025 Apr 9.PMID: 40209576

Alternative theories of COVID-19: social dimensions and information sources.

Shrum W, Miller P, Asiamah NO, Zou F.J Public Health Policy. 2025 Jun;46(2):444-459. doi: 10.1057/s41271-025-00560-2. Epub 2025 Feb 19.PMID: 39972218

Nanoparticle-Based Pulmonary Immune Engineering.

Trautmann-Rodriguez M, Fromen CA.Annu Rev Chem Biomol Eng. 2025 Jun;16(1):249-270. doi: 10.1146/annurev-chembioeng-082223-105117. Epub 2025 Mar 12.PMID: 40073112

Circular RNAs in gynecological cancer: From molecular mechanisms to clinical applications (Review).

Liu Y, Ai H.Oncol Lett. 2025 Apr 11;29(6):291. doi: 10.3892/ol.2025.15037. eCollection 2025 Jun.PMID: 40271005

Potential blocker of SARS-CoV entry and a narrow functionality of its spike protein motifs on Qubevirus platform.

Dzelamonyuy A, Ntemafack A, Georgiadis MM, Waffo AB.J Biol Chem. 2025 Jun 12:110371. doi: 10.1016/j.jbc.2025.110371. Online ahead of print.PMID: 40516871

COVID-19 infection and vaccination in children with Dravet syndrome or infantile epileptic spasms syndrome: An internet survey in Japan.

Ito S, Nishikawa A, Kuroiwa R, Honda K, Nagata S.Brain Dev. 2025 Jun;47(3):104352. doi: 10.1016/j.braindev.2025.104352. Epub 2025 Mar 30.PMID: 40163980

Characteristics of Invasive Pneumococcal Diseases Cases Among U.S. Children With Hematologic Malignancies Before and After Introduction of Thirteen-valent Pneumococcal Conjugate Vaccine, 2005-2019.

Hamilton K, Luvsansharav UO, Xing W, Gierke R, King J, Farley MM, Schaffner W, Thomas A, Chai SJ, Harrison LH, Holtzman C, McGuire SM, Petit S, Barnes M, Angeles KM, Chochua S, McGee L, Kobayashi M.Pediatr Infect Dis J. 2025 Jun 1;44(6):564-570. doi: 10.1097/INF.0000000000004730. Epub 2025 Jan 17.PMID: 39836562

Effectiveness of a new cationic lipid-based nanovaccine for enhancing immersion vaccination against Flavobacterium oreochromis in red tilapia (Oreochromis sp.).

Kitiyodom S, Kamble MT, Yostawonkul J, Thompson KD, Pirarat N.Fish Shellfish Immunol. 2025 Jun;161:110289. doi: 10.1016/j.fsi.2025.110289. Epub 2025 Mar 19.PMID: 40118230

Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with IgG4-related disease.

Mastromanno L, Giardina F, Gattamelata A, Colafrancesco S, Truglia S, Spinelli FR, Simoncelli E, Lucchino B, Conti F, Priori R.Reumatismo. 2025 Jun 10;77(2). doi: 10.4081/reumatismo.2025.1744. Epub 2025 Jan 22.PMID: 39849976

Variation in anti-SARS-CoV-2 spike antibody responses by variants in patients with severe mental illness after COVID-19 vaccination.

Lin CY, Song YC, Yang CC, Yeh PS, Yu YY, Huang CC.Brain Behav Immun. 2025 Jun 9:S0889-1591(25)00229-6. doi: 10.1016/j.bbi.2025.06.015. Online ahead of print.PMID: 40499845

Economic Evaluation of PHID-CV versus PCV10-SII Compared with no Vaccination in the Philippines.

Ahmed N, Han R, Rodriguez E, Bibera GL, Ortiz E, Oladehin O, Gomez JA.Infect Dis Ther. 2025 Jun 2. doi: 10.1007/s40121-025-01162-x. Online ahead of print.PMID: 40455125

The saga to monitor and control norovirus: the rise of GII.17.

Parra GI, Tohma K, Ford-Siltz LA, Pilewski KA, Kendra JA.J Gen Virol. 2025 Jun;106(6). doi: 10.1099/jgv.0.002118.PMID: 40476850

COVID-19 vaccination atlas using an integrative systems vaccinology approach.

Prates-Syed WA, Fonseca DLMD, Pour SZ, Lira A, Cortes N, Silva JDQ, Carvalho E, Filgueiras IS, Vinces TGC, Schimke LF, Chaves LCS, Wunderlich G, Durães-Carvalho R, Dias HD, Ochs HD, Câmara NOS, Nakaya HI, Krieger JE, Cabral-Marques O, Cabral-Miranda G.NPJ Vaccines. 2025 Jun 2;10(1):111. doi: 10.1038/s41541-025-01148-3.PMID: 40456760

Immunological insights into the re-emergence of human metapneumovirus.

Acharya A, Byrareddy SN.Curr Opin Immunol. 2025 Jun;94:102562. doi: 10.1016/j.coi.2025.102562. Epub 2025 May 12.PMID: 40359650

Coronavirus research topics, tracking twenty years of research.

Aryani A, Wang J, Salvador-Carulla L, Woo J, Cheung CPW, Wu Z, Yin H, Xiao J, Lambert EA, Howitt J, Davidson JM, Yoong S, Dixon JB, Climie RE, Salinas-Perez JA, Bagheri N, Santiago C, Williams J, Wickramasinghe N, Ng L, Zwack CC, Lambert GW.Sci Data. 2025 Jun 10;12(1):978. doi: 10.1038/s41597-025-04992-z.PMID: 40494890

Acute rheumatic fever.

Hirani K, Rwebembera J, Webb R, Beaton A, Kado J, Carapetis J, Bowen A.Lancet. 2025 Jun 14;405(10495):2164-2178. doi: 10.1016/S0140-6736(25)00185-0. Epub 2025 Jun 5.PMID: 40484016

Health team practices to improve vaccination coverage of children in a favela.

Gomes GM, Assis GGT, Silva SCSB, Trotte LAC, Stipp MAC.Rev Esc Enferm USP. 2025 Jun 6;59:e20240337. doi: 10.1590/1980-220X-REEUSP-2024-0337en. eCollection 2025.PMID: 40488398

Apolipoprotein E4 facilitates transfection of human monocyte-derived dendritic cells by lipid nanoparticles.

Lambart I, Zaryouh H, Audenaerde JV, Liu D, Quatannens D, Lion E, Schiller S, Geissler S, Smits E, Mäder K.Int J Pharm. 2025 Jun 10;678:125720. doi: 10.1016/j.ijpharm.2025.125720. Epub 2025 May 11.PMID: 40360096

Malaria parasite phenotypic heterogeneity and the power of single-cell technologies.

Gyamfi E, Baum J.Trends Parasitol. 2025 Jun;41(6):460-470. doi: 10.1016/j.pt.2025.04.006. Epub 2025 May 7.PMID: 40340169

Nanomaterial Applications in Prevention and Treatment Strategies of Virus: A Review.

Xin GL, Zhang C, Ni JL, Li YK, Sun Y, He XX.Bioconjug Chem. 2025 Jun 12. doi: 10.1021/acs.bioconjchem.5c00170. Online ahead of print.PMID: 40503813

Production and evaluation of rabies immunoglobulin extracted from chicken egg yolk.

Kerdput V, Yodkamol V, Sookprasong M, Wongwadhunyoo W, Khunsri I, Masrinoul P, Wisedchanwet T, Uthailak N, Limpanont Y, Reamtong O, Adisakwattana P, Thawornkuno C.Biotechnol Rep (Amst). 2025 May 8;46:e00897. doi: 10.1016/j.btre.2025.e00897. eCollection 2025 Jun.PMID: 40487875

A scientific case for revisiting the embryonic chicken model in biomedical research.

McGrew MJ, Holmes T, Davey MG.Dev Biol. 2025 Jun;522:220-226. doi: 10.1016/j.ydbio.2025.02.013. Epub 2025 Feb 25.PMID: 40015500

Perspectives of healthcare workers on drone-enabled healthcare delivery in challenging terrains of Manipur and Nagaland, India: a qualitative research.

Aggarwal S, Mahajan N, Gupta P, Balaji S, Simmy, Singh NS, Saku A, Bhargava B, Panda S.J Public Health Policy. 2025 Jun;46(2):326-341. doi: 10.1057/s41271-025-00553-1. Epub 2025 Jan 27.PMID: 39870900

Hyperleukocytosis associated with pertussis: Two case reports.

Han HW, Wang XX, Wang Y, Zhang WH.World J Clin Cases. 2025 Jun 16;13(17):102207. doi: 10.12998/wjcc.v13.i17.102207.PMID: 40524766

Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department.

Silva-Afonso RF, Platas-Abenza G, Guerrero-Soler M, Gallardo-Rodríguez P, Gil-Sánchez F, Pérez-Paz G, Cartagena-Llopis L, Fuster-Pérez M, Sánchez-Valero M, Esclapez-Martínez A, Solís-Aniorte N, Fernández-Martínez Y, Ronda-Pérez E, Escribano-Cañadas I, Rodríguez-Díaz JC, Merino De Lucas E, Chico-Sánchez P, Sánchez-Payá J, Gras-Valentí P.Enferm Infecc Microbiol Clin (Engl Ed). 2025 Jun 3:S2529-993X(25)00139-X. doi: 10.1016/j.eimce.2025.03.017. Online ahead of print.PMID: 40467410

Meningococcal Disease (Neisseria meningitidis Infection).

Rausch-Phung EA, Hall WA, Ashong D.2025 Jun 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.PMID: 31751039

Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations.

Aditham AK, Radford CE, Carr CR, Jasti N, King NP, Bloom JD.Cell Host Microbe. 2025 Jun 11;33(6):988-1003.e10. doi: 10.1016/j.chom.2025.04.018. Epub 2025 May 20.PMID: 40398416

Low and inequitable influenza and COVID-19 vaccination coverage among pregnant women in Norway: Nationwide population-based cohort study.

Hansen BT, Dahl J, Greve-Isdahl M, Winje BA, Rydland KM, Campbell S, Pay ASD, Michelsen TM, Meijerink H.Vaccine. 2025 Jun 14;61:127386. doi: 10.1016/j.vaccine.2025.127386. Online ahead of print.PMID: 40517499

Is equitable priority vaccination of vulnerable people feasible in a real-world context? The case of Belgium.

Vermeiren E, Scheerens C, Stouten V, Crombez J, De Maeseneer J, van Loenhout JAF.Eur J Public Health. 2025 Jun 10:ckaf075. doi: 10.1093/eurpub/ckaf075. Online ahead of print.PMID: 40493534

Depressive Symptoms Before and During the COVID-19 Pandemic in Veteran Nursing Home Residents.

Benz MB, Rudolph JL, DeVone F, Bayer TA, Garbin A, Singh M, Gravenstein S, Hartronft S, Toms R, Gaudiano BA, Metrik J, Browne J.Int J Geriatr Psychiatry. 2025 Jun;40(6):e70108. doi: 10.1002/gps.70108.PMID: 40450594

Androgens inhibit protective CD8⁺ T cell responses against pre-erythrocytic malaria parasites in mice.

Duncombe CJ, Sen N, Watson FN, Poehlman AS, Layton ED, Boey K, Conrad EN, Kalata AC, Seilie AM, Dill-McFarland KA, Seshadri C, Shears MJ, Murphy SC.Nat Commun. 2025 Jun 4;16(1):5172. doi: 10.1038/s41467-025-60193-7.PMID: 40467616

Bioactive polydopamine nanomedicines-assisted cancer immunotherapy.

Zhou X, Wang L, Wu Y, Lin X, Liu F, Sun X, Song K, Jiang C, Zhao F, Li X.Mater Today Bio. 2025 May 13;32:101864. doi: 10.1016/j.mtbio.2025.101864. eCollection 2025 Jun.PMID: 40487166

Respiratory syncytial virus vaccination in pregnancy - Position statement by the European board and college of obstetrics and gynaecology (EBCOG).

Ramasauskaite D, Savona-Ventura C, Minkauskiene M, Mahmood T.Eur J Obstet Gynecol Reprod Biol. 2025 Jun;310:113978. doi: 10.1016/j.ejogrb.2025.113978. Epub 2025 Apr 17.PMID: 40267825

Residue-specific protein-glycan conjugation strategies for the development of pharmaceutically promising glycoconjugate vaccines: A recent update.

Sarkar R, Bandyopadhyay A, Brahmachari G.Carbohydr Res. 2025 Jun;552:109476. doi: 10.1016/j.carres.2025.109476. Epub 2025 Apr 1.PMID: 40188503

Helminthic intestinal perforations in children: our experience.

Bhagwat AD, Patil R, Makan A, Vaze D, Jadhav P.J Parasit Dis. 2025 Jun;49(2):368-377. doi: 10.1007/s12639-024-01764-1. Epub 2024 Nov 13.PMID: 40458513

Molecular characterization of a synthetic neutralizing antibody targeting p67 of Theileria parva.

Miersch S, Singer AU, Chen C, Fellouse F, Gopalsamy A, Costa LSE, Lacasta A, Chege H, Chege N, Nene V, Sidhu SS.Protein Sci. 2025 Jun;34(6):e70153. doi: 10.1002/pro.70153.PMID: 40384600

Immunoproteomic analyses identify broadly cross-reactive sporozoite immunogens of Eimeria maxima recognized by antisera from chickens infected with E. maxima, E. necatrix, E. tenella or E. acervulina.

Gong H, Deng H, Song F, Han T, Wang X, Feng S, Chen W, Liu L.Vet Parasitol. 2025 Jun;336:110462. doi: 10.1016/j.vetpar.2025.110462. Epub 2025 Apr 8.PMID: 40239458

Resurgence of pertussis: Epidemiological trends, contributing factors, challenges, and recommendations for vaccination and surveillance.

Wang S, Zhang S, Liu J.Hum Vaccin Immunother. 2025 Dec;21(1):2513729. doi: 10.1080/21645515.2025.2513729. Epub 2025 Jun 9.PMID: 40491090

Iontophoresis and electroporation-assisted microneedles: advancements and therapeutic potentials in transdermal drug delivery.

Abbasi M, Heath B.Drug Deliv Transl Res. 2025 Jun;15(6):1962-1984. doi: 10.1007/s13346-024-01722-7. Epub 2024 Oct 21.PMID: 39433696

Highly suitable LFBK cells for African swine fever virus replication and type I interferon-induced immune studies.

Lee EG, Kang SM, Tark D.Vet Res. 2025 Jun 11;56(1):116. doi: 10.1186/s13567-025-01543-7.PMID: 40500801

Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response.

Matsuda K, Harrison M, Wettstein E, Pederson J, Pullano AA, Bolkhovitinov L, Kim B, Steinberg I, Griesman T, Stuccio S, Rogan D, Patamawenu A, Shofner T, Wright NE, Webber JD, Van't Veer F, Roenicke R, Koory E, Roeder PM, Ober E, Leach B, Tsybovsky Y, Stephens T, Del Moral-Sanchez I, Bontjer I, McGinnes-Cullen LW, Chu E, Liang J, Torres JL, Lin RN, Tran AS, Dziubla G, Serebryannyy L, Narpala S, Lin B, Castro M, Ozorowski G, Ward AB, Sanders RW, Kwong PD, Guenaga J, Wyatt R, Morrison T, Connors M.Nat Commun. 2025 Jun 3;16(1):5162. doi: 10.1038/s41467-025-60481-2.PMID: 40461490

Bridging knowledge gaps in phytotherapy for a neglected zoonotic disease: Rift valley fever.

Sharifan A.Biomed Pharmacother. 2025 Jun;187:118092. doi: 10.1016/j.biopha.2025.118092. Epub 2025 Apr 29.PMID: 40306173

On value compatibility: reflections on the ethical framework for pandemic healthcare distribution.

Wang Y.Med Health Care Philos. 2025 Jun;28(2):303-313. doi: 10.1007/s11019-025-10261-y. Epub 2025 Mar 7.PMID: 40053306

Well-Child Care: Newborns and Infants.

Turner K, Barnes JE, Morrison L, McEvoy A.FP Essent. 2025 Jun;553:7-15.PMID: 40523122

Conceptualization of the Africa CDC Public Health Risk Communication and Community Engagement Community of Practice for Africa (PH-RCCE-CoPA) in 2020: successes and challenges in implementation.

Djoudalbaye B, Kabanda R, Mavuto T, Njai M, Mhiraf A, Gweh GN.Glob Health Promot. 2025 Jun 13:17579759251320648. doi: 10.1177/17579759251320648. Online ahead of print.PMID: 40509804

Measles Outbreak Investigation in Chandigarh in 2023: A Case Series.

Mahajan V, Singh MP, Sharma A, Kanta P, Gupta S, Guglani V.Indian Pediatr. 2025 Jun 10. doi: 10.1007/s13312-025-00112-7. Online ahead of print.PMID: 40493112

Comparison between Western Reserve strain and Tiantan strain of oncolytic vaccinia virus vector expressing exogenous gene Aphracilistes vastus lectin.

Zhang H, Pang W, Zhou J, Ye T, Chen K, Zhou Y, Li G.Biochem Biophys Res Commun. 2025 Jun 3;775:152155. doi: 10.1016/j.bbrc.2025.152155. Online ahead of print.PMID: 40482588

Force of Infection Model for Estimating Time to Dengue Virus Seropositivity among Expatriate Populations, Thailand.

Rapheal E, Kitro A, Imad H, Hamins-Peurtolas M, Olanwijitwong J, Chatapat L, Hunsawong T, Anderson K, Piyaphanee W.Emerg Infect Dis. 2025 Jun;31(6):1149-1157. doi: 10.3201/eid3106.241686.PMID: 40439444

Chitosan, derivatives, and its nanoparticles: Preparation, physicochemical properties, biological activities, and biomedical applications - A comprehensive review.

El-Saadony MT, Saad AM, Alkafaas SS, Dladla M, Ghosh S, Elkafas SS, Hafez W, Ezzat SM, Khedr SA, Hussien AM, Fahmy MA, Elesawi IE, Salem HM, Mohammed DM, Abd El-Mageed TA, Ahmed AE, Mosa WFA, El-Tarabily MK, AbuQamar SF, El-Tarabily KA.Int J Biol Macromol. 2025 Jun;313:142832. doi: 10.1016/j.ijbiomac.2025.142832. Epub 2025 Apr 3.PMID: 40187443

[BRICS in the management of the COVID-19 pandemic: a comparative study on social distancing and vaccination measures in the nations of the bloc].

Martins TCF, Guimarães RM, Pereira AMM.Cad Saude Publica. 2025 Jun 9;41(5):e00069024. doi: 10.1590/0102-311XPT069024. eCollection 2025.PMID: 40498914

Differential patterns of cross-protection against antigenically distinct variants in small animal models of SARS-CoV-2 infection.

Selvaraj P, Stauft CB, Liu S, Sangare K, Wang TT.Npj Viruses. 2025 Jun 4;3(1):49. doi: 10.1038/s44298-025-00125-w.PMID: 40467943

Cell membrane nanoparticles in cancer therapy: From basic structure to surface functionalization.

Kim M, Choi R, Kim L, Kim YC, Noh I.J Control Release. 2025 Jun 10;382:113752. doi: 10.1016/j.jconrel.2025.113752. Epub 2025 Apr 18.PMID: 40254140

Evaluating the Accuracy of the Annual Statewide Kindergarten Vaccination Survey Submitted to Public Health Authorities by School Systems, Oklahoma, 2018.

Naqvi OH, Wendelboe AM, Burnsed L, Mannell M, Janitz A, Natt S.J Sch Nurs. 2025 Jun;41(3):325-332. doi: 10.1177/10598405221130701. Epub 2022 Oct 12.PMID: 36221975

Self-assembled ferritin nanoparticles using SpyCatcher/SpyTag multimerization of Mycobacterium tuberculosis TB10.4 protein induce potent immunogenicity.

Guo F, Dong S, Song Y, Xiesihan G, Jiang H, Qian Z, Wang X, Wang H, Xu T.Int Immunopharmacol. 2025 Jun 12;161:115019. doi: 10.1016/j.intimp.2025.115019. Online ahead of print.PMID: 40513336

Triazolinedione Modification of Prenylated Peptides, Proteins, and DNA: Toward a Single-Site Multilabeling Approach for Biomolecules.

Tack L, Manicardi A, Leszczynska G, Dziergowska A, Ghielmetti A, Unal K, Decoene K, Winne J, Madder A.ACS Omega. 2025 May 18;10(21):21187-21194. doi: 10.1021/acsomega.4c10125. eCollection 2025 Jun 3.PMID: 40488083

Intracellular Bacteria-Mimicking Whole-Cell Cancer Vaccine Potentiates Immune Responses via Concurrent Activation of NLRP3 Inflammasome and STING Pathway.

Xie X, Shen Z, He Y, Chen Y, Zhang W, Chen F, Tang J, Guan S, Wang L, Shao D, Yang C.Nano Lett. 2025 Jun 6. doi: 10.1021/acs.nanolett.5c01666. Online ahead of print.PMID: 40476548

Progress in the development of cancer vaccines for lung cancer utilizing dendritic cells (Review).

Hu H, Chen WJ, Sun C, Xie JP.Oncol Lett. 2025 Apr 14;29(6):298. doi: 10.3892/ol.2025.15044. eCollection 2025 Jun.PMID: 40276084

Decoding codon usage in human papillomavirus type 59.

Tan X, Zhou W, Jing S, Shen W, Lu B.Virus Genes. 2025 Jun;61(3):313-323. doi: 10.1007/s11262-025-02148-0. Epub 2025 Mar 4.PMID: 40038214

A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy.

You Q, Wu G, Li H, Liu J, Cao F, Ding L, Liang F, Zhou B, Ma L, Zhu L, Wang C, Yang Y, Chen X.Nat Nanotechnol. 2025 Jun 16. doi: 10.1038/s41565-025-01952-x. Online ahead of print.PMID: 40523938

Health-care burden related to respiratory syncytial virus in a resource-constrained setting: a prospective observational study.

Saha S, Saha S, Kanon N, Hooda Y, Islam MS, Islam S, Ahmed ZB, Rahman SW, Alam MJ, Anik AM, Sarkar PK, Ahsan MR, Amin MR, Saha SK.Lancet Glob Health. 2025 Jun;13(6):e1072-e1081. doi: 10.1016/S2214-109X(25)00048-8.PMID: 40412396

Humoral and cellular immune responses to mRNA COVID-19 vaccinations in the elderly: A longitudinal study in Japan.

Fukushima K, Kubo T, Ito Y, Oda Y, Nagayoshi Y, Fukuda M, Takazono T, Sakamoto N, Mukae H.J Infect Chemother. 2025 Jun;31(6):102695. doi: 10.1016/j.jiac.2025.102695. Epub 2025 Apr 4.PMID: 40189203

Association Between Vaccination for Human Papillomavirus (HPV) and Autonomic Dysfunction and Menstrual Irregularities: A Self-Controlled Case Series Analysis.

Wastila L, Fu YH, Tung CC, Qato DM.Drugs Real World Outcomes. 2025 Jun 16. doi: 10.1007/s40801-025-00504-y. Online ahead of print.PMID: 40524098

Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years.

Mayer EF, Falsey AR, Clark R, Ferguson M, Cardona J, She F, Jones B, Reuter C, Collins A, Mannan A, Kapoor A, Slobod K, Stoszek SK, Du J, Mou J, Lan L, Zhou H, Wilson E, Goswami J, Das R, Priddy F.Clin Infect Dis. 2025 Jun 4:ciaf292. doi: 10.1093/cid/ciaf292. Online ahead of print.PMID: 40464662

The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama.

Sáez-Llorens X, Lasalvia P, Jaramillo P, DeAntonio R.Expert Rev Pharmacoecon Outcomes Res. 2025 Jun 4:1-14. doi: 10.1080/14737167.2025.2514530. Online ahead of print.PMID: 40458968

AeroVax: study protocol for a randomised, double-blind, placebo-controlled, phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans.

Komorowski AS, Mbuagbaw L, Jeyanathan M, Afkhami S, Swinton M, D'Agostino MR, Howie K, Medina MFC, Gauvreau GM, Brister DL, Satia I, Lichty BD, Miller MS, Cameron DW, Halperin S, Thabane L, Loeb M, Xing Z, Smaill FM.ERJ Open Res. 2025 Jun 9;11(3):00758-2024. doi: 10.1183/23120541.00758-2024. eCollection 2025 May.PMID: 40491461

Global burden of vaccine-associated Raynaud's phenomenon, 1968-2024: A comprehensive analysis of the pharmacovigilance database.

Jeong J, Kim H, Jo H, Park J, Cho J, Lee H, Cho H, Rahmati M, Woo HG, Yon DK.Eur J Clin Pharmacol. 2025 Jun 6. doi: 10.1007/s00228-025-03854-2. Online ahead of print.PMID: 40478262

Pediatric Neuropsychiatric Syndromes: Updates on COVID-19 Infection and Vaccination.

O'Dor S, Adams C, Gavin J, Zagaroli JS, Carlisle E, Downer OM, Williams KA, Masterson EE.J Child Adolesc Psychopharmacol. 2025 Jun;35(5):294-303. doi: 10.1089/cap.2024.0129. Epub 2025 Mar 24.PMID: 40127994

Streptococcus pneumoniae carriage in adults during the COVID-19 pandemic in Portugal: dominance of serotypes included in broader PCVs and of serotype 3.

Almeida ST, Paulo AC, Simões AS, Ferreira B, Sá-Leão R.mSphere. 2025 Jun 10:e0008225. doi: 10.1128/msphere.00082-25. Online ahead of print.PMID: 40492709

The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, double-blind, positive control, phase III clinical trial.

Liu X, Li J, Zha Y, Wang Z, Jiang Y, Zhang X, Guo J, Yu J, Li X, Zhang Q, Reid C, McClain JB, Tsao E.Vaccine. 2025 Jun 5;61:127289. doi: 10.1016/j.vaccine.2025.127289. Online ahead of print.PMID: 40479926

Efficacy, safety, and immunogenicity of the AS01(E)-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.

Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Cuadripani S, Deraedt Q, Dezutter N, Gerard C, Fissette L, Xavier S, David MP, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group.Lancet Respir Med. 2025 Jun;13(6):517-529. doi: 10.1016/S2213-2600(25)00048-7. Epub 2025 Apr 14.PMID: 40245915

Mpox in Africa: What we know and what is still lacking.

Kangbai JB, Sesay U, Vickos U, Kagbanda F, Fallah MP, Osborne A.PLoS Negl Trop Dis. 2025 Jun 12;19(6):e0013148. doi: 10.1371/journal.pntd.0013148. eCollection 2025 Jun.PMID: 40504780

RSV vaccines and Guillain-Barré syndrome: Insights into an emerging concern.

Anastassopoulou C, Panagiotopoulos AP, Ferous S, Poland GA, Dodick DW, Tsakris A.Vaccine. 2025 Jun 3;61:127338. doi: 10.1016/j.vaccine.2025.127338. Online ahead of print.PMID: 40466480

A robust DNA walker for simplified, rapid, and sensitive detection of HBV DNA in blood.

Lai R, Lai M, He B, Li B, Huang L, Xie H, Chen L.Mikrochim Acta. 2025 Jun 13;192(7):422. doi: 10.1007/s00604-025-07284-w.PMID: 40512258

Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimer.

Schleich FA, Bale S, Guenaga J, Ozorowski G, Àdori M, Lin X, Castro Dopico X, Wilson R, Chernyshev M, Cotgreave AT, Mandolesi M, Cluff J, Doyle ED, Sewall LM, Lee WH, Zhang S, O'Dell S, Healy BS, Lim D, Lewis VR, Ben-Akiva E, Irvine DJ, Doria-Rose NA, Corcoran M, Carnathan D, Silvestri G, Wilson IA, Ward AB, Karlsson Hedestam GB, Wyatt RT.Immunity. 2025 Jun 10;58(6):1598-1613.e8. doi: 10.1016/j.immuni.2025.04.010. Epub 2025 May 7.PMID: 40339576

A painful twist: Wandering spleen with torsion and infarction: A case report.

Elnour AS, Yagoub A, Saeed A, Nugud F, Alshaikh AA.Int J Surg Case Rep. 2025 Jun;131:111391. doi: 10.1016/j.ijscr.2025.111391. Epub 2025 Apr 28.PMID: 40306103

Data fitting and optimal control strategies for HBV acute patient cases in the United States.

Chen X, Li Y, Azimaqin N, Wu Y, Tan C, Duan X, Yuan Y.Infect Dis Model. 2025 Feb 10;10(2):660-679. doi: 10.1016/j.idm.2025.02.004. eCollection 2025 Jun.PMID: 40027593

High-resolution cryo-EM analysis visualizes hydrated type I and IV pilus structures from enterotoxigenic Escherichia coli.

Kawahara K, Oki H, Iimori M, Muramoto R, Imai T, Gerle C, Shigematsu H, Matsuda S, Iida T, Nakamura S.Structure. 2025 Jun 5;33(6):1040-1050.e3. doi: 10.1016/j.str.2025.03.010. Epub 2025 Apr 11.PMID: 40220752

mRNA vaccines against HIV: Hopes and challenges.

Zubair A, Ahmad H, Arif MM, Ali M.HIV Med. 2025 Jun;26(6):824-838. doi: 10.1111/hiv.70024. Epub 2025 Apr 7.PMID: 40195015

Parents' Level of COVID-19 Fear, Anxiety and Their Attitudes and Behaviors Toward Vaccination of Their Children.

Baş K, Gürarslan Baş N.Omega (Westport). 2025 Jun;91(2):964-976. doi: 10.1177/00302228221146377. Epub 2022 Dec 14.PMID: 36516015

Recombinant BCG Expressing IL-12 as A Novel Immunomodulatory Strategy for Allergic Asthma: Opportunities and Challenges.

Campos-Povea R, González-Madrid E, Troncoso-Bravo T, Peñaloza HF, González PA, Bueno SM, Kalergis AM.Clin Rev Allergy Immunol. 2025 Jun 7;68(1):54. doi: 10.1007/s12016-025-09066-x.PMID: 40483388

Immune imprinting blunts omicron pathogenicity fluctuations and highlights the essential role of cellular immunity in SARS-CoV-2 infection.

Wei X, Yang H, Wu J, Zhao B, Mu Y, Rong N, Zhang G, Peng W, Zhang L, Zhang W, Ding X, Zhang G, Chen Z, Liu J.Cell Rep. 2025 Jun 3;44(6):115784. doi: 10.1016/j.celrep.2025.115784. Online ahead of print.PMID: 40471788

Prior anogenital herpes and human papillomavirus infections are associated with increased risk of lichen sclerosus in a large retrospective cohort study.

Singal A, Curtis KL, Lipner SR.Int J Womens Dermatol. 2025 Jun 4;11(2):e210. doi: 10.1097/JW9.0000000000000210. eCollection 2025 Jun.PMID: 40469715

Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction.

Grace PS, Peters JM, Sixsmith J, Lu R, Irvine EB, Luedeman C, Fenderson BA, Vickers A, Slein MD, McKitrick T, Wei MH, Cummings RD, Wallace A, Cavacini LA, Choudhary A, Proulx MK, Sundling C, Källenius G, Reljic R, Ernst JD, Casadevall A, Locht C, Pinter A, Sassetti CM, Bryson BD, Fortune SM, Alter G.Immunity. 2025 Jun 10;58(6):1586-1597.e5. doi: 10.1016/j.immuni.2025.05.004. Epub 2025 May 30.PMID: 40449485

[Pain Treatment for Herpes zoster].

Gaik C, Volberg C.Anasthesiol Intensivmed Notfallmed Schmerzther. 2025 Jun;60(6):371-375. doi: 10.1055/a-2281-1256. Epub 2025 Jun 13.PMID: 40513584

Characterising Dissolution Dynamics of Engineered Nanomaterials: Advances in Analytical Techniques and Safety-by-Design.

Chakraborty S, Valsami-Jones E, K Misra S.Small. 2025 Jun 2:e2500622. doi: 10.1002/smll.202500622. Online ahead of print.PMID: 40454937

Outer Membrane Vesicles from *Caulobacter crescentus*: A Platform for Recombinant Antigen Presentation.

Ginez LD, Osorio A, Correal-Medina V, Arenas T, González-Espinosa C, Camarena L, Poggio S.ACS Nano. 2025 Jun 10;19(22):20526-20538. doi: 10.1021/acsnano.4c17885. Epub 2025 May 28.PMID: 40434063

The design, manufacture and LNP formulation of mRNA for research use.

Leighton LJ, Chaudhary N, Tompkins HT, Kulkarni A, Carrodus NL, Budzinska MA, Lakshman Das S, Cheetham SW, Mercer TR.Nat Protoc. 2025 Jun 10. doi: 10.1038/s41596-025-01174-4. Online ahead of print.PMID: 40494942

Diversity and T-cell antigenic potentials of Mycoplasma mycoides subsp. mycoides vaccine candidates.

Wynn EL, Dassanayake RP, Nielsen DW, Casas E, Clawson M.Genome. 2025 Jun 3. doi: 10.1139/gen-2024-0177. Online ahead of print.PMID: 40460457

Mysterious Oropouche virus: Transmission, symptoms, and control.

Porwal S, Malviya R, Sridhar SB, Shareef J, Wadhwa T.Infect Med (Beijing). 2025 Mar 17;4(2):100177. doi: 10.1016/j.imj.2025.100177. eCollection 2025 Jun.PMID: 40290155

siRNA-based delivery systems: Technologies, carriers, applications, and approved products.

Ghasemiyeh P, Mohammadi-Samani S.Eur J Pharmacol. 2025 Jun 5;996:177441. doi: 10.1016/j.ejphar.2025.177441. Epub 2025 Feb 27.PMID: 40023357

Antibody response to SARS-CoV-2 vaccine in patients with asthma.

Zhang X, Tao Y, Song Z, Sun L, Sun Y, Jin R, Chang C.J Asthma. 2025 Jun;62(6):1082-1091. doi: 10.1080/02770903.2025.2458523. Epub 2025 Feb 13.PMID: 39932243

Cost-Utility Analysis of COVID-19 Vaccination Strategies for Endemic SARS-CoV-2.

Miranda RN, Simmons AE, Li MWZ, Gebretekle GB, Xi M, Salvadori MI, Warshawsky B, Wong E, Ximenes R, Andrew MK, Sander B, Singh D, Wilson S, Tunis M, Tuite AR.JAMA Netw Open. 2025 Jun 2;8(6):e2515534. doi: 10.1001/jamanetworkopen.2025.15534.PMID: 40512495

Measurement, Characterization, and Mapping of COVID-19 Misinformation in Spain: Cross-Sectional Study.

Alvarez-Galvez J, Lagares-Franco C, Ortega-Martin E, De Sola H, Rojas-García A, Sanz-Marcos P, Almenara-Barrios J, Kassianos AP, Montagni I, Camacho-García M, Serrano-Macías M, Carretero-Bravo J.JMIR Infodemiology. 2025 Jun 16;5:e69945. doi: 10.2196/69945.PMID: 40523274

Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster randomized controlled trial.

Chen J, Xie W, Huang X, Huang A, Lu T, Zhang R, Xiao J, He S, Wang J, Xu L.BMC Med. 2025 Jun 4;23(1):333. doi: 10.1186/s12916-025-04156-1.PMID: 40468328

Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster.

Wachter BT, Xu Q, Shi L, Burbelo PD, Myint-Hpu K, Schwartzberg PL, Rehman MT, Dewar RL, Boswell KL, Koup RA, Oguz C, Imberti L, Bellusci L, Pourhashemi S, Khurana S, Manthiram K, Notarangelo LD, Delmonte OM.J Allergy Clin Immunol. 2025 Jun;155(6):2038-2051. doi: 10.1016/j.jaci.2025.02.026. Epub 2025 Mar 3.PMID: 40044048

The Influence of Protein Corona on Liposomal Delivery Systems: A Comprehensive Review.

Mojarad-Jabali S, Fatahi Y, Dinarvand R.Eur J Pharm Sci. 2025 Jun 11:107166. doi: 10.1016/j.ejps.2025.107166. Online ahead of print.PMID: 40513682

Pharmacists' acceptability of provision of sexually transmitted infection services: a scoping review.

Bergin KM, Black EK, Murphy AL, Kelly DV, Wilby KJ.Int J Pharm Pract. 2025 Jun 12:riaf039. doi: 10.1093/ijpp/riaf039. Online ahead of print.PMID: 40504984

Seroprevalence of Hepatitis A in Non-vaccinated Adolescents Aged 9 to 12 Years in New Delhi, India: A Cross-Sectional Study.

Agarwal A, Sajlan S, Chawla R, Mathur SB.Indian Pediatr. 2025 Jun 3. doi: 10.1007/s13312-025-00090-w. Online ahead of print.PMID: 40459807

Steroid hormone binding and modulation of *Trichinella spiralis* progesterone receptor: A computational approach.

Aleem MT, Lakho SA, Mohsin M, Ul Haq S, Ali A, Huang D, Gao F.Biochem Biophys Rep. 2025 May 5;42:102031. doi: 10.1016/j.bbrep.2025.102031. eCollection 2025 Jun.PMID: 40458199

Prevalence of missed opportunities for vaccination (MOV) indicators among children aged 12-23 months in sub-Saharan African countries: An individual-level meta-analysis of DHS and MICS national household data surveys.

Tamuzi JL, Katoto PDMC, Ndwandwe DE, Wiysonge CS, Nyasulu PS.Hum Vaccin Immunother. 2025 Dec;21(1):2510714. doi: 10.1080/21645515.2025.2510714. Epub 2025 Jun 3.PMID: 40457858

Circular RNAs as a therapeutic modality for viral infections and innovative strategies to overcome key challenges: A review.

Hussen BM, Abdullah SR, Khudhur ZO, Samsami M, Taheri M.Int J Biol Macromol. 2025 Jun 9;318(Pt 2):145088. doi: 10.1016/j.ijbiomac.2025.145088. Online ahead of print.PMID: 40499865

Impact of Reduction in Myeloid-derived Suppressor Cells by Wilms' Tumor 1-targeted Dendritic Cell Vaccines on Clinical Outcomes in Acute Leukemia Patients.

Ogasawara M, Miyashita M, Yamagishi Y, Ota S.EJHaem. 2025 May 14;6(3):e70048. doi: 10.1002/jha2.70048. eCollection 2025 Jun.PMID: 40370631

Bibliometric analysis of advances in polysaccharide pharmacology research: A review.

Yang J, Lei S, Wei Y, Li Y, Wang R, Xue H, Huang Q, Huang K, Lei X.Int J Biol Macromol. 2025 Jun;313:144159. doi: 10.1016/j.ijbiomac.2025.144159. Epub 2025 May 12.PMID: 40368214

TCR CDR3 chemical complementarity to HPV epitopes is associated with a better outcome for cervical cancer.

Agnila DRL, Jain R, Diaz MJ, Hudlock TR, Eakins RA, Chobrutskiy A, Chobrutskiy BI, Blanck G.Mamm Genome. 2025 Jun;36(2):683-691. doi: 10.1007/s00335-025-10127-x. Epub 2025 Apr 11.PMID: 40216662

Stakeholder Perceptions of the School Vaccination Program in Special Schools for Adolescents With Intellectual and Developmental Disability.

Zaina D, Aemehdoust Z, Klinner C, Young A, Strnadová I, Wong H, Newman CE, Davies C, Skinner SR, Danchin M, Guy R, Carter A.J Sch Health. 2025 Jun;95(6):379-388. doi: 10.1111/josh.70003. Epub 2025 Mar 23.PMID: 40121558

The Mediterranean sea bass Dicentrarchus labrax: A marine model species in fish immunology.

Picchietti S, Pianese V, Fausto AM, Scapigliati G.Fish Shellfish Immunol. 2025 Jun;161:110288. doi: 10.1016/j.fsi.2025.110288. Epub 2025 Mar 20.PMID: 40120781

The social delegitimization of individualism: Exploring potential drivers during the COVID-19 pandemic.

Kubin PRM.Z Evid Fortbild Qual Gesundhwes. 2025 Jun;195:42-50. doi: 10.1016/j.zefq.2025.03.001. Epub 2025 Apr 4.PMID: 40187994

Cultural context and pandemic preparedness: Reassessing the Global Health Security Index's predictive power during COVID-19.

Kim H, Kim T, Ten GK.Soc Sci Med. 2025 Jun 6;381:118239. doi: 10.1016/j.socscimed.2025.118239. Online ahead of print.PMID: 40499233

Active Chemical Messenger-Driven Immune Activation via Electrochemical Patch for *In-Situ* Tumor Vaccination.

Zou Y, Lyu L, Xie Y, Yan S, Zhao Y, Chen W, Liu YN, Zhao Y.ACS Nano. 2025 Jun 10. doi: 10.1021/acsnano.5c06418. Online ahead of print.PMID: 40493454

T Cell Responses During Dengue Infection.

de Arruda LB, Marques ETA.Curr Top Microbiol Immunol. 2025 Jun 6. doi: 10.1007/82_2025_312. Online ahead of print.PMID: 40473809

Rational Development of a Novel Emulgel Adjuvant for Single-Shot Effective Vaccination: A Multivariate Analysis Approach.

Shalash AO, Hussein WM, Nahar UJ, Wang J, Lu L, Azuar A, Kiong JJE, Koirala P, Khalil ZG, Toth I.Adv Mater. 2025 Jun 3:e2506496. doi: 10.1002/adma.202506496. Online ahead of print.PMID: 40459521

Multi-omics and AI-driven immune subtyping to optimize neoantigen-based vaccines for colorectal cancer.

Vasudevan K, T D, Hebbar SR, Selvam PK, Rambabu M, Anbarasu K, Rohini K.Sci Rep. 2025 Jun 2;15(1):19333. doi: 10.1038/s41598-025-01680-1.PMID: 40456769

Vaccination policies for dentists and other dental professionals in Europe: a systematic report.

Maltezou HC, Camilleri A, Carney N, Chainier A, Guðmundsdóttir K, Guzaitienė E, Heuzé C, Krainhöfner J, Kukolik P, Linninger M, Nagaba J, Pavao M, Selikowitz HS, Sharkov N, Sloth-Lisbjerg F, Smucler R, Szewczyński M, van Dam B, Vettore L, Woods L, Zeyer O, Tzoutzas I.Expert Rev Vaccines. 2025 Jun 5. doi: 10.1080/14760584.2025.2516254. Online ahead of print.PMID: 40470721

Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies.

Hui RW, Fung J, Seto WK, Yuen MF, Mak LY.Hepatol Int. 2025 Jun 11. doi: 10.1007/s12072-025-10828-0. Online ahead of print.PMID: 40495020

Evaluating size exclusion chromatography for nucleic acid removal in Klebsiella pneumoniae cell surface polysaccharide purification.

Mihooliya KN, Kumar A, Heiss C, Kumari A, Boniche-Alfaro C, Azadi P, Fries BC.Carbohydr Polym. 2025 Jun 15;358:123531. doi: 10.1016/j.carbpol.2025.123531. Epub 2025 Mar 24.PMID: 40383590

ARTdeConv: adaptive regularized tri-factor non-negative matrix factorization for cell type deconvolution.

Liu T, Liu C, Li Q, Zheng X, Zou F.NAR Genom Bioinform. 2025 Apr 26;7(2):lqaf046. doi: 10.1093/nargab/lqaf046. eCollection 2025 Jun.PMID: 40290316

Symptoms and Management of Painful Progressive Swelling in Eswatini Snakebite Patients: A Prospective Observational Study.

Steinhorst J, Litschka-Koen T, Ascenção B, Mmema L, Shongwe N, Murray J, VanderWal H, Cuginotti de Oliveira R, Sithole T, Padidar S, Casewell NR, Pons J, Harrison RA, Lalloo DG, Stienstra Y.Am J Trop Med Hyg. 2025 Apr 15;112(6):1345-1354. doi: 10.4269/ajtmh.24-0671. Print 2025 Jun 4.PMID: 40233729

Duck plague virus UL47 gene affects the release and cell-to-cell spread of the virus and its deletion strains can provide strong protection for ducks.

Cui Y, Chen S, Wang M, Zhang W, Yang Q, Ou X, Sun D, He Y, Tian B, Wu Z, Zhang S, Huang J, Wu Y, Zhao X, Zhu D, Chen S, Liu M, Jia R, Cheng A.Poult Sci. 2025 Jun;104(6):105092. doi: 10.1016/j.psj.2025.105092. Epub 2025 Mar 24.PMID: 40158279

Respiratory syncytial virus vaccination: likely and less likely outcomes.

Gatt D, Hazan G.Curr Opin Pediatr. 2025 Jun 1;37(3):259-265. doi: 10.1097/MOP.0000000000001455. Epub 2025 Mar 19.PMID: 40105190

High Risk, High Reward: By Selecting Tsg101, A Protein That Sorts The Trash, As Our Personal ESCRT, Both HIV And I Were Able To Bud.

Carter CA.J Mol Biol. 2025 Jun 1;437(11):169053. doi: 10.1016/j.jmb.2025.169053. Epub 2025 Feb 28.PMID: 40024433

Selected infectious disease topics in the ED: Optimizing logistics to optimize care.

Flack T, Howington GT.Am J Health Syst Pharm. 2025 Jun 3:zxaf126. doi: 10.1093/ajhp/zxaf126. Online ahead of print.PMID: 40459367

Systematic literature review and meta-analysis on the prevalence of rotavirus genotypes in Asia from 2015 to 2021.

Jesudason T, Fleetwood K, Bermudez M, Sharomi O, Schirrmacher H, Hauck C, Hungerford D, Tordrup D, Matthijnssens J, Carias C.Hum Vaccin Immunother. 2025 Dec;21(1):2500261. doi: 10.1080/21645515.2025.2500261. Epub 2025 Jun 2.PMID: 40455410

Resistance to ceftriaxone and penicillin G among contemporary syphilis strains confirmed by natural in vitro mutagenesis.

Pospíšilová P, Bosák J, Hrala M, Krbková L, Vrbová E, Šmajs D.Commun Med (Lond). 2025 Jun 10;5(1):224. doi: 10.1038/s43856-025-00948-x.PMID: 40494996

[The road to prevention - navigating vision zero strategies in oncology].

Löffler J, von Bergwelt-Baildon M.Dtsch Med Wochenschr. 2025 Jun;150(12):683-689. doi: 10.1055/a-2381-4586. Epub 2025 May 19.PMID: 40388978

Immunological characteristics of the recombinant pseudorabies virus with chimeric PCV Cap protein in pigs.

Lu C, Chen W, Chen H, Xing G, Ma J, Zhou H, Qin L, Da L, Sun S, Peng P, Li H, Jin Y, Yan Y, Pan S, Dong W, Gu J, Zhou J.Vet Microbiol. 2025 Jun;305:110529. doi: 10.1016/j.vetmic.2025.110529. Epub 2025 Apr 23.PMID: 40288026

Glycoengineering of the hepatitis C virus E2 glycoprotein improves biochemical properties and enhances immunogenicity.

Kulakova L, Li KH, Chiang AWT, Schwoerer MP, Suzuki S, Schoffelen S, Elkholy KH, Chao KL, Shahid S, Kumar B, Murray NB, Archer-Hartmann S, Azadi P, Voldborg BG, Marin A, Mariuzza RA, Andrianov AK, Ploss A, Lewis NE, Toth EA, Fuerst TR.NPJ Vaccines. 2025 Jun 11;10(1):121. doi: 10.1038/s41541-025-01161-6.PMID: 40500295

Eliminating malaria in Nigeria: insights from Egypt's success and pathways to sustainable eradication.

Eneh SC, Obi CG, Ekwebene OC, Edeh GC, Awoso O, Udoewah SA, Onukansi FO, Ikhuoria OV, Okoli IA, Ojo TO.Malar J. 2025 Jun 9;24(1):183. doi: 10.1186/s12936-025-05391-w.PMID: 40490749

Pathogenicity analysis of a Chinese Genogroup II Akabane virus strain (TJ2016) in mouse models.

Wang J, Yu R, Wei F, Chen D, Wu S.Virol J. 2025 Jun 7;22(1):186. doi: 10.1186/s12985-025-02819-2.PMID: 40483453

Awareness and willingness towards Mpox vaccination among men who have sex with men seeking HIV-related services.

Liu WD, Cheng CY, Sun HY, Chen KH, Li SY, Lin CY, Chen WY, Wu PY, Chen LY, Chen YT, Luo YZ, Chang HY, Peng AT, Wang PY, Chen YC, Lin CY, Hung CH, Hung CC.J Formos Med Assoc. 2025 Jun 6:S0929-6646(25)00276-1. doi: 10.1016/j.jfma.2025.06.001. Online ahead of print.PMID: 40483238

Variation of COVID-19 vaccination percentage by industry and occupation in Michigan.

Rosenman KD, Wang L.Vaccine. 2025 Jun 6;61:127349. doi: 10.1016/j.vaccine.2025.127349. Online ahead of print.PMID: 40482458

Bispecific Antibody Targeting VEGF/TGF-β Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal Effects.

Lyu L, Yi M, Chen J, Zhang J, Ma X, Zhang X, Zeng L, Xue Y, Wen H, Deng Y, Zhou P, Wu K, Kang H, Dai Z.Adv Sci (Weinh). 2025 Jun 5:e01819. doi: 10.1002/advs.202501819. Online ahead of print.PMID: 40470716

Molecular epidemiology, immunobiology, genomics and proteomics insights into bovine brucellosis.

Prabhakar YK, Skariah S, Shanmugam G, Shome R.Vet Microbiol. 2025 Jun;305:110505. doi: 10.1016/j.vetmic.2025.110505. Epub 2025 Apr 9.PMID: 40233684

Imaging oligomers of alpha-toxin (Hla) variants using high-speed AFM and neutralizing Hla hemolytic activity with their antisera.

Le NTP, Ngo KX, Nguyen TTN, Tran LT, Nguyen HD.Arch Biochem Biophys. 2025 Jun;768:110403. doi: 10.1016/j.abb.2025.110403. Epub 2025 Mar 25.PMID: 40147500

Tuberculosis and HIV coinfection: Progress and challenges towards reducing incidence and mortality.

Sossen B, Kubjane M, Meintjes G.Int J Infect Dis. 2025 Jun;155:107876. doi: 10.1016/j.ijid.2025.107876. Epub 2025 Mar 8.PMID: 40064284

Production and cryo-electron microscopy structure of an internally tagged SARS-CoV-2 spike ecto-domain construct.

Singh S, Liu Y, Burke M, Rayaprolu V, Stein SE, Hasan SS.J Struct Biol X. 2025 Feb 11;11:100123. doi: 10.1016/j.yjsbx.2025.100123. eCollection 2025 Jun.PMID: 40046771

Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trial.

Jongihlati B, Segall N, Block SL, Absalon J, Perez J, Munson S, Sanchez-Pearson Y, Simon R, Silmon de Monerri NC, Radley D, McLaughlin LC, Gaylord M, Gruber WC, Jansen KU, Scott DA, Anderson AS.Lancet Infect Dis. 2025 Jun 13:S1473-3099(25)00216-6. doi: 10.1016/S1473-3099(25)00216-6. Online ahead of print.PMID: 40523378

Perspectives of healthcare professionals on the pharmacist's role in delivering vaccinations for patients with cancer: a qualitative study using role theory.

Johnstone K, Cooper J, Smithson J, Glass B.Int J Clin Pharm. 2025 Jun 16. doi: 10.1007/s11096-025-01945-9. Online ahead of print.PMID: 40522402

Unveiling the translational and therapeutic potential of small interfering RNA molecules in combating SARS-CoV-2: A review.

Aram C, Firuzpour F, Barancheshmeh M, Kamali MJ.Int J Biol Macromol. 2025 Jun 11:145203. doi: 10.1016/j.ijbiomac.2025.145203. Online ahead of print.PMID: 40513718

The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort study in Brazil.

Leung C, Su L, Zdanowicz A, Collins L, Simões E Silva AC.Hum Vaccin Immunother. 2025 Dec;21(1):2516314. doi: 10.1080/21645515.2025.2516314. Epub 2025 Jun 11.PMID: 40497727

The emergence of oropouche fever: A potential new threat?

Srivastava S, Sah R, Babu MR, Sharma D, Sharma D, Kumar S, Sridhar SB, Wadhwa T, Shareef J, Rao GSNK, Feehan J, Apostolopoulos V, Sah S, Mehta R, Mehta V, Mohanty A, Zambrano L, Bonilla-Aldana DK,

Luna C, Chaves TDSS, Quispe P, Angerami RN, Rodriguez-Morales AJ.New Microbes New Infect. 2025 May 10;65:101596. doi: 10.1016/j.nmni.2025.101596. eCollection 2025 Jun.PMID: 40491501

Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review).

Feng H, Jin Y, Wu B.Int J Oncol. 2025 Jun;66(6):43. doi: 10.3892/ijo.2025.5749. Epub 2025 May 9.PMID: 40342048

Exudative epidermitis by Staphylococcus hyicus producing ExhC: Control proposals against an emergent pathogen in intensive pig production.

Romero-Salmoral A, Álvarez-Delgado C, Muñoz-Jiménez RA, Barraza P, Vela AI, Fernández-Garayzábal JF, Gómez-Laguna J, Luque I, Tarradas C.Vet J. 2025 Jun;311:106338. doi: 10.1016/j.tvjl.2025.106338. Epub 2025 Mar 28.PMID: 40158685

Hepatitis B prevention interventions during HIV post-exposure prophylaxis visits: A retrospective chart review.

Monti EB, Penichet D, Rudd M, Yoong D, Pathan SS, Moin A, Myers SA, Tan DH.Int J STD AIDS. 2025 Jun;36(7):550-557. doi: 10.1177/09564624251325312. Epub 2025 Mar 12.PMID: 40072487

Vaccination against furunculosis and vibriosis as a model of immunization induces transcript cellular stress response in rainbow trout mucosal surfaces.

Khansari AR, Wallbom N, Sundh H, Sandblom E, Tort L, Jönsson E.Fish Shellfish Immunol. 2025 Jun;161:110231. doi: 10.1016/j.fsi.2025.110231. Epub 2025 Feb 24.PMID: 40010617

Recent developments in peptide vaccines against Glioblastoma, a review and update.

Salahlou R, Farajnia S, Alizadeh E, Dastmalchi S.Mol Brain. 2025 Jun 13;18(1):50. doi: 10.1186/s13041-025-01221-x.PMID: 40514725

Lung-resident memory Th2 cells regulate pulmonary cryptococcosis by inducing type-II granuloma formation.

Ueno K, Nagamori A, Honkyu NO, Kwon-Chung KJ, Miyazaki Y.Mucosal Immunol. 2025 Jun;18(3):631-642. doi: 10.1016/j.mucimm.2025.02.004. Epub 2025 Feb 19.PMID: 39984054

Identification of T-cell epitopes of the intracellular parasite Babesia bovis by immunopeptidomic analysis of BoLA-II presented peptides.

Valenzano MN, Parker R, Nicastri A, Valentini B, Gravisaco MJ, Muñiz XF, Eirin ME, Montenegro VN, Nielsen M, Ternette N, Wilkowsky SE.Vaccine. 2025 Jun 11;61:127369. doi: 10.1016/j.vaccine.2025.127369. Online ahead of print.PMID: 40505327

Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor models.

Pojar K, Reckendorfer D, Strauss J, Szaffich S, Ahmadi-Erber S, Schippers T, Berraondo P, Orlinger KK, Raguz J, Lauterbach H.Oncoimmunology. 2025 Dec;14(1):2514040. doi: 10.1080/2162402X.2025.2514040. Epub 2025 Jun 10.PMID: 40492380

The Different Cellular Entry Routes for Drug Delivery Using Cell Penetrating Peptides.

Okafor M, Schmitt D, Ory S, Gasman S, Hureau C, Faller P, Vitale N.Biol Cell. 2025 Jun;117(6):e70012. doi: 10.1111/boc.70012.PMID: 40490965

Antigen-presenting cells and lung CD8$^+$ resident memory T cells coordinate local immune protection and shape responses to respiratory virus infection.

Kawasaki T, Ikegawa M, Kawai T.Int Immunol. 2025 Jun 10:dxaf033. doi: 10.1093/intimm/dxaf033. Online ahead of print.PMID: 40490946

ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis.

Fukami H, Oike Y.J Atheroscler Thromb. 2025 Jun 5. doi: 10.5551/jat.RV22038. Online ahead of print.PMID: 40467521

Traditional Chinese medicine as a promising choice for future control of PEDV.

Ji C, Li S, Hu C, Liu T, Huang Q, Yang M, Yang M, Wang Q, Li A, Guo D, Huang Y, Yin S, Feng S.Virus Res. 2025 Jun;356:199572. doi: 10.1016/j.virusres.2025.199572. Epub 2025 Apr 10.PMID: 40220931

Establishment of a cell line from the hematophagous Bat Desmodus rotundus susceptible to Lyssavirus rabies.

Violet-Lozano L, Paredes-Galarza B, Gasparetto R, Mangini AT, Timm FB, Melgarejo AS, Prandi BA, Witt A, Oliveira MT, Batista HBCR, Roehe PM, Franco AC.Braz J Microbiol. 2025 Jun;56(2):1311-1320. doi: 10.1007/s42770-025-01651-8. Epub 2025 Mar 4.PMID: 40038190

[Epidemiological characteristics and immune effects of pertussis in Jiangxi Province, 2020-2023].

Wu H, Guo SC, Liu J, Zhao YQ, Wu J, Liu KM.Zhonghua Liu Xing Bing Xue Za Zhi. 2025 Jun 10;46(6):973-978. doi: 10.3760/cma.j.cn112338-20250106-00012.PMID: 40518390

Mucosal administration of lipid nanoparticles containing self-amplifying mRNA induces local uptake and expression in a pig model as a potential vaccination platform against STIs.

Van de Casteele I, Plovyt M, Stuchlíková M, Lanssens M, Verschueren B, Denon Q, Van der Meeren P, McCafferty S, Gitsels A, Cornillie P, Sanders NN, Vandierendonck A, Poelaert KCK, Vanrompay D.Drug Deliv Transl Res. 2025 Jun 11. doi: 10.1007/s13346-025-01877-x. Online ahead of print.PMID: 40498372

Epstein-Barr Virus (EBV)-Specific Humoral Immune Responses in Health and Disease.

Mautner J, Middeldorp JM.Curr Top Microbiol Immunol. 2025 Jun 11. doi: 10.1007/82_2025_302. Online ahead of print.PMID: 40495085

Optimizing Microfluidic Channel Design with Tilted Rectangular Baffles for Enhanced mRNA-Lipid Nanoparticle Preparation.

Yu M, Liu D, Shah P, Qiu B, Mathew A, Yao L, Guan T, Cong H, Zhang N.ACS Biomater Sci Eng. 2025 Jun 9;11(6):3762-3772. doi: 10.1021/acsbiomaterials.4c02373. Epub 2025 May 21.PMID: 40396945

Unlocking therapeutic synergy: IDH inhibitors and immunotherapy combination in preclinical and clinical IDH mutant glioma models - A systematic review.

Ramadas M, Jacob N, Ameratunga M, Gately L.J Clin Neurosci. 2025 Jun;136:111281. doi: 10.1016/j.jocn.2025.111281. Epub 2025 May 1.PMID: 40315665

Subacute sclerosing panencephalitis as a re-emerging condition due to low vaccination coverage: a case-series.

Errichiello G, Tengattini F, Gioacchini S, De Leva MF, Graziano S, Bruno G, Bucci P, D'Ugo E, Ruggiero C, Magurano F, Varone A.Ital J Pediatr. 2025 Jun 7;51(1):173. doi: 10.1186/s13052-025-02026-3.PMID: 40483442

Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children.

Carbonell-Estrany X, Simões EAF, Bont L, Manzoni P, Zar HJ, Greenough A, Ramilo O, Stein R, Law B, Mejias A, Sanchez Luna M, Checchia PA, Krilov L, Lanari M, Dagan R, Fauroux B, Resch B, Heikkinen T, Domachowske JB, Wildenbeest JG, Martinon-Torres F, Thwaites R, Cetinkaya M, Alharbi AS, Rodriguez-Martinez CE, Noyola DE, Kassim A, Kusuda S, Kang JM, Rodgers-Gray B, Platonova A, Jah F, Paes B.Expert Rev Anti Infect Ther. 2025 Jun;23(6):359-378. doi: 10.1080/14787210.2025.2481908. Epub 2025 Apr 1.PMID: 40111069

New mouse model for inducible hACE2 expression enables to dissect SARS-CoV-2 pathology beyond the respiratory system.

Gambini F, Arbon D, Nickl P, Zatecka V, Fedosieieva O, Labaj J, Novosadova V, Trylcova J, Weber J, Prochazka J, Balounova J, Sedlacek R.Mamm Genome. 2025 Jun;36(2):403-416. doi: 10.1007/s00335-025-10115-1. Epub 2025 Feb 22.PMID: 39985688

Trypan Blue-Based Carbon Dots for Sensing of Al^{3+} in Real Samples and Living Cells.

Li J, Liang T, Wang H, Tu M, Wang X.ACS Omega. 2025 May 20;10(21):21463-21472. doi: 10.1021/acsomega.5c00220. eCollection 2025 Jun 3.PMID: 40488077

Treatment and Management of Crimean-Congo Hemorrhagic Fever.

Bulut R, Kandemir B, Erayman İ, Keskin PB, Kurt EK.J Vector Borne Dis. 2025 Jun 10. doi: 10.4103/jvbd.jvbd_18_25. Online ahead of print.PMID: 40485565

SARS-COV-2 mutations in North Rift, Kenya.

Mbogori E, Thiongo K, Deng HY, Gikunyu CW, Cheriro W, Musyoki S, Biegon R, Matoke-Muhia D, Patel K, Liang B, Songok E.PLoS One. 2025 Jun 6;20(6):e0325133. doi: 10.1371/journal.pone.0325133. eCollection 2025.PMID: 40478857

Differentiated strategies for nanovaccines in lymphoma immunotherapy: advances and challenges.

Xia Y, Tao L, Shang W, Zhang G, Lu Y.J Mater Chem B. 2025 Jun 5. doi: 10.1039/d5tb00528k. Online ahead of print.PMID: 40468788

A Versatile High-Throughput Single-Cell Screening Platform for Profiling Antigen-Specific Long-Lived B Cells in Blood and Bone Marrow.

Zhao T, Lei Y, Liu C, Zhang D, Li K, Shan S, Li C, Wei Z, Yang Y, Zhang T, Sun K, Sun H, Zhang L, Liu P.Adv Sci (Weinh). 2025 Jun;12(21):e2414945. doi: 10.1002/advs.202414945. Epub 2025 Apr 9.PMID: 40202243

How to Improve People's Intentions Regarding COVID-19 Vaccination in China: A Randomized Controlled Trial.

Ju Q, Xiao H, Peng H, Gan Y.Int J Behav Med. 2025 Jun;32(3):443-454. doi: 10.1007/s12529-024-10258-6. Epub 2024 Feb 20.PMID: 38378973

Recent advances in inhibitor development and metabolic targeting in tuberculosis therapy.

Patel RR, Vidyasagar, Singh SK, Singh M.Microb Pathog. 2025 Jun;203:107515. doi: 10.1016/j.micpath.2025.107515. Epub 2025 Mar 26.PMID: 40154850

Human Papillomavirus Genotype Distribution and Viral Load in Relation to Cervical Disease Severity: A Retrospective Study of Outpatient Data in Beijing, China.

Chen Z, Li H, Zhao J, Feng H, Ma J, Feng X, Hao Y, Li H, Zhan S, Zhang X, Zhang Y, Li S.J Med Virol. 2025 Jun;97(6):e70409. doi: 10.1002/jmv.70409.PMID: 40432368

Perspective of Quilombola Communities in Brazil on a Yellow Fever Outbreak and Vaccination.

Leão ACQ, Raymundo SF, Fialkovitz G, Casadio LVB, Roemer T, Pisciotta KR, Levin AS.Am J Trop Med Hyg. 2025 Apr 1;112(6):1302-1312. doi: 10.4269/ajtmh.24-0519. Print 2025 Jun 4.PMID: 40168978

Autonomic lysosomal escape via sialic acid modification enhances mRNA lipid nanoparticles to eradicate tumors and build humoral immune memory.

Tang X, Zhang J, Sun Y, Xu Z, Huang T, Liu X, Song Y, Zhang Y, Deng Y.J Control Release. 2025 Jun 10;382:113647. doi: 10.1016/j.jconrel.2025.113647. Epub 2025 Mar 28.PMID: 40158813

Bayesian spatio-temporal modeling of severe acute respiratory syndrome in Brazil: A comparative analysis across pre-, during, and post-COVID-19 eras.

Souza Bulhões R, Pimentel JS, Rodrigues PC.Infect Dis Model. 2024 Dec 19;10(2):466-476. doi: 10.1016/j.idm.2024.12.010. eCollection 2025 Jun.PMID: 39834649

Seroprevalence of varicella zoster virus in Colombia: A community-based mixture models study.

Lenis-Ballesteros V, Hincapié-Palacio D, Ochoa J, Ospina M, Buitrago S.IJID Reg. 2025 May 7;15:100662. doi: 10.1016/j.ijregi.2025.100662. eCollection 2025 Jun.PMID: 40520255

Marburg Virus Disease: Pathophysiology, Diagnostic Challenges, and Global Health Preparedness Strategies.

Francis DL, Reddy SSP, Logaranjani A, Sai Karthikeyan SS, Rathi M.Ann Glob Health. 2025 Jun 2;91(1):24. doi: 10.5334/aogh.4671. eCollection 2025.PMID: 40487708

Rational synthesis, activity and mechanism insights of a new aminoquinoline salt against malaria parasites: in vitro and in vivo approaches.

de Oliveira BA, Raimundo FO, de Paula WT, Bezerra Bellei JC, Glanzmann N, Machado LF, da Fonseca AL, Freitas CS, da Costa Nunes IK, Neto AF, Rocha VN, Pereira HMG, Coelho EAF, de Pilla Varotti F, Scopel KKG, da Silva AD.Chem Biol Interact. 2025 Jun 4;418:111588. doi: 10.1016/j.cbi.2025.111588. Online ahead of print.PMID: 40480411

Purification, refolding, and pH-dependent stability evaluation of Zika virus EDIII protein.

Das M, Kumar V, Madhukalya R, Saroj A, Rout A, Upadhyay A, Naidu G, Poluri KM, Tomar S, Kumar D, Kumar R.Int Microbiol. 2025 Jun 6. doi: 10.1007/s10123-025-00679-y. Online ahead of print.PMID: 40478414

Mechanistic Insights into the Stabilizing Role of Deep Eutectic Solvents for Nucleic Acids: An *In Silico* Analysis.

Hardy DE, Albert A, Lipani J, Metott ZJ, Mirjafari A, Wagle DV.J Phys Chem B. 2025 Jun 12;129(23):5674-5682. doi: 10.1021/acs.jpcb.5c00799. Epub 2025 Jun 3.PMID: 40460042

SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020-July 2022.

Petrie JG, Pattinson D, King JP, Neumann G, Guan L, Jester P, Rolfes MA, Meece JK, Kieke BA, Belongia EA, Kawaoka Y, Nguyen HQ.Am J Epidemiol. 2025 Jun 3;194(6):1574-1583. doi: 10.1093/aje/kwae125.PMID: 38885957

High prevalence of Duck Hepatitis B virus-associated coinfection in Southwest China.

Lin X, Gong L, Gou Y, Liu Y, Mao S, Chen S, Liu M, Zhu D, Wang M, Jia R, Zhang S, Wu Y, Huang J, Tian B, Yang Q, Zhao X, Cheng A, Ou X.PLoS One. 2025 Jun 16;20(6):e0324682. doi: 10.1371/journal.pone.0324682. eCollection 2025.PMID: 40523019

The waning of maternal measles antibodies: a multi-country maternal-infant seroprevalence study.

Tiley KS, Overbeek HTH, Basnet S, van Binnendijk R, Clarke E, Cose S, Dang DA, Thi Thu Hoang H, Holder B, Idoko OT, Kampmann B, Kibengo F, van der Klis F, Kazi AM, Leuridan E, Maertens K, Maldonado H, Nyantaro M, Omer S, Pasetti MF, Pollard AJ, Rots N, Sharma AK, Shrestha S, Tapia M, Wanlapakorn N, Voysey M.J Infect. 2025 Jun 11:106531. doi: 10.1016/j.jinf.2025.106531. Online ahead of print.PMID: 40513621

First trimester mRNA COVID-19 vaccination and risk of congenital malformation: a prospective observational embryotox cohort study.

Kayser A, Lohse L, Padberg S, Keller-Stanislawski B, Oberle D, Beck E, Stegherr R, Beyersmann J, Dathe K.Clin Microbiol Infect. 2025 Jun 7:S1198-743X(25)00291-5. doi: 10.1016/j.cmi.2025.06.005. Online ahead of print.PMID: 40490195

Regulator experiences of trials during Ebola epidemics in Sierra Leone, Guinea, and the Democratic Republic of the Congo.

Kasonia K, Baiden F, Le Marcis F, Lapika B, Kiyulu J, Kimina H, Bikioli F, Attas F, Mansaray A, Burns R, Nouvet E, Thys S, Paviotti A, Manno D, Fahnbulleh MK, Leigh B, Samai M, Greenwood B, Lees S, Mulopo

PM, Watson-Jones D.Trop Med Int Health. 2025 Jun;30(6):539-546. doi: 10.1111/tmi.14111. Epub 2025 Apr 3.PMID: 40177998

Peritumoral Infiltration of Regulatory T Cells Reduces the Therapeutic Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Carcinoma In Situ.

Fukiage Y, Muramoto A, Terada N, Kobayashi M.Int J Urol. 2025 Jun;32(6):737-746. doi: 10.1111/iju.70044. Epub 2025 Mar 14.PMID: 40084633

Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington's disease and Prion diseases.

Mukherjee A, Biswas S, Roy I.Acta Pharmacol Sin. 2025 Jun;46(6):1511-1538. doi: 10.1038/s41401-024-01455-w. Epub 2025 Jan 31.PMID: 39890942

Mechanistic investigation of calcium phosphate mineralization potentiating the cellular immune response of foot-and-mouth disease virus-like particle vaccines.

Teng Z, Li J, Ren M, Xie Q, Dong H, Zhou J, Mu S, Bai M, Sun S, Guo H.Nanoscale. 2025 Jun 13. doi: 10.1039/d5nr00866b. Online ahead of print.PMID: 40512119

α-GalCer-LNP ehanced mRNA delivery and activates natural killer T cells for superior tumor immunotherapy.

Zhang K, Xu Z, Xiao Z, Cao F, Wang J, Xu Y, Ma WMJ, Long S, Zha GF.Mater Today Bio. 2025 May 21;32:101893. doi: 10.1016/j.mtbio.2025.101893. eCollection 2025 Jun.PMID: 40502368

Challenges and Opportunities for Global Cervical Cancer Elimination: How Can We Build a Model for Other Cancers?

Adebamowo C, Rossi PG, Castle PE.Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473702. doi: 10.1200/EDBK-25-473702. Epub 2025 Jun 11.PMID: 40499075

Isolation and possibility of vertical transmission of G9P[23] and G12P[7] group A rotavirus strains in pigs.

Li Y, Gao C, Wu L, Qing J, Zhang M, Qiao M, Hu Z, Zhang B, Yang C, Wang Z, Li L, Yan Z, Wu W, Liu W, Ren J, Li X.Porcine Health Manag. 2025 Jun 6;11(1):32. doi: 10.1186/s40813-025-00445-6.PMID: 40481587

Deconvolution of cargo delivery and immunogenicity following intranasal delivery of mRNA lipid nanoparticle vaccines.

Vu MN, Pilapitiya D, Kelly A, Koutsakos M, Kent SJ, Juno JA, Tan HX, Wheatley AK.Mol Ther Nucleic Acids. 2025 Apr 24;36(2):102547. doi: 10.1016/j.omtn.2025.102547. eCollection 2025 Jun 10.PMID: 40474942

Innovative exploration of Hep-2 cell culture in the isolation and culture of *Mycoplasma pneumoniae*.

Wu W, Zhu W, Tong J, Zhou Q, Xu Y, Zhou X, Du Y, Bi J, Zhu L.Infect Med (Beijing). 2025 Apr 12;4(2):100178. doi: 10.1016/j.imj.2025.100178. eCollection 2025 Jun.PMID: 40370497

Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates.

Malewana RD, Stalls V, May A, Lu X, Martinez DR, Schäfer A, Li D, Barr M, Sutherland LL, Lee E, Parks R, Beck WE, Newman A, Bock KW, Minai M, Nagata BM, DeMarco CT, Denny TN, Oguin TH 3rd, Rountree W, Wang Y, Mansouri K, Edwards RJ, Smith L, Sempowski GD, Eaton A, Muramatsu H, Henderson R, Tam Y, Barbosa C, Tang J, Cain DW, Santra S, Moore IN, Andersen H, Lewis MG, Golding H, Seder R, Khurana S, Montefiori DC, Pardi N, Weissman D, Baric RS, Acharya P, Haynes BF, Saunders KO.Sci Transl Med. 2025 Jun 11;17(802):eadn5651. doi: 10.1126/scitranslmed.adn5651. Epub 2025 Jun 11.PMID: 40498855

Comparative molecular, innate, and adaptive impacts of chemically diverse STING agonists.

Mizuno N, Boehm D, Jimenez-Perez K, Abraham J, Springgay L, Rose I, DeFilippis VR.Vaccine. 2025 Jun 14;61:127389. doi: 10.1016/j.vaccine.2025.127389. Online ahead of print.PMID: 40517500

Optimizing TB policies using the global TB portfolio model: an economic analysis.

Satyanarayana S, Mandal S, McQuaid F, Nair S, Sahu S, Menzies NA, Sweeney S, Sanders R, Baena IG, White RG, Adam T, Smit M, Pretorius C.medRxiv [Preprint]. 2025 Jun 5:2025.06.03.25328801. doi: 10.1101/2025.06.03.25328801.PMID: 40502558

In vivo labeling reveals that degranulation is increased under supraphysiological TCR stimulation, but not infection, in CD8$^+$ T cells from old mice.

Dahlquist KJV, Dehm EM, Smith DM, Lucas ED, Pierson M, Hamilton SE, Camell CD.Geroscience. 2025 Jun 6. doi: 10.1007/s11357-025-01723-5. Online ahead of print.PMID: 40478430

A phage-displayed nanobody-based competitive immunoassay for the detection of African swine fever virus antibodies.

Chen W, Yang J, Niu Q, Wang J, Liu Y, Li X, Zhao Y, Zhang Z, Liu Z, Guan G, Yin H.Virol J. 2025 Jun 5;22(1):182. doi: 10.1186/s12985-025-02781-z.PMID: 40474190

Physiologically Stable, Epitope-Imprinted, and Double-Gated Metal-Organic Framework Drug Delivery System for Tumor-Targeted Combination Therapy.

Luan X, Jin X, Li X, Dong J, Du X.ACS Appl Mater Interfaces. 2025 Jun 11;17(23):34819-34832. doi: 10.1021/acsami.5c06175. Epub 2025 May 29.PMID: 40439335

Preparation and epitope mapping of monoclonal antibodies against African swine fever virus A238L protein.

Yan Z, Liu G, Zheng N, Cai M, Si X, You L, Wang X, Liang J, Li H, Yuan Y, Du Y, Zhang G.Int J Biol Macromol. 2025 Jun;311(Pt 2):143658. doi: 10.1016/j.ijbiomac.2025.143658. Epub 2025 Apr 29.PMID: 40311975

Symptoms and Otorhinolaryngological Sequalae in Long Covid.

Loli A, Müller JVC, de Azevedo ES, Martins RHG.Int Arch Otorhinolaryngol. 2025 Jun 3;29(2):1-6. doi: 10.1055/s-0045-1809026. eCollection 2025 Apr.PMID: 40470173

A case of infectious endocarditis and vertebral discitis caused by Streptococcus pneumoniae serotype 23A.

Kawamura M, Ono D, Kawamura T, Mimura K, Ebata E, Chang B, Akeda Y, Yoshitake A, Mitsutake K, Oka H.J Infect Chemother. 2025 Jun 7;31(8):102749. doi: 10.1016/j.jiac.2025.102749. Online ahead of print.PMID: 40490099

The effectiveness of the states' crisis response policies: Survival analysis on the COVID-19 transmission suppression in the United States.

Kim H, Lee K, Yeo J.Health Policy Open. 2025 Mar 20;8:100140. doi: 10.1016/j.hpopen.2025.100140. eCollection 2025 Jun.PMID: 40226207

Respiratory viral detection in children hospitalized with pneumonia during periods of major population disruptions in Nepal, 2014-2018.

Shrestha S, Bijukchhe S, Wahl B, Carter MJ, Kandasamy R, Gurung M, O'Reilly PJ, Voice M, Pokhrel B, Amatya P, Bhandari S, Shrestha S, Kelly S, Kelly DF, Thorson S, Murdoch DR, Fink C, Knoll MD, Pollard AJ; PneumoNepal study group.J Pediatric Infect Dis Soc. 2025 Jun 11:piaf052. doi: 10.1093/jpids/piaf052. Online ahead of print.PMID: 40495349

Investigation of potential relationship betweenmazEF3, relJK, and vapBC3 genes and antimicrobial resistance inMycobacterium bovis.

Shafipour M, Mohammadzadeh A, Ghaemi EA, Mahmoodi P, Mosavari N.BMC Infect Dis. 2025 Jun 3;25(1):791. doi: 10.1186/s12879-025-11168-y.PMID: 40461986

Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancer.

Volkmar M, Hoser D, Lauenstein C, Rebmann J, Hotz-Wagenblatt A, Rieger J, Poschke I, Becker JP, Riemer AB, Sprick M, Trumpp A, Strobel O, Blankenstein T, Willimsky G, Offringa R.J Immunother Cancer. 2025 Jun 3;13(6):e011802. doi: 10.1136/jitc-2025-011802.PMID: 40461160

Biosecurity measures and effects on health performance and antibiotic use in semi-intensive broiler farms in Uganda.

Ayebare D, Mbatidde I, Kemunto NP, Muloi DM, Ibayi EL, Nielsen SS, Ndoboli D, Roesel K, Tenhagen BA, Moodley A.One Health. 2025 Apr 15;20:101039. doi: 10.1016/j.onehlt.2025.101039. eCollection 2025 Jun.PMID: 40331079

An overview of the role of steroid hormones in various parasitic infections.

Shaukat A, Aleem MT, Munir F, Gao F, Su RW.J Reprod Immunol. 2025 Jun;169:104533. doi: 10.1016/j.jri.2025.104533. Epub 2025 Apr 14.PMID: 40267633

Factors associated with vaccination against mpox in people under preexposure prophylaxis against HIV in the Community of Madrid.

Gutiérrez Rodríguez MA, Rodríguez Luque C, Sánchez Gómez A, Lasheras Carbajo MD, Cañellas Llabrés S, Lopez Centeno B, Morales Irala D, Vázquez Torres MC, Molina Olivas M.Enferm Infecc Microbiol Clin (Engl Ed). 2025 Jun-Jul;43(6):317-322. doi: 10.1016/j.eimce.2025.02.003. Epub 2025 Feb 28.PMID: 40023676

With Increasing Vaccination Reluctance, Does Rubella Immunity Predict Rubeola Immunity Well Enough?

Marohl R, McCormick K, Okut H, Keomany J, Wallace D, Grainger DA, Tatpati L.J Womens Health (Larchmt). 2025 Jun 11. doi: 10.1089/jwh.2024.0975. Online ahead of print.PMID: 40495574

In silico, in vitro and *in vivo* toxicity assessment of the antitumoral peptide GK-1.

Sifontes-Rodríguez S, Hernández-Aceves JA, Salas-Garrido CG, Rocha DM, Pérez-Osorio IN, Villalobos N, Sciutto E, Fragoso G.Toxicol Rep. 2025 Feb 12;14:101962. doi: 10.1016/j.toxrep.2025.101962. eCollection 2025 Jun.PMID: 40034548

Health-related SDGs in the national science agendas of Latin America and the Caribbean: a scoping review.

Ragusa MA, Tortosa F, Monteiro M, Saiso SG, Reveiz L.Int J Equity Health. 2025 Jun 16;24(1):177. doi: 10.1186/s12939-024-02350-w.PMID: 40524170

Epidemiology and control strategies for foot-and-mouth disease in livestock and wildlife in Uganda: systematic review.

Byamukama B, Amin A, Mwiine FN, Ekiri AB.Vet Res Commun. 2025 Jun 16;49(4):227. doi: 10.1007/s11259-025-10791-z.PMID: 40522510

Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.

Santamaria-Castro I, Leiva-Rebollo R, Marín-Wong S, Jimenez-Guardeño JM, Ortega-Prieto AM.Microbiol Mol Biol Rev. 2025 Jun 12:e0026024. doi: 10.1128/mmbr.00260-24. Online ahead of print.PMID: 40503878

Addition of dendritic cell vaccination to conditioning cyclophosphamide and chemoembolisation in patients with hepatocellular carcinoma: the ImmunoTACE trial.

Ma YT, Zuo J, Kirkham A, Curbishley S, Blahova M, Rowe AL, Bathurst C, Mehrzad H, Karkhanis S, Punia P, James MW, Stern N, Rao A, Hull D, Lowe F, Sylla P, Webster L, Hussain S, Yap C, Palmer D, Adams DH.Clin Cancer Res. 2025 Jun 11. doi: 10.1158/1078-0432.CCR-25-0142. Online ahead of print.PMID: 40499144

Establishment of a Novel Cell Line From the Fry of Grouper (Epinephelus coioides) for Fish Virus-Host Interactions.

Zheng J, Pan G, Chen H, Lin F, Liu Q, Huang Y, Qin Q, Huang X.J Fish Dis. 2025 Jun 10:e14162. doi: 10.1111/jfd.14162. Online ahead of print.PMID: 40495274

Tumor microenvironment remodeling with a telomere-targeting agent and its cooperative antitumor effects with a nanovaccine.

Bai J, Wang M, Luo Y, Duan B, Yang Y, Fu Y, Li S, Yang Z, Zheng P, Yu T, Yin X, Bai H, Long Q, Ma Y.J Nanobiotechnology. 2025 Jun 8;23(1):429. doi: 10.1186/s12951-025-03471-2.PMID: 40484928

Susceptibility to Hepatitis B Virus Infection Among People Who Inject Drugs in Montreal, Canada.

Price O, Larney S, Martel-Laferrière V, Bruneau J, Harney B.Drug Alcohol Rev. 2025 Jun 3. doi: 10.1111/dar.14091. Online ahead of print.PMID: 40457849

Integrin β3 N125 glycosylation is essential for human cytomegalovirus entry into fibroblasts.

Zheng L, Pan T, Wang H, He Z, Tian J.Int J Biol Macromol. 2025 Jun;313:144322. doi: 10.1016/j.ijbiomac.2025.144322. Epub 2025 May 16.PMID: 40383337

ADP-heptose-LPS heptosyltransferase I (WaaC) as a key molecule maintains morphological structure and metabolic activity, simultaneously influences pathogenicity in Vibrio mimicus.

Zhou K, Peng K, Lin J, Wang J, Jiang Q, Ai M, Xu L, Ouyang P, Huang X, Chen D, Geng Y.Int J Biol Macromol. 2025 Jun;313:144203. doi: 10.1016/j.ijbiomac.2025.144203. Epub 2025 May 13.PMID: 40373916

Comparison of mid-turbinate nasal and combined nasal-throat specimen types for detection of respiratory viruses in children.

Onalan I, Teoh Z, Steele SL, Klein EJ, Strelitz B, Lacombe K, Sullivan EM, Nalla AK, Zerr DM, Englund JA.J Clin Virol. 2025 Jun;178:105801. doi: 10.1016/j.jcv.2025.105801. Epub 2025 Apr 29.PMID: 40334554

A dissolvable microneedle platform for the delivery of tumor-derived total RNA nanovaccines for enhanced tumor immunotherapy.

Wang J, Huang S, Wei H, Liang S, Ding Y, Xiao Z, Shuai X.Acta Biomater. 2025 Jun 1;199:120-131. doi: 10.1016/j.actbio.2025.04.039. Epub 2025 Apr 22.PMID: 40274056

Optimizing influenza vaccine allocation by age using cost-effectiveness analysis: A comparison of 6720 vaccination program scenarios in children and adults in Belgium.

Manansala R, Bilcke J, Willem L, Hens N, Beutels P.Epidemics. 2025 Jun;51:100826. doi: 10.1016/j.epidem.2025.100826. Epub 2025 Apr 5.PMID: 40245525

Online Discourse and Trends Surrounding HPV Vaccination for Head and Neck Cancer Prevention.

Meci A, Tseng CC, Jensen Z, Goyal N.Otolaryngol Head Neck Surg. 2025 Jun;172(6):1962-1970. doi: 10.1002/ohn.1222. Epub 2025 Mar 19.PMID: 40105426

Evaluation of the Reliability of ChatGPT to Provide Guidance on Recombinant Zoster Vaccination for Patients With Rheumatic and Musculoskeletal Diseases.

Sood A, Moyer A, Jahangiri P, Mar D, Nitichaikulvatana P, Ramreddy N, Stolyar L, Lin J.J Clin Rheumatol. 2025 Jun 1;31(4):156-161. doi: 10.1097/RHU.0000000000002198. Epub 2025 Jan 15.PMID: 39814338

Analytical review of facial nerve palsy following SARS-CoV-2 vaccination: comprehensive assessment.

Mirza AA, Almalki AH, AlMubarak Z, Spiegel JL, Dahm V, Lin VY.Eur Arch Otorhinolaryngol. 2025 Jun;282(6):2787-2797. doi: 10.1007/s00405-024-09173-z. Epub 2025 Jan 10.PMID: 39792199

Health and Economic Impacts of Introducing Vaccae and Enhanced Drug-Resistant Tuberculosis Management Strategies in China.

Zhai PY, Zang X, Jiang T, Feng J, Zhang B, Zhang L, Chen ZX, Zhao YL, Qin G.J Infect Dis. 2025 Jun 2;231(5):1271-1280. doi: 10.1093/infdis/jiae590.PMID: 39576253

Clinical features and immune memory of breakthrough infection in children after age-appropriate 13-valent pneumococcal conjugate vaccination in Taiwan.

Chen CH, Hsu MH, Ou-Yang MC, Yin CT, Li HC, Su LH, Cheng SS, Chiu CH.Infection. 2025 Jun;53(3):1069-1077. doi: 10.1007/s15010-024-02426-3. Epub 2024 Nov 5.PMID: 39499493

Trends of Anogenital Warts: A 32-Year Retrospective Observational Study (Italy, 1991-2022).

Giuliani E, Donà MG, Zaccarelli M, Stingone C, Gianserra L, Capodieci S, Cafaro V, Fulgenzio C, Latini A, Giuliani M.J Clin Med. 2025 Jun 4;14(11):3962. doi: 10.3390/jcm14113962.PMID: 40507723

B-Cell Epitope Mapping of the *Treponema pallidum* Tp0435 Immunodominant Lipoprotein for Peptide-Based Syphilis Diagnostics.

Keane JL, Bose M, Molini BJ, Konda KA, Vargas SK, Reyes Diaz M, Caceres CF, Klausner JD, Treger RS, Giacani L.Diagnostics (Basel). 2025 Jun 5;15(11):1443. doi: 10.3390/diagnostics15111443.PMID: 40507015

Effective strategies in human papillomavirus (HPV) vaccination interventions to increase uptake in rural, low socioeconomic, indigenous and migrant populations: A scoping review.

Roux K, Roux F, Burns S, Guy R.Vaccine. 2025 Jun 4;61:127359. doi: 10.1016/j.vaccine.2025.127359. Online ahead of print.PMID: 40472670

A budget impact analysis of adult immunization with tetanus, diphtheria, and pertussis vaccination for the prevention of pertussis in at-risk populations in Colombia.

Ahmed N, Rodriguez E, Saravia V, Triana L, Gomez JA.Hum Vaccin Immunother. 2025 Dec;21(1):2507885. doi: 10.1080/21645515.2025.2507885. Epub 2025 Jun 5.PMID: 40469053

Passive maternal immunity in children born to women with systemic autoimmune rheumatic disease - A case-control study.

Mazzucato-Puchner A, Ramspeck H, Ritschl V, Stamm T, Kuczwara V, Szlatinay A, Mandl P, Blüml S, Haslacher H, Baranyi U, Falcone V, Aletaha D, Rosta K.J Autoimmun. 2025 Jun;154:103439. doi: 10.1016/j.jaut.2025.103439. Epub 2025 May 22.PMID: 40408885

Policy stakeholders' perspectives and use of data, research evidence, and misinformation in three counties in California, USA during the COVID-19 pandemic, 2020-2022.

Murillo J, Pulido TR, Loyd AB, Subica AM, Yen IH, Payán DD.Prev Med Rep. 2025 May 3;54:103098. doi: 10.1016/j.pmedr.2025.103098. eCollection 2025 Jun.PMID: 40469249

Time series modelling and forecasting of mpox incidence and mortality in Nigeria.

Bakare EA, Mogbojuri OA, Oniyelu DO, Abidemi A, Daniel DO, Olasupo II, Osikoya SA, Nwana AO, Olorunfemi RD, Olagbami SO.BMC Infect Dis. 2025 Jun 4;25(1):794. doi: 10.1186/s12879-025-11174-0.PMID: 40468189

Scalable Production of Recombinant Vesicular Stomatitis Virus Pseudoparticles Using HEK293 Suspension Cultures.

Zhang Z, Wloga E, Fulton BO, Coplan L, Bak H, Tustian AD.Biotechnol Bioeng. 2025 Jun 4. doi: 10.1002/bit.29042. Online ahead of print.PMID: 40462709

Have Live Viral Vaccine Practices Among the Pediatric Liver Transplant Community Changed? A Survey Study of Pediatric Liver Transplant Centers Across the United States.

Feldman AG, Beaty BL, Cetin BS, Danziger-Isakov L.Pediatr Transplant. 2025 Jun;29(4):e70100. doi: 10.1111/petr.70100.PMID: 40346844

Changes in Epidemiology in Pediatric Invasive Group A Streptococcal Infections in Ireland During the 2022-2023 Outbreak.

Foley DJ, Cotter O, Davidson L, Lawler M, Walsh AM, Cloak F, Ward M, Meehan M, Cunney R, Martin C, McKeown P, Fallon U, Ó Maoldomhnaigh C.Pediatr Infect Dis J. 2025 Jun 1;44(6):511-516. doi: 10.1097/INF.0000000000004746. Epub 2025 Mar 17.PMID: 40106787

Incidence of Myocarditis Associated with Diphtheria, Tetanus, and Pertussis Vaccine: A Rare Case Series.

Iqbal M, Febrianora M, Putra ICS, Pramudyo M, Achmad C.Int J Angiol. 2023 Mar 29;34(2):130-133. doi: 10.1055/s-0043-1767740. eCollection 2025 Jun.PMID: 40365148

Characterization of Antigenically Dominant Regions in the Hemagglutinin Protein of B/Victoria-Lineage Influenza B Virus Using Monoclonal Antibody Escape Mutants.

Matsuzaki Y, Sugawara K, Kadowaki Y, Kidoguchi Y, Shimotai Y, Mizuta K.Virus Res. 2025 Jun 14:199598. doi: 10.1016/j.virusres.2025.199598. Online ahead of print.PMID: 40523503

Serological insights into MERS-CoV dynamics of antibody responses during acute and convalescent phases and their clinical relevance for diagnostics and immunity.

Shrwani KJ, Alharbi AM, Mahallawi WH, Asiri AY, Assiri AM, Algaissi A, Hashem AM, Alsafi R, Jubran MA, Gadour E, Alghamdi SA, Okmi EA, Dhayhi N, Asiri HA, Eisa ZM, Cunliffe N, Zhang Q.J Infect Public Health. 2025 Jun 2;18(9):102854. doi: 10.1016/j.jiph.2025.102854. Online ahead of print.PMID: 40472481

Structure and stabilization of the antigenic glycoprotein building blocks of the New World mammarenavirus spike complex.

Paesen GC, Ng WM, Kimuda S, Sutton G, Doores KJ, Bowden TA.mBio. 2025 Jun 13:e0107625. doi: 10.1128/mbio.01076-25. Online ahead of print.PMID: 40511941

Modulating Dendritic Cell function in Allergic Asthma with Toxoplasma gondii serine-protease inhibitor 1.

Katan Piñeiro J, Soto AS, Farias A, Perrone Sibilia M, Sanchez VR, Martin V, Berguer PM, Seigelshifer DJ, Martín Fenoy I, Goldman A.Int Immunol. 2025 Jun 9:dxaf034. doi: 10.1093/intimm/dxaf034. Online ahead of print.PMID: 40489241

Mechanism of Inhibition of the Active Triphosphate Form of 2'-α-Fluoro,2'-β-bromouridine against Yellow Fever Virus RNA-Dependent RNA Polymerase.

Gordon CJ, Walker SM, LeCher JC, Amblard F, Schinazi RF, Götte M.ACS Infect Dis. 2025 Jun 13;11(6):1528-1538. doi: 10.1021/acsinfecdis.5c00086. Epub 2025 May 5.PMID: 40323779

Anti-platelet Factor 4 Antibody-Mediated Disorders: An Updated Narrative Review.

Napolitano A, Spiezia L, Biolo M, Radu CM, Toffanin S, Campello E, Simioni P.Semin Thromb Hemost. 2025 Jun;51(5):578-593. doi: 10.1055/a-2528-5425. Epub 2025 Jan 30.PMID: 39884292

A potent and broad CD4 binding site neutralizing antibody with strong ADCC activity from a Chinese HIV-1 elite neutralizer.

Wang Y, Ji P, Liu Q, Jia N, Ma Y, Yuan T, Rehati P, Chen J, Wen Y, Wu F, Huang J.Cell Discov. 2025 Jun 10;11(1):55. doi: 10.1038/s41421-025-00808-x.PMID: 40490455

Mpox: emergence following smallpox eradication, ongoing outbreaks and strategies for prevention.

Bryant AE, Shulman ST.Curr Opin Infect Dis. 2025 Jun 1;38(3):222-227. doi: 10.1097/QCO.0000000000001100. Epub 2025 Jan 29.PMID: 39878084

Identifying patterns and profiles of vaccination hesitancy among nurses for tailoring healthcare policies in the UK: A cross-sectional study.

Erfani G, McCready J, Nichol B, Gordon C, Unsworth J, Croston M, Comparcini D, Simonetti V, Cicolini G, Mikkonen K, Keisala J, Tomietto M.Int Nurs Rev. 2025 Jun;72(2):e13035. doi: 10.1111/inr.13035. Epub 2024 Aug 19.PMID: 39158159

SCIT With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG_1 Instead of IgG_4.

Aglas L, Tannert LK, Versteeg SA, Smith SA, Bartko EA, Wenger M, Kraiem A, Widauer H, Nunes N, Sinkunaite S, Stolz F, Jongejan L, Neubauer A, Blom LH, Ferreira F, Poulsen LK, Bindslev-Jensen C, van Ree R.Allergy. 2025 Jun 2. doi: 10.1111/all.16606. Online ahead of print.PMID: 40452413

Diagnostic and Therapeutic Challenges in Lyme Disease and Co-Infections: Unraveling Neuropsychiatric and Neurological Complexities-A Comprehensive Case Series Analysis.

Garg K, Booth R, Cobey A, Gilbert L, Ozdemir A.Integr Med (Encinitas). 2025 Jun;24(3):10-27.PMID: 40453233

Effects of community action on animal vaccination uptake, antimicrobial usage, and farmers' wellbeing in Ghana: study protocol for a cluster-randomized controlled trial.

Nuvey FS, Fink G, Hattendorf J, Haydon DT, Fokou G, Addo KK, Zinsstag J, Esse-Dibby C, Bonfoh B.One Health. 2024 Dec 15;20:100952. doi: 10.1016/j.onehlt.2024.100952. eCollection 2025 Jun.PMID: 39811078

Difficult-to-treat recurrent pericarditis after SARS-CoV-2 vaccination.

Marchetta M, Lopez RI, Golino M, Thomas G, Abbate A.Int J Cardiol. 2025 Jun 14:133516. doi: 10.1016/j.ijcard.2025.133516. Online ahead of print.PMID: 40523563

A repeated cross-sectional analysis of SARS-CoV-2 seroprevalence in Manila, the Philippines after implementation of the national COVID-19 vaccination program.

Malijan GMB, Suzuki S, Sayo AR, Villanueva AM, Agrupis KA, Ortal-Cruz A, Salazar MA, Evangelista JW, Solante R, Go GD, Saludar NR, Miranda D, Dimapilis A, Ariyoshi K, Smith C.Trop Med Health. 2025 Jun 16;53(1):81. doi: 10.1186/s41182-025-00767-9.PMID: 40524246

The effect of COVID-19 (SARS-CoV-2) vaccines on vulvar condylomata.

Şahin M, Arslanca ŞB.J Turk Ger Gynecol Assoc. 2025 Jun 10;26(2):116-120. doi: 10.4274/jtgga.galenos.2025.2025-4-8.PMID: 40495551

CagA-dependent Hobit⁺ gastric tissue-resident memory T cells confer full protection from *Helicobacter pylori* reinfection.

Gong R, Huang B, Ralser A, Friedrich V, Mibus C, Engelsberger V, Koch MRA, Skerhut M, Giese T, Andrä I, Vieth M, van Gisbergen KPJM, Semper RP, Gerhard M, Mejías-Luque R.Gut. 2025 Jun 5:gutjnl-2025-334781. doi: 10.1136/gutjnl-2025-334781. Online ahead of print.PMID: 40473399

Integrated lncRNA and mRNA analysis reveals the immune modulatory mechanisms of antimicrobial peptide BSN-37 in mouse peritoneal macrophages.

Zhang H, Lv Y, Li J, Jiao B, Fu J, Zhao X, Cheng L, Bai Y, Wang L, Li Y, Hang B, Wei X, Liu M, Teng Z, Chang M, Liao C, Bai Y, Xia X, Ding K, Hu J.Sci Rep. 2025 Jun 2;15(1):19252. doi: 10.1038/s41598-025-03969-7.PMID: 40457006

Developing of SARS-CoV-2 fusion protein expressed in E. coli Shuffle T7 for enhanced ELISA detection sensitivity - an integrated experimental and bioinformatic approach.

Sam S, Ofoghi H, Farahmand B.J Biomol Struct Dyn. 2025 Jun;43(9):4440-4455. doi: 10.1080/07391102.2024.2302941. Epub 2024 Jan 17.PMID: 38234051

MCMC-Driven mathematical modeling of the impact of HPV vaccine uptake in reducing cervical cancer.

Oswald S, Mureithi E, Tsanou B, Chapwanya M, Mashoto K, Kahesa C.Sci Afr. 2025 Jun;28:None. doi: 10.1016/j.sciaf.2025.e02633.PMID: 40520055

Exploring the Potential Regulatory Mechanisms of Mitophagy in Ischemic Cardiomyopathy.

Li Z, Kong J, Xi S, Jin Z, Yang F, Zhu Z, Liu L.Int J Gen Med. 2025 Jun 5;18:2881-2899. doi: 10.2147/IJGM.S519388. eCollection 2025.PMID: 40492232

Stable SARS-CoV-2 antibody levels and functionality in serum and COVID-19 convalescent plasma after long-term storage.

Laner-Plamberger S, Siller A, Lauth W, Kern JM, Baskova L, Held N, Kartal O, Schennach H, Rohde E, Grabmer C.Vox Sang. 2025 Jun 9. doi: 10.1111/vox.70059. Online ahead of print.PMID: 40490397

Psychological Effects of the COVID-19 Pandemic and eHealth Literacy Among Nursing Students in the United States and Türkiye, 2022.

Ayaz-Alkaya S, Belay H.Public Health Rep. 2025 Jun 9:333549251341230. doi: 10.1177/00333549251341230. Online ahead of print.PMID: 40488438

Pediatric antibiotic use associated with respiratory syncytial virus and influenza in the United States, 2008-2018.

King LM, Bruxvoort KJ, Tartof SY, Lewnard JA.J Infect Dis. 2025 Jun 7:jiaf309. doi: 10.1093/infdis/jiaf309. Online ahead of print.PMID: 40479527

Clinical and Sociodemographic Factors Associated with Ocular Mpox in California, May 2022-September 2023.

Hanft W, Saadeh K, Snyder RE, Watson J, Tang EC, Chapman E, Ramos M, Johnson KA.Sex Transm Dis. 2025 Jun 4. doi: 10.1097/OLQ.0000000000002195. Online ahead of print.PMID: 40464384

Comorbidities and Sociodemographic Factors as Determinants of COVID-19 Outcome in Hospitalized Pregnant Women in Brazil.

Azevedo FM, Rocha ARF, de Morais NS, Ribeiro SAV, Priore SE, Rodrigues JM, Franceschini SDCC.Arch Med Res. 2025 Jun;56(4):103184. doi: 10.1016/j.arcmed.2025.103184. Epub 2025 Feb 24.PMID: 39999617

Probiotics and Prebiotics Intervention in Respiratory and Digestive Infections Linked to Covid-19.

Amrouche T, Lammi S, Drider D.Probiotics Antimicrob Proteins. 2025 Jun;17(3):1356-1367. doi: 10.1007/s12602-024-10404-2. Epub 2024 Nov 30.PMID: 39614066

Association Between Severity of COVID-19 and Social Determinants of Health with Adverse Pregnancy Outcomes in a Study of Mother-Infant Pairs in Los Angeles, California.

Daouk S, Kerin T, Fuller T, Man O, Cambou MC, Fajardo-Martinez V, Paiola S, Mok T, Rao R, Nielsen-Saines K.Women (Basel). 2025 Jun;5(2):12. doi: 10.3390/women5020012. Epub 2025 Apr 2.PMID: 40302893

Comparing different viral strains in identifying risk factors for the development of venous thromboembolism in hospitalized COVID-19 patients.

Panesar H, Raval R, Chan AW, Tancredi J, Simonian G, O'Connor DJ.J Investig Med. 2025 Jun;73(5):418-426. doi: 10.1177/10815589251320042. Epub 2025 Feb 20.PMID: 39980139

Protective effects of BCG vaccination against multibacillary disease, reactions, and disabilities in childhood leprosy: Insights from a retrospective observational study from a tertiary care center in India.

Narang T, Sharma A, Kaushal I, Chatterjee D, Dogra S.Int J Dermatol. 2025 Jun;64(6):1086-1091. doi: 10.1111/ijd.17636. Epub 2025 Jan 5.PMID: 39757134

Wells syndrome: emerging triggers and treatments- an updated systematic review.

Ahmed A, Cahn B, Haber R.Arch Dermatol Res. 2025 Jun 9;317(1):805. doi: 10.1007/s00403-025-04305-9.PMID: 40488888

Comparative performance and age dependence of tuberculin and defined antigen bovine tuberculosis skin tests assessed with Bayesian latent class analysis.

Lakew M, Conlan AJK, Tadesse B, Srinivasan S, Yalew B, Benti T, Olani A, Kinfe G, Ashagrie T, Abebe A, Fromsa A, Abdela MG, Bayissa B, Gebre S, Mihret A, Mekonnen GA, Ameni G, Ashenafi H, Wood JLN, Gumi B, Kapur V.Sci Rep. 2025 Jun 5;15(1):19728. doi: 10.1038/s41598-025-05223-6.PMID: 40473835

Association between parental and child influenza vaccination: A national health survey analysis.

Kim C, Lee D, Oh YW, Jung SJ.Vaccine. 2025 Jun 3;61:127345. doi: 10.1016/j.vaccine.2025.127345. Online ahead of print.PMID: 40466486

Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19.

Moawad MHED, Abbas A, Sabet H, Zanaty MA, Hamad AA, Rezkallah A, Ballut O, Fayad T, Elsakka MM, Eshun F, Abdelgawad HAH.Virol J. 2025 Jun 2;22(1):178. doi: 10.1186/s12985-025-02814-7.PMID: 40457387

Factors affecting progression to frailty in community-dwelling older adults during all COVID-19 waves.

Çakir E, Yazir HT, Çetin M, Sarikaya Demirbaş Z, Naharci MI.Australas J Ageing. 2025 Jun;44(2):e70050. doi: 10.1111/ajag.70050.PMID: 40450679

Effects of early access to feed and water in hatchers on growth performance in broiler chickens.

Boyner M, Ivarsson E, Wattrang E, Sun L, Wistedt A, Wall H.Animal. 2025 Jun;19(6):101519. doi: 10.1016/j.animal.2025.101519. Epub 2025 Apr 15.PMID: 40424958

Interventions for SARS-CoV-2 prevention among Jailed adults: A network-based modeling analysis.

Schneider I, Wallrafen-Sam K, Kennedy S, Akiyama MJ, Spaulding AC, Jenness SM.Infect Dis Model. 2025 Feb 4;10(2):628-638. doi: 10.1016/j.idm.2025.02.001. eCollection 2025 Jun.PMID: 40027595

Estimates of SARS-CoV-2 Infections and Population Immunity After the COVID-19 Pandemic in Austria: Analysis of National Wastewater Data.

Riedmann U, Chalupka A, Richter L, Sprenger M, Rauch W, Schenk H, Krause R, Willeit P, Oberacher H, Høeg TB, Ioannidis JPA, Pilz S.J Infect Dis. 2025 Jun 2;231(5):e921-e928. doi: 10.1093/infdis/jiaf054.PMID: 39964838

Evaluation of HPV and Related Cancer Awareness and Vaccination Attitudes Among Patients with Anogenital Warts: a Survey-Based Study.

Solak B, Arslan M.J Community Health. 2025 Jun;50(3):560-567. doi: 10.1007/s10900-025-01444-y. Epub 2025 Feb 2.PMID: 39894901

Association between COVID-19 vaccination and first healthcare utilization for chronic obstructive pulmonary disease: A nationwide population-based cohort study.

Kim SH, You SH, Lee JW, Kim E, Kim Y, Lee H, Jung SY, Moon JY.Vaccine. 2025 Jun 6;61:127367. doi: 10.1016/j.vaccine.2025.127367. Online ahead of print.PMID: 40482456

Development of a double-antigen sandwich ELISA for rapid and accurate detection of antibodies against Capripoxvirus.

Wang W, Shi Z, Luo J, Liao H, Feng L, Zhu Y, Lin Y, Shi X, Zhang F, Xi T, Chen J, Tian H, Zheng H.Microbiol Spectr. 2025 Jun 3;13(6):e0272924. doi: 10.1128/spectrum.02729-24. Epub 2025 May 5.PMID: 40323098

Immunogenicity of NSDV GP38 and the role of furin in GP38 proteolytic processing.

Bost C, Tomaz F, Schmacke LC, Reiche S, Seidah NG, Steinmetzer T, Groschup MH, Karger A, Diederich S, Fischer K.J Virol. 2025 Jun 10:e0053725. doi: 10.1128/jvi.00537-25. Online ahead of print.PMID: 40492757

Serotype distribution, virulence factors, and antimicrobial resistance profiles of Streptococcus agalactiae (Group B Streptococcus) isolated from pregnant women in the Brazilian Amazon.

Carvalho AG, Belém MGL, Rodrigues RS, da Silva MEP, Dorneles NWDS, da Silva Lima NC, Rodrigues MD, Pinto TCA, Taborda RLM, Matos NB.BMC Microbiol. 2025 Jun 7;25(1):361. doi: 10.1186/s12866-025-04077-2.PMID: 40481415

Epidemiological and clinical profiles of respiratory syncytial virus infections in hospitalized children: a retrospective cohort study utilizing targeted next-generation sequencing.

Fu C, Ruan J, Mo L, Zhao J, Lu J, Huang Y, Hu X, Huang Q, Feng Y, Tang W, Zhu N, Lu C, Lu X, Chen R, Liu G, Huang H, Li Q, Tan J.Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1391-1403. doi: 10.1007/s10096-025-05112-w. Epub 2025 Mar 26.PMID: 40133679

Efficacy of vitamin D replacement therapy on 28 cases of myalgic encephalomyelitis/chronic fatigue syndrome after COVID-19 vaccination.

Kodama S, Konishi N, Hirai Y, Fujisawa A, Nakata M, Teramukai S, Fukushima M.Nutrition. 2025 Jun;134:112718. doi: 10.1016/j.nut.2025.112718. Epub 2025 Feb 18.PMID: 40090177

Safety and efficacy of intravesical Bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer: A retrospective study.

Du G, Guan Y, Xie R, Li C, Liu Y, Zhou A, Bi X, Shi H, Shou J.Urol Oncol. 2025 Jun;43(6):392.e1-392.e6. doi: 10.1016/j.urolonc.2025.01.011. Epub 2025 Feb 12.PMID: 39947946

A recurrent neural network for soft sensor development using CHO stable pools in fed-batch process for SARS-CoV-2 spike protein production as a vaccine antigen.

Reyes SJ, Voyer R, Durocher Y, Henry O, Pham PL.Biotechnol Prog. 2025 Jun 2:e70046. doi: 10.1002/btpr.70046. Online ahead of print.PMID: 40454837

Progression towards microelimination of hepatitis B virus infection among people living with HIV in Spain.

Santos M, Martín Carmona J, Corma-Gómez A, Pérez-García M, Martín-Sierra C, Rincón-Mayo P, Pineda JA, Real LM, Macías J.Enferm Infecc Microbiol Clin (Engl Ed). 2025 Jun 3:S2529-993X(25)00135-2. doi: 10.1016/j.eimce.2025.02.016. Online ahead of print.PMID: 40467413

Estimating cumulative infection rate of COVID-19 after adjusting the dynamic zero-COVID policy in China.

Zhou S, Lai M, Tang S, Liu W, Shen M, Peng Z.Infect Dis Model. 2024 Dec 18;10(2):429-438. doi: 10.1016/j.idm.2024.12.012. eCollection 2025 Jun.PMID: 39816753

Ashwagandha, Withania somnifera (L.) Dunal, for the prophylaxis against SARS-CoV-2 infection: A multicentric randomized hydroxychloroquine controlled clinical trial in Indian health care workers.

Kulkarni-Munshi R, Talmohite D, More A, Chakravarty J, Kamat S, Khobragade A, Reddy DH, Patel M, Kajaria D, Singh R, Kumari S, Mishra P, Srivastava AK, Bhagat V, Pandey S, Yadav M, Darnule R, Bhat S, Kansal S, Munot S, Kumbhar D, Tripathi R, Gajbhiye S, Marathe P, Parvatkar J, Shukla D, Panchal P, Shah J, Bhale J, Sattigeri V, Amarsheda A, Avhad A, Kshirsagar N, Mondhe DM, Chopra A.J Ayurveda Integr Med. 2025 Jun 6;16(3):101135. doi: 10.1016/j.jaim.2025.101135. Online ahead of print.PMID: 40482293

Hospitalization Due to Acute Coronary Syndrome and Myocarditis in Patients Under 45 Years Old: A Single-Center Coronary Care Unit Retrospective Analysis of Hospitalizations Before, During, and After the Coronavirus Disease 2019 Pandemic.

Demirci M, Özben B, Yurdabakan S, Aktaş İİ, Çetin AE, Bilgin YE, Şaşmaz M, Güner AE, Tigen MK.Turk Kardiyol Dern Ars. 2025 Jun;53(4):254-262. doi: 10.5543/tkda.2025.93630.PMID: 40459139

Vaccination Status is Not Associated With Adverse Postoperative Outcomes Following Total Joint Arthroplasty in Patients With a Preoperative COVID-19 Diagnosis.

Kamalapathy P, Vennitti C, Ramamurti P, Browne J.Arthroplast Today. 2025 Mar 29;33:101673. doi: 10.1016/j.artd.2025.101673. eCollection 2025 Jun.PMID: 40231045

Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age.

Rostad CA, Campbell JD, Paulsen GC, Ghamloush SS, Xu W, Zheng L, McElrath MJ, De Rosa SC, Girard B, Das R, Anderson EJ, Creech CB.J Infect Dis. 2025 Jun 2;231(5):e945-e955. doi: 10.1093/infdis/jiaf144.PMID: 40119775

Sea buckthorn regulates PXR/CAR/NF-κB signaling and restores CYP2C metabolic function in BCG-induced hepatitis.

Hao P, Ding R, Bai X, Zhang A, Jin Z, Zhang J, Xue Y.J Ethnopharmacol. 2025 Jun 11;351:120142. doi: 10.1016/j.jep.2025.120142. Online ahead of print.PMID: 40513919

Evaluating the impact of COVID-19 vaccination strategies on infections and hospitalisations in Victoria with non-seasonal epidemic wave patterns: a modelling study.

McAndrew F, Abeysuriya R, Scott N.Med J Aust. 2025 Jun 16;222(11):558-566. doi: 10.5694/mja2.52677. Epub 2025 Jun 1.PMID: 40450593

Associations between vaccination clinic factors and DTaP dropout in China: A cross-sectional study.

Ye J, Cao L, Song Y, Yu W, Zhang Z, Li L, Yin Z.Hum Vaccin Immunother. 2025 Dec;21(1):2510007. doi: 10.1080/21645515.2025.2510007. Epub 2025 Jun 13.PMID: 40509928

Arsenic Trioxide Enhances the Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma by Inducing Immunogenic Cell Death via the ROS/ERS Pathway.

Wang X, Cheng S, Xu Y, Zheng T, Ling C, Du J.Immun Inflamm Dis. 2025 Jun;13(6):e70214. doi: 10.1002/iid3.70214.PMID: 40504080

Perceived safety, usability, and acceptability of microarray patches for vaccination among key populations: A mixed methods study.

Berger MN, Davies C, Mathieu E, Harmer-Ross J, Shaban RZ, Cassidy-Matthews C, Wilson B, Bag S, Skinner SR.Vaccine. 2025 Jun 9;61:127387. doi: 10.1016/j.vaccine.2025.127387. Online ahead of print.PMID: 40494226

Seroprevalence Trends of Antibodies to SARS-CoV-2 in South Korea, 2021-2022: A Repeated Cross-Sectional Study.

Kim AR, Achangwa C, Do HN, Jang EY, Nam Y, Cho S, Kim T, Jeong HS, Rhie GE, Oh K, Kwon SL, Lee S, Lee J, Ryu S.Influenza Other Respir Viruses. 2025 Jun;19(6):e70117. doi: 10.1111/irv.70117.PMID: 40462400

Follow-up of antibody changes in brucellosis patients in Gansu, China.

Sha H, Duan Q, Lyu D, Qian F, Zheng X, Guo J, He Z, Lu X, Bukai A, Qin S, Duan R, Guli S, Zhang P, Xiao M, Jing H, Wang X.Microbiol Spectr. 2025 Jun 3;13(6):e0286224. doi: 10.1128/spectrum.02862-24. Epub 2025 Apr 30.PMID: 40304471

Construction of a Bacillus subtilis-based expression system for Eimeria acervulina profilin.

Panebra A, Lee Y, Lillehoj HS.Poult Sci. 2025 Jun;104(6):105112. doi: 10.1016/j.psj.2025.105112. Epub 2025 Apr 5.PMID: 40222348

Comparison of two continuous cell lines BHK-21 and IB-IS2 for isolating field serotypes O and A of Foot-and-Mouth disease virus.

Khoshnood S, Azimi SM, Kafi ZZ, Najafi H, Langeroudi AG.Virus Genes. 2025 Jun 13. doi: 10.1007/s11262-025-02166-y. Online ahead of print.PMID: 40512422

Stakeholder perspectives on HPV vaccination uptake among Aboriginal and Torres Strait Islander adolescents via the school immunisation programmes in Queensland: a qualitative study.

Morseu-Diop A, Butler T, Anderson K, Brotherton J, Cunningham J, Jaure A, Garvey G, AhWing E, Clements V, Egert S, Lomas F, Ross C, Whop LJ.BMJ Open. 2025 Jun 4;15(6):e097518. doi: 10.1136/bmjopen-2024-097518.PMID: 40467324

Human Papillomavirus in the Neovagina of Transgender Women in Thailand: Prevalence, Diversity, and Associated Risk Factors.

Rerkasem A, Oo MZ, Mattawanon N, Sakkhachornphop S, Siriaunkgul S, Jakkaew T, Rerkasem K, Smith MK.Sex Transm Dis. 2025 Jun 2. doi: 10.1097/OLQ.0000000000002196. Online ahead of print.PMID: 40456170

Estimating risk of acquiring SARS-COV2 infection in treatment-experienced PLWH: A case-control study.

Salvo PF, Iannone V, Lombardi F, Ciccullo A, Lamanna F, Passerotto RA, Baldin G, Steiner RJ, Carbone A, Massaroni V, Di Giambenedetto S, Borghetti A.Glob Epidemiol. 2025 Mar 22;9:100198. doi: 10.1016/j.gloepi.2025.100198. eCollection 2025 Jun.PMID: 40225776

Negative influence of suboptimal quality of drinking water on avian coronavirus pathogenesis and immune response: A Controlled Study.

Farooq M, Ghaffar A, Ali A, Rahimi R, Azhar M, Isham IM, Herath-Mudiyanselage H, Suhail SM, Abdul-Careem MF.Vet Immunol Immunopathol. 2025 Jun 3;285:110964. doi: 10.1016/j.vetimm.2025.110964. Online ahead of print.PMID: 40479838

Identification of circulating human papillomavirus types through high-throughput sequencing of Canadian municipal and institutional wastewater samples.

Giesbrecht SJ, Krosta SJ, Fox R, Kolsun K, Quill Z, Gibbons S, Sivro A, Sandstrom P, Mangat CS, Becker MG.Appl Environ Microbiol. 2025 Jun 5:e0034825. doi: 10.1128/aem.00348-25. Online ahead of print.PMID: 40470962

Changes in first-episode psychosis care delivery and outcomes throughout the COVID-19 pandemic: Insights from a learning healthcare system in Massachusetts.

Saluja A, Johnson KA, Öngür D, Lanca M, DeLisi LE, Mesholam-Gately RI, Guyer ME, Keshavan MS; MAPNET/LEAP Consortium.Schizophr Res. 2025 Jun;280:130-139. doi: 10.1016/j.schres.2025.04.010. Epub 2025 Apr 28.PMID: 40300255

Predicting mobile health clinic utilization for COVID-19 vaccination in South Carolina: A statistical framework for strategic resource allocation.

Gezer F, Howard KA, Bennett KJ, Litwin AH, Sease KK, Rennert L.PLOS Glob Public Health. 2025 Jun 4;5(6):e0003837. doi: 10.1371/journal.pgph.0003837. eCollection 2025.PMID: 40465702

Comedications Associated with Immune-Related Adverse Events from Immune-Checkpoint Inhibitors.

Laurent L, Abbar B, Bihan K, Dumas E, Jochum F, Lebrun-Vignes B, Spano JP, Salem JE, Hamy AS, Reyal F, Gougis P.Clin Pharmacol Ther. 2025 Jun 16. doi: 10.1002/cpt.3721. Online ahead of print.PMID: 40521636

SARS-CoV-2 Testing Behavior in Symptomatic Adults and the Role of Exposure Risk, Susceptibility and Healthcare Access in a U.S. National Cohort (2020-2023).

Sanborn J, Qasmieh S, Penrose K, Parcesepe A, Shen Y, Piltch-Loeb R, Nunez J, Nash D, Robertson M.Res Sq [Preprint]. 2025 Jun 3:rs.3.rs-5194738. doi: 10.21203/rs.3.rs-5194738/v1.PMID: 40502746

Recurrent invasive pneumococcal disease in children: A retrospective cohort study, England, 2006/07-2017/18.

Bertran M, Abdullahi F, D'Aeth JC, Amin-Chowdhury Z, Andrews NJ, Eletu S, Litt D, Ramsay ME, Oligbu G, Ladhani SN.J Infect. 2025 Jun;90(6):106490. doi: 10.1016/j.jinf.2025.106490. Epub 2025 Apr 24.PMID: 40286915

Estimates of the global prevalence of occult hepatitis B virus infection in population under 18 years old: a systematic review and meta-analysis.

Pan Y, Jia Z, Zhang Y, Wu Y, Jiang J.Hepatol Int. 2025 Jun;19(3):493-506. doi: 10.1007/s12072-025-10816-4. Epub 2025 Apr 4.PMID: 40184003

Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial.

Kansiime S, Hansen CH, Ruzagira E, McCormack S, Hayes R, Dunn D.Clin Trials. 2025 Jun;22(3):289-300. doi: 10.1177/17407745241304721. Epub 2024 Dec 31.PMID: 39847674

Scenario Projections of Respiratory Syncytial Virus Hospitalizations Averted Due to New Immunizations.

Hansen CL, Lee L, Bents SJ, Perofsky AC, Sun K, Starita LM, Adler A, Englund JA, Chow EJ, Chu HY, Viboud C.JAMA Netw Open. 2025 Jun 2;8(6):e2514622. doi: 10.1001/jamanetworkopen.2025.14622.PMID: 40498487

Socio-demographic determinants of COVID-19 vaccination status among people living with HIV; a cross-sectional study in selected regions in Tanzania.

Stephen KJ, Mshiu J, Christopher F, Wiketye V, Kimbute O, Martin A, Makasi C, Range N, Majaha M, Mgina E, Shemdoe A, Maokola W, Rwebembera A, Ngowi B, Kilale AM.BMC Infect Dis. 2025 Jun 5;25(1):796. doi: 10.1186/s12879-025-10809-6.PMID: 40474068

Hepatitis B vaccination coverage and associated factors among children living in northwest Ethiopia city administrations: A community-based study.

Geta M, Hailu A, Woldeamanuel Y.Public Health Pract (Oxf). 2025 Mar 27;9:100608. doi: 10.1016/j.puhip.2025.100608. eCollection 2025 Jun.PMID: 40236602

Phagocytic activity of blood monocytes and neutrophils in moderate COVID-19 patients and impact of immune therapy with bacterial lysates.

Kostinov M, Svitich O, Chuchalin A, Gajnitdinova V, Bisheva I, Skhodova S, Osiptsov V, Tatevosov V, Kryukova N, Khrapunova I, Cherdantsev A, Soloveva I, Akhmatova N, Kurbatova E, Polishchuk V, Kostinova A, Vlasenko A, Loktionova M, Poddubikov A.PLoS One. 2025 Jun 5;20(6):e0324987. doi: 10.1371/journal.pone.0324987. eCollection 2025.PMID: 40472051

Patentes registradas en Patentscope

Estrategia de búqueda: (Vaccine) AND DP:([01.06.2025 TO 16.06.2025]) *as the publication date 47 records.*

1.12324835MRNA VACCINE ENCODING FUSION ANTIGEN AGAINST MPOX AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

US - 10.06.2025

Clasificación Internacional A61K 9/50Nº de solicitud 19026296Solicitante ACADEMY OF MILITARY MEDICAL SCIENCES, AMS, PLAInventor/a Yilong Yang

An mRNA molecule is disclosed. The mRNA molecule contains a polynucleotide encoding an M1R antigen of Mpox and a polynucleotide encoding an RBD antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and further contains a polynucleotide encoding an A35R antigen of Mpox. An application of the mRNA molecule in the preparation of an mRNA vaccine against Mpox or SARS-CoV-2 is further disclosed. Compared to an mRNA vaccine encoding separately corresponding antigens, the provided mRNA vaccine encoding a fusion antigen can induce considerable or even higher-level neutralizing antibody responses against Mpox and SARS-CoV-2, and provides 100% immune protection against the lethal challenge of ectromelia virus. The vaccine is obtained by synthesizing a single mRNA molecule and encapsulating the single mRNA within lipid nanoparticles. Therefore, the single-component fusion mRNA vaccine has a wider application prospect than multivalent mRNA vaccine compositions.

2.4566624IMPFSTOFFE GEGEN PROTOZOENPARASITEN

EP - 11.06.2025

Clasificación Internacional A61K 39/002Nº de solicitud 23213860Solicitante VACCIMED ORAL GMBHInventor/a LUJAN HUGO

In a first aspect, the present invention relates to vaccines for preventing or treating protozoan parasite infections in an individual whereby the vaccine contains multiple protozoan variable surface antigens (VSAs) of said protozoan parasites microorganism. In particular, protective vaccines are disclosed. In a further aspect, a method for the preparation of the vaccine, in particular, the protective vaccine is described. The vaccine is composed of multiple distinguishable VSAs, preferably comprising the full repertoire of the different VSA encoded by the gene family in said protozoan parasite. In a second aspect, the present invention relates to vaccines for preventing or treating microbial infections in an individual whereby the vaccine contains microvesicles induced by confronting protozoan microorganisms with antibodies directed to their VSAs. In particular, protective vaccines are disclosed. The vaccine is composed of multiple antigens of said protozoan parasite. In a further aspect, methods for the preparation and administration of these vaccines, in particular, the protective vaccines are described.

3.WO/2025/119867VACCINES AGAINST PROTOZOAN PARASITES

WO - 12.06.2025

Clasificación Internacional A61K 39/002Nº de solicitud PCT/EP2024/084410Solicitante VACCIMED-ORAL GMBHInventor/a LUJAN, Hugo

In a first aspect, the present invention relates to vaccines for preventing or treating protozoan parasite infections in an individual, whereby the vaccine contains multiple protozoan variable surface antigens (VSAs) of said protozoan parasite microorganism. In particular, protective vaccines are disclosed. In a further aspect, a method for the preparation of the vaccine, particularly the protective vaccine, is described.

The vaccine comprises multiple distinguishable VSAs, preferably comprising the entire repertoire of the different VSAs encoded by the gene family in said protozoan parasite. In a second aspect, the present invention relates to vaccines for preventing or treating microbial infections in an individual, whereby the vaccine contains microvesicles induced by confronting protozoan microorganisms with antibodies directed to their VSAs. In particular, protective vaccines are disclosed. The vaccine is composed of multiple antigens of said protozoan parasite. In a further aspect, methods for the preparation and administration of these vaccines, particularly the protective vaccines, are described.

4.WO/2025/113407PREPARATION AND USE OF LIPOSOME CARRIER FOR EFFICIENT VACCINE DELIVERY AND LIPOSOME VACCINE

WO - 05.06.2025

Clasificación Internacional A61K 9/127Nº de solicitud PCT/CN2024/134387Solicitante SUN YAT-SEN UNIVERSITY CANCER CENTER (THE AFFILIATED CANCER HOSPITAL OF SUN YAT-SEN UNIVERSITY, THE CANCER RESEARCH INSTITUTE OF SUN YAT-SEN UNIVERSITY)Inventor/a XU, Ruihua

A liposome carrier, a liposome vaccine, preparation methods therefor, and use thereof. The liposome carrier comprises: a first component, comprising at least one of 2,3-dioleoyloxypropyl-1-trimethylammonium bromide (DOTMA) or 1,2-dioleoyl-3-trimethylammonium propane (DOTAP); a second component, comprising at least one of 1,2-di(9Z-oleoyl)-sn-glycero-3-phosphoethanolamine (DOPE) or 1,2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC); and a third component, comprising at least one of didodecyldimethylammonium bromide (DDAB) and cholesterol or a modifier thereof. The liposome vaccine comprises the liposome carrier and active ingredients of a vaccine and can stimulate antigen presenting cells to mature, thereby improving the immunotherapeutic effect of the liposome vaccine on tumors.

5.4561617IMPFSTOFFKONSTRUKTE MIT TUBERKULOSEANTIGENEN

EP - 04.06.2025

Clasificación Internacional A61K 39/04Nº de solicitud 23754847Solicitante UNIV CAPE TOWNInventor/a MUSVOSVI MUNYARADZI N

The present invention relates to polygenic nucleic acid constructs comprising nucleotide sequences encoding Mycobacterium tuberculosis antigens and to mRNA vaccine constructs transcribed or obtained therefrom. Also provided are lipid nanoparticles including the mRNA vaccine constructs and vaccine compositions comprising the constructs described. The constructs, lipid nanoparticles containing them, and vaccine compositions described may be useful in methods for eliciting a protective immune response against Mycobacterium tuberculosis in a subject.

6.20250177505CANCER VACCINE COMPRISING EPITOPE OF C-MET AND EPITOPE OF HIF1ALPHA, AND USE THEREOF

US - 05.06.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18836943Solicitante KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventor/a Kyong Hwa PARK

The present invention relates to: a use of an epitope of c-MET and an epitope of HIF1α as a cancer vaccine; and a use of said cancer vaccine. The cancer vaccine according to the present invention decreases the expression level of HIF1α and/or c-MET and the expression of angiogenesis-related markers in various types of cancer known to overexpress the protein, and can inhibit tumor growth and furthermore, activates T1 cells and induces infiltration of the tumor, and thus can be used as a general-purpose cancer vaccine for suppressing the progression of cancer and preventing the metastasis thereof without being limited to the above-mentioned cancer types. In addition, the vaccine according to the present disclosure can more effectively inhibit the growth and progression of cancer and the formation of metastatic cancer by being administered in combination with an immune checkpoint inhibitor.

7.4566671KONSTRUKTION UND ANWENDUNG EINER FUSIONSPROTEINIMPFSTOFFPLATTFORM

EP - 11.06.2025

Clasificación Internacional A61P 31/12Nº de solicitud 25168339Solicitante INST BIOPHYSICS CASInventor/a FU YANGXIN

The present invention relates to the construction and application of a fusion protein vaccine platform. The present invention provides a vaccine, comprising a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope. The present invention also relates to use of a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope in the preparation of prophylactic or therapeutic compositions. The vaccine of the present invention can be produced by eukaryotic cell expression systems to prepare wild-type and various mutant antigen vaccines, and vaccination by means of subcutaneous/muscular or nasal or other routes can lead to a strong immune response to a body. The vaccine of the present invention can be used as a prophylactic or therapeutic vaccine.

8.4565270REPLIKATIONSUNKOMPETENTER HERPES-SIMPLEX-VIRUS-TYP-1-VIRUSIMPFSTOFF

EP - 11.06.2025

Clasificación Internacional A61K 39/245Nº de solicitud 23849514Solicitante IMMVIRA BIOPHARMACEUTICALS CO LTDInventor/a LIU YUANYUAN

Disclosed is a replication incompetent HSV-1 viral vaccine comprising a modified genome of HSV-1 and at least one antigen. The modification comprises a deletion of internal repeats, an inactivating mutation in ICP47 and an inactivating mutation in the other copy of ICP4. A first antigen of the at least one antigen is driven by a promoter of an immediate early gene, such as ICP4. In a specific example, the HSV-1 viral vaccine expresses antigens from SARS-Cov, SARS-Cov-2 and variants thereof and is used for inducing immune responses against sarbecoviruses in a subject to which the vaccine is administered.

9.WO/2025/118050CHIMERIC VACCINE ANTIGEN WITH TRIPLE ACTION AGAINST EHRLICHIOSIS, ANAPLASMOSIS AND CANINE BABESIOSIS, EXPRESSION VECTOR, RECOMBINANT CELL, VACCINE COMPOSITION, DIAGNOSTIC KIT, TREATMENT METHOD AND USE OF CHIMERIC PROTEIN

WO - 12.06.2025

Clasificación Internacional C07K 14/195Nº de solicitud PCT/BR2024/050553Solicitante LABORATÓRIO BIO-VET LTDAInventor/a ANTÔNIO DE OLIVEIRA MENDES, Tiago

The present invention relates to the development of vaccine formulations obtained from a chimeric recombinant protein (rTripEAB) with epitopes of T CD8+ and T CD4+ cells and built in an optimized form for bioinformatic tools, the sequence of which has conserved regions. The invention likewise relates to composition of the vaccine formulation with the chimeric antigen together with adjuvants, as well as to the evaluation of protective efficacy against infection by Ehrlichia canis, Anaplasma platys and Babesia canis. The technology is directly applicable for protection against infectious diseases in dogs, pigs, cows, horses, and humans, directly impacting the health and well-being of individuals.

10.WO/2025/121814TUBERCULOSIS VACCINE COMPOSITION COMPRISING FUSION PROTEIN INDUCING BACTERICIDAL IMMUNITY AGAINST MYCOBACTERIUM TUBERCULOSIS

WO - 12.06.2025

Clasificación Internacional A61K 39/04Nº de solicitud PCT/KR2024/019479Solicitante MYCO-RAPHA INC.Inventor/a KIM, Hwa Jung

The present invention relates to a tuberculosis vaccine composition comprising a fusion protein inducing bactericidal immunity against Mycobacterium tuberculosis. Specifically, a tuberculosis vaccine composition comprising a fusion protein of Rv2299cD2D3-ESAT6-Ag85B(REA) or Rv2299cD2D3-Rv3463-Ag85B(RRA) induces sterilization of 99% or more of Mycobacterium tuberculosis, and thus can prevent adult tuberculosis and can be used as a vaccine for infants/toddlers.

11.WO/2025/113554VARICELLA-ZOSTER VACCINE COMPOSITION AND USE THEREOF

WO - 05.06.2025

Clasificación Internacional A61K 39/25Nº de solicitud PCT/CN2024/135229Solicitante HUAPU SHIJIAZHUANG PHARMACEUTICAL CO., LTD.Inventor/a WANG, Xinzhong

A varicella-zoster vaccine composition and use thereof, belonging to the technical field of biological vaccines. The composition comprises a VZV gE antigen and a CpG ODN adjuvant and further comprises an aluminum adjuvant. The nucleotide sequence of the CpG ODN adjuvant is set forth in SEQ ID NO: 1. The CpG ODN adjuvant with a specific nucleotide sequence has better immunostimulatory activity. The provided varicella-zoster vaccine composition can generate a higher humoral immune response earlier and induce protective immunity in advance for at least one month. One immunization can reach or be close to the antibody level of two immunizations of the Shingrix vaccine. Moreover, the longer-time stable high-humoral immunity level can be kept, and cellular immunity can also be generated.

12.WO/2025/113478TUMOR NANO-VACCINE AND PREPARATION METHOD THEREFOR

WO - 05.06.2025

Clasificación Internacional A61K 39/00Nº de solicitud PCT/CN2024/134827Solicitante SHANGHAI BAJIUBA BIOTECHNOLOGY CO., LTDInventor/a ZHANG, Ming

A tumor nano-vaccine and a preparation method therefor, belonging to the technical field of biopharmaceuticals. The tumor nano-vaccine comprises tumor cell lysate nanoparticles. The tumor cell lysate nanoparticles are formed by taking an acryloyl ester as a monomer, utilizing a biodegradable cross-linking

agent, and synthesizing in situ a nano-thickness polymer shell on the surface of a protein or a tumor specific antigen in a tumor cell lysate by utilizing a free radical polymerization reaction. The tumor cell lysate nanoparticles can enhance the immunogenicity of a tumor antigen, thereby improving the immune response of an organism to a tumor. The tumor nano-vaccine enhances the stability of the tumor antigen, thereby ensuring the in vivo persistent circulation of the tumor antigen, and induces the organism to generate cell immunity and activate T cells, thereby achieving the effect of treating and/or preventing tumors.

13.4563159MUKOSALE IMPFUNG ÜBER EINE IGA-FEEDBACKSCHLEIFE

EP - 04.06.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23213600Solicitante FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUMInventor/a FREY ANDREAS

The present invention relates to the field of immunology, in particular, to mucosal vaccination. It provides a vaccine comprising a conjugate of an agent capable of specifically binding to an IgA or IgM, and an antigen. Said vaccine is advantageous for use in mucosal vaccination of a subject against said antigen, as it exploits an IgA feedback loop. The invention also provides methods for mucosal vaccination comprising administration of the vaccine of the invention to a subject. Furthermore, improved IgA binding peptides are disclosed.

14.4566625VERFAHREN ZUR HERSTELLUNG EINES INAKTIVIERTEN SARS-COV-2-IMPFSTOFFS, INAKTIVIERTER SARS-COV-2-IMPFSTOFF, VERFAHREN ZUR REINIGUNG VON SARS-COV-2 ODER INAKTIVIERTER SARS-COV-2 ANTIGENZUSAMMENSETZUNG

EP - 11.06.2025

Clasificación Internacional A61K 39/215Nº de solicitud 23850024Solicitante KM BIOLOGICS CO LTDInventor/a OKUMURA MINAKO

The present invention relates to a production method of an inactivated SARS-CoV-2 vaccine, the method including: a step of bringing a SARS-CoV-2 containing solution or an inactivated SARS-CoV-2 containing solution into contact with a cellulose sulfate ester gel at a pH of 8 or more and 10 or less to adsorb the SARS-CoV-2 or the inactivated SARS-CoV-2 to the gel; then removing impurities; and then eluting and recovering the SARS-CoV-2 or the inactivated SARS-CoV-2.

15.WO/2025/114521MUCOSAL VACCINATION VIA AN IGA FEEDBACK LOOP

WO - 05.06.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2024/084064Solicitante FORSCHUNGSZENTRUM BORSTEL, LEIBNIZ LUNGENZENTRUMInventor/a FREY, Andreas

The present invention relates to the field of immunology, in particular, to mucosal vaccination. It provides a vaccine comprising a conjugate of an agent capable of specifically binding to an IgA or IgM, and an antigen. Said vaccine is advantageous for use in mucosal vaccination of a subject against said antigen, as it exploits an IgA feedback loop. The invention also provides methods for mucosal vaccination comprising administration of the vaccine of the invention to a subject. Furthermore, improved IgA binding peptides are disclosed.

16.WO/2025/116751MULTIVALENT VACCINE COMPOSITIONS

WO - 05.06.2025

Clasificación Internacional C07K 14/31Nº de solicitud PCT/NZ2024/050129Solicitante AUCKLAND UNISERVICES LIMITEDInventor/a CLOW, Fiona

The present invention relates to multivalent S. aureus vaccine constructs, including multivalent polypeptide and polynucleotide constructs, compositions comprising such constructs including compositions such as pharmaceutical compositions comprising the constructs, methods of eliciting immune responses in a subject and methods of vaccinating a subject, related uses of such constructs, and uses of the constructs in the manufacture of medicaments for such purposes.

17.WO/2025/119162METAPNEUMOVIRUS (MPV) VACCINE

WO - 12.06.2025

Clasificación Internacional C12N 15/45Nº de solicitud PCT/CN2024/136380Solicitante SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD.Inventor/a LI, Linxian

Provided is a metapneumovirus (MPV) vaccine. Specifically, provided is a nucleic acid comprising a polynucleotide for encoding a mutant of an MPV F protein, compared with a wild-type MPV F protein, the mutant comprises a disulfide bond mutation.

18.4561618ENTWICKLUNG VON KOHLENHYDRATBASIERTEN ANTI-SALMONELLA-IMPFSTOFFEN

EP - 04.06.2025

Clasificación Internacional A61K 39/112Nº de solicitud 23847294Solicitante UNIV MICHIGAN STATEInventor/a HUANG XUEFEI

Provided herein are vaccine composition comprising a *Salmonella* antigen conjugated to a capsid, wherein the capsid comprises wild type or native sequence. Provided herein are also vaccine composition comprising a Salmonella antigen conjugated to a capsid, wherein said capsid comprises at least one mutation, such as a non-natural mutation. Such compositions are useful in the treatment and prevention of preventing or treating a *Salmonella* infection (salmonellosis), gastroenteritis, typhoid fever, and/or paratyphoid fever; and may be effective against multiple strains of *Salmonella*.

19.WO/2025/121971ALPHAVIRUS-BASED VECTOR SYSTEM FOR PRODUCING VIRUS-LIKE PARTICLE COMPRISING SELF-AMPLIFYING RNA

WO - 12.06.2025

Clasificación Internacional C12N 15/86Nº de solicitud PCT/KR2024/020063Solicitante INSTITUTE FOR BASIC SCIENCEInventor/a CHOI, Young Ki

One aspect of the present invention provides: a vector including a gene encoding a non-structural alphavirus protein of and a gene encoding a target protein; a cell infected with the vector; a virus-like particle (VLP); and a vaccine composition comprising same. The vector is a single-vector system and can easily and conveniently produce VLP containing saRNA without a helper vector. The VLP and vaccine composition produced through the vector produce a sufficient amount of antibody from only a single administration, have excellent safety

due to the absence of additional proliferation, can be administered to mucous membranes, and induces mucous membrane immunity, and thus exhibits a remarkably superior respiratory disease prevention or treatment effect compared to therapeutic agents for intramuscular administration.

20.202501775O9RECOMBINANT ADENOVIRUS VACCINE FOR AFRICAN SWINE FEVER AND METHOD FOR CONSTRUCTING SAME

US - 05.06.2025

Clasificación Internacional A61K 39/12Nº de solicitud 18014874Solicitante JIAXING ANYU BIOTECHNOLOGY CO., LTDInventor/a Ping CHEN

An african swine fever virus vaccine includes five groups of antigens in total, and each group is respectively obtained by constructing recombinant adenovirus vectors co-expressing four antigen genes of african swine fever virus, and packaged by 293TD37 cells. The four antigenic genes of African swine fever virus in each group are 1, P72, B602L, P30 and P54; 2, CP129Rubiqutin, MGF5L6L, CP312R, and MGF110-4L; 3, L8Lubiqutin, I215L, I73RHBsAgHBsAg and E146L; 4, EP402R, EP153R, I177L, and K205Rubiqutin; 5, F317L, A151R, P34, and pp62. The construction of the recombinant adenovirus vector for co-expression of four antigen genes of the african swine fever virus mainly includes: knocking out E1, E3, E2a and E4 genes of the adenovirus vector by CRISPR/cas9 technology, constructing an ORF6/7 expression frame of E4 in an E2a region, and constructing shuttle plasmids in E1 and E4 regions for appropriately expressing four antigen genes, thereby obtaining a completely new adenovirus vector.

21.4561432VERFAHREN UND VORRICHTUNG ZUR ERKENNUNG VON ZUSTÄNDEN AUS PHYSIOLOGIEDATEN

EP - 04.06.2025

Clasificación Internacional A61B 5/00Nº de solicitud 23847291Solicitante PROLAIO INCInventor/a SEKARIC JADRANKA

A computerized system for measuring and/or detecting responses or conditions in human beings based on data from wearable sensors worn in a natural free-living context. Based upon the measurements and/or detection, various actions can be taken. Physiological data is taken and instructions are transmitted to a vaccine manufacturer to alter a composition and/or dosage of a vaccine.

22.202501775I7TRIPLE VACCINE PROTECTS AGAINST BACTERIAL AND FUNGAL PATHOGENS VIA TRAINED IMMUNITY

US - 05.06.2025

Clasificación Internacional A61K 39/39Nº de solicitud 18944574Solicitante University of Southern CaliforniaInventor/a Brad Spellberg

An optimized protein-free tripartite vaccine that protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram-positive bacteria, Gram-negative bacteria, and fungi.

23.WO/2025/119999EXTRACELLULAR VESICLE BASED VACCINE PLATFORM

WO - 12.06.2025

Clasificación Internacional A61K 39/385Nº de solicitud PCT/EP2024/084721Solicitante UNIVERSITÄT DUISBURG-ESSENInventor/a GIEBEL, Bernd

The invention is based on fusion proteins comprising immunogenic antigens and partial cell adhesion proteins expressed in secreted extracellular vesicles for use in inducing immune responses in mammals. The invention is applicable as a novel platform technology for the development of vaccines, for methods of vaccination, for example against diseases or the generation of immune responses in mammals. The invention is for example useful as a platform technology for the generation of novel antibodies. The invention provides the cell adhesion protein based fusion proteins, recombinant cells, extracellular vesicles, and methods and uses thereof, for vaccination and vaccine development against for example infectious diseases.

24.20250177508PREPARATION OF LIVE VACCINES

US - 05.06.2025

Clasificación Internacional A61K 39/02Nº de solicitud 19048200Solicitante Elanco Tiergesundheit AGInventor/a Klaus LINDE

Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.

25.WO/2025/112200RABIES VACCINE IMMUNOGEN COMPOSITION

WO - 05.06.2025

Clasificación Internacional C12N 15/47Nº de solicitud PCT/CN2024/076204Solicitante ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventor/a XU, Jianqing

An anti-rabies virus immunogen composition capable of simultaneously inducing a humoral immune response and a cellular immune response and a use thereof. The anti-rabies virus immunogen composition involves a dual-immunogen combination, comprising a rabies virus glycoprotein G as an immunogen for activating neutralizing antibodies and a polymerase large protein L as a T-cell immunogen. The rabies virus glycoprotein is derived from the full length of a glycoprotein or extracellular region amino acids thereof or an antigenic fragment thereof, and the T-cell immunogen is derived from a recombinant sequence of a conserved region of a polymerase large protein. Optionally, the two immunogens are loaded onto the same type of carrier or different types of carriers. The vaccine is safe and can simultaneously activate anti-rabies virus T cells and an antibody response, thereby realizing combined protection for preventing and treating rabies virus infection.

26.WO/2025/114381MUC1 ANTIBODIES AND USES THEREOF

WO - 05.06.2025

Clasificación Internacional C07K 16/30Nº de solicitud PCT/EP2024/083802Solicitante DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventor/a VERDI, Joseph

The present invention concerns the field of antibodies. More specifically, it relates to an antibody that specifically binds to hypoglycosylated MUC1, wherein said antibody binds to an epitope formed by a carbohydrate moiety of the hypoglycosylated MUC1 and by a peptide backbone portion of the MUC1 protein. The present invention also relates to said antibody for use in in treating and/or preventing cancer associated with aberrant cancer specific MUC1 expression and, preferably, adenocarcinoma. Moreover, the present

invention refers to VAST bound immunogen for use as a vaccine, wherein said VAST-bound immunogen comprises a peptide having an amino acid sequence as shown in SEQ ID NO: 92 (PAHGVTSAPDTRPAPGSTAP) wherein sialyated N-acetylgalactosamine (GalNAc) is linked to the serine residue at position 17 or threonine residue at position 18 in SEQ ID NO: 92 by a glycosidic bond. The invention also relates to method for manufacturing an antibody that specifically binds to hypoglycosylated MUC1, said method comprising the step of obtaining the antibody from a sample of an animal which has been immunized with a VAST-bound immunogen, wherein said immunogen comprises a peptide having an amino acid sequence as shown in SEQ ID NO: 92 (PAHGVTSAPDTRPAPGSTAP), wherein sialyated N-acetylgalactosamine (GalNAc) is linked to the serine residue at position 17 or threonine residue at position 18 in SEQ ID NO: 92 by a glycosidic bond.

27.WO/2025/122533MULTIVALENT VACCINE COMPOSITIONS

WO - 12.06.2025

Clasificación Internacional A61K 39/02Nº de solicitud PCT/US2024/058331Solicitante INVENTPRISE, INCInventor/a KAPRE, Subhash V.

The invention is directed to compositions and methods for the prevention and treatment of infections where the causative agent is a Klebsiella microorganism. In particular, the invention is directed to multivalent immunogenic compositions and vaccines containing multiple different serotypes of Klebsiella capsular polysaccharides and/or subcapsular polysaccharides that are prevalent in low- and middle-income countries where the burden of disease is high.

28.3024937VACCINE FOR PROPHYLAXIS OR TREATMENT OF AN ALLERGEN-DRIVEN AIRWAY PATHOLOGY

ES - 05.06.2025

Clasificación Internacional A61K 39/10Nº de solicitud 19176782Solicitante Institut National de la Santé et de la Recherche MédicaleInventor/a LOCHT, Camille

29.WO/2025/118638TUMOR CELL MEMBRANE ULTRASOUND MICROBUBBLE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN ENHANCING TUMOR IMMUNOTHERAPY

WO - 12.06.2025

Clasificación Internacional A61K 49/22Nº de solicitud PCT/CN2024/108307Solicitante THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITYInventor/a ZHANG, Liang

A tumor cell membrane ultrasound microbubble, a preparation method therefor, and use thereof in enhancing tumor immunotherapy. The tumor cell membrane ultrasound microbubble comprises a phospholipid bilayer shell composed of a tumor cell membrane, and an inert gas is encapsulated within the shell. The tumor cell membrane ultrasound microbubble is prepared by the following method: mixing the tumor cell membrane with a glycerol-containing phosphate buffer solution, carrying out ultrasonic treatment to obtain a tumor cell membrane suspension, and transferring the tumor cell membrane suspension into a container; adding perfluorotributylamine, and sealing the container; and extracting air in the container, injecting the inert gas, and carrying out oscillation treatment to obtain the tumor cell membrane ultrasound microbubble. The

microbubble can be used as a tumor vaccine to stimulate organism immunity, thereby solving the problems of a single antigen and the low immunogenicity of traditional tumor vaccines. The microbubble is of a typical hollow structure, can be used for enhancing ultrasonic contrast imaging and promoting the maturation of dendritic cells in vivo and in vitro, and has application prospects in tumor immunotherapy.

30.202501775 11DENGUE VACCINE BATCH MIXING PROCESS

US - 05.06.2025

Clasificación Internacional A61K 39/12Nº de solicitud 18837783Solicitante Takeda Vaccines, Inc.Inventor/a Sean Bronson

The present invention relates to a batch mixing process for preparing a liquid pharmaceutical composition (LPC) comprising at least one biological active agent and at least one adjustable excipient, wherein the at least one biological active agent has a target concentration in the LPC ($^{T}[A_i]_{LPC}$) and the at least one adjustable excipient has a target concentration in the LPC ($^{T}[E_x]_{LPC}$).

31.269904PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING

IL - 01.06.2025

Clasificación Internacional A61K 38/03Nº de solicitud 269904Solicitante INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor/a

32.202501791 32VARIANT SURVIVIN VACCINE FOR TREATMENT OF CANCER

US - 05.06.2025

Clasificación Internacional C07K 14/47Nº de solicitud 19029187Solicitante H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventor/a FREDERICK L. LOCKE

The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.

33.4565715ZUSAMMENSETZUNGEN, KITS UND VERFAHREN ZUM NACHWEIS VARIANTER STÄMME DES AFRIKANISCHEN SCHWEINEPESTVIRUS

EP - 11.06.2025

Clasificación Internacional C12Q 1/6851Nº de solicitud 23758107Solicitante LIFE TECHNOLOGIES CORPInventor/a MARTIN ELISE

Disclosed are compositions, methods, systems, and kits for the detection of African swine fever virus (ASFV) in a test sample, and in particular for distinguishing between wild/reference type ASFV and mutant/variant strains of ASFV. A variant ASFV assay includes a first set of primers and a first probe that correspond to a first ASFV target, and a second set of primers and a second probe that correspond to a second ASFV target. The first and second probes are differentially labelled. The first ASFV target is a MGF360 gene and the second ASFV target is the CD2v gene. Absence of these targets, in conjunction with a positive determination for

another generic ASFV target such as the p72 gene, is indicative of a vaccine-associated variant strain of ASFV.

34.WO/2025/122814VALACYCLOVIR AND CELECOXIB IN COMBINATION WITH NIRMATRELVIR AND RITONAVIR FOR THE TREATMENT OF COVID-19

WO - 12.06.2025

Clasificación Internacional A61K 45/06Nº de solicitud PCT/US2024/058782Solicitante PRIDGEN, William LangleyInventor/a PRIDGEN, William Langley

The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.

35.320040SUPERANTIGEN VACCINE CONJUGATE FOR THE TREATMENT OF CANCER

IL - 01.06.2025

Clasificación Internacional C07K 14/315Nº de solicitud 320040Solicitante MUSC FOUNDATION FOR RESEARCH DEVELOPMENTInventor/a

36.WO/2025/116699GENE AMPLIFICATION METHOD FOR PRODUCING IVT TEMPLATE

WO - 05.06.2025

Clasificación Internacional C12Q 1/6844Nº de solicitud PCT/KR2024/096518Solicitante THERAGEN BIO CO., LTD.Inventor/a KIM, Seong Gwang

The present invention relates to a novel PCR method used to prepare a template for performing in vitro transcription (IVT) in a neoantigen screening method and a vaccine production method using mRNA and, more specifically, to a novel PCR method for preparing a template for performing in vitro transcription (IVT), the method comprising: an amplification step of a plurality of DNA templates including a first barcode sequence, a second barcode sequence, and a coding sequence, respectively, the amplification step involving replicating the plurality of DNA templates with a first forward primer specific to the first barcode sequence; and an amplification step of valid DNA templates selected from the plurality of DNA templates, the amplification step involving replicating the valid DNA templates with a second forward primer specific to the second barcode sequence, whereby a template for performing IVT is more simply produced.

37.4561616EGFR-IMPFSTOFFKASSETTEN

EP - 04.06.2025

Clasificación Internacional A61K 39/00Nº de solicitud 23847518Solicitante GRITSTONE BIO INCInventor/a JOOSS KARIN

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of EGFR neoepitope-encoding sequences. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

38.4565264CTA-IMPFSTOFFKASSETTEN

EP - 11.06.2025

Clasificación Internacional A61K 39/00Nº de solicitud 23850975Solicitante GRITSTONE BIO INCInventor/a JOOSS KARIN

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of CTA epitope-encoding sequences or Cancer Testis Antigen (CTA)-encoding nucleic acid sequences and KRAS-encoding nucleic acid sequences. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

39.WO/2025/120616METHOD AND DEVICE FOR MICROFLUIDIC FORMULATION OF STABLE NANOPARTICLES AS DRUG/BIOMOLECULES CARRIERS

WO - 12.06.2025

Clasificación Internacional B22F 1/054Nº de solicitud PCT/IB2024/062698Solicitante SHABANI, ShahrzadInventor/a SHABANI, Shahrzad

This invention involves a microfluidic chip used to create carrier nanoparticles for applications like cancer treatment and vaccine production. The chip is made of PDMS polymer and utilizes soft lithography techniques. The chip's design includes inlets for cationic water and oil phases, and an outlet with channels arranged perpendicular to each other to control nanoparticle size. The nanoparticles produced are 20-100 nm with a lipid coating which enhances cell absorption. They are also stable in vitro and in vivo, with a PDI index of 0. 07 indicating optimal uniformity and homogeneity.

40.20250177512MRNA VACCINE

US - 05.06.2025

Clasificación Internacional A61K 39/12Nº de solicitud 18838972Solicitante PHION THERAPEUTICS LTDInventor/a Helen MCCARTHY

The present specification relates to vaccines comprising an mRNA polynucleotide encoding an antigen from an infectious microorganism; and an amphipathic cell penetrating RALA peptide.

41.WO/2025/116198METHOD FOR PRODUCING VIRUS-LIKE PARTICLES OF COWPEA MOSAIC VIRUS AND USE THEREOF

WO - 05.06.2025

Clasificación Internacional C12N 15/74Nº de solicitud PCT/KR2024/011531Solicitante SOGANG UNIVERSITY RESEARCH & BUSINESS DEVELOPMENT FOUNDATIONInventor/a KIM, Seong-ryong

The present invention relates to a method for producing virus-like particles (VLPs) of *Cowpea mosaic virus* (CPMV) and a use thereof. The CPMV VLPs produced using the method were found to collect target RNA and thus have the effect of allowing RNA to be safely maintained for a long period of time even when stored in a refrigerator. Accordingly, the excellent RNA preservation properties are expected to be positively applied to mRNA vaccine development research.

42.20250177507MULTIVALENT VACCINE COMPOSITIONS

US - 05.06.2025

Clasificación Internacional A61K 39/108Nº de solicitud 18967715Solicitante Inventprise, IncInventor/a Subhash V. Kapre

The invention is directed to compositions and methods for the prevention and treatment of infections where the causative agent is a *Klebsiella* microorganism. In particular, the invention is directed to multivalent immunogenic compositions and vaccines containing multiple different serotypes of *Klebsiella* capsular polysaccharides and/or subcapsular polysaccharides that are prevalent in low- and middle-income countries where the burden of disease is high.

43.20250179165USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS

US - 05.06.2025

Clasificación Internacional C07K 16/22Nº de solicitud 19054130Solicitante George J. TodaroInventor/a George J. Todaro

The invention provides a method of treating a disease or disorder in a subject by inducing a TGF alpha immune response or by administering an anti-TGF-alpha antibody or a biologically active fragment thereof. The TGF-alpha immune response is induced using a TGF-alpha polypeptide or biologically active fragment, a vaccine, a genetic construct or a transformed cell, for example.

44.WO/2025/118212ANIMAL CASTRATION METHOD

WO - 12.06.2025

Clasificación Internacional C07K 7/23Nº de solicitud PCT/CN2023/136969Solicitante SHENZHEN HERZ LIFE SCIENCE TECHNOLOGY CO., LTDInventor/a ZHA, Lisha

The present invention relates to the technical field of biology, and particularly to an animal castration method. The present invention provides a non-surgical animal castration method, comprising administering a GnRH-I-AP205 virus-like particle subunit vaccine to an animal. The method is good in safety and non-irritant, does not cause anaphylaxis, and is still safe under overdosage. Moreover, the required dosage is small, and 0.25 ml per animal is able to take effect.

45.20250177506VACCINATION AND ANTIBODY GENERATION PLATFORM

US - 05.06.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18946744Solicitante Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventor/a Fotini Nina Papavasiliou

The invention is based on a platform for vaccination and/or antibody generation. The invention is based on the display of small molecular immunogenic compounds on the coat of variant surface glycoproteins (VSG) on trypanosomes which results in a highly effective immune response when used as a vaccine or in immunization for antibody production. The herein disclosed antigenic particles are applicable for producing antibodies or can be directly used as vaccines for the treatment of various medical conditions. Most preferably the invention relates to the VSG based vaccines specific for dependency causing substances for the treatment of addiction or avoidance of adverse events during drug abuse. Other applications include methods and uses involving the disclosed compounds and compositions for a treatment or prevention of cancer, infectious

disease, contagious neurodegenerative diseases, non-communicable disorders (e.g. certain neurodegenerative diseases, allergies) and any condition or industrial use for which an immune response from vaccination or antibody use would be desirable.

46.320077DENGUE VACCINE FORMULATION

IL - 01.06.2025

Clasificación Internacional A61K 39/12Nº de solicitud 320077Solicitante TAKEDA VACCINES, INC.Inventor/a KOMMAREDDY, Sushma

47.4565269DOMINANT-NEGATIVES ANTIGEN ZUR PROPHYLAKTISCHEN UND POSTINFEKTIÖSEN BEHANDLUNG VON SCHWEINEN GEGEN AFRIKANISCHES SCHWEINEPESTVIRUS

EP - 11.06.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23850989Solicitante MALCOLM THOMASInventor/a MALCOLM THOMAS

The disclosed invention pertains and encompasses a composition comprising modified ASFV outer-membrane protein antigen mutants (termed dominant negatives) that exhibit non-binding affinity to RBCs while inducing an antibody-mediated response capable of neutralizing unmodified proteins found on infectious outer-membrane-laden ASFV virions. Additionally, a method for the treatment and/or prevention of ASFV is provided, involving the administration of a dominant negative antigenic composition to animals, thereby averting RBC aggregation caused by said antigen and concurrently treating and/or preventing ASFV. Furthermore, the invention encompasses an ASFV vaccine composition containing the dominant negative antigen as a constituent. Moreover, the invention covers a formulation incorporating these dominant negative antigens in conjunction with antigens derived from capsid-based proteins, which collectively target both lysogenic and lytic viral replication cycles, thereby achieving optimal immune stimulatory protection.

Edición: Annia Ramos Rodríguez *aramos@finlay.edu.cu*
Randelys Molina Castro *rmolina@finlay.edu.*
Claudia Camejo Salas *ccamejo@finlay.edu.cu*
Yamira Puig Fernández *yamipuig@finlay.edu.cu*

FINLAY EDICIONES